/api/developer/v5/auth","description":"Use this call to obtain JWT token. Api Key and Secret Key are could be obtained form your EdCast Administrator.
\nX-API-KEY = api_key
\nX-AUTH-TOKEN = JWT.encode(payload, secret_key)
\npayload = { email: \"test@test.com\" }
\nIn response you get JWT-TOKEN. Use it in each API request to be authorized in system.
\nThe JWT-TOKEN has expiration time of 12 hours.
\nThe email used in payload has to be user of the system and must have developer permission given.
\n![Watch the video]
\n
\n
\n
\n
\n\nNOTES
\nWe have changed the error code for unauthorized access from 401 to 403.\nif the user is performing illegitimate action the API will respond 403 with message \"You are not authorized for this action\"
\nFollowing are the list of api's which got affected due to the change.
\nProfile
\n\nPOST : /api/developer/v5/profiles/custom_fields
\nGET : /api/developer/v5/profiles/custom_fields
\n
\n\nTeam
\n\nPOST : /api/developer/v5/teams
\nGET : /api/developer/v5/teams/:id
\nPUT : /api/developer/v5/teams/:id
\nPOST : /api/developer/v5/teams/:id/add_member
\nDELETE : /api/developer/v5/teams/:id/remove_member
\n
\nPathway
\n\nGET : /api/developer/v5/pathways/:id
\nPUT : /api/developer/v5/pathways/path:id/add_card/card:id
\nPUT : /api/developer/v5/pathways/path:id/remove_card/card:id
\n
\n\nChannel
\n\nGET : /api/developer/v5/channels/:id
\n","auth":{"type":"oauth2","oauth2":{},"isInherited":true,"source":{"_postman_id":"c7de3a2b-dfc5-4e55-9e00-b68d8d692ac8","id":"c7de3a2b-dfc5-4e55-9e00-b68d8d692ac8","name":"Authentication","type":"folder"}},"urlObject":{"protocol":"https","path":["api","developer","v5","auth"],"host":[""],"query":[],"variable":[]}},"response":[{"id":"da2ee5e9-252c-492b-88a2-16d127178009","name":"/api/developer/v5/auth","originalRequest":{"method":"GET","header":[{"key":"X-API-KEY ","value":""},{"key":"X-AUTH-TOKEN","value":""}],"body":{"mode":"formdata","formdata":[]},"url":"https://BASE-ORG-URL/api/developer/v5/auth"},"status":"OK","code":200,"_postman_previewlanguage":"","header":[],"cookie":[],"responseTime":null,"body":"{\n\tjwt_token: \"nkdnlkikjf4753408yhlsdkbfhb43rgcdjbvjkh8fyu\"\n}"}],"_postman_id":"d8e5773a-4bd3-45ac-8cef-8a637d15d1fb"}],"id":"c7de3a2b-dfc5-4e55-9e00-b68d8d692ac8","description":"EdCast uses JWT authentication standard.
\n","auth":{"type":"oauth2","oauth2":{},"isInherited":false},"event":[{"listen":"prerequest","script":{"id":"e522ca80-2c92-45d0-bc9b-e843c82580df","type":"text/javascript","exec":[""]}},{"listen":"test","script":{"id":"b0b0dd05-71be-44db-8359-3a79a91e7d8b","type":"text/javascript","exec":[""]}}],"_postman_id":"c7de3a2b-dfc5-4e55-9e00-b68d8d692ac8"},{"name":"User Management","item":[{"name":"Add Custom Field","id":"26c19424-9e0e-4897-84bb-1056d30f3cda","request":{"auth":{"type":"bearer","bearer":{},"isInherited":false},"method":"POST","header":[{"key":"X-API-KEY","value":""},{"key":"X-ACCESS-TOKEN","value":""},{"key":"Content-Type","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"name_fields\": [\n \"manager_id\",\n \"job_type\"\n ]\n}"},"url":"https:///api/developer/v5/profiles/custom_fields","description":"Use this API to create new Custom Fields/Attributes.
\n","urlObject":{"protocol":"https","path":["api","developer","v5","profiles","custom_fields"],"host":[""],"query":[],"variable":[]}},"response":[{"id":"6aa955fe-93bf-42a8-b705-69af7ac2c095","name":"Add Custom Field","originalRequest":{"method":"POST","header":[{"key":"X-API-KEY","value":""},{"key":"X-ACCESS-TOKEN","value":""},{"key":"Content-Type","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"name_fields\": [\n \"manager_id\",\n \"job_type\"\n ]\n}"},"url":"https://BASE-ORG-URL/api/developer/v5/profiles/custom_fields"},"status":"OK","code":200,"_postman_previewlanguage":"","header":[],"cookie":[],"responseTime":null,"body":"OK"}],"_postman_id":"26c19424-9e0e-4897-84bb-1056d30f3cda"},{"name":"Get Organization's Custom Fields","id":"f23ae5f7-2033-4988-935b-1610b181277d","request":{"auth":{"type":"bearer","bearer":{},"isInherited":false},"method":"GET","header":[{"key":"X-API-KEY","value":""},{"key":"X-ACCESS-TOKEN","value":""}],"body":{"mode":"formdata","formdata":[]},"url":"https:///api/developer/v5/profiles/custom_fields","description":"Get Organization's Custom Fields/Attributes.
\nAlso you can set such params as:
\nlimit - count of records in response, 10 by default
\noffset - from what record send custom_field list in response, 0 by default
\n","urlObject":{"protocol":"https","path":["api","developer","v5","profiles","custom_fields"],"host":[""],"query":[],"variable":[]}},"response":[{"id":"7428337d-5c47-4fd3-adcb-e6f833bbd195","name":"Get Organization Custom Fields","originalRequest":{"method":"GET","header":[{"key":"X-API-KEY","value":"","warning":""},{"key":"X-ACCESS-TOKEN","value":"","warning":""}],"body":{"mode":"formdata","formdata":[]},"url":"https://BASE-ORG-URL/api/developer/v5/profiles/custom_fields"},"status":"OK","code":200,"_postman_previewlanguage":"","header":[],"cookie":[],"responseTime":null,"body":"{\n\t\"customFields\" : [\n\t {\n\t \"id\" : 2,\n\t \"name\" : \"location\"\n\t },\n\t {\n\t \"id\" : 3,\n\t \"name\" : \"jobID\"\n\t },\n\t {\n\t \"id\" : 4,\n\t \"name\" : \"jobTitle\"\n\t }\n ]\n}"}],"_postman_id":"f23ae5f7-2033-4988-935b-1610b181277d"},{"name":"Create/Update User Records","id":"62212f1a-2a7b-4065-a7da-a10acbd945f3","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"method":"POST","header":[{"key":"X-API-KEY","value":""},{"key":"X-ACCESS-TOKEN","value":""},{"key":"Content-Type","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"allow_email_update\": \"false\",\n \"profiles\": [\n {\n \"external_id\": \"ID20240501\",\n \"first_name\": \"Firstname2024\",\n \"last_name\": \"Lastname2024\", \n \"email\": \"email20241@edcast.com\",\n\t\t\t\"name\": \"Han Solo\",\n \"employee_type\": \"full time\",\n \"department\": \"sale\",\n \"location\": \"Washington\",\n \"language\": \"en\",\n \"avatar\": \"https://www.gravatar.com/avatar/205e460b479e2e5b48aec07710c08d50?s=200&r=pg&d=404\",\n \"language\": \"en\",\n \"send_email_notification\": false,\n \"status\": \"Active\",\n\t\t\t\"manager_name\": \"Chewbacca\",\n \"send_email_notification\": true,\n \"manager_external_id\": \"34\",\n \"manager_edcast_id\": \"89\",\n \"job_id\": \"23\",\n \"job_title\": \"saler\",\n \"organization_unit_external_ids\":[\"d1001\"],\n \"work_location_external_id\":\"101011\",\n \"roles\": [\n \"member\",\n \"admin\"\n ]\n\t\t}\n\t\t\n ]\t\n}"},"url":"https:///api/developer/v5/profiles","description":"API to Create/Update User records on EdCast System
\nRequired params: first_name, last_name, email, external_id
\n
\nINFO:
\nAdded new profile field send_email_notification , by default it is true.
\nNOTE: We recommend creating max 10 users per request
\nThe request body should be array of hashes
\nRequest Param Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \nexternal_id | \nString | \nExternal_id of the user | \nYes | \n\"A00564E\" | \n
\n\n| 2 | \nemail | \nString | \nEmail of the user | \nYes | \n\"han@test.com\" | \n
\n\n| 3 | \nfirst_name | \nString | \nFirst Name of the user | \nYes | \n\"Han\" | \n
\n\n| 4 | \nlast_name | \nString | \nLast Name of the user | \nYes | \n\"Solo\" | \n
\n\n| 5 | \nstatus | \nString | \nStatus (active or suspended) of the user | \nNo | \n\"active\" | \n
\n\n| 6 | \nlanguage | \nString | \nLanguage of the user | \nNo | \n\"en\" | \n
\n\n| 7 | \nroles | \nArray | \nRole names for the user, default member | \nNo | \n[member] | \n
\n\n| 8 | \navatar | \nString | \nAvatar image (aka profile image), supports image url | \nNo | \n-- | \n
\n\n| 9 | \njob_title | \nString | \nJob Role of the Users | \nNo | \n-- | \n
\n\n| 10 | \nwork_country | \nString | \nWork country of the user | \nNo | \n-- | \n
\n\n| 11 | \nsend_email_notification | \nBoolean | \nBoolean value to send Welcome email to new Users. (default: true) | \nNo | \nfalse | \n
\n\n| 12 | \ncustom_field1_abbr | \nString | \nCustom field of the org | \nNo | \n-- | \n
\n\n| 13 | \ncustom_field2_abbr | \nString | \nCustom field of the org | \nNo | \n-- | \n
\n\n| 14 | \nadditional_fields | \nHash | \nCollects additional info such as dob, gender, billing address for user | \nNo | \n | \n
\n\n| 14.1 | \ndob | \nString | \nDate of birth of user. Format: '%m-%d-%Y' | \nNo | \n\"11-24-1992\" | \n
\n\n| 14.2 | \ngender | \nInteger | \nGender of user Values for male: 0, female: 1, other: 2 | \nNo | \n1 | \n
\n\n| 14.3 | \nmobile_number | \nString | \nMobile number of user | \nNo | \n\"9999999999\" | \n
\n\n| 14.4 | \noccupation_id | \nInteger | \nOccupation Id of user | \nNo | \n1 | \n
\n\n| 14.5 | \ndomain | \nInteger | \nDomain of user. values for 'Non IT Field': 0,'IT Field': 1,'Unemployed with job offer': 2,'Unemployed without job offer': 3 | \nNo | \n1 | \n
\n\n| 14.6 | \naddress_line1 | \nString | \nLine 1 of billing address | \nNo | \n\"1102, Everest World\" | \n
\n\n| 14.7 | \naddress_line2 | \nString | \nLine 2 of billing address | \nNo | \n\"Mumbai\" | \n
\n\n| 14.8 | \ncity | \nString | \nCity of residence | \nNo | \n\"Mumbai\" | \n
\n\n| 14.9 | \nstate | \nString | \nState of residence | \nNo | \n\"Maharashtra\" | \n
\n\n| 14.10 | \nzip | \nString | \nPostal code | \nNo | \n400607 | \n
\n\n| 14.11 | \ncountry | \nString | \nCountry of residence | \nNo | \n\"India\" | \n
\n\n| 14.12 | \nuser_gstin_number | \nString | \nGST code of user | \nNo | \n\"06BBBBB1111B1ZE\" | \n
\n\n| 15 | \njob_external_id | \nString | \nExternal id of job role | \nNo | \n | \n
\n\n| 16 | \norganization_unit_external_ids | \nArray | \nExternal Ids of organization units | \nNo | \n[\"DIV1001\"] | \n
\n\n| 17 | \nwork_location_external_id | \nString | \nExternal id of work location id | \nNo | \n\"Loc-US\" | \n
\n\n
\n
Note: Any other key present in user's hash will be considered as custom_field
\nResponse Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nexternalId | \nString | \nExternal Id of the user. | \n
\n\n| 2 | \nuid | \nString | \nUid of the user. | \n
\n\n| 3 | \nuserId | \nInteger | \nId of the user in edcast. | \n
\n\n| 4 | \nemail | \nString | \nemail of the user. | \n
\n\n| 5 | \nfirstName | \nString | \nFirst name of the user. | \n
\n\n| 6 | \nlastName | \nString | \nLast name of the user. | \n
\n\n| 7 | \nstatus | \nString | \nStatus of the user - active, suspended. | \n
\n\n| 8 | \nroles | \nArray | \nRoles assigned to the user. | \n
\n\n| 9 | \nlanguage | \nString | \nlanguage of the user. | \n
\n\n| 10 | \navatar | \nHash | \nHash of user images in different sizes. | \n
\n\n| 11 | \njobTitle | \nString | \nJob title of the user. | \n
\n\n| 12 | \nworkCountry | \nString | \nWork country of the user. | \n
\n\n| 13 | \nlearningTopics | \nArray | \nArray of learning topics. | \n
\n\n| 14 | \nlastSignInAt | \nDatetime | \nDate time of the user's last sign in at | \n
\n\n
\n
send_email_notification is a bool param in order to sending Welcome email to new Users; possible values: true, false, 1, 0, t, f
\n
\nINFO:
Added new profile field language
\nlanguage is a string param; possible values: EN, en, English, english and other available languages in Edcast system
\n
\nINFO:
Added new parameter allow_email_update
\nallow_email_update is a bool param which will update the email id of the user if true; possible values: true, false
\n
\n","auth":{"type":"oauth2","oauth2":{},"isInherited":true,"source":{"_postman_id":"b5ac2864-157f-4d67-8f4a-68d9dafac31b","id":"b5ac2864-157f-4d67-8f4a-68d9dafac31b","name":"User Management","type":"folder"}},"urlObject":{"protocol":"https","path":["api","developer","v5","profiles"],"host":[""],"query":[],"variable":[]}},"response":[{"id":"2295e52c-ef74-42d1-92eb-3f9f1f48567c","name":"Create User Records","originalRequest":{"method":"POST","header":[{"key":"X-API-KEY","value":"7241ccbb0add371cd4b04a941e5714f3"},{"key":"X-ACCESS-TOKEN","value":"eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjE2MDU4OCwiZW1haWwiOiJjc2hlc2hhbkBjc29kLmNvbSIsInRpbWVzdGFtcCI6IjIwMjQtMDUtMDFUMTY6MDE6MjguMDIwKzAwOjAwIiwiZXhwIjoxNzE0NjIyNDg4fQ.90TKxJGfgcg24FUa48g81Yqo0AKQEVSbEI9tIwT7DmE"},{"key":"Content-Type","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"allow_email_update\": \"false\",\n \"profiles\": [\n {\n \"external_id\": \"ID20240501\",\n \"first_name\": \"Firstname2024\",\n \"last_name\": \"Lastname2024\", \n \"email\": \"email20241@edcast.com\",\n\t\t\t\"name\": \"Han Solo\",\n \"employee_type\": \"full time\",\n \"department\": \"sale\",\n \"location\": \"Washington\",\n \"language\": \"en\",\n \"avatar\": \"https://www.gravatar.com/avatar/205e460b479e2e5b48aec07710c08d50?s=200&r=pg&d=404\",\n \"language\": \"en\",\n \"send_email_notification\": false,\n \"status\": \"Active\",\n\t\t\t\"manager_name\": \"Chewbacca\",\n \"send_email_notification\": true,\n \"manager_external_id\": \"34\",\n \"manager_edcast_id\": \"89\",\n \"job_id\": \"23\",\n \"job_title\": \"saler\",\n \"organization_unit_external_ids\":[\"d1001\"],\n \"work_location_external_id\":\"101011\",\n \"roles\": [\n \"member\",\n \"admin\"\n ]\n\t\t}\n\t\t\n ]\t\n}"},"url":"https://uswest.edcastqa.com/api/developer/v5/profiles"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Type","value":"application/json; charset=utf-8"},{"key":"Transfer-Encoding","value":"chunked"},{"key":"Connection","value":"keep-alive"},{"key":"Date","value":"Wed, 01 May 2024 16:28:59 GMT"},{"key":"X-UA-Compatible","value":"IE=edge"},{"key":"X-XSS-Protection","value":"1; mode=block"},{"key":"X-Content-Type-Options","value":"nosniff"},{"key":"X-Frame-Options","value":"SAMEORIGIN"},{"key":"Cache-Control","value":"no-store"},{"key":"Pragma","value":"no-cache"},{"key":"Expires","value":"Fri, 01 Jan 1990 00:00:00 GMT"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains; preload"},{"key":"Access-Control-Allow-Origin","value":"uswest.edcastqa.com"},{"key":"Vary","value":"Accept, Accept-Encoding, Origin"},{"key":"Content-Encoding","value":"gzip"},{"key":"X-Request-Id","value":"f3f05b65-e57b-4a14-85d3-bc343348423f"},{"key":"X-Runtime","value":"2.918991"},{"key":"Referrer-Policy","value":"strict-origin-when-cross-origin"},{"key":"Expect-CT","value":"enforce; max-age=3600"},{"key":"X-Cache","value":"Miss from cloudfront"},{"key":"Via","value":"1.1 44dd03c6d93a5b4e66aa5cea227acbb2.cloudfront.net (CloudFront)"},{"key":"X-Amz-Cf-Pop","value":"IAD55-P3"},{"key":"X-Amz-Cf-Id","value":"4Ob11l7ofC1BWPHY3VBv1AyyxZA2JTzUAYzGTCk6Ybpsjdp6fJZ51A=="}],"cookie":[],"responseTime":null,"body":"{\n \"profiles\": [\n {\n \"externalId\": \"ID20240501\",\n \"uid\": \"55291acc-87d5-480b-823f-b1a2d2d8d78a\",\n \"userId\": 1007181,\n \"email\": \"email20241@edcast.com\",\n \"firstName\": \"Firstname2024\",\n \"lastName\": \"Lastname2024\",\n \"status\": \"active\",\n \"roles\": [\n \"admin\",\n \"member\"\n ],\n \"language\": \"es\",\n \"avatar\": {\n \"tiny\": null,\n \"small\": null,\n \"medium\": null,\n \"large\": null\n },\n \"jobTitle\": null,\n \"workCountry\": null,\n \"learningTopics\": [],\n \"lastSignInAt\": null,\n \"createdAt\": \"2024-05-01T16:28:57.000Z\",\n \"circleId\": null,\n \"terminationDate\": null\n }\n ],\n \"messages\": {\n \"0\": {\n \"messages\": [\n \"Organization units added. Invalid organization unit external ids :d1001,\",\n \"has already been taken\",\n \"name key is missing in custom fields\",\n \"employee_type key is missing in custom fields\",\n \"department key is missing in custom fields\",\n \"location key is missing in custom fields\",\n \"manager_name key is missing in custom fields\",\n \"manager_external_id key is missing in custom fields\",\n \"manager_edcast_id key is missing in custom fields\",\n \"job_id key is missing in custom fields\"\n ],\n \"external_id\": \"ID20240501\"\n }\n },\n \"totalCreatedProfiles\": 1\n}"}],"_postman_id":"62212f1a-2a7b-4065-a7da-a10acbd945f3"},{"name":"Update User Record by ID","id":"bfb232f9-fb38-4017-9eed-4a03cac2c130","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"noauth","isInherited":false},"method":"PUT","header":[{"key":"X-API-KEY","value":""},{"key":"X-ACCESS-TOKEN","value":""},{"key":"Content-Type","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"profile\": {\n \"email\": \"hansolo@edcast.com\",\n \"bio\" : \"new text of bio\",\n \"employee_type\" : \"part time\",\n \"manager_name\": \"Chewbacca 2.0\",\n \"manager_external_id\": \"35\",\n \"language\": \"French\",\n \"roles\": [\"curator\"],\n \"anonymize\": \"true\",\n \"job_title\": \"saler\",\n \"avatar\": \"https://www.gravatar.com/avatar/205e460b479e2e5b48aec07710c08d50?s=200&r=pg&d=404\",\n \"organization_unit_external_ids\":[\"12012\"],\n \"work_location_external_id\":\"101011\"\n }\n}"},"url":"https:///api/developer/v5/profiles/<:ID>","description":"Use this API to update User Details.
You can use ExternalID or UID or email as :ID value.
\nNote: Email has to be url encoded.
For eg: hansolo@edcast.com -> encoded value: hansolo@edcast.com. (i.e @ -> @****, . ->.)
\n
\nINFO:
Added new profile field language
\nlanguage is a string param; possible values: EN, en, English, english and other available languages in Edcast system
\nRequest Param Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \nemail | \nString | \nEmail of the user | \nYes | \n\"han@test.com\" | \n
\n\n| 2 | \nfirst_name | \nString | \nFirst Name of the user | \nYes | \n\"Han\" | \n
\n\n| 3 | \nlast_name | \nString | \nLast Name of the user | \nYes | \n\"Solo\" | \n
\n\n| 4 | \nstatus | \nString | \nStatus (active or suspended) of the user | \nNo | \n\"active\" | \n
\n\n| 5 | \nlanguage | \nString | \nLanguage of the user | \nNo | \n\"en\" | \n
\n\n| 6 | \nroles | \nArray | \nRole names for the user, default member | \nNo | \n[member] | \n
\n\n| 7 | \navatar | \nString | \nAvatar image (aka profile image), supports image url | \nNo | \n-- | \n
\n\n| 8 | \njob_title | \nString | \nJob Role of the Users | \nNo | \n-- | \n
\n\n| 9 | \nwork_country | \nString | \nWork country of the user | \nNo | \n-- | \n
\n\n| 10 | \nsend_email_notification | \nBoolean | \nBoolean value to send Welcome email to new Users true | \nNo | \nfalse | \n
\n\n| 11 | \ncustom_field1_abbr | \nString | \nCustom field of the org | \nNo | \n-- | \n
\n\n| 12 | \ncustom_field2_abbr | \nString | \nCustom field of the org | \nNo | \n-- | \n
\n\n| 13 | \nadditional_fields | \nHash | \nCollects additional info such as dob, gender, billing address for user | \nNo | \n-- | \n
\n\n| 13.1 | \ndob | \nString | \nDate of birth of user. Format: '%m-%d-%Y' | \nNo | \n\"11-24-1992\" | \n
\n\n| 13.2 | \ngender | \nInteger | \nGender of user Values for male: 0, female: 1, other: 2 | \nNo | \n1 | \n
\n\n| 13.3 | \nmobile_number | \nString | \nMobile number of user | \nNo | \n\"9999999999\" | \n
\n\n| 13.4 | \noccupation_id | \nInteger | \nOccupation Id of user | \nNo | \n1 | \n
\n\n| 13.5 | \ndomain | \nInteger | \nDomain of user. values for 'Non IT Field': 0,'IT Field': 1,'Unemployed with job offer': 2,'Unemployed without job offer': 3 | \nNo | \n1 | \n
\n\n| 13.6 | \naddress_line1 | \nString | \nLine 1 of billing address | \nNo | \n\"1102, Everst world\" | \n
\n\n| 13.7 | \naddress_line2 | \nString | \nLine 2 of billing address | \nNo | \n\"Mumbai\" | \n
\n\n| 13.8 | \ncity | \nString | \nCity of residence | \nNo | \n\"Mumbai\" | \n
\n\n| 13.9 | \nstate | \nString | \nState of residence | \nNo | \n\"Maharashtra\" | \n
\n\n| 13.10 | \nzip | \nString | \nPostal code | \nNo | \n400607 | \n
\n\n| 13.11 | \ncountry | \nString | \nCountry of residence | \nNo | \n\"India\" | \n
\n\n| 13.12 | \nuser_gstin_number | \nString | \nGST code of user | \nNo | \n\"16BBBBB1111B1ZE\" | \n
\n\n| 14 | \njob_external_id | \nString | \nExternal Id of Job Role | \nNo | \n | \n
\n\n| 15 | \norganization_unit_external_ids | \nArray | \nExternal Ids of organization units | \nNo | \n[\"DIV1001\"] | \n
\n\n| 16 | \nwork_location_external_id | \nString | \nExternal Id of work location | \nNo | \n\"Loc-US\" | \n
\n\n
\n
Note: Any other key present in user's hash will be considered as custom_field
\nResponse Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nexternalId | \nString | \nExternal Id of the user. | \n
\n\n| 2 | \nuid | \nString | \nUid of the user. | \n
\n\n| 3 | \nuserId | \nInteger | \nId of the user in edcast. | \n
\n\n| 4 | \nemail | \nString | \nemail of the user. | \n
\n\n| 5 | \nfirstName | \nString | \nFirst name of the user. | \n
\n\n| 6 | \nlastName | \nString | \nLast name of the user. | \n
\n\n| 7 | \nstatus | \nString | \nStatus of the user - active, suspended. | \n
\n\n| 8 | \nroles | \nArray | \nRoles assigned to the user. | \n
\n\n| 9 | \nlanguage | \nString | \nlanguage of the user. | \n
\n\n| 10 | \navatar | \nHash | \nHash of user images in different sizes. | \n
\n\n| 11 | \njobTitle | \nString | \nJob title of the user. | \n
\n\n| 12 | \nworkCountry | \nString | \nWork country of the user. | \n
\n\n| 13 | \nlearningTopics | \nArray | \nArray of learning topics. | \n
\n\n| 14 | \nlastSignInAt | \nDatetime | \nDate time of the user's last sign in at | \n
\n\n
\n
\nINFO:
Added new profile field anonymize
\nanonymize is a string param; possible values: true, false
\n
\n","urlObject":{"protocol":"https","path":["api","developer","v5","profiles","<:ID>"],"host":[""],"query":[],"variable":[]}},"response":[{"id":"1d064f20-ff1e-4b57-8127-4be55e35cb78","name":"Update User Record by ID","originalRequest":{"method":"PUT","header":[{"key":"X-API-KEY","value":"7241ccbb0add371cd4b04a941e5714f3"},{"key":"X-ACCESS-TOKEN","value":"eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjE2MDU4OCwiZW1haWwiOiJjc2hlc2hhbkBjc29kLmNvbSIsInRpbWVzdGFtcCI6IjIwMjQtMDUtMDJUMTA6MjQ6MDguNDM1KzAwOjAwIiwiZXhwIjoxNzE0Njg4NjQ4fQ.FUj4TSNaMbUOcO2h9zmMCO3BxxZPYfJjBUl35sPmBYU"},{"key":"Content-Type","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"profile\": {\n \"email\": \"hansolo@edcast.com\",\n \"bio\" : \"new text of bio\",\n \"employee_type\" : \"part time\",\n \"manager_name\": \"Chewbacca 2.0\",\n \"manager_external_id\": \"35\",\n \"language\": \"French\",\n \"roles\": [\"curator\"],\n \"anonymize\": \"true\",\n \"job_title\": \"saler\",\n \"avatar\": \"https://www.gravatar.com/avatar/205e460b479e2e5b48aec07710c08d50?s=200&r=pg&d=404\",\n \"organization_unit_external_ids\":[\"12012\"],\n \"work_location_external_id\":\"101011\"\n }\n}"},"url":"https://uswest.edcastqa.com/api/developer/v5/profiles/cbc600e7-629d-4885-8b99-940b48496ca8"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Type","value":"application/json; charset=utf-8"},{"key":"Transfer-Encoding","value":"chunked"},{"key":"Connection","value":"keep-alive"},{"key":"Date","value":"Thu, 02 May 2024 11:03:11 GMT"},{"key":"X-UA-Compatible","value":"IE=edge"},{"key":"X-XSS-Protection","value":"1; mode=block"},{"key":"X-Content-Type-Options","value":"nosniff"},{"key":"X-Frame-Options","value":"SAMEORIGIN"},{"key":"Cache-Control","value":"no-store"},{"key":"Pragma","value":"no-cache"},{"key":"Expires","value":"Fri, 01 Jan 1990 00:00:00 GMT"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains; preload"},{"key":"Access-Control-Allow-Origin","value":"uswest.edcastqa.com"},{"key":"Vary","value":"Accept, Accept-Encoding, Origin"},{"key":"Content-Encoding","value":"gzip"},{"key":"X-Request-Id","value":"6d6ba502-5c09-48a4-bc8e-98b6b6a5db17"},{"key":"X-Runtime","value":"2.056557"},{"key":"Referrer-Policy","value":"strict-origin-when-cross-origin"},{"key":"Expect-CT","value":"enforce; max-age=3600"},{"key":"X-Cache","value":"Miss from cloudfront"},{"key":"Via","value":"1.1 765ade8c6b70e0e7c0b0572f4e039b98.cloudfront.net (CloudFront)"},{"key":"X-Amz-Cf-Pop","value":"IAD55-P3"},{"key":"X-Amz-Cf-Id","value":"mbKRTPveJnJw6r7DygiD_MZVAIuUD9p3oItWmxTRSzYjRWcPkkik4A=="}],"cookie":[],"responseTime":null,"body":"{\n \"externalId\": \"cbc600e7-629d-4885-8b99-940b48496ca8\",\n \"uid\": \"cbc600e7-629d-4885-8b99-940b48496ca8\",\n \"userId\": 995287,\n \"email\": \"hansolo@edcast.com\",\n \"firstName\": \"Han\",\n \"lastName\": \"Solo\",\n \"status\": \"active\",\n \"roles\": [\n \"curator\"\n ],\n \"language\": \"fr\",\n \"avatar\": {\n \"tiny\": null,\n \"small\": null,\n \"medium\": null,\n \"large\": null\n },\n \"jobTitle\": \"saler\",\n \"workCountry\": null,\n \"learningTopics\": [],\n \"lastSignInAt\": null,\n \"createdAt\": \"2023-01-24T06:28:07.000Z\",\n \"circleId\": null,\n \"terminationDate\": null,\n \"organizationUnit\": \"Organization units added. Invalid organization unit external ids :12012,\",\n \"message\": [\n \"bio key is missing in custom fields\",\n \"employee_type key is missing in custom fields\",\n \"manager_name key is missing in custom fields\",\n \"manager_external_id key is missing in custom fields\",\n \"anonymize key is missing in custom fields\"\n ]\n}"}],"_postman_id":"bfb232f9-fb38-4017-9eed-4a03cac2c130"},{"name":"Get list of users","id":"33a99b37-bb26-45c9-9f3c-1c9de2d46b7c","request":{"auth":{"type":"bearer","bearer":{},"isInherited":false},"method":"GET","header":[{"key":"X-API-KEY","value":""},{"key":"X-ACCESS-TOKEN","value":""}],"body":{"mode":"formdata","formdata":[]},"url":"https:///api/developer/v5/profiles","description":"Get a list of users for an organization
\nAlso you can set such params as:
\nlimit - count of users in response, 10 by default
\noffset - from what user send user list in response, 0 by default
\nResponse Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nexternalId | \nString | \nExternal Id of the user. | \n
\n\n| 2 | \nuid | \nString | \nUid of the user. | \n
\n\n| 3 | \nuserId | \nInteger | \nId of the user in edcast. | \n
\n\n| 4 | \nemail | \nString | \nemail of the user. | \n
\n\n| 5 | \nfirstName | \nString | \nFirst name of the user. | \n
\n\n| 6 | \nlastName | \nString | \nLast name of the user. | \n
\n\n| 7 | \nstatus | \nString | \nStatus of the user - active, suspended. | \n
\n\n| 8 | \nroles | \nArray | \nRoles assigned to the user. | \n
\n\n| 9 | \nlanguage | \nString | \nlanguage of the user. | \n
\n\n| 10 | \navatar | \nHash | \nHash of user images in different sizes. | \n
\n\n| 11 | \njobTitle | \nString | \nJob title of the user. | \n
\n\n| 12 | \nworkCountry | \nString | \nWork country of the user. | \n
\n\n| 13 | \nlearningTopics | \nArray | \nArray of learning topics. | \n
\n\n| 14 | \nlastSignInAt | \nDatetime | \nDate time of the user's last sign in at | \n
\n\n
\n
sort_by - name of sorting field, created_at by default
\norder_label - ASC or DESC order data, ASC by default
\nfrom_date - Filter to get profiles updated after a given date, format: DD/MM/YYYY
\ntill_date - Filter to get profiles updated before a given date, format: DD/MM/YYYY
\n","urlObject":{"protocol":"https","path":["api","developer","v5","profiles"],"host":[""],"query":[],"variable":[]}},"response":[{"id":"1f2259df-c079-4e64-8cb8-f4884cea8a71","name":"error get list of Users","originalRequest":{"method":"GET","header":[{"key":"X-API-KEY","value":"","warning":""},{"key":"X-ACCESS-TOKEN","value":"","warning":""},{"key":"","value":"","warning":"","disabled":true}],"body":{"mode":"formdata","formdata":[]},"url":"https:///api/developer/v5/profiles"},"status":"Unauthorized","code":401,"_postman_previewlanguage":"","header":[],"cookie":[],"responseTime":null,"body":"message: \"Request is invalid\""},{"id":"4909c86b-cd86-48c2-a591-3131bc50cd50","name":"Get list of Users","originalRequest":{"method":"GET","header":[{"key":"X-API-KEY","value":"","warning":""},{"key":"X-ACCESS-TOKEN","value":"","warning":""}],"url":{"raw":"https://BASE-ORG-URL/api/developer/v5/profiles?limit=10&offset=0","protocol":"https","host":["BASE-ORG-URL"],"path":["api","developer","v5","profiles"],"query":[{"key":"limit","value":"10"},{"key":"offset","value":"0"}]}},"status":"OK","code":200,"_postman_previewlanguage":"","header":[],"cookie":[],"responseTime":null,"body":"{\n \"profiles\": [\n {\n \"externalId\": \"641be2a3-0811-484a-aaa8-5adccd8f4d02\",\n \"uid\": \"641be2a3-0811-484a-aaa8-5adccd8f4d02\",\n \"userId\": 75008,\n \"email\": \"edcastmobile+30@gmail.com\",\n \"firstName\": \"Edcast\",\n \"lastName\": \"Mobile\",\n \"status\": \"active\",\n \"roles\": [\n \"learner\",\n \"curator\",\n \"collaborator\",\n \"MAIN member\"\n ],\n \"language\": \"en\",\n \"avatar\": {\n \"tiny\": \"https://dp598loym07sk.cloudfront.net/assets/new-anonymous-user-tiny.jpeg\",\n \"small\": \"https://dp598loym07sk.cloudfront.net/assets/new-anonymous-user-small.jpeg\",\n \"medium\": \"https://dp598loym07sk.cloudfront.net/assets/new-anonymous-user-medium.jpeg\",\n \"large\": \"https://dp598loym07sk.cloudfront.net/assets/new-anonymous-user-large.jpeg\"\n },\n \"jobTitle\": null,\n \"workCountry\": null,\n \"learningTopics\": [],\n \"lastSignInAt\": \"2016-10-08T21:32:11.000Z\"\n }\n ],\n \n},\n\t\t{\n\t\t\t...\n\t\t},\n\t\t...\n\t]\n\n \"total\": 35074\n}"}],"_postman_id":"33a99b37-bb26-45c9-9f3c-1c9de2d46b7c"},{"name":"Get User by ID","id":"e273c9de-3025-4652-a6f3-f24eb08b36b3","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"bearer","bearer":{},"isInherited":false},"method":"GET","header":[{"key":"X-API-KEY","value":""},{"key":"X-ACCESS-TOKEN","value":""}],"url":"https:///api/developer/v5/profiles/<:ID>","description":"Get user details.
\nYou can use ExternalID or UID or email as :ID value.
\nNote: Email has to be url encoded.\nFor eg: hansolo@edcast.com -> encoded value: hansolo%40edcast%2Ecom. (i.e @ -> %40, . ->%2E)
\nResponse Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nexternalId | \nString | \nExternal Id of the user. | \n
\n\n| 2 | \nuid | \nString | \nUid of the user. | \n
\n\n| 3 | \nuserId | \nInteger | \nId of the user in edcast. | \n
\n\n| 4 | \nemail | \nString | \nemail of the user. | \n
\n\n| 5 | \nfirstName | \nString | \nFirst name of the user. | \n
\n\n| 6 | \nlastName | \nString | \nLast name of the user. | \n
\n\n| 7 | \nstatus | \nString | \nStatus of the user - active, suspended. | \n
\n\n| 8 | \nroles | \nArray | \nRoles assigned to the user. | \n
\n\n| 9 | \nlanguage | \nString | \nlanguage of the user. | \n
\n\n| 10 | \navatar | \nHash | \nHash of user images in different sizes. | \n
\n\n| 11 | \njobTitle | \nString | \nJob title of the user. | \n
\n\n| 12 | \nworkCountry | \nString | \nWork country of the user. | \n
\n\n| 13 | \nlearningTopics | \nArray | \nArray of learning topics. | \n
\n\n| 14 | \nlastSignInAt | \nDatetime | \nDate time of the user's last sign in at | \n
\n\n
\n
Get Recommendation / Todays Learning content for a user
\nAlso you can set such params as:
\nemail - Recommendation for given user with email
\nexternal_id - ExternalId of the user.
\nNote - Either email or external_id should be present
\n","auth":{"type":"oauth2","oauth2":{},"isInherited":true,"source":{"_postman_id":"b5ac2864-157f-4d67-8f4a-68d9dafac31b","id":"b5ac2864-157f-4d67-8f4a-68d9dafac31b","name":"User Management","type":"folder"}},"urlObject":{"protocol":"https","path":["api","developer","v5","users","todays_insights"],"host":[""],"query":[{"description":{"content":"Recomendation for user with email test@example.com
\n","type":"text/plain"},"key":"email","value":"test@example.com"}],"variable":[]}},"response":[{"id":"f1417e87-3466-4b04-b01f-25b73adec57e","name":"Default","originalRequest":{"method":"GET","header":[{"key":"X-API-KEY","value":"","type":"text"},{"key":"X-ACCESS-TOKEN","value":"","type":"text"}],"url":{"raw":"https://BASE-ORG-URL/api/developer/v5/users/todays_insights?email=test@example.com","protocol":"https","host":["BASE-ORG-URL"],"path":["api","developer","v5","users","todays_insights"],"query":[{"key":"email","value":"test@example.com","description":"Recommendation for user with email test@example.com"},{"key":"external_id","value":"test-external-id-of-user","description":"ExternalId of user (either email or external_id should be present)","disabled":true}]}},"_postman_previewlanguage":null,"header":null,"cookie":[],"responseTime":null,"body":"{\n \" {\n \"author\": null,\n \"cardMetadatum\": null,\n \"cardSubtype\": \"link\",\n \"cardType\": \"media\",\n \"channels\": [],\n \"createdAt\": \"2018-05-30T21:15:12.000Z\",\n \"duration\": 480,\n \"externalId\": null,\n \"id\": \"ECL-VwvAqmRDyol98eoEDJ/SCw==\",\n \"isPaid\": false,\n \"isPublic\": true,\n \"message\": \"Card message\",\n \"prices\": [],\n \"provider\": \"Sociative\",\n \"readableCardType\": \"Article\",\n \"resource\": {\n \"id\": null,\n \"imageUrl\": \"https://www.jeffbullas.com/wp-content/uploads/2017/06/The-Top-5-Project-Management-Tools-to-Accelerate-Your-Goals.jpg\",\n \"title\": \"The Top 5 Project Management Tools to Accelerate Your Goals\",\n \"description\": \"description of the resource\",\n \"siteName\": null,\n \"type\": null,\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"slug\": \"ECL-VwvAqmRDyol98eoEDJ/SCw==\",\n \"tags\": [],\n \"teams\": [],\n \"language\": \"en\",\n \"shareUrl\": \"https://edqa.cmnetwork.co/insights/ECL-VwvAqmRDyol98eoEDJ/SCw==\",\n \"additionalMetadata\": {\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"contentLanguages\": [],\n \"publishedAt\": \"2018-05-30T21:15:12.000Z\",\n \"filestack\": []\n },\n ....\n ]\n}"}],"_postman_id":"995e64b6-17ce-4fb5-9ad5-d1e0db11e7c6"},{"name":"Add learning goals to the user","id":"284d6c85-d607-4e42-aeb9-0b2286d7c734","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"method":"POST","header":[{"key":"X-API-KEY","type":"text","value":""},{"key":"X-ACCESS-TOKEN","type":"text","value":""},{"key":"Content-Type","name":"Content-Type","type":"text","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"external_id\":\"a57c51d8-XXXXXXXXXXX\",\n \"topic_label\":\"Accounting Software\"\n}"},"url":"https:///api/developer/v5/profiles/add_learning_topic","description":"Param Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \nexternal_id | \nString | \nExternalId of the user | \nYes | \n\"a57c51d8-XXXXXXXXXX\" | \n
\n\n| 2 | \nemail | \nString | \nEmail of the user | \nNo | \n\"test@edcast.com\" | \n
\n\n| 3 | \ntopic_label | \nString | \nTopic label | \nYes | \n\"Accounts\" | \n
\n\n| 4 | \ntopic_id | \nString | \nId of the topic | \nNo | \n\"4561360XXXXXX\" | \n
\n\n
\n
Note - Either email or external_id can be used for user identification.
\n","auth":{"type":"oauth2","oauth2":{},"isInherited":true,"source":{"_postman_id":"b5ac2864-157f-4d67-8f4a-68d9dafac31b","id":"b5ac2864-157f-4d67-8f4a-68d9dafac31b","name":"User Management","type":"folder"}},"urlObject":{"protocol":"https","path":["api","developer","v5","profiles","add_learning_topic"],"host":[""],"query":[],"variable":[]}},"response":[{"id":"fe255e1b-bfcd-4ca6-8488-0c9d524cd40f","name":"Add learning goals to the user","originalRequest":{"method":"POST","header":[{"key":"X-API-KEY","type":"text","value":""},{"key":"X-ACCESS-TOKEN","type":"text","value":""},{"key":"Content-Type","name":"Content-Type","type":"text","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"external_id\":\"a57c51d8-XXXXXXXXXXX\",\n \"topic_label\":\"Accounting Software\"\n}"},"url":"https:///api/developer/v5/profiles/add_learning_topic"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Type","value":"application/json; charset=utf-8"},{"key":"Content-Length","value":"90"},{"key":"Connection","value":"keep-alive"},{"key":"Cache-Control","value":"no-cache, no-store, max-age=0, must-revalidate"},{"key":"Content-Encoding","value":"gzip"},{"key":"Date","value":"Wed, 07 Aug 2019 14:12:34 GMT"},{"key":"Expires","value":"Fri, 01 Jan 1990 00:00:00 GMT"},{"key":"Pragma","value":"no-cache"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains"},{"key":"Vary","value":"Accept-Encoding, Origin"},{"key":"X-Content-Type-Options","value":"nosniff"},{"key":"X-Frame-Options","value":"SAMEORIGIN"},{"key":"X-Request-Id","value":"5776a6a6-8ca9-462f-b738-14a813c4168d"},{"key":"X-Runtime","value":"18.227175"},{"key":"X-UA-Compatible","value":"IE=edge"},{"key":"X-Cache","value":"Miss from cloudfront"},{"key":"Via","value":"1.1 1bd5f00ea27576d8ebb7218eb6f7c678.cloudfront.net (CloudFront)"},{"key":"X-Amz-Cf-Pop","value":"HYD50-C3"},{"key":"X-Amz-Cf-Id","value":"TafoPl0Qy-hfFTTOZSJs1HV9b80981iWHkAOaeQx14lhsKGMvy06cA=="}],"cookie":[],"responseTime":null,"body":"{\n \"topic_id\": \"456136XXXXXXX\",\n \"topic_label\": \"Accounting Software\"\n}"}],"_postman_id":"284d6c85-d607-4e42-aeb9-0b2286d7c734"},{"name":"Remove learning goals of the user","id":"c45ac8c2-1cfa-4bff-9dff-40a20b3e83e6","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"method":"PUT","header":[{"key":"X-API-KEY","type":"text","value":""},{"key":"X-ACCESS-TOKEN","type":"text","value":""},{"key":"Content-Type","name":"Content-Type","type":"text","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"external_id\":\"a57c51d8-3e5b-4586-9391-05f250853588\",\n \"topic_id\":\"4561360797908199458\"\n}"},"url":"https:///api/developer/v5/profiles/remove_learning_topic","description":"Param Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \nexternal_id | \nString | \nExternalId of the user | \nYes | \n\"a57c51d8-XXXXXXXXXX\" | \n
\n\n| 2 | \nemail | \nString | \nEmail of the user | \nNo | \ntest@example.com | \n
\n\n| 3 | \ntopic_id | \nString | \nId of the topic | \nNo | \n\"4561360XXXXXX\" | \n
\n\n
\n
Note - Either email or external_id can be used for user identification.
\n","auth":{"type":"oauth2","oauth2":{},"isInherited":true,"source":{"_postman_id":"b5ac2864-157f-4d67-8f4a-68d9dafac31b","id":"b5ac2864-157f-4d67-8f4a-68d9dafac31b","name":"User Management","type":"folder"}},"urlObject":{"protocol":"https","path":["api","developer","v5","profiles","remove_learning_topic"],"host":[""],"query":[],"variable":[]}},"response":[{"id":"04b9d32b-bdc5-4ce7-8a7d-061f436435c6","name":"Remove learning goals of the user","originalRequest":{"method":"PUT","header":[{"key":"X-API-KEY","type":"text","value":""},{"key":"X-ACCESS-TOKEN","type":"text","value":""},{"key":"Content-Type","name":"Content-Type","type":"text","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"external_id\":\"a57c51d8-XXXXXXX\",\n \"topic_id\":\"456136XXXXXXXXX\"\n}"},"url":"https:///api/developer/v5/profiles/remove_learning_topic"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Type","value":"application/json; charset=utf-8"},{"key":"Content-Length","value":"59"},{"key":"Connection","value":"keep-alive"},{"key":"Cache-Control","value":"no-cache, no-store, max-age=0, must-revalidate"},{"key":"Content-Encoding","value":"gzip"},{"key":"Date","value":"Wed, 07 Aug 2019 14:26:27 GMT"},{"key":"Expires","value":"Fri, 01 Jan 1990 00:00:00 GMT"},{"key":"Pragma","value":"no-cache"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains"},{"key":"Vary","value":"Accept-Encoding, Origin"},{"key":"X-Content-Type-Options","value":"nosniff"},{"key":"X-Frame-Options","value":"SAMEORIGIN"},{"key":"X-Request-Id","value":"15ce6ba7-b212-428e-a4ad-e0a9bea24e4b"},{"key":"X-Runtime","value":"0.189732"},{"key":"X-UA-Compatible","value":"IE=edge"},{"key":"X-Cache","value":"Miss from cloudfront"},{"key":"Via","value":"1.1 1bd5f00ea27576d8ebb7218eb6f7c678.cloudfront.net (CloudFront)"},{"key":"X-Amz-Cf-Pop","value":"HYD50-C3"},{"key":"X-Amz-Cf-Id","value":"F1h8MbImlNvQyOKPBu-ZaFNcxNqurw9WdDtRsnH54B0VOAQVK69sjw=="}],"cookie":[],"responseTime":null,"body":"{\n \"message\": \"Removed successfully\"\n}"},{"id":"af44a0bd-0322-4ea2-92df-0063e29b00dd","name":"Remove learning goals of the user","originalRequest":{"method":"PUT","header":[{"key":"X-API-KEY","type":"text","value":""},{"key":"X-ACCESS-TOKEN","type":"text","value":""},{"key":"Content-Type","name":"Content-Type","type":"text","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"external_id\":\"a57c51d8-3e5b-4586-9391-05f250853588\",\n \"topic_id\":\"4561360797908199458\"\n}"},"url":"https:///api/developer/v5/profiles/remove_learning_topic"},"_postman_previewlanguage":null,"header":null,"cookie":[],"responseTime":null,"body":null}],"_postman_id":"c45ac8c2-1cfa-4bff-9dff-40a20b3e83e6"},{"name":"Update User status","id":"b0b756b4-192f-4861-aebe-d8c4028ad88c","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"noauth","isInherited":false},"method":"PUT","header":[{"key":"X-API-KEY","value":""},{"key":"X-ACCESS-TOKEN","value":""},{"key":"Content-Type","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"profile\": {\n \"status\": \"suspended\"\n }\n}"},"url":"https:///api/developer/v5/profiles/<:ID>","description":"You can use ExternalID or UID or email as :ID value.
\nNote: Email has to be url encoded.\nFor eg: hansolo@edcast.com -> encoded value: hansolo%40edcast%2Ecom. (i.e @ -> %40, . ->%2E)
\nINFO:\nprofile field status
\nstatus is a string param; possible values: active,inactive or suspended
\n","urlObject":{"protocol":"https","path":["api","developer","v5","profiles","<:ID>"],"host":[""],"query":[],"variable":[]}},"response":[{"id":"239305ce-dbd2-445f-b6bb-8cc8dbc7e494","name":"Default","originalRequest":{"method":"PUT","header":[{"key":"X-API-KEY","value":"","warning":""},{"key":"X-ACCESS-TOKEN","value":"","warning":""},{"key":"Content-Type","value":"application/json","warning":""}],"body":{"mode":"raw","raw":"{\n\t\"profile\": {\n\t\t\"bio\" : \"new text of bio\",\n\t\t\"employee_type\" : \"part time\",\n\t\t\"manager_name\": \"Chewbacca 2.0\",\n\t\t\"manager_external_id\": \"35\",\n\t\t\"language\": \"French\",\n\t\t\"role_names\": [\"curator\"],\n\t\t\"anonymize\": \"true\"\n\t}\n}"},"url":"https://BASE-ORG-URL/api/developer/v5/profiles/12djfj453fjdfkn"},"code":200,"_postman_previewlanguage":"json","header":null,"cookie":[],"responseTime":null,"body":"{\n \"profile\": {\n\t \"externalID\" : 828,\n\t \"handle\" : \"@hansolo\",\n\t \"firstName\" : \"Han\",\n\t \"lastName\" : \"Solo\",\n\t \"bio\" : \"new text of bio\",\n\t \"name\" : \"Han Solo\",\n\t \"employeeType\" : \"part time\",\n\t \"email\" : \"hansolo@edcast.com\",\n\t \"department\": \"sale\",\n\t \"location\": \"Washington\",\n\t \"language\": \"fr\",\n\t \"status\": \"Active\",\n\t \"edcastUID\": \"12djfj453fjdfkn\",\n\t \"managerName\": \"Chewbacca 2.0\",\n\t \"managerExternalID\": \"35\",\n\t \"managerEdcastID\": \"102\",\n\t \"jobID\": \"23\",\n\t \"jobTitle\": \"saler\",\n\t \"anonymize\": \"true\",\n\t \"roles\": [\"curator\"]\n }\n}"},{"id":"687a8758-a0ad-47f8-9b48-30105e10deb9","name":"Suspend a user","originalRequest":{"method":"PUT","header":[{"key":"X-API-KEY","value":"7fa93df5599fde9926265564705707cb"},{"key":"X-ACCESS-TOKEN","value":"eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOiJxYSIsInVzZXJfaWQiOjQzOCwiZW1haWwiOiJzYWdhckBlZGNhc3QuY29tIiwidGltZXN0YW1wIjoiMjAxOS0wOC0yMVQwOTowODoxMS4zNzgrMDA6MDAiLCJleHAiOjE1NjY0MjE2OTF9.7fAx8YjlyIqZxtME1nCEoxwZqeDcU2KSDsZzmhWSiks"},{"key":"Content-Type","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"profile\": {\n \"status\": \"suspended\"\n }\n}"},"url":"https:///api/developer/v5/profiles/<:ID>"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Type","value":"application/json; charset=utf-8"},{"key":"Content-Length","value":"319"},{"key":"Connection","value":"keep-alive"},{"key":"Cache-Control","value":"no-cache, no-store, max-age=0, must-revalidate"},{"key":"Content-Encoding","value":"gzip"},{"key":"Date","value":"Wed, 21 Aug 2019 09:23:57 GMT"},{"key":"Expires","value":"Fri, 01 Jan 1990 00:00:00 GMT"},{"key":"Pragma","value":"no-cache"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains"},{"key":"Vary","value":"Accept-Encoding, Origin"},{"key":"X-Content-Type-Options","value":"nosniff"},{"key":"X-Frame-Options","value":"SAMEORIGIN"},{"key":"X-Request-Id","value":"55049489-802e-489a-9736-1e9e7567cad5"},{"key":"X-Runtime","value":"0.245822"},{"key":"X-UA-Compatible","value":"IE=edge"},{"key":"X-Cache","value":"Miss from cloudfront"},{"key":"Via","value":"1.1 017d342814c21e57a8ef05ae15be24f5.cloudfront.net (CloudFront)"},{"key":"X-Amz-Cf-Pop","value":"BLR50-C1"},{"key":"X-Amz-Cf-Id","value":"qzmjdsKvVPAC9mAZ6xWaozDfT3iojAi0MU1fV999kWr0MgknqYeKRg=="}],"cookie":[],"responseTime":null,"body":"{\n \"externalId\": \"0b7cbda7-c1cb-428b-9bd1-8244bf2b7c15\",\n \"uid\": \"0b7cbda7-c1cb-428b-9bd1-8244bf2b7c15\",\n \"userId\": 481,\n \"email\": \"hils1930@gustr.com\",\n \"firstName\": \"new n\",\n \"lastName\": \"new\",\n \"status\": \"suspended\",\n \"roles\": [\n \"learner\",\n \"curator\",\n \"collaborator\",\n \"trusted_collaborator\",\n \"member\"\n ],\n \"language\": \"en\",\n \"avatar\": {\n \"tiny\": \"https://dp598loym07sk.cloudfront.net/assets/new-anonymous-user-tiny.jpeg\",\n \"small\": \"https://dp598loym07sk.cloudfront.net/assets/new-anonymous-user-small.jpeg\",\n \"medium\": \"https://dp598loym07sk.cloudfront.net/assets/new-anonymous-user-medium.jpeg\",\n \"large\": \"https://dp598loym07sk.cloudfront.net/assets/new-anonymous-user-large.jpeg\"\n },\n \"jobTitle\": null,\n \"learningTopics\": []\n}"}],"_postman_id":"b0b756b4-192f-4861-aebe-d8c4028ad88c"},{"name":"Get user teams.","id":"ebf6bb2d-b2c1-41c8-b815-2e4061c135f0","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"noauth","isInherited":false},"method":"GET","header":[{"key":"X-API-KEY","value":"","type":"text"},{"key":"X-ACCESS-TOKEN","value":"","type":"text"},{"key":"Content-Type","value":"application/json","type":"text"}],"url":"https:///api/developer/v5/users/<:external_id>/teams","description":"You can use ExternalID or UID or email as :ID value.
\nNote: Email has to be url encoded.\nFor eg: hansolo@edcast.com -> encoded value: hansolo%40edcast%2Ecom. (i.e @ -> %40, . ->%2E)
\nParam Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \nexternal_id | \nString | \nExternalId of the user | \nYes | \ntest | \n
\n\n| 2 | \nfilter_type | \nString | \nFilter results.
Values Description
all:- will fetch private and public team in which the user is member
public: - will fetch all the public team in which user is a member
private:- will fetch all the private team in which user is a member
| \nNo | \nall | \n
\n\n| 3 | \nlimit | \nInteger | \nNumber of records to fetch. Default 10 | \nNo | \n4 | \n
\n\n| 4 | \noffset | \nInteger | \nOffset for pagination. Default 0 | \nNo | \n5 | \n
\n\n| 5 | \nsort | \nString | \nSort results. Values: name, created_at . updated_at | \nNo | \ncreated_at | \n
\n\n| 6 | \norder | \nString | \nasc or desc. Default: asc | \nNo | \nasc | \n
\n\n
\n
This api will return all teams in which user is a Member , group admin , group leader.
\n","urlObject":{"protocol":"https","path":["api","developer","v5","users","<:external_id>","teams"],"host":[""],"query":[],"variable":[]}},"response":[{"id":"19558b1c-bdb4-4d8f-8826-bd32915f216d","name":"Get user teams.","originalRequest":{"method":"GET","header":[{"key":"X-API-KEY","value":"","type":"text"},{"key":"X-ACCESS-TOKEN","value":"","type":"text"},{"key":"Content-Type","value":"application/json","type":"text"}],"url":"https:///api/developer/v5/users/<:External_id>/teams"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Type","value":"application/json; charset=utf-8"},{"key":"Content-Length","value":"553"},{"key":"Connection","value":"keep-alive"},{"key":"Cache-Control","value":"no-cache, no-store"},{"key":"Content-Encoding","value":"gzip"},{"key":"Date","value":"Fri, 17 Apr 2020 08:49:10 GMT"},{"key":"ETag","value":"W/\"2f2821b97727ef18af676b6e098b2364\""},{"key":"Expires","value":"Fri, 01 Jan 1990 00:00:00 GMT"},{"key":"Pragma","value":"no-cache"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains; preload"},{"key":"Vary","value":"Accept-Encoding, Origin"},{"key":"X-Content-Type-Options","value":"nosniff"},{"key":"X-Frame-Options","value":"SAMEORIGIN"},{"key":"X-Request-Id","value":"fddba9c3-fff3-4b59-a6a9-d7708cfce64f"},{"key":"X-Runtime","value":"0.044392"},{"key":"X-UA-Compatible","value":"IE=edge"},{"key":"X-Cache","value":"Miss from cloudfront"},{"key":"Via","value":"1.1 2606bc577d5e46e4fb5a12cdb996e3f0.cloudfront.net (CloudFront)"},{"key":"X-Amz-Cf-Pop","value":"BOM51-C2"},{"key":"X-Amz-Cf-Id","value":"cEnHEmGDvnte68GFuiBqopxsnFVHpJaShWCoTyNhWVgPWpuX__Rx3Q=="}],"cookie":[],"responseTime":null,"body":"{\n \"teams\": [\n {\n \"id\": 58,\n \"name\": \"Everyone\",\n \"description\": \"This is a default group. It has all the members in your organization...\",\n \"is_private\": false,\n \"slug\": \"everyone\",\n \"is_everyone_team\": true,\n \"auto_assign_content\": false,\n \"image_urls\": {\n \"small\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"medium\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"large\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\"\n },\n \"only_admin_can_post\": true\n },\n {\n \"id\": 1143,\n \"name\": \"test11\",\n \"description\": \"tt\",\n \"is_private\": true,\n \"slug\": \"test11\",\n \"is_everyone_team\": false,\n \"auto_assign_content\": true,\n \"image_urls\": {\n \"small\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"medium\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"large\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\"\n },\n \"only_admin_can_post\": false\n },\n {\n \"id\": 20466,\n \"name\": \"75008\",\n \"description\": \"Group created using Workflow\",\n \"is_private\": true,\n \"slug\": \"75008\",\n \"is_everyone_team\": false,\n \"auto_assign_content\": true,\n \"image_urls\": {\n \"small\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"medium\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"large\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\"\n },\n \"only_admin_can_post\": false\n },\n {\n \"id\": 33087,\n \"name\": \"testsharecrgr\",\n \"description\": \"123\",\n \"is_private\": false,\n \"slug\": \"testsharecrgr\",\n \"is_everyone_team\": false,\n \"auto_assign_content\": false,\n \"image_urls\": {\n \"small\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"medium\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"large\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\"\n },\n \"only_admin_can_post\": false\n },\n {\n \"id\": 33088,\n \"name\": \"assigncrgr\",\n \"description\": \"123\",\n \"is_private\": false,\n \"slug\": \"assigncrgr\",\n \"is_everyone_team\": false,\n \"auto_assign_content\": false,\n \"image_urls\": {\n \"small\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"medium\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"large\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\"\n },\n \"only_admin_can_post\": false\n },\n {\n \"id\": 34398,\n \"name\": \"scas\",\n \"description\": \"asc\",\n \"is_private\": false,\n \"slug\": \"scas\",\n \"is_everyone_team\": false,\n \"auto_assign_content\": false,\n \"image_urls\": {\n \"small\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"medium\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"large\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\"\n },\n \"only_admin_can_post\": false\n },\n {\n \"id\": 34400,\n \"name\": \"Dynamic group\",\n \"description\": \"this is dynamic group for test\",\n \"is_private\": false,\n \"slug\": \"dynamic-group\",\n \"is_everyone_team\": false,\n \"auto_assign_content\": false,\n \"image_urls\": {\n \"small\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"medium\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"large\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\"\n },\n \"only_admin_can_post\": false\n },\n {\n \"id\": 34612,\n \"name\": \"hgfty\",\n \"description\": \"tytyt\",\n \"is_private\": false,\n \"slug\": \"hgfty\",\n \"is_everyone_team\": false,\n \"auto_assign_content\": false,\n \"image_urls\": {\n \"small\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"medium\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"large\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\"\n },\n \"only_admin_can_post\": false\n },\n {\n \"id\": 37047,\n \"name\": \"active - test Group\",\n \"description\": \"Group created using Workflow\",\n \"is_private\": true,\n \"slug\": \"active-test-group\",\n \"is_everyone_team\": false,\n \"auto_assign_content\": true,\n \"image_urls\": {\n \"small\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"medium\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"large\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\"\n },\n \"only_admin_can_post\": false\n },\n {\n \"id\": 37660,\n \"name\": \"blah 20\",\n \"description\": \"Group created using Workflow\",\n \"is_private\": true,\n \"slug\": \"blah-20\",\n \"is_everyone_team\": false,\n \"auto_assign_content\": true,\n \"image_urls\": {\n \"small\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"medium\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\",\n \"large\": \"//dp598loym07sk.cloudfront.net/assets/default_banner_image_min.jpg\"\n },\n \"only_admin_can_post\": false\n }\n ],\n \"total\": 11\n}"}],"_postman_id":"ebf6bb2d-b2c1-41c8-b815-2e4061c135f0"},{"name":"Get time spent of the user.","id":"f0f1951b-11e8-4d35-aa7f-773d50e519b3","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"noauth","isInherited":false},"method":"GET","header":[{"key":"X-API-KEY","value":"","type":"text"},{"key":"X-ACCESS-TOKEN","value":"","type":"text"},{"key":"Content-Type","value":"application/json","type":"text"}],"url":"https:///api/developer/v5/users/<:External_id>/metrics","description":"You can use ExternalID or UID or email as :ID value.
\nNote: Email has to be url encoded.\nFor eg: hansolo@edcast.com -> encoded value: hansolo%40edcast%2Ecom. (i.e @ -> %40, . ->%2E)
\nParam Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \nexternal_id | \nString | \nExternalId of the user | \nYes | \ntest | \n
\n\n| 2 | \nfrom_date | \nString | \nStarting date. Format: mm/dd/yyyy. Metrics are inclusive of this date | \nNo | \n | \n
\n\n| 3 | \nto_date | \nString | \nEnd date. Format: mm/dd/yyyy. Metrics are inclusive of this date | \nNo | \n | \n
\n\n
\n
This api will return time spent of the user in sec.
\n","urlObject":{"protocol":"https","path":["api","developer","v5","users","<:External_id>","metrics"],"host":[""],"query":[],"variable":[]}},"response":[{"id":"3bf661c2-d405-4f32-8032-57bd510bba78","name":"Get user time spent.","originalRequest":{"method":"GET","header":[{"key":"X-API-KEY","value":"","type":"text"},{"key":"X-ACCESS-TOKEN","value":"","type":"text"},{"key":"Content-Type","value":"application/json","type":"text"}],"url":"https:///api/developer/v5/users/<:external_id>/metrics"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Type","value":"application/json; charset=utf-8"},{"key":"Content-Length","value":"42"},{"key":"Connection","value":"keep-alive"},{"key":"Cache-Control","value":"no-cache, no-store"},{"key":"Content-Encoding","value":"gzip"},{"key":"Date","value":"Fri, 17 Apr 2020 09:01:21 GMT"},{"key":"ETag","value":"W/\"724ce28b1b6b548616e280a6b0af30dc\""},{"key":"Expires","value":"Fri, 01 Jan 1990 00:00:00 GMT"},{"key":"Pragma","value":"no-cache"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains; preload"},{"key":"Vary","value":"Accept-Encoding, Origin"},{"key":"X-Content-Type-Options","value":"nosniff"},{"key":"X-Frame-Options","value":"SAMEORIGIN"},{"key":"X-Request-Id","value":"9d5b47dc-4b2a-425f-9976-1bc9dc6b5b2c"},{"key":"X-Runtime","value":"0.033409"},{"key":"X-UA-Compatible","value":"IE=edge"},{"key":"X-Cache","value":"Miss from cloudfront"},{"key":"Via","value":"1.1 51a5ba5390c46a4a3602d19ffd3d17ad.cloudfront.net (CloudFront)"},{"key":"X-Amz-Cf-Pop","value":"BOM51-C2"},{"key":"X-Amz-Cf-Id","value":"RIAGwoqsDrpCb7l9TTDlIUBTF8kJsO8jJitYu3tSv3Y1EuXUmA5X1g=="}],"cookie":[],"responseTime":null,"body":"{\n \"time_spent\": 98250\n}"}],"_postman_id":"f0f1951b-11e8-4d35-aa7f-773d50e519b3"},{"name":"Create User.","id":"08e856d6-aa38-4804-9447-cb738f77f59a","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"method":"POST","header":[{"key":"X-API-KEY","type":"text","value":""},{"key":"X-ACCESS-TOKEN","type":"text","value":""},{"key":"Content-Type","name":"Content-Type","type":"text","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"user\": {\n \"external_id\": \"EP000000078\",\n \"email\": \"test_12@edcast.com \",\n \"first_name\": \"han\",\n \"last_name\": \"solo\",\n \"status\": \"active\",\n \"roles\": [\n \"member\",\n \"admin\"\n ],\n \"age\": \"28\",\n \"department_id\": \"451\",\n \"organization_unit_external_ids\":[\"Division100\",\"BusinessArea100\"]\n }\n}"},"url":"https:///api/developer/v5/users","description":"Request Param Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \nexternal_id | \nString | \nExternal_id of the user | \nYes | \n\"A00564E\" | \n
\n\n| 2 | \nemail | \nString | \nEmail of the user | \nYes | \n\"han@test.com\" | \n
\n\n| 3 | \nfirst_name | \nString | \nFirst Name of the user | \nYes | \n\"Han\" | \n
\n\n| 4 | \nlast_name | \nString | \nLast Name of the user | \nYes | \n\"Solo\" | \n
\n\n| 5 | \nstatus | \nString | \nStatus (active or suspended) of the user | \nNo | \n\"active\" | \n
\n\n| 6 | \nlanguage | \nString | \nLanguage of the user | \nNo | \n\"en\" | \n
\n\n| 7 | \nroles | \nArray | \nRole names for the user, default member | \nNo | \n[member] | \n
\n\n| 8 | \navatar | \nString | \nAvatar image (aka profile image), supports image url | \nNo | \n-- | \n
\n\n| 9 | \njob_title | \nString | \nJob Role of the Users | \nNo | \n-- | \n
\n\n| 10 | \nsend_email_notification | \nBoolean | \nBoolean value to send Welcome email to new Users true | \nNo | \nfalse | \n
\n\n| 11 | \ncustom_field1 | \nString | \nCustom field of the org | \nNo | \n-- | \n
\n\n| 12 | \ncustom_field2 | \nString | \nCustom field of the org | \nNo | \n-- | \n
\n\n| 13 | \nadditional_fields | \nHash | \nCollects additional info such as dob, gender, billing address for user | \nNo | \n | \n
\n\n| 13.1 | \ndob | \nString | \nDate of birth of user. Format: '%m-%d-%Y' | \nNo | \n\"11-24-1992\" | \n
\n\n| 13.2 | \ngender | \nInteger | \nGender of user Values for male: 0, female: 1, other: 2 | \nNo | \n0 | \n
\n\n| 13.3 | \nmobile_number | \nString | \nMobile number of user | \nNo | \n\"9999999999\" | \n
\n\n| 13.4 | \noccupation_id | \nInteger | \nOccupation Id of user | \nNo | \n2 | \n
\n\n| 13.5 | \ndomain | \nInteger | \nDomain of user. values for 'Non IT Field': 0,'IT Field': 1,'Unemployed with job offer': 2,'Unemployed without job offer': 3 | \nNo | \n0 | \n
\n\n| 13.6 | \naddress_line1 | \nString | \nLine 1 of billing address | \nNo | \n\"1102 everest world\" | \n
\n\n| 13.7 | \naddress_line2 | \nString | \nLine 2 of billing address | \nNo | \n\"Shivaji Nagar\" | \n
\n\n| 13.8 | \ncity | \nString | \nCity of residence | \nNo | \n\"Mumbai | \n
\n\n| 13.9 | \nstate | \nString | \nState of residence | \nNo | \n\"Maharashtra\" | \n
\n\n| 13.10 | \nzip | \nString | \nPostal code | \nNo | \n\"500607\" | \n
\n\n| 13.11 | \ncountry | \nString | \nCountry of residence | \nNo | \n\"India\" | \n
\n\n| 13.12 | \nuser_gstin_number | \nString | \nGST code of user | \nNo | \n\"06BBBBB1111B1ZE\" | \n
\n\n| 14 | \njob_external_id | \nString | \nExternal ID of Job role | \nNo | \n | \n
\n\n| 16 | \norganization_unit_external_ids | \nArray | \nExternal id's of organization unit that the user will be associated with | \nNo | \n[\"Division100\",\"BusinessArea100\"] | \n
\n\n
\n
Note: Any other key present in user's hash will be considered as custom_field
\nResponse Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nexternalId | \nString | \nExternal Id of the user. | \n
\n\n| 2 | \nuid | \nString | \nUid of the user. | \n
\n\n| 3 | \nuserId | \nInteger | \nId of the user in edcast. | \n
\n\n| 4 | \nemail | \nString | \nemail of the user. | \n
\n\n| 5 | \nfirstName | \nString | \nFirst name of the user. | \n
\n\n| 6 | \nlastName | \nString | \nLast name of the user. | \n
\n\n| 7 | \nstatus | \nString | \nStatus of the user - active, suspended. | \n
\n\n| 8 | \nroles | \nArray | \nRoles assigned to the user. | \n
\n\n| 9 | \nlanguage | \nString | \nlanguage of the user. | \n
\n\n| 10 | \navatar | \nHash | \nHash of user images in different sizes. | \n
\n\n| 11 | \njobTitle | \nString | \nJob title of the user. | \n
\n\n| 12 | \nworkCountry | \nString | \nWork country of the user. | \n
\n\n| 13 | \nlearningTopics | \nArray | \nArray of learning topics. | \n
\n\n| 14 | \nlastSignInAt | \nDatetime | \nDate time of the user's last sign in at | \n
\n\n
\n
This api will assign manager to the user
\nAtleast one param of user & manager is required
\nRequest Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nexternal_id | \nString | \nExternal Id of the user. | \n
\n\n| 2 | \nemail | \nString | \nEmail of the user. | \n
\n\n| 3 | \nmanager_external_id | \nString | \nExternal Id of the manager. | \n
\n\n| 4 | \nmanager_email | \nString | \nEmail of the manager. | \n
\n\n
\n
This api will unassign manager to the user
\nRequest Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nexternal_id | \nString | \nExternal Id of the user. | \n
\n\n| 2 | \nemail | \nString | \nEmail of the user. | \n
\n\n
\n
This API process wallet transaction and debits skill coins from the user's wallet.
\nRequest Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \ncard_id | \nString | \nExternal ID of the user. | \n
\n\n| 3 | \nprice | \nInteger | \nPrice for the card. | \n
\n\n
\n
Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nmessage | \nString | \nMessage to be displayed. | \n
\n\n| 3 | \ntransaction_details | \nhash | \nDetails of transaction status. | \n
\n\n
\n
This API will fetch the current user wallet balance details.
\n","auth":{"type":"oauth2","oauth2":{},"isInherited":true,"source":{"_postman_id":"b5ac2864-157f-4d67-8f4a-68d9dafac31b","id":"b5ac2864-157f-4d67-8f4a-68d9dafac31b","name":"User Management","type":"folder"}},"urlObject":{"protocol":"GET - https","path":["","api","developer","v5","users","wallets","wallet_balance"],"host":[""],"query":[],"variable":[]}},"response":[{"id":"dda67043-5f73-440c-b937-a1956aa35967","name":"User wallet balance","originalRequest":{"method":"GET","header":[{"key":"X-API-KEY","value":""},{"key":"X-ACCESS-TOKEN","value":""},{"key":"Content-Type","value":"application/json"},{"key":"","value":"","disabled":true}],"url":"GET - https:////api/developer/v5/users/wallets/wallet_balance"},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Type","value":"application/json; charset=utf-8"},{"key":"Transfer-Encoding","value":"chunked"},{"key":"Connection","value":"keep-alive"},{"key":"Date","value":"Mon, 08 Mar 2021 08:36:57 GMT"},{"key":"Server","value":"nginx"},{"key":"X-UA-Compatible","value":"IE=edge"},{"key":"X-Frame-Options","value":"SAMEORIGIN"},{"key":"X-Content-Type-Options","value":"nosniff"},{"key":"Cache-Control","value":"no-cache, no-store"},{"key":"Pragma","value":"no-cache"},{"key":"Expires","value":"Fri, 01 Jan 1990 00:00:00 GMT"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains; preload"},{"key":"Vary","value":"Accept-Encoding, Origin"},{"key":"Content-Encoding","value":"gzip"},{"key":"ETag","value":"W/\"4017febdfd31dc2a886f2ef1cb0c4497\""},{"key":"X-Request-Id","value":"c194c15b-0e73-48f1-a846-1c423a0f29e4"},{"key":"X-Runtime","value":"0.064941"},{"key":"X-Cache","value":"Miss from cloudfront"},{"key":"Via","value":"1.1 3827f36fc3dc677f720906b048257052.cloudfront.net (CloudFront)"},{"key":"X-Amz-Cf-Pop","value":"BOM52-C1"},{"key":"X-Amz-Cf-Id","value":"Au_ic7JmWpQUSsSHXZ83n_jbAumJdV_Dmb4s30umRdHi_ncn9h0r2Q=="}],"cookie":[],"responseTime":null,"body":"{\n \"balance\": 10400\n}"}],"_postman_id":"c0119aff-a991-43e8-96a2-cbb4628a825d"},{"name":"Add user to the circle","id":"caa2317d-08a7-4cf2-92e4-98522d439b59","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"noauth","isInherited":false},"method":"PUT","header":[{"key":"X-API-KEY","value":"","type":"text"},{"key":"X-ACCESS-TOKEN","value":"","type":"text"},{"key":"Content-Type","value":"application/json","type":"text"}],"body":{"mode":"raw","raw":"{\n \"id\":117,\n\t\"external_id\":\"623820fb-XXXX-XXXXX-552366bf02de\"\n}"},"url":"https:///api/developer/v5/circles/add_user","description":"Param Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \nid | \nInteger | \nId of the circle | \nyes | \n33 | \n
\n\n| 2 | \nexternal_id | \nInteger | \nexternal_id of user | \nyes | \n12345-qqwerty | \n
\n\n| 3 | \nemail | \nString | \nEmail of user | \nNo | \ntest@test.com | \n
\n\n
\n
Request Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \nRequired | \n
\n\n\n\n| 1 | \nemail | \nString | \nEmail of user for whom we need to create skill. | \nyes | \n
\n\n| 2 | \ncredential_details | \nHash | \n | \nyes | \n
\n\n| 2.1 | \ncredential_name | \nString | \nSkill name. (Should match the taxonomy topics for any given skills) | \nyes | \n
\n\n| 2.2 | \ndescription | \nString | \nDescription of the skill . Max limit 500 characters | \nno | \n
\n\n| 2.3 | \ncredential_type | \nString | \nskill. | \nyes | \n
\n\n| 2.4 | \ncredential_id | \nString | \nLimited to 50 chars and alphanumeric code allowing for special characters \"-\", \"/\", \".\", \"\\\", \" | \nno | \n
\n\n| 2.5 | \ncredential_url | \nString | \nValid URL. | \nno | \n
\n\n| 2.6 | \nexperience | \nHash | \nIn terms of years and month. | \nno | \n
\n\n| 2.6.1 | \nyears | \nInteger | \n | \n | \n
\n\n| 2.6.2 | \nmonths | \nInteger | \n | \n | \n
\n\n| 2.7 | \nskill_level | \nString | \nOne of beginner, intermediate or advanced. | \nno | \n
\n\n| 2.8 | \nissuer | \nString | \nPlain text name for issuer. | \nno | \n
\n\n| 2.9 | \nissue_date | \nString | \nIssue date of skill. | \nno | \n
\n\n| 2.10 | \nexpiry_date | \nString | \nExpiry date of skill. | \nno | \n
\n\n| 2.11 | \nskills | \nArray | \nArray of skill names. | \nno | \n
\n\n| 2.12 | \nscore | \nInteger | \nAssessment score. | \nno | \n
\n\n| 2.13 | \nimage_url | \nString | \nValid image URL. | \nno | \n
\n\n| 2.14 | \nskill_source | \nString | \nshould be Code value of skill source. ex - 'edcast' | \nyes | \n
\n\n
\n
Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nuser_id | \nInteger | \nUser for whom credential is created. | \n
\n\n| 2 | \nskill_id | \nInteger | \n | \n
\n\n| 2.1 | \ndescription | \nString | \nDescription for credential. Max limit 500 characters. | \n
\n\n| 2.2 | \ncredential | \nHash | \nImage for credential when uploaded via Web. | \n
\n\n| 2.3 | \ncreated_at | \nDateTime | \nCreation timestamp. | \n
\n\n| 2.4 | \nupdated_at | \nDateTime | \nUpdation timestamp | \n
\n\n| 2.5 | \nexperience | \nString | \nIn terms of years and months | \n
\n\n| 2.6 | \nskill_level | \nString | \nOne of beginner, intermediate or advanced. | \n
\n\n| 2.6.1 | \ncredential_name | \nString | \nCan be Skill name, Badge name, Credential name or Assessment name. | \n
\n\n| 2.6.2 | \ncredential_url | \nString | \nValid credential URL. | \n
\n\n| 2.7 | \nexpiry_date | \nString | \nExpiry date of credential. | \n
\n\n| 2.8 | \nissue_date | \nString | \nIssue date of credential. | \n
\n\n| 2.9 | \nissuer | \nString | \nPlain text name for issuer. | \n
\n\n| 2.10 | \nexpiry_date | \nString | \nExpiry date of credential. | \n
\n\n| 2.11 | \nskills | \nArray | \nSkills for given credential with taxonomies. | \n
\n\n| 2.12 | \ncredential_id | \nString | \nLimited to 50 chars and alphanumeric code allowing for special characters \"-\", \"/\", \".\", \"\\\", \" | \n
\n\n| 2.13 | \ncredential_type | \nString | \nOne of skill, badge, certificate, assessment. | \n
\n\n| 2.14 | \nverified | \nString | \nCredentials added by Dev API will be verified by default. | \n
\n\n| 2.15 | \nscore | \nString | \nAssessment score. | \n
\n\n
\n
API for Deletion of User's skill record
\nRequired params: email, credential_details.credential_name, credential_details.credential_type, credential_details.skill_source
\n
\nINFO:
\nRequest Param Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \nemail | \nString | \nEmail of user for whom we need to delete credential | \nYes | \n\"han@test.com\" | \n
\n\n| 2 | \ncredential_details | \nHash | \n | \nYes | \n | \n
\n\n| 2.1 | \ncredential_name | \nString | \nSkill name. (Should match the taxonomy topics for any given skills) | \nYes | \n\"Tester\" | \n
\n\n| 2.2 | \ncredential_type | \nString | \nskill | \nYes | \n\"skill\" | \n
\n\n| 2.3 | \ncredential_id | \nString | \nLimited to 50 chars and alphanumeric code allowing for special characters \"-\", \"/\", \".\", \"\", \" | \nNo | \n | \n
\n\n| 2.4 | \nskill_source | \nString | \nCode for skill source | \nYes | \n\"gloat\" | \n
\n\n
\n
Request Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \nRequired | \n
\n\n\n\n| 1 | \nemail | \nString | \nEmail of user for whom we need to create badge. | \nyes | \n
\n\n| 2 | \ncredential_details | \nHash | \n | \nyes | \n
\n\n| 2.1 | \ncredential_name | \nString | \nBadge name. | \nyes | \n
\n\n| 2.2 | \ndescription | \nString | \nDescription of the badge . Max limit 500 characters | \nno | \n
\n\n| 2.3 | \ncredential_type | \nString | \nbadge. | \nyes | \n
\n\n| 2.4 | \ncredential_id | \nString | \nLimited to 50 chars and alphanumeric code allowing for special characters \"-\", \"/\", \".\", \"\\\", \"|\", \",\". | \nyes | \n
\n\n| 2.5 | \ncredential_url | \nString | \nValid URL. | \nyes | \n
\n\n| 2.6 | \nexperience | \nHash | \nIn terms of years and month. | \nno | \n
\n\n| 2.6.1 | \nyears | \nInteger | \n | \n | \n
\n\n| 2.6.2 | \nmonths | \nInteger | \n | \n | \n
\n\n| 2.7 | \nskill_level | \nString | \nOne of beginner, intermediate or advanced. | \nno | \n
\n\n| 2.8 | \nissuer | \nString | \nPlain text name for issuer. | \nyes | \n
\n\n| 2.9 | \nissue_date | \nString | \nIssue date of badge. | \nno | \n
\n\n| 2.10 | \nexpiry_date | \nString | \nExpiry date of badge. | \nno | \n
\n\n| 2.11 | \nskills | \nArray | \nArray of skill names. | \nno | \n
\n\n| 2.12 | \nscore | \nInteger | \nAssessment score. | \nno | \n
\n\n| 2.13 | \nimage_url (coming soon) | \nString | \nValid image URL. | \nno | \n
\n\n
\n
Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nuser_id | \nInteger | \nUser for whom credential is created. | \n
\n\n| 2 | \nskill_id | \nInteger | \n | \n
\n\n| 2.1 | \ndescription | \nString | \nDescription for credential. Max limit 500 characters. | \n
\n\n| 2.2 | \ncredential | \nHash | \nImage for credential when uploaded via Web. | \n
\n\n| 2.3 | \ncreated_at | \nDateTime | \nCreation timestamp. | \n
\n\n| 2.4 | \nupdated_at | \nDateTime | \nUpdation timestamp | \n
\n\n| 2.5 | \nexperience | \nString | \nIn terms of years and months | \n
\n\n| 2.6 | \nskill_level | \nString | \nOne of beginner, intermediate or advanced. | \n
\n\n| 2.6.1 | \ncredential_name | \nString | \nCan be Skill name, Badge name, Credential name or Assessment name. | \n
\n\n| 2.6.2 | \ncredential_url | \nString | \nValid credential URL. | \n
\n\n| 2.7 | \nexpiry_date | \nString | \nExpiry date of credential. | \n
\n\n| 2.8 | \nissue_date | \nString | \nIssue date of credential. | \n
\n\n| 2.9 | \nissuer | \nString | \nPlain text name for issuer. | \n
\n\n| 2.10 | \nexpiry_date | \nString | \nExpiry date of credential. | \n
\n\n| 2.11 | \nskills | \nArray | \nSkills for given credential with taxonomies. | \n
\n\n| 2.12 | \ncredential_id | \nString | \nLimited to 50 chars and alphanumeric code allowing for special characters \"-\", \"/\", \".\", \"\\\", \"|\", \",\". | \n
\n\n| 2.13 | \ncredential_type | \nString | \nOne of skill, badge, certificate, assessment. | \n
\n\n| 2.14 | \nverified | \nString | \nCredentials added by Dev API will be verified by default. | \n
\n\n| 2.15 | \nscore | \nString | \nAssessment score. | \n
\n\n
\n
Request Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \nRequired | \n
\n\n\n\n| 1 | \nemail | \nString | \nEmail of user for whom we need to create assessment. | \nyes | \n
\n\n| 2 | \ncredential_details | \nHash | \n | \nyes | \n
\n\n| 2.1 | \ncredential_name | \nString | \nAssessment name. | \nyes | \n
\n\n| 2.2 | \ndescription | \nString | \nDescription of the assesment . Max limit 500 characters | \nyes | \n
\n\n| 2.3 | \ncredential_type | \nString | \nassessment. | \nyes | \n
\n\n| 2.4 | \ncredential_id | \nString | \nLimited to 50 chars and alphanumeric code allowing for special characters \"-\", \"/\", \".\", \"\\\", \"|\", \",\". | \nyes | \n
\n\n| 2.5 | \ncredential_url | \nString | \nValid URL. | \nyes | \n
\n\n| 2.6 | \nexperience | \nHash | \nIn terms of years and month. | \nno | \n
\n\n| 2.6.1 | \nyears | \nInteger | \n | \n | \n
\n\n| 2.6.2 | \nmonths | \nInteger | \n | \n | \n
\n\n| 2.7 | \nskill_level | \nString | \nOne of beginner, intermediate or advanced. | \nno | \n
\n\n| 2.8 | \nissuer | \nString | \nPlain text name for issuer. | \nyes | \n
\n\n| 2.9 | \nissue_date | \nString | \nIssue date of assessment. | \nno | \n
\n\n| 2.10 | \nexpiry_date | \nString | \nExpiry date of assessment. | \nno | \n
\n\n| 2.11 | \nskills | \nArray | \nArray of skill names. | \nno | \n
\n\n| 2.12 | \nscore | \nInteger | \nAssessment score. | \nyes | \n
\n\n| 2.13 | \nimage_url(coming soon) | \nString | \nValid image URL. | \nno | \n
\n\n
\n
Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nuser_id | \nInteger | \nUser for whom credential is created. | \n
\n\n| 2 | \nskill_id | \nInteger | \n | \n
\n\n| 2.1 | \ndescription | \nString | \nDescription for credential. Max limit 500 characters. | \n
\n\n| 2.2 | \ncredential | \nHash | \nImage for credential when uploaded via Web. | \n
\n\n| 2.3 | \ncreated_at | \nDateTime | \nCreation timestamp. | \n
\n\n| 2.4 | \nupdated_at | \nDateTime | \nUpdation timestamp | \n
\n\n| 2.5 | \nexperience | \nString | \nIn terms of years and months | \n
\n\n| 2.6 | \nskill_level | \nString | \nOne of beginner, intermediate or advanced. | \n
\n\n| 2.6.1 | \ncredential_name | \nString | \nCan be Skill name, Badge name, Credential name or Assessment name. | \n
\n\n| 2.6.2 | \ncredential_url | \nString | \nValid credential URL. | \n
\n\n| 2.7 | \nexpiry_date | \nString | \nExpiry date of credential. | \n
\n\n| 2.8 | \nissue_date | \nString | \nIssue date of credential. | \n
\n\n| 2.9 | \nissuer | \nString | \nPlain text name for issuer. | \n
\n\n| 2.10 | \nexpiry_date | \nString | \nExpiry date of credential. | \n
\n\n| 2.11 | \nskills | \nArray | \nSkills for given credential with taxonomies. | \n
\n\n| 2.12 | \ncredential_id | \nString | \nLimited to 50 chars and alphanumeric code allowing for special characters\"-\", \"/\", \".\", \"\\\", \"|\", \",\". | \n
\n\n| 2.13 | \ncredential_type | \nString | \nOne of skill, badge, certificate, assessment. | \n
\n\n| 2.14 | \nverified | \nString | \nCredentials added by Dev API will be verified by default. | \n
\n\n| 2.15 | \nscore | \nString | \nAssessment score. | \n
\n\n
\n
Request Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \nRequired | \n
\n\n\n\n| 1 | \nemail | \nString | \nEmail of user for whom we need to create certificate. | \nyes | \n
\n\n| 2 | \ncredential_details | \nHash | \n | \nyes | \n
\n\n| 3 | \ncredential_name | \nString | \ncertificate name. | \nyes | \n
\n\n| 4 | \ndescription | \nString | \nDescription of the certificate . Max limit 500 characters | \nno | \n
\n\n| 5 | \ncredential_type | \nString | \ncertificate. | \nyes | \n
\n\n| 6 | \ncredential_id | \nString | \nLimited to 50 chars and alphanumeric code allowing for special characters \"-\", \"/\", \".\", \"\\\", \"|\", \",\". | \nyes | \n
\n\n| 2.5 | \ncredential_url | \nString | \nValid URL. | \nyes | \n
\n\n| 2.6 | \nexperience | \nHash | \nIn terms of years and month. | \nno | \n
\n\n| 2.6.1 | \nyears | \nInteger | \n | \n | \n
\n\n| 2.6.2 | \nmonths | \nInteger | \n | \n | \n
\n\n| 2.7 | \nskill_level | \nString | \nOne of beginner, intermediate or advanced. | \nno | \n
\n\n| 2.8 | \nissuer | \nString | \nPlain text name for issuer. | \nyes | \n
\n\n| 2.9 | \nissue_date | \nString | \nIssue date of certificate. | \nno | \n
\n\n| 2.10 | \nexpiry_date | \nString | \nExpiry date of certificate. | \nno | \n
\n\n| 2.11 | \nskills | \nArray | \nArray of skill names. | \nno | \n
\n\n| 2.12 | \nscore | \nInteger | \nAssessment score. | \nno | \n
\n\n| 2.13 | \nimage_url (coming soon) | \nString | \nValid image URL. | \nno | \n
\n\n
\n
Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nuser_id | \nInteger | \nUser for whom credential is created. | \n
\n\n| 2 | \nskill_id | \nInteger | \n | \n
\n\n| 2.1 | \ndescription | \nString | \nDescription for credential. Max limit 500 characters. | \n
\n\n| 2.2 | \ncredential | \nHash | \nImage for credential when uploaded via Web. | \n
\n\n| 2.3 | \ncreated_at | \nDateTime | \nCreation timestamp. | \n
\n\n| 2.4 | \nupdated_at | \nDateTime | \nUpdation timestamp | \n
\n\n| 2.5 | \nexperience | \nString | \nIn terms of years and months | \n
\n\n| 2.6 | \nskill_level | \nString | \nOne of beginner, intermediate or advanced. | \n
\n\n| 2.6.1 | \ncredential_name | \nString | \nCan be Skill name, Badge name, Credential name or Assessment name. | \n
\n\n| 2.6.2 | \ncredential_url | \nString | \nValid credential URL. | \n
\n\n| 2.7 | \nexpiry_date | \nString | \nExpiry date of credential. | \n
\n\n| 2.8 | \nissue_date | \nString | \nIssue date of credential. | \n
\n\n| 2.9 | \nissuer | \nString | \nPlain text name for issuer. | \n
\n\n| 2.10 | \nexpiry_date | \nString | \nExpiry date of credential. | \n
\n\n| 2.11 | \nskills | \nArray | \nSkills for given credential with taxonomies. | \n
\n\n| 2.12 | \ncredential_id | \nString | \nLimited to 50 chars and alphanumeric code allowing for special characters \"-\", \"/\", \".\", \"\\\", \"|\", \",\". | \n
\n\n| 2.13 | \ncredential_type | \nString | \nOne of skill, badge, certificate, assessment. | \n
\n\n| 2.14 | \nverified | \nString | \nCredentials added by Dev API will be verified by default. | \n
\n\n| 2.15 | \nscore | \nString | \nAssessment score. | \n
\n\n| 2.13 | \nimage_url | \nString | \nValid image URL. | \n
\n\n
\n
Get credentials for a use
\nRequest Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nemail | \nString | \nEmail of user for whom we need to get credentials. | \n
\n\n
\n
Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nskills | \nArray | \nSkills of user credential. | \n
\n\n| 1.1 | \nskill_name | \nString | \nSkill name. | \n
\n\n| 1.2 | \ndescription | \nString | \nSkill description. | \n
\n\n| 1.3 | \nlevel | \nString | \nSkill level i.e beginner, expert. | \n
\n\n| 1.4 | \nexperience | \nString | \nSkill experience in years and months. | \n
\n\n| 2 | \nbadges | \nArray | \nBadges of user credentials. | \n
\n\n| 2.1 | \nbadge_name | \nString | \nBadge name. | \n
\n\n| 2.2 | \ndescription | \nString | \nBadge description. | \n
\n\n| 2.3 | \nlevel | \nString | \nBadge level i.e beginner, expert. | \n
\n\n| 2.4 | \nskills | \nArray | \nSkills for badges. | \n
\n\n| 2.4.1 | \nname | \nString | \nSkill name | \n
\n\n| 2.4.2 | \ndomain_name | \nString | \nSkill Domain | \n
\n\n| 2.4.3 | \ntaxo_id | \nString | \n | \n
\n\n| 2.4.4 | \ntopic_id | \nString | \n | \n
\n\n| 2.4.5 | \ntopic_label | \nString | \n | \n
\n\n| 2.4.6 | \ndomain_id | \nString | \n | \n
\n\n| 2.4.7 | \ndomain_label | \nString | \n | \n
\n\n| 2.5 | \nissuer | \nString | \nName of the issuer | \n
\n\n| 2.6 | \nbadge_id | \nString | \nBadge ID of credential | \n
\n\n| 2.7 | \nbadge_url | \nString | \nBadge URL of credential | \n
\n\n| 2.8 | \nissue_date | \nString | \nIssue date of credential | \n
\n\n| 2.9 | \nexpiry_date | \nString | \nExpiry date of credential | \n
\n\n| 3 | \ncertifications | \nArray | \nCertifications of user credentials | \n
\n\n| 3.1 | \ncertification_name | \nString | \nCertification name | \n
\n\n| 3.2 | \ndescription | \nString | \nCertification description | \n
\n\n| 3.3 | \nlevel | \nString | \nCertification level i.e beginner, expert | \n
\n\n| 3.4 | \nskills | \nArray | \nSkills for badges | \n
\n\n| 3.4.1 | \nname | \nString | \nSkill name | \n
\n\n| 3.4.2 | \ndomain_name | \nString | \nSkill Domain | \n
\n\n| 3.4.3 | \ntaxo_id | \nString | \n | \n
\n\n| 3.4.4 | \ntopic_id | \nString | \n | \n
\n\n| 3.4.5 | \ntopic_label | \nString | \n | \n
\n\n| 3.4.6 | \ndomain_id | \nString | \n | \n
\n\n| 3.4.7 | \ndomain_label | \nString | \n | \n
\n\n| 3.5 | \nissuer | \nString | \nName of the issuer | \n
\n\n| 3.6 | \ncertification_id | \nString | \nCertificate ID of credential | \n
\n\n| 3.7 | \ncertification_url | \nString | \nCerificate URL of credential | \n
\n\n| 3.8 | \nissue_date | \nString | \nIssue date of credential | \n
\n\n| 3.9 | \nexpiry_date | \nString | \nExpiry date of credential | \n
\n\n| 4 | \nassessments | \nArray | \nAssessments of user credentials | \n
\n\n| 4.1 | \nassessment_name | \nString | \nAssessment name | \n
\n\n| 4.2 | \ndescription | \nString | \nAssessment description | \n
\n\n| 4.3 | \nlevel | \nString | \nAssessment level i.e beginner, expert | \n
\n\n| 4.4 | \nskills | \nArray | \nSkills for assessments | \n
\n\n| 4.4.1 | \nname | \nString | \nSkill name | \n
\n\n| 4.4.2 | \ndomain_name | \nString | \nSkill Domain | \n
\n\n| 4.4.3 | \ntaxo_id | \nString | \n | \n
\n\n| 4.4.4 | \ntopic_id | \nString | \n | \n
\n\n| 4.4.5 | \ntopic_label | \nString | \n | \n
\n\n| 4.4.6 | \ndomain_id | \nString | \n | \n
\n\n| 4.4.7 | \ndomain_label | \nString | \n | \n
\n\n| 4.5 | \nissuer | \nString | \nName of the issuer | \n
\n\n| 4.6 | \nreport_url | \nString | \nAssessment URL of credential | \n
\n\n| 4.7 | \nassessment_date | \nString | \nDate of assessment | \n
\n\n| 4.8 | \nscore | \nString | \nScore assigned for the assessment | \n
\n\n
\n
API to get user's managers
\nRequest Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nuser_id | \nInteger | \nuser_id of user for whom we need to get managers. | \n
\n\n| 2 | \nexternal_id | \nString | \nexternal_id of user for whom we need to get managers. | \n
\n\n| 3 | \nemail | \nString | \nEmail of user for whom we need to get managers. | \n
\n\n
\n
Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \n | \nmanagers | \nArray | \n
\n\n| 2. | \nuid | \nString | \nUid of the user. | \n
\n\n| 3. | \nuserId | \nInteger | \nId of the user in edcast. | \n
\n\n| 4. | \nemail | \nString | \nemail of the user. | \n
\n\n| 5. | \nfirstName | \nString | \nFirst name of the user. | \n
\n\n| 6. | \nlastName | \nString | \nLast name of the user. | \n
\n\n| 7. | \nstatus | \nString | \nStatus of the user - active, suspended. | \n
\n\n| 8. | \nroles | \nArray | \nRoles assigned to the user. | \n
\n\n| 9. | \nlanguage | \nString | \nlanguage of the user. | \n
\n\n| 10. | \navatar | \nHash | \nHash of user images in different sizes. | \n
\n\n| 11. | \njobTitle | \nString | \nJob title of the user. | \n
\n\n| 12. | \nworkCountry | \nString | \nWork country of the user. | \n
\n\n| 13. | \nlearningTopics | \nArray | \nArray of learning topics. | \n
\n\n| 14. | \nlastSignInAt | \nDateTime | \nUser last signin into the system | \n
\n\n| 15. | \nisPrimaryManager | \nBoolean | \nManage is a primary manager. | \n
\n\n
\n
Set of user management APIs
\n","auth":{"type":"oauth2","oauth2":{},"isInherited":false},"_postman_id":"b5ac2864-157f-4d67-8f4a-68d9dafac31b"},{"name":"Card Management","item":[{"name":"Search Organization's Cards","id":"c4d586bd-3c66-4a6b-b137-9df033613a6f","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"noauth","isInherited":false},"method":"GET","header":[{"key":"X-API-KEY","value":""},{"key":"X-ACCESS-TOKEN","value":""},{"key":"Content-Type","name":"Content-Type","type":"text","value":"application/json"}],"url":"https:///api/developer/v5/cards/search?email=test@test.com&q=python&limit=1&offset=0&from_date=DD/MM/YYYY HH:MM:SS&till_date=DD/MM/YYYY HH:MM:SS&source_ids[]=SOURCE_ID","description":"Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nid | \nString | \nCard id provided by edcast. | \n
\n\n| 2 | \nslug | \nString | \nslug of the card. | \n
\n\n| 3 | \ncardType | \nString | \nType of the card like media, pathway, journey. | \n
\n\n| 4 | \ncreatedAt | \nDateTime | \nCreated time of the card. | \n
\n\n| 5 | \nduration | \nInteger | \nDuration of the card in seconds. | \n
\n\n| 6 | \ntitle | \nString | \ntitle of the card. | \n
\n\n| 7 | \nmessage | \nString | \nMessage of the card. | \n
\n\n| 8 | \nlanguage | \nString | \nCard language. | \n
\n\n| 9 | \nprices | \nArray[Hash] | \nContains the list of prices(i.e {id, amount, curreny, symbol} ). | \n
\n\n| 10 | \nprovider | \nString | \nProvider(Source) of the card. | \n
\n\n| 11 | \nreadableCardType | \nSgtring | \nReadable card type of card. | \n
\n\n| 12 | \nresource | \nHash | \nResources data associated with the card. | \n
\n\n| 13 | \nadditionalMetadata | \nHash | \nExtra Info can be passed. | \n
\n\n| 14 | \nproviderImage | \nString | \nProvider(Source) Image of the card. | \n
\n\n| 15 | \nshareUrl | \nString | \nUrl to share. | \n
\n\n| 16 | \npublishedAt | \nString | \nPublished datetime of the card. | \n
\n\n| 17 | \ncontentLanguages | \nArray[Hash] | \nInformation of the card in other languages if present. | \n
\n\n
\n
\nNote - We can fetch max 10k records using this API Signature. If you want more than 10k records please check Search with Deep Pagination
\n
\n","urlObject":{"protocol":"https","path":["api","developer","v5","cards","search"],"host":[""],"query":[{"description":{"content":"Email of user doing search
\n","type":"text/plain"},"key":"email","value":"test@test.com"},{"description":{"content":"Query string
\n","type":"text/plain"},"key":"q","value":"python"},{"description":{"content":"Number of records to fetch. Default 10
\n","type":"text/plain"},"key":"limit","value":"1"},{"description":{"content":"Offset for pagination. Default 0
\n","type":"text/plain"},"key":"offset","value":"0"},{"description":{"content":"Filter to get cards created after a date, format: DD/MM/YYYY HH:MM:SS
\n","type":"text/plain"},"key":"from_date","value":"DD/MM/YYYY HH:MM:SS"},{"description":{"content":"Filter to get cards created before a date, format: DD/MM/YYYY HH:MM:SS
\n","type":"text/plain"},"key":"till_date","value":"DD/MM/YYYY HH:MM:SS"},{"description":{"content":"Array of source ids
\n","type":"text/plain"},"key":"source_ids[]","value":"SOURCE_ID"}],"variable":[]}},"response":[{"id":"99f88744-528f-4aff-b019-6c3c2a0b7170","name":"Search Organization's Cards","originalRequest":{"method":"GET","header":[{"key":"X-API-KEY","value":"2d468e83991964cba0004f131a278a53"},{"key":"X-ACCESS-TOKEN","value":"eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOiJxYSIsInVzZXJfaWQiOjQzOCwiZW1haWwiOiJzYWdhckBlZGNhc3QuY29tIiwidGltZXN0YW1wIjoiMjAxOS0wNS0xNVQwNjozNDo0OC4zOTYrMDA6MDAiLCJleHAiOjE1NTc5NDUyODh9.9gE66mxhQALdB_f6jXULpL2P5Fd85yCTkdG30qjVBDA"},{"key":"Content-Type","name":"Content-Type","value":"application/json","type":"text"}],"url":{"raw":"https://qa.cmnetwork.co/api/developer/v5/cards/search?email=test@edcast.com&q=python&limit=1&offset=0","protocol":"https","host":["qa","cmnetwork","co"],"path":["api","developer","v5","cards","search"],"query":[{"key":"email","value":"test@edcast.com","description":"Email of user doing search"},{"key":"q","value":"python","description":"Query string"},{"key":"limit","value":"1","description":"Number of records to fetch. Default 10"},{"key":"offset","value":"0","description":"Offset for pagination. Default 0"}]}},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Type","value":"application/json; charset=utf-8"},{"key":"Content-Length","value":"557"},{"key":"Connection","value":"keep-alive"},{"key":"Cache-Control","value":"no-cache, no-store, max-age=0, must-revalidate"},{"key":"Content-Encoding","value":"gzip"},{"key":"Date","value":"Wed, 15 May 2019 07:25:24 GMT"},{"key":"Expires","value":"Fri, 01 Jan 1990 00:00:00 GMT"},{"key":"Pragma","value":"no-cache"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains"},{"key":"Vary","value":"Accept-Encoding, Origin"},{"key":"X-Content-Type-Options","value":"nosniff"},{"key":"X-Frame-Options","value":"SAMEORIGIN"},{"key":"X-Request-Id","value":"e3c33000-3318-4756-90f2-4271bac1a885"},{"key":"X-Runtime","value":"0.155231"},{"key":"X-UA-Compatible","value":"IE=edge"},{"key":"X-Cache","value":"Miss from cloudfront"},{"key":"Via","value":"1.1 055c4abd8940e8047b22320e9cd587d7.cloudfront.net (CloudFront)"},{"key":"X-Amz-Cf-Id","value":"vyMR0-_9OI_oKl2nsnQtElf8T9ezA09mj0VYAkdUEAH1h5j7T5Mslg=="}],"cookie":[],"responseTime":null,"body":"{\n \"cards\": [\n {\n \"id\": \"ECL-9eeb3886-c01e-4bde-b97e-7204eb2be35b\",\n \"slug\": \"python-tutorial-with\",\n \"cardType\": \"media\",\n \"createdAt\": \"2020-03-23T10:28:43.000Z\",\n \"duration\": 0,\n \"title\": \"Python Tutorial with tag\",\n \"message\": \"Python Tutorial with tag\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"User Generated Content\",\n \"readableCardType\": \"Article\",\n \"resource\": {\n \"id\": 5664145,\n \"imageUrl\": \"https://edqa.cmnetwork.co/uploads/730ecef30962b8663949ae019ad7a78e:538c871e6e336afca7be4da0d9138494d575c20db3326e94e83ed302cd168066c57364c6fb2cd490935dc1dd3e42b528c1adaa25cc9cb91dded3ad43a3c2c7fe28010b7ff6317c442269cb64ce2ca6a3d2b17f49caa55f0bce961a7f0a66dd0aa4bc47558bfb69851cf5c536f36e1e8b30d4f2b48f521c31174c11e8899c5583bec62b9db6cd2d49e20a3090bf3bb5400ce5903da9acd556b99b389cd1ec218d06b9f6b7e34dffee322be1fa65f262901f6ba3ee65bd2a49f032259e41b69c73d8ff01e5dd810b52b0f5840f4f83766eddbe5c798921c4c4de17527c6a6110fdd697648c3a230be646675a59b7f1c57e\",\n \"title\": \"Python Tutorial\",\n \"description\": \"\",\n \"url\": \"https://www.w3schools.com/python/default.asp\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://edqa.cmnetwork.co/insights/4591754\",\n \"publishedAt\": \"2020-03-23T10:28:43.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 744475,\n \"message\": \"\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 5664145,\n \"imageUrl\": \"https://cdn.filestackcontent.com/xIOzdWuZTB2HLZ8Dkp0K\",\n \"title\": \"Python Tutorial\",\n \"description\": \"\",\n \"url\": \"https://www.w3schools.com/python/default.asp\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n }\n ],\n \"total\": 3969\n}"}],"_postman_id":"c4d586bd-3c66-4a6b-b137-9df033613a6f"},{"name":"Search Organization's Cards(Deep Pagination)","id":"5a112284-a67e-41e2-b46c-794b9ffd922d","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"noauth","isInherited":false},"method":"GET","header":[{"key":"X-API-KEY","value":""},{"key":"X-ACCESS-TOKEN","value":""},{"key":"Content-Type","name":"Content-Type","type":"text","value":"application/json"}],"url":"https:///api/developer/v5/cards/search?email=test@test.com&q=python&limit=10&from_date=DD/MM/YYYY HH:MM:SS&till_date=DD/MM/YYYY HH:MM:SS&source_ids[]=SOURCE_ID&deep_pagination=true&search_after=1632137099&sort=created_at&order=asc","description":"Deep pagination is an approach to paginate through the larger set of records. Sort and Order parameters are required for deep pagination.
\nResponse Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nid | \nString | \nCard id provided by edcast. | \n
\n\n| 2 | \nslug | \nString | \nslug of the card. | \n
\n\n| 3 | \ncardType | \nString | \nType of the card like media, pathway, journey. | \n
\n\n| 4 | \ncreatedAt | \nDateTime | \nCreated time of the card. | \n
\n\n| 5 | \nduration | \nInteger | \nDuration of the card in seconds. | \n
\n\n| 6 | \ntitle | \nString | \ntitle of the card. | \n
\n\n| 7 | \nmessage | \nString | \nMessage of the card. | \n
\n\n| 8 | \nlanguage | \nString | \nCard language. | \n
\n\n| 9 | \nprices | \nArray[Hash] | \nContains the list of prices(i.e {id, amount, curreny, symbol} ). | \n
\n\n| 10 | \nprovider | \nString | \nProvider(Source) of the card. | \n
\n\n| 11 | \nreadableCardType | \nSgtring | \nReadable card type of card. | \n
\n\n| 12 | \nresource | \nHash | \nResources data associated with the card. | \n
\n\n| 13 | \nadditionalMetadata | \nHash | \nExtra Info can be passed. | \n
\n\n| 14 | \nproviderImage | \nString | \nProvider(Source) Image of the card. | \n
\n\n| 15 | \nshareUrl | \nString | \nUrl to share. | \n
\n\n| 16 | \npublishedAt | \nString | \nPublished datetime of the card. | \n
\n\n| 17 | \ncontentLanguages | \nArray[Hash] | \nInformation of the card in other languages if present. | \n
\n\n
\n
Email of user doing search
\n","type":"text/plain"},"key":"email","value":"test@test.com"},{"description":{"content":"Query string
\n","type":"text/plain"},"key":"q","value":"python"},{"description":{"content":"Number of records to fetch. Default 10
\n","type":"text/plain"},"key":"limit","value":"10"},{"description":{"content":"Filter to get cards created after a date, format: DD/MM/YYYY HH:MM:SS
\n","type":"text/plain"},"key":"from_date","value":"DD/MM/YYYY HH:MM:SS"},{"description":{"content":"Filter to get cards created before a date, format: DD/MM/YYYY HH:MM:SS
\n","type":"text/plain"},"key":"till_date","value":"DD/MM/YYYY HH:MM:SS"},{"description":{"content":"Array of source ids
\n","type":"text/plain"},"key":"source_ids[]","value":"SOURCE_ID"},{"description":{"content":"Boolean flag to Enable Deep Pagination. Possible values: true, false, 1, 0, t, f
\n","type":"text/plain"},"key":"deep_pagination","value":"true"},{"description":{"content":"The very first request will not have search_after param, but for subsequent requests we pass the search_after value returned from the response
\n","type":"text/plain"},"key":"search_after","value":"1632137099"},{"description":{"content":"Attribute name to sort by, eg\n created_at, updated_at, published_at
\n","type":"text/plain"},"key":"sort","value":"created_at"},{"description":{"content":"Order of sorting, eg: asc or desc
\n","type":"text/plain"},"key":"order","value":"asc"}],"variable":[]}},"response":[{"id":"a7834f50-8e14-4f7f-a3c3-5df4136ee1ab","name":"Search Organization's Cards","originalRequest":{"method":"GET","header":[{"key":"X-API-KEY","value":"2d468e83991964cba0004f131a278a53"},{"key":"X-ACCESS-TOKEN","value":"eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOiJxYSIsInVzZXJfaWQiOjQzOCwiZW1haWwiOiJzYWdhckBlZGNhc3QuY29tIiwidGltZXN0YW1wIjoiMjAxOS0wNS0xNVQwNjozNDo0OC4zOTYrMDA6MDAiLCJleHAiOjE1NTc5NDUyODh9.9gE66mxhQALdB_f6jXULpL2P5Fd85yCTkdG30qjVBDA"},{"key":"Content-Type","name":"Content-Type","value":"application/json","type":"text"}],"url":{"raw":"https://qa.cmnetwork.co/api/developer/v5/cards/search?email=test@edcast.com&q=python&limit=1&offset=0","protocol":"https","host":["qa","cmnetwork","co"],"path":["api","developer","v5","cards","search"],"query":[{"key":"email","value":"test@edcast.com","description":"Email of user doing search"},{"key":"q","value":"python","description":"Query string"},{"key":"limit","value":"1","description":"Number of records to fetch. Default 10"},{"key":"offset","value":"0","description":"Offset for pagination. Default 0"}]}},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Type","value":"application/json; charset=utf-8"},{"key":"Content-Length","value":"557"},{"key":"Connection","value":"keep-alive"},{"key":"Cache-Control","value":"no-cache, no-store, max-age=0, must-revalidate"},{"key":"Content-Encoding","value":"gzip"},{"key":"Date","value":"Wed, 15 May 2019 07:25:24 GMT"},{"key":"Expires","value":"Fri, 01 Jan 1990 00:00:00 GMT"},{"key":"Pragma","value":"no-cache"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains"},{"key":"Vary","value":"Accept-Encoding, Origin"},{"key":"X-Content-Type-Options","value":"nosniff"},{"key":"X-Frame-Options","value":"SAMEORIGIN"},{"key":"X-Request-Id","value":"e3c33000-3318-4756-90f2-4271bac1a885"},{"key":"X-Runtime","value":"0.155231"},{"key":"X-UA-Compatible","value":"IE=edge"},{"key":"X-Cache","value":"Miss from cloudfront"},{"key":"Via","value":"1.1 055c4abd8940e8047b22320e9cd587d7.cloudfront.net (CloudFront)"},{"key":"X-Amz-Cf-Id","value":"vyMR0-_9OI_oKl2nsnQtElf8T9ezA09mj0VYAkdUEAH1h5j7T5Mslg=="}],"cookie":[],"responseTime":null,"body":"{\n \"cards\": [\n {\n \"id\": \"ECL-9eeb3886-c01e-4bde-b97e-7204eb2be35b\",\n \"slug\": \"python-tutorial-with\",\n \"cardType\": \"media\",\n \"createdAt\": \"2020-03-23T10:28:43.000Z\",\n \"duration\": 0,\n \"title\": \"Python Tutorial with tag\",\n \"message\": \"Python Tutorial with tag\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"User Generated Content\",\n \"readableCardType\": \"Article\",\n \"resource\": {\n \"id\": 5664145,\n \"imageUrl\": \"https://edqa.cmnetwork.co/uploads/730ecef30962b8663949ae019ad7a78e:538c871e6e336afca7be4da0d9138494d575c20db3326e94e83ed302cd168066c57364c6fb2cd490935dc1dd3e42b528c1adaa25cc9cb91dded3ad43a3c2c7fe28010b7ff6317c442269cb64ce2ca6a3d2b17f49caa55f0bce961a7f0a66dd0aa4bc47558bfb69851cf5c536f36e1e8b30d4f2b48f521c31174c11e8899c5583bec62b9db6cd2d49e20a3090bf3bb5400ce5903da9acd556b99b389cd1ec218d06b9f6b7e34dffee322be1fa65f262901f6ba3ee65bd2a49f032259e41b69c73d8ff01e5dd810b52b0f5840f4f83766eddbe5c798921c4c4de17527c6a6110fdd697648c3a230be646675a59b7f1c57e\",\n \"title\": \"Python Tutorial\",\n \"description\": \"\",\n \"url\": \"https://www.w3schools.com/python/default.asp\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://edqa.cmnetwork.co/insights/4591754\",\n \"publishedAt\": \"2020-03-23T10:28:43.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 744475,\n \"message\": \"\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 5664145,\n \"imageUrl\": \"https://cdn.filestackcontent.com/xIOzdWuZTB2HLZ8Dkp0K\",\n \"title\": \"Python Tutorial\",\n \"description\": \"\",\n \"url\": \"https://www.w3schools.com/python/default.asp\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n }\n ],\n \"total\": 3969\n}"}],"_postman_id":"5a112284-a67e-41e2-b46c-794b9ffd922d"},{"name":"Create a Smart Card","id":"d8c63198-0191-4710-b5d2-0faeafc27394","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"method":"POST","header":[{"key":"X-API-KEY","type":"text","value":""},{"key":"X-ACCESS-TOKEN","type":"text","value":""},{"key":"Content-Type","name":"Content-Type","type":"text","value":"application/json"}],"body":{"mode":"raw","raw":"{\n \"card\": {\n \"message\": \"test message\",\n \"prices\": [\n {\n \"amount\": 15,\n \"currency\": \"INR\"\n },\n {\n \"amount\": 10,\n \"currency\": \"USD\"\n }\n ],\n \"content_type\": \"video\",\n \"tags\": [\n \"tag1\",\n \"tag2\"\n ],\n \"card_metadata\": {\n \"level\": \"intermediate\",\n \"custom_data\": \"sd\"\n },\n \"resource\": {\n \"title\": \"source title\",\n \"url\": \"http://www.africau.edu/images/default/sample.pdf\"\n },\n \"duration\": 45,\n \"channel_ids\": [\n 215\n ],\n \"team_ids\": [\n 483\n ]\n }\n}"},"url":"https:///api/developer/v5/cards","description":"Request Param Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \nmessage | \nString | \nMessage to be displayed | \nYes | \n\"Message of the card\" | \n
\n\n| 2 | \ncontent_type | \nString | \nContent type: image/file/audio/video/course/link | \nNo | \n\"audio\" | \n
\n\n| 3 | \nreadable_card_type | \nString | \nType of the card: course/article/video/imageblog_post | \nNo | \n\"course\" | \n
\n\n| 4 | \nexternal_id | \nString | \nExternal id should be unique | \nNo | \n\"8fc0-9fa13dbd99b7\" | \n
\n\n| 5 | \nsource_id | \nString | \nSource id | \nNo | \n\"ea0cfdc7-7b00-4e47\" | \n
\n\n| 6 | \nis_public | \nBoolean | \nTo make card public or private | \nNo | \ntrue | \n
\n\n| 7 | \nduration | \nInteger | \nDuration of the card(secs) | \nNo | \n120 | \n
\n\n| 8 | \ntags | \nArray | \nArray of the tags/topics | \nNo | \n[\"tag1\",\"tag2\"] | \n
\n\n| 9 | \nchannel_ids | \nArray | \nArray of channels ids to post | \nNo | \n[45,67] | \n
\n\n| 10 | \nteam_ids | \nArray | \nArray of team_ids to be shared | \nNo | \n[23,13] | \n
\n\n| 11 | \nprices | \nArray | \nPrice of the cards | \nNo | \n[{\"amount\":15,\"currency\":\"INR\"}, {\"amount\":10,\"currency\":\"USD\"}] | \n
\n\n| 11.1 | \namount | \nInteger | \nAmount should be integer | \nNo | \n15 | \n
\n\n| 11.2 | \ncurrency | \nString | \nValid currency are: INR and USD | \nNo | \nINR | \n
\n\n| 12 | \nresource | \nHash | \nDetails of the resource | \nNo | \n\"resource\":{\"title\": \"Title of the resource\",\"url\":\"https://www.youtube.com/watch?v=lwyymCxLbv0\"} | \n
\n\n| 12.1 | \nurl | \nString | \nUrl of the resource | \nYes | \n\"https://www.youtube.com/watch?v=lwyymCxLbv0\" | \n
\n\n| 12.2 | \ntitle | \nString | \nTitle of the resource | \nYes | \n\"Title\" | \n
\n\n| 12.3 | \ndescription | \nString | \nDescription of the resource | \nNo | \n\"Description\" | \n
\n\n| 12.4 | \nimage_url | \nString | \nImage url of the resource | \nNo | \n\"https://picsum.photos/id/240/200/300\" | \n
\n\n| 12.5 | \nvideo_url | \nString | \nVideo url of the resource | \nNo | \n | \n
\n\n| 12.6 | \nembed_html | \nString | \nEmbed html of the resource | \nNo | \n\"<iframe src='''https://player.vimeo.com/video/129482491?autoplay=1'\\'' width='''1280''' height='''504''' frameborder='''0''' title='''Looking Glas''' webkitallowfullscreen mozallowfullscreen allowfullscreen>\"\" | \n
\n\n| 13 | \ncard_metadata | \nHash | \nMetadata of the card | \nNo | \n\"card_metadata\":{\"level\": \"intermediate\",\"custom_data\": \"extra info\"} | \n
\n\n| 13.1 | \nlevel | \nString | \nLevel of the card: beginner, intermediate or advanced | \nNo | \n\"intermediate\" | \n
\n\n| 13.2 | \ncustom_data | \nString | \nConsists of any additional information to be shown on card standalone page. This information can be as simple as a string (e.g. \"Business Analytics\") to something with HTML tags | \nNo | \n<b>Business Analytics</b> | \n
\n\n| 14 | \nauthor | \nHash | \nAuthor of a Card | \nNo | \n\"author\" : { \"email\": \"author@example.com\"} or \"author\" : { \"external_id\": \"134143\" } | \n
\n\n| 14.1 | \nemail | \nString | \nEmail of the author | \nNo | \nauthor@example.com | \n
\n\n| 14.2 | \nexternal_id | \nString | \nExternal id of the user | \nNo | \n134143 | \n
\n\n| 15 | \npublished_at | \nDatetime | \nPulished Datetime of the card, - valid format -> dd/mm/yyyy hh:mm:ss | \nNo | \n | \n
\n\n| 16 | \nadditional_metadata | \nHash | \nExtra Info can be passed | \nNo | \n | \n
\n\n
\n
Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nauthor | \nHash | \nAuthor details of the card, will be empty if created by source. | \n
\n\n| 2 | \ncardMetadatum | \nHash | \nMeta data of the card like plan and level. | \n
\n\n| 3 | \ncardSubtype | \nString | \nSub type of the card, like text, audio, video. | \n
\n\n| 4 | \ncardType | \nString | \nType of the card like media, pathway, journey. | \n
\n\n| 5 | \nchannels | \nArray[Hash] | \nContains the list of channels(i.e {id, label} ) in which the card is shared. | \n
\n\n| 6 | \ncreatedAt | \nDateTime | \nCreated time of the card. | \n
\n\n| 7 | \nduration | \nInteger | \nDuration of the card in seconds. | \n
\n\n| 8 | \nexternalId | \nString | \nCard id provided by client. | \n
\n\n| 9 | \nid | \nString | \nCard id provided by edcast. | \n
\n\n| 10 | \nisPaid | \nBoolean | \nFlag to represent free or paid. | \n
\n\n| 11 | \nisPublic | \nBoolean | \nFlag to represent public or private. | \n
\n\n| 12 | \nmessage | \nString | \nMessage of the card. | \n
\n\n| 13 | \nprices | \nArray[Hash] | \nContains the list of prices(i.e {id, amount, curreny, symbol} ). | \n
\n\n| 14 | \nprovider | \nString | \nProvider(Source) of the card. | \n
\n\n| 15 | \nreadableCardType | \nSgtring | \nReadable card type of card. | \n
\n\n| 16 | \nresource | \nHash | \nResources data associated with the card. | \n
\n\n| 17 | \nslug | \nString | \nslug of the card. | \n
\n\n| 18 | \ntags | \nArray[Hash] | \nArray of related tags/topics(i.e {id, name}) to the card. | \n
\n\n| 19 | \nteams | \nArray[Hash] | \nContains the list of teams/groups(i.e {id, name} ) in which the card is shared. | \n
\n\n| 20 | \nlanguage | \nString | \nCard language. | \n
\n\n| 21 | \nshareUrl | \nString | \nUrl to share. | \n
\n\n| 22 | \nadditionalMetadata | \nHash | \nExtra Info can be passed. | \n
\n\n| 23 | \ncontentLanguages | \nArray[Hash] | \nInformation of the card in other languages if present. | \n
\n\n| 24 | \npublishedAt | \nString | \nPublished datetime of the card. | \n
\n\n
\n
Request Param Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \nmessage | \nString | \nMessage to be displayed | \nYes | \n\"Message of the card\" | \n
\n\n| 2 | \nreadable_card_type | \nString | \nType of the card: course/article/video/imageblog_post | \nNo | \n\"course\" | \n
\n\n| 3 | \nis_public | \nBoolean | \nTo make card public or private | \nNo | \ntrue | \n
\n\n| 4 | \nduration | \nInteger | \nDuration of the card(secs) | \nNo | \n120 | \n
\n\n| 5 | \ntags | \nArray | \nArray of the tags/topics | \nNo | \n[\"tag1\",\"tag2\"] | \n
\n\n| 6 | \nchannel_ids | \nArray | \nArray of channels ids to post | \nNo | \n[45,67] | \n
\n\n| 7 | \nteam_ids | \nArray | \nArray of team_ids to be shared | \nNo | \n[23,13] | \n
\n\n| 8 | \nprices | \nArray | \nPrice of the cards | \nNo | \n[{\"amount\":15,\"currency\":\"INR\"}, {\"amount\":10,\"currency\":\"USD\"}] | \n
\n\n| 8.1 | \namount | \nInteger | \nAmount should be integer | \nNo | \n15 | \n
\n\n| 8.2 | \ncurrency | \nString | \nValid currency are: INR and USD | \nNo | \nINR | \n
\n\n| 9 | \nresource | \nHash | \nDetails of the resource | \nNo | \n\"resource\":{\"title\": \"Title of the resource\",\"url\":\"https://www.youtube.com/watch?v=lwyymCxLbv0\"} | \n
\n\n| 9.1 | \nurl | \nString | \nUrl of the resource | \nYes | \n\"https://www.youtube.com/watch?v=lwyymCxLbv0\" | \n
\n\n| 9.2 | \ntitle | \nString | \nTitle of the resource | \nYes | \n\"Title\" | \n
\n\n| 9.3 | \ndescription | \nString | \nDescription of the resource | \nNo | \n\"Description\" | \n
\n\n| 9.4 | \nimage_url | \nString | \nImage url of the resource | \nNo | \n\"https://picsum.photos/id/240/200/300\" | \n
\n\n| 9.5 | \nvideo_url | \nString | \nVideo url of the resource | \nNo | \n | \n
\n\n| 9.6 | \nembed_html | \nString | \nEmbed html of the resource | \nNo | \n\"https://player.vimeo.com/video/129482491?autoplay=1'\\''; width='''1280''' height='''504''' frameborder='''0''' title='''Looking Glas''' webkitallowfullscreen mozallowfullscreen allowfullscreen>\"\" | \n
\n\n| 10 | \ncard_metadata | \nHash | \nMetadata of the card | \nNo | \n\"card_metadata\":{\"level\": \"intermediate\",\"custom_data\": \"extra info\"} | \n
\n\n| 10.1 | \nlevel | \nString | \nLevel of the card: beginner, intermediate or advanced | \nNo | \n\"intermediate\" | \n
\n\n| 10.2 | \ncustom_data | \nString | \nConsists of any additional information to be shown on card standalone page. This information can be as simple as a string (e.g. \"Business Analytics\") to something with HTML tags | \nNo | \nBusiness Analytics | \n
\n\n| 12 | \npublished_at | \nDatetime | \nPulished Datetime of the card, - valid format -> dd/mm/yyyy hh:mm:ss | \nNo | \n | \n
\n\n| 13 | \nadditional_metadata | \nHash | \nExtra Info can be passed | \nNo | \n | \n
\n\n| 14 | \ncontent_languages | \nArray | \nThe parameter should include language-specific details such as URL, message, language code, and description. | \n | \n | \n
\n\n
\n
Response Param Description
\n\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nauthor | \nHash | \nAuthor details of the card, will be empty if created by source. | \n
\n\n| 2 | \ncardMetadatum | \nHash | \nMeta data of the card like plan and level. | \n
\n\n| 3 | \ncardSubtype | \nString | \nSub type of the card, like text, audio, video. | \n
\n\n| 4 | \ncardType | \nString | \nType of the card like media, pathway, journey. | \n
\n\n| 5 | \nchannels | \nArray[Hash] | \nContains the list of channels(i.e {id, label} ) in which the card is shared. | \n
\n\n| 6 | \ncreatedAt | \nDateTime | \nCreated time of the card. | \n
\n\n| 7 | \nduration | \nInteger | \nDuration of the card in seconds. | \n
\n\n| 8 | \nexternalId | \nString | \nCard id provided by client. | \n
\n\n| 9 | \nid | \nString | \nCard id provided by edcast. | \n
\n\n| 10 | \nisPaid | \nBoolean | \nFlag to represent free or paid. | \n
\n\n| 11 | \nisPublic | \nBoolean | \nFlag to represent public or private. | \n
\n\n| 12 | \nmessage | \nString | \nMessage of the card. | \n
\n\n| 13 | \nprices | \nArray[Hash] | \nContains the list of prices(i.e {id, amount, curreny, symbol} ). | \n
\n\n| 14 | \nprovider | \nString | \nProvider(Source) of the card. | \n
\n\n| 15 | \nreadableCardType | \nSgtring | \nReadable card type of card. | \n
\n\n| 16 | \nresource | \nHash | \nResources data associated with the card. | \n
\n\n| 17 | \nslug | \nString | \nslug of the card. | \n
\n\n| 18 | \ntags | \nArray[Hash] | \nArray of related tags/topics(i.e {id, name}) to the card. | \n
\n\n| 19 | \nteams | \nArray[Hash] | \nContains the list of teams/groups(i.e {id, name} ) in which the card is shared. | \n
\n\n| 20 | \nlanguage | \nString | \nCard language. | \n
\n\n| 21 | \nshareUrl | \nString | \nUrl to share. | \n
\n\n| 22 | \nadditionalMetadata | \nHash | \nExtra Info can be passed. | \n
\n\n| 23 | \ncontentLanguages | \nArray[Hash] | \nInformation of the card in other languages if present. | \n
\n\n| 24 | \npublishedAt | \nString | \nPublished datetime of the card. | \n
\n\n
\n
Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nauthor | \nHash | \nAuthor details of the card, will be empty if created by source. | \n
\n\n| 2 | \ncardMetadatum | \nHash | \nMeta data of the card like plan and level. | \n
\n\n| 3 | \ncardSubtype | \nString | \nSub type of the card, like text, audio, video. | \n
\n\n| 4 | \ncardType | \nString | \nType of the card like media, pathway, journey. | \n
\n\n| 5 | \nchannels | \nArray[Hash] | \nContains the list of channels(i.e {id, label} ) in which the card is shared. | \n
\n\n| 6 | \ncreatedAt | \nDateTime | \nCreated time of the card. | \n
\n\n| 7 | \nduration | \nInteger | \nDuration of the card in seconds. | \n
\n\n| 8 | \nexternalId | \nString | \nCard id provided by client. | \n
\n\n| 9 | \nid | \nString | \nCard id provided by edcast. | \n
\n\n| 10 | \nisPaid | \nBoolean | \nFlag to represent free or paid. | \n
\n\n| 11 | \nisPublic | \nBoolean | \nFlag to represent public or private. | \n
\n\n| 12 | \nmessage | \nString | \nMessage of the card. | \n
\n\n| 13 | \nprices | \nArray[Hash] | \nContains the list of prices(i.e {id, amount, curreny, symbol} ). | \n
\n\n| 14 | \nprovider | \nString | \nProvider(Source) of the card. | \n
\n\n| 15 | \nreadableCardType | \nSgtring | \nReadable card type of card. | \n
\n\n| 16 | \nresource | \nHash | \nResources data associated with the card. | \n
\n\n| 17 | \nslug | \nString | \nslug of the card. | \n
\n\n| 18 | \ntags | \nArray[Hash] | \nArray of related tags/topics(i.e {id, name}) to the card. | \n
\n\n| 19 | \nteams | \nArray[Hash] | \nContains the list of teams/groups(i.e {id, name} ) in which the card is shared. | \n
\n\n| 20 | \nlanguage | \nString | \nCard language. | \n
\n\n| 21 | \nshareUrl | \nString | \nUrl to share. | \n
\n\n| 22 | \nadditionalMetadata | \nHash | \nExtra Info can be passed. | \n
\n\n| 23 | \ncontentLanguages | \nArray[Hash] | \nInformation of the card in other languages if present. | \n
\n\n| 24 | \npublishedAt | \nString | \nPublished datetime of the card. | \n
\n\n
\n
Request Param Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \nq | \nString | \nQuery string
(Note: minimun 4 characters) | \nNo | \ntest | \n
\n\n| 2 | \ncontent_types | \nArray | \nFilter to get cards on type of content | \nNo | \n[video] | \n
\n\n| 3 | \nauthor_ids | \nArray | \nSearch for cards created by given users ids | \nNo | \n[959] | \n
\n\n| 4 | \nchannel_ids | \nArray | \nSearch for cards in channels. | \nNo | \n[85] | \n
\n\n| 5 | \nteam_ids | \nArray | \nSearch for cards in teams | \nNo | \n[49] | \n
\n\n| 6 | \nfrom_date | \nString | \nFilter to get cards created from date, format: DD/MM/YYYY | \nNo | \n05/01/2019 | \n
\n\n| 7 | \ntill_date | \nString | \nFilter to get cards create till date, format: DD/MM/YYYY | \nNo | \n06/02/2019 | \n
\n\n| 8 | \nlimit | \nInteger | \nNumber of records to fetch. Default 10 | \nNo | \n4 | \n
\n\n| 9 | \noffset | \nInteger | \nOffset for pagination. Default 0 | \nNo | \n5 | \n
\n\n| 5 | \nsort | \nString | \nSort results. Values: created_at, updated_at | \nNo | \ncreated_at | \n
\n\n| 6 | \norder | \nString | \nacs or desc. Default: asc | \nNo | \nacs | \n
\n\n
\n
Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nauthor | \nHash | \nAuthor details of the card, will be empty if created by source. | \n
\n\n| 2 | \ncardMetadatum | \nHash | \nMeta data of the card like plan and level. | \n
\n\n| 3 | \ncardSubtype | \nString | \nSub type of the card, like text, audio, video. | \n
\n\n| 4 | \ncardType | \nString | \nType of the card like media, pathway, journey. | \n
\n\n| 5 | \nchannels | \nArray[Hash] | \nContains the list of channels(i.e {id, label} ) in which the card is shared. | \n
\n\n| 6 | \ncreatedAt | \nDateTime | \nCreated time of the card. | \n
\n\n| 7 | \nduration | \nInteger | \nDuration of the card in seconds. | \n
\n\n| 8 | \nexternalId | \nString | \nCard id provided by client. | \n
\n\n| 9 | \nid | \nString | \nCard id provided by edcast. | \n
\n\n| 10 | \nisPaid | \nBoolean | \nFlag to represent free or paid. | \n
\n\n| 11 | \nisPublic | \nBoolean | \nFlag to represent public or private. | \n
\n\n| 12 | \nmessage | \nString | \nMessage of the card. | \n
\n\n| 13 | \nprices | \nArray[Hash] | \nContains the list of prices(i.e {id, amount, curreny, symbol} ). | \n
\n\n| 14 | \nprovider | \nString | \nProvider(Source) of the card. | \n
\n\n| 15 | \nreadableCardType | \nSgtring | \nReadable card type of card. | \n
\n\n| 16 | \nresource | \nHash | \nResources data associated with the card. | \n
\n\n| 17 | \nslug | \nString | \nslug of the card. | \n
\n\n| 18 | \ntags | \nArray[Hash] | \nArray of related tags/topics(i.e {id, name}) to the card. | \n
\n\n| 19 | \nteams | \nArray[Hash] | \nContains the list of teams/groups(i.e {id, name} ) in which the card is shared. | \n
\n\n| 20 | \nlanguage | \nString | \nCard language. | \n
\n\n| 21 | \nshareUrl | \nString | \nUrl to share. | \n
\n\n| 22 | \nadditionalMetadata | \nHash | \nExtra Info can be passed. | \n
\n\n| 23 | \ncontentLanguages | \nArray[Hash] | \nInformation of the card in other languages if present. | \n
\n\n| 24 | \npublishedAt | \nString | \nPublished datetime of the card. | \n
\n\n| 25 | \nupdatedAt | \nDateTime | \nUpdate datetime of the card. | \n
\n\n
\n
Share a card with a User
\nRequest Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \ncard_id | \nString | \nExternal ID of the user. | \n
\n\n| 2 | \nexternal_id | \nString | \nExternal ID of the user. | \n
\n\n| 3 | \nemail | \nString | \nEmail ID of the user. | \n
\n\n
\n
Unshare a card with a User
\nRequest Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \ncard_id | \nString | \nExternal ID of the user. | \n
\n\n| 2 | \nexternal_id | \nString | \nExternal ID of the user. | \n
\n\n| 3 | \nemail | \nString | \nEmail ID of the user. | \n
\n\n
\n
Request Param Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \ntags | \nArray | \nFilter cards by tags | \nYes | \n[gulf coast united] | \n
\n\n
\n
Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nid | \nString | \nCard id provided by edcast. | \n
\n\n| 2 | \nslug | \nString | \nslug of the card. | \n
\n\n| 3 | \ncardType | \nString | \nType of the card like media, pathway, journey. | \n
\n\n| 4 | \ncreatedAt | \nDateTime | \nCreated time of the card. | \n
\n\n| 5 | \nduration | \nInteger | \nDuration of the card in seconds. | \n
\n\n| 6 | \ntitle | \nString | \ntitle of the card. | \n
\n\n| 7 | \nmessage | \nString | \nMessage of the card. | \n
\n\n| 8 | \nlanguage | \nString | \nCard language. | \n
\n\n| 9 | \nprices | \nArray[Hash] | \nContains the list of prices(i.e {id, amount, curreny, symbol} ). | \n
\n\n| 10 | \nprovider | \nString | \nProvider(Source) of the card. | \n
\n\n| 11 | \nreadableCardType | \nSgtring | \nReadable card type of card. | \n
\n\n| 12 | \nresource | \nHash | \nResources data associated with the card. | \n
\n\n| 13 | \nadditionalMetadata | \nHash | \nExtra Info can be passed. | \n
\n\n| 14 | \nproviderImage | \nString | \nProvider(Source) Image of the card. | \n
\n\n| 15 | \nshareUrl | \nString | \nUrl to share. | \n
\n\n| 16 | \npublishedAt | \nString | \nPublished datetime of the card. | \n
\n\n| 17 | \ncontentLanguages | \nArray[Hash] | \nInformation of the card in other languages if present. | \n
\n\n
\n
\nNote - We can fetch max 10k records using this API Signature. If you want more than 10k records please check Search with Deep Pagination
\n
\n","urlObject":{"protocol":"https","path":["api","developer","v5","cards","search"],"host":[""],"query":[{"disabled":true,"key":"deep_pagination","value":"true"},{"key":"limit","value":"200"},{"key":"email","value":"test@gmail.com"},{"disabled":true,"key":"sort","value":"created_at"},{"disabled":true,"key":"order","value":"asc"},{"disabled":true,"key":"search_after","value":"1630511074699"},{"disabled":true,"key":"offset","value":"0"},{"disabled":true,"key":"fields","value":"card_message"},{"disabled":true,"key":"from_date","value":"04/05/2021"},{"key":"tags[]","value":"gulf coast united"}],"variable":[]}},"response":[{"id":"a8deb1f1-b4de-442d-b62a-8225f7155de9","name":"Search cards by tags","originalRequest":{"method":"GET","header":[{"key":"X-API-KEY","value":""},{"key":"X-ACCESS-TOKEN","value":""},{"key":"Accept","value":"application/json"},{"key":"Content-Type","value":"application/json"},{"key":"Cookie","value":"_d=acMFjmeVSoJv5L98uDixvg; access=2022-07-27; remember_user_token=BAhbCFsGaQPm%2Bg1JIiIkMmEkMTAkaTc4bjRJa3R3Y3dJSmVKejc4NGtQLgY6BkVUSSIXMTY1ODkxODgwMy4zOTM0NjA4BjsARg%3D%3D--403fa7e0d00fa31b3816568a1724bb13bf289fff"},{"key":"email","value":"sunil.kumar@edcast.com","type":"text","disabled":true}],"url":{"raw":"https:///api/developer/v5/cards/search?limit=200&email=test@gmail.com&tags[]=gulf coast united","protocol":"https","host":[""],"path":["api","developer","v5","cards","search"],"query":[{"key":"deep_pagination","value":"true","disabled":true},{"key":"limit","value":"200"},{"key":"email","value":"test@gmail.com"},{"key":"sort","value":"created_at","disabled":true},{"key":"order","value":"asc","disabled":true},{"key":"search_after","value":"1630511074699","disabled":true},{"key":"offset","value":"0","disabled":true},{"key":"fields","value":"card_message","type":"text","disabled":true},{"key":"from_date","value":"04/05/2021","type":"text","disabled":true},{"key":"tags[]","value":"gulf coast united"}]}},"status":"OK","code":200,"_postman_previewlanguage":"json","header":[{"key":"Content-Type","value":"application/json; charset=utf-8"},{"key":"Transfer-Encoding","value":"chunked"},{"key":"Connection","value":"keep-alive"},{"key":"Date","value":"Fri, 17 Feb 2023 06:15:43 GMT"},{"key":"X-UA-Compatible","value":"IE=edge"},{"key":"X-XSS-Protection","value":"1; mode=block"},{"key":"X-Content-Type-Options","value":"nosniff"},{"key":"X-Frame-Options","value":"SAMEORIGIN"},{"key":"Cache-Control","value":"no-cache, no-store"},{"key":"Pragma","value":"no-cache"},{"key":"Expires","value":"Fri, 01 Jan 1990 00:00:00 GMT"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains"},{"key":"Strict-Transport-Security","value":"max-age=31536000; includeSubDomains; preload"},{"key":"Access-Control-Allow-Origin","value":"novartis.edcast.com"},{"key":"Vary","value":"Accept-Encoding, Origin"},{"key":"Content-Encoding","value":"gzip"},{"key":"X-Request-Id","value":"24f6a84a-b0c3-4696-8268-345ffe355a53"},{"key":"X-Runtime","value":"9.731286"},{"key":"Referrer-Policy","value":"strict-origin-when-cross-origin"},{"key":"Expect-CT","value":"enforce; max-age=3600"},{"key":"X-Cache","value":"Miss from cloudfront"},{"key":"Via","value":"1.1 9d2cb76b4db7323ef3d6d8eca4a4fe54.cloudfront.net (CloudFront)"},{"key":"X-Amz-Cf-Pop","value":"DEL54-P1"},{"key":"X-Amz-Cf-Id","value":"qk2ZL2bxqDbsgs53pZneOWm4kQ7jityuRSnhR3cwVixf-o7cPzBmyg=="}],"cookie":[],"responseTime":null,"body":"{\n \"cards\": [\n {\n \"id\": \"ECL-5d04e360-16ce-4e6d-bf3d-33d29b43c466\",\n \"slug\": \"efficacy-and-safety-of-guselkumab-in-patients-with-active-ps\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-05-08T19:46:47.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) | Annals of the Rheum...\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9286458,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/5SxOMo6PQbiaJXaykk7J_3.cover-source.jpg?file_detail=141b0877a76985163caa5b6767230f56837b1c8ec1c552a906ee444f0fc915f1ecbbb3ca14a59d9f524fe160d7c46022ab8ea16f588f2f398436c12e2fde88c59f19036c41903a127e2c9c464b47415e7d9fd12b84d4d88e16e8103df7c7a4374de1951d8905c9b4435d46dc7bfecafa:560c25dd0a6e506923e48bdaa852029d:16762370e0b1c7a5c6a18d99b7f25863&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM3Ljk4MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.TBIMFgSMR0wjZ-TcOQIMqM9Y7OT3bEzoGXCTQk8GAUA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQxfX19XX0_&Signature=JPDFumwLqlBCCw4X~OSf5QmV1qFkfYdiGuCMRPMKEkdi8vWz67R-0uRiyDbjMVYZDCi3VHcs6IwBvVgwffIcc~8UK0Xd8WOZ79hIITK2WqXp2ea0a2I~2RFnQjz4J7aobdl49og8L0GbF4qxJ0MjoxNa5QPdD0rf9dcKv4R~cyUQjJbSS-RPzhJvgeMAKF32q1tr6to-AjB0sOTy4pOwQ78cPWn7ctYMU0GwT~w2e08MeTw0JUOL6BucdVWXGLc6IGQNQm8-guAjr9S4dBlEfXd4pTPmroM2y7w9LlifeDkhZ~Osr99MxvkfHUN~zur5R8h6HzFbPp2TRXGM~JK0pA__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) | Annals of the Rheum...\",\n \"description\": \"Objective To evaluate efficacy and safety of guselkumab, an anti-interleukin-23p19-subunit antibody, in patients with psoriatic arthritis (PsA) with prior inadequate response (IR) to tumour necrosis factor inhibitors (TNFi).\\n\\nMethods Adults with active PsA (≥3 swollen and ≥3 tender joints) who discontinued ≤2 TNFi due to IR (lack of efficacy or intolerance) were randomised (2:1) to subcutaneous guselkumab 100 mg or placebo at week 0, week 4, then every 8 weeks (Q8W) through week 44. Patients ...\",\n \"url\": \"https://ard.bmj.com/content/81/3/359\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109364977\",\n \"publishedAt\": \"2022-05-08T19:46:47.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4039317,\n \"message\": \"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) | Annals of the Rheum...\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9286458,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/5SxOMo6PQbiaJXaykk7J_3.cover-source.jpg?file_detail=6be9db991cc1451b81c0eb053f46a6729ba29866dc5799a551aa073bda01a54fbb9c9bea5ebd616fe57e0a8f0742c1fc40de1999987bf0e5621834d192eb3181d84d2f39a0e28fd2c96b8dbcd910e9273e6e9d19533e6b2129376e37dccfaa090a3e99ff3f4c9c74056076997af734d9:89460fe41ca94bc4ead21c51c5dc8630:51ca96b25e82f275b3457ff913e54dea&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM3Ljk5MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.vZxw8XL4AM9pY8Xv6YV_NO2CTsTaTMQK8yVDFeoTWYU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQxfX19XX0_&Signature=JPDFumwLqlBCCw4X~OSf5QmV1qFkfYdiGuCMRPMKEkdi8vWz67R-0uRiyDbjMVYZDCi3VHcs6IwBvVgwffIcc~8UK0Xd8WOZ79hIITK2WqXp2ea0a2I~2RFnQjz4J7aobdl49og8L0GbF4qxJ0MjoxNa5QPdD0rf9dcKv4R~cyUQjJbSS-RPzhJvgeMAKF32q1tr6to-AjB0sOTy4pOwQ78cPWn7ctYMU0GwT~w2e08MeTw0JUOL6BucdVWXGLc6IGQNQm8-guAjr9S4dBlEfXd4pTPmroM2y7w9LlifeDkhZ~Osr99MxvkfHUN~zur5R8h6HzFbPp2TRXGM~JK0pA__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) | Annals of the Rheum...\",\n \"description\": \"Objective To evaluate efficacy and safety of guselkumab, an anti-interleukin-23p19-subunit antibody, in patients with psoriatic arthritis (PsA) with prior inadequate response (IR) to tumour necrosis factor inhibitors (TNFi).\\n\\nMethods Adults with active PsA (≥3 swollen and ≥3 tender joints) who discontinued ≤2 TNFi due to IR (lack of efficacy or intolerance) were randomised (2:1) to subcutaneous guselkumab 100 mg or placebo at week 0, week 4, then every 8 weeks (Q8W) through week 44. Patients ...\",\n \"url\": \"https://ard.bmj.com/content/81/3/359\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-1e836401-5d0b-45c1-8253-abc211c02502\",\n \"slug\": \"the-safety-of-jak-inhibitors-pubmed\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-07T11:07:44.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"The safety of JAK-1 inhibitors - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9022727,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/INhWZm9VQHebdunOxifT_pubmed-meta-image.png?file_detail=716a102ffd205e902225660346b679ca36f42ea65d610205a8dc653c9bc6891f9dfd01cafc83ff1312e7c514b2cfc6006a63656ac0858f6392cc698274979e7f4d3f558f25bdccd9311f377904eda932e8b24674e10a7d3978f0d78402d59fa3dadde0c264ef38913722f0b15b603594:80cb1fd03dfe70356c1feeade74ef86c:d74fc55bf01a8b25438bd38e3b57989f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjAwNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.LD8K2Pnjf2CLqUv6DSexxPTadKsd2YXm5XloHYwWVIw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The safety of JAK-1 inhibitors - PubMed\",\n \"description\": \"As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; m …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33950230/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109058732\",\n \"publishedAt\": \"2022-02-07T11:07:44.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3733245,\n \"message\": \"The safety of JAK-1 inhibitors - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9022727,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/INhWZm9VQHebdunOxifT_pubmed-meta-image.png?file_detail=82d66ed220da1fd2baf3a04990cc235d9669060a3479e6dabec8b319a5183f5e5cb79e9faa302fd838116aa0c793ebfa31b766e2872763d419efccefb5f49ab50e550a88ee4138cb9ede0fbc95a6e9b771f9d65b6731b3ffc2d470467b557c28a8a45c6fa55d42c75adf74a50618e9d7:b26cd764928972db78f31b6c338ce962:6fb5747473f109c194285e2fc830544c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjAxNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.bjruI7sTCzq9-npfkOZXpm5ZzfL6zNJbFq7PPq_K3ig&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The safety of JAK-1 inhibitors - PubMed\",\n \"description\": \"As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; m …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33950230/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-21d99b82-c5c5-465c-9227-4122add13c6d\",\n \"slug\": \"patients-with-early-onset-primary-sjogren-s-syndrome-have-di\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-13T01:50:45.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Patients with early-onset primary Sjögren’s syndrome have distinctive clinical manifestations and circulating lymphocyte profiles | Rheumatology | Oxford Academic\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9045015,\n \"imageUrl\": \"https://oup.silverchair-cdn.com/oup/backfile/content_public/journal/rheumatology/61/2/10.1093_rheumatology_keab367/2/m_keab367f1.jpeg?Expires=1707570907&Signature=E6iy1XbR-FH7ZYDgIphcMqbt5wEnM~WBUf1mK6QSe~ajILNBNPU6YuMqcgWXLdww952Al71Vm0D237q3UYanqDJhTV8zNHFQtMgTv4Fl5Rpxl7IhN~juLDoP0C~uMI-dJViLAecWf3KJ9Bo7UMYev9-Dqn~luaW~qE7NJPVZLzVzRpa0vAG0ODjR56pjgxtB3~eZqaYYVM~NfwFK16GbPUWo-izkPuusFOHyCbUruamRJPgEh5M9mFdqjBX7Tgu2uNz08zxTBlLh1YyZLEed5k76RgC~Swf6CvnCL2qHmvrrKRJQG1ji1lvd8m5uFaGCQorUzrpPRyYJeriMkphb4Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\",\n \"title\": \"Patients with early-onset primary Sjögren’s syndrome have distinctive clinical manifestations and circulating lymphocyte profiles | Rheumatology | Oxford Academic\",\n \"description\": \"AbstractObjectives. To further investigate the clinical characteristics and circulating lymphocyte profiles of patients with early-onset primary Sjögren’s syndr\",\n \"url\": \"https://academic.oup.com/rheumatology/article/61/2/597/6241090\",\n \"siteName\": \"OUP Academic\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109082045\",\n \"publishedAt\": \"2022-02-13T01:50:45.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3757618,\n \"message\": \"Patients with early-onset primary Sjögren’s syndrome have distinctive clinical manifestations and circulating lymphocyte profiles | Rheumatology | Oxford Academic\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9045015,\n \"imageUrl\": \"https://oup.silverchair-cdn.com/oup/backfile/content_public/journal/rheumatology/61/2/10.1093_rheumatology_keab367/2/m_keab367f1.jpeg?Expires=1707570907&Signature=E6iy1XbR-FH7ZYDgIphcMqbt5wEnM~WBUf1mK6QSe~ajILNBNPU6YuMqcgWXLdww952Al71Vm0D237q3UYanqDJhTV8zNHFQtMgTv4Fl5Rpxl7IhN~juLDoP0C~uMI-dJViLAecWf3KJ9Bo7UMYev9-Dqn~luaW~qE7NJPVZLzVzRpa0vAG0ODjR56pjgxtB3~eZqaYYVM~NfwFK16GbPUWo-izkPuusFOHyCbUruamRJPgEh5M9mFdqjBX7Tgu2uNz08zxTBlLh1YyZLEed5k76RgC~Swf6CvnCL2qHmvrrKRJQG1ji1lvd8m5uFaGCQorUzrpPRyYJeriMkphb4Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\",\n \"title\": \"Patients with early-onset primary Sjögren’s syndrome have distinctive clinical manifestations and circulating lymphocyte profiles | Rheumatology | Oxford Academic\",\n \"description\": \"AbstractObjectives. To further investigate the clinical characteristics and circulating lymphocyte profiles of patients with early-onset primary Sjögren’s syndr\",\n \"url\": \"https://academic.oup.com/rheumatology/article/61/2/597/6241090\",\n \"siteName\": \"OUP Academic\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-2947a762-aca0-4950-b09f-3c714459b112\",\n \"slug\": \"evidence-for-the-use-of-secukinumab-in-patients-with-radiogr\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T21:07:43.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years | SpringerLink\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018081,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/NM3B1s9kTkuqcpuDmmXr_40744.jpg?file_detail=aed3d157f4cee27e9438b7f58b5c1a01fe2cd2220c97d5a63e2fe5bb4c5af8a4099f230279361b0889a1ad6366bd31d7ec232a6d3cf251e3ab960f4f2e7d0095a946a9c28d2709c3479c2c16bc615beabab13d8846dcc28643939df2c485635c:0cd528a4c7a491924beea03f49302d17:b5917fa3be755639993c8110d809e553&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjA0NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.30JmjeEJFxA5Ne53W1YisgeGvVGG1c9Ej6fJOCvV_zU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years | SpringerLink\",\n \"description\": \"Axial spondyloarthritis (axSpA) is an inflammatory rheumatic disorder that causes chronic pain, primarily in the spine and sacroiliac joints. It is charact\",\n \"url\": \"https://link.springer.com/article/10.1007/s40744-021-00400-1\",\n \"siteName\": \"SpringerLink\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109054015\",\n \"publishedAt\": \"2022-02-05T21:07:43.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728545,\n \"message\": \"Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years | SpringerLink\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018081,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/NM3B1s9kTkuqcpuDmmXr_40744.jpg?file_detail=2a5bb59da661ad8fca1ccd7d720e8230b4eceef613bb7b1cfb2240cd2dbb144c019e81f5ed060394df6410bce672d6571c402df84147ea5ec11392d393765e990a76a316d1fb9d9b0e7defaddb0e48685ed5f2e1e12ff46c8e89e70232f5faab:393ce4351e1f0d76c67ad6926ee67853:df5edb4842cd5ce2b4bc494cbe09ca3b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjA2MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.AcR9FIhajPJJmQ3UXTTxCUGYNTcVZA2W5u165yjjR80&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years | SpringerLink\",\n \"description\": \"Axial spondyloarthritis (axSpA) is an inflammatory rheumatic disorder that causes chronic pain, primarily in the spine and sacroiliac joints. It is charact\",\n \"url\": \"https://link.springer.com/article/10.1007/s40744-021-00400-1\",\n \"siteName\": \"SpringerLink\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-1a866fb0-3d13-4655-81e0-e005964dbed1\",\n \"slug\": \"incidence-and-clinical-predictors-of-psoriatic-arthritis-in\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-12T20:49:25.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population‐based study\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9044961,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/1CnqMzxnSQaSN4k2WsCr_creative-business-background-with-globe_fyCRNR8u_L%20(NXPowerLite%20Copy).jpg?file_detail=ac95381e506cda76bced731ee7ebcc361ade9525113ba78a9c1e04736b7572c61b209daecf554e9e45d5d417dbb28b43e7aed1f50b8e649a2604f91286cfdb4ce33d9a9633401a442e15a7e5057b3333baa7f95cfe501704868132286e2b8eee1db0aa118985a979be3c9e611d7ccc5cd4f285ece4c07d1cb0d32a39ca642b1ee050aa00ed2b1f291b15abd640011adcebd562086aa2e6403361b5a3d7cc2da8:6f8f26d3a074f440898d730a08dbf33b:cd5ce001895ef7ed971759c8818d0e54&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjA3MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.2M0qfBajnQ33c0cfrVtFIn-N3x4Ntp7egphmWo_79kU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population‐based study\",\n \"description\": \"Incidence and clinical predictors of PSA w PSO\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.24172\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109081982\",\n \"publishedAt\": \"2022-02-12T20:49:25.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3757555,\n \"message\": \"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population‐based study\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9044961,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/1CnqMzxnSQaSN4k2WsCr_creative-business-background-with-globe_fyCRNR8u_L%20(NXPowerLite%20Copy).jpg?file_detail=5ea423e5480ba4993028ea5cfb28a2e49b68d43533fd8e88cf29bc230255df067bb1afe31d52ca176aa131b0641632b18e25f375b705c2c2292d71b2e20dcd41e6a3207a34e1dd7cce22a9eca6b30e7525d3baa433873aeda1378e29ec27acd2d2087f3d0581d1798089619f403f71058124eb7468ab6072e17e2004574315a3d5e62c9b09d382dc8dbe50455bbe8dd06040bb65237b1d0ad79f677592e2a8f8:6f80d15879671314a846c0a42a53ec0b:98c5034ea9d001296d4230a6feeb99ba&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjA4MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Hh5wMD7cOUnnuTBfePt3_Vq1u4WHLXSg8m4pV2AWhOw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population‐based study\",\n \"description\": \"Incidence and clinical predictors of PSA w PSO\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.24172\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-354b50c2-fe6e-4b11-ab78-780c48989f64\",\n \"slug\": \"secukinumab-provides-clinical-improvements-in-patients-with\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-09T00:27:47.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab Provides Clinical Improvements in Patients with Active Oligoarticular Psoriatic Arthritis: Results from a Pooled Analysis of 5 Phase 3 Studies - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9027999,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/kGNtKJoAQwS778f7YdoG_ACR_1063501_1.jpg?file_detail=f879fff62efa173d28abf4c2e021874b814be8fd646d8a7eb9b0d23bfadfbf4645fd9d4d14a6fa93137077a168266707529530bc5d5c56d7410e8008d190d2f13de6ad4171f9afbb3b21c2d7c9590842c47ba8cca7d25af3eab3aaebf499d0cfc6a92cad5afb1d8c17709ce831afa12f:dd3548a17e49d7866a578086f12a56f2:5e82f1dd8ae44823d3a6f9317982fe0f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjA5NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.euNR189EOb2hU2i22U9dKTJyh5_UWUhZpMBPKj86924&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Provides Clinical Improvements in Patients with Active Oligoarticular Psoriatic Arthritis: Results from a Pooled Analysis of 5 Phase 3 Studies - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Oligoarticular psoriatic arthritis (PsA), defined as involvement of ≤ 4 joints, affects approximately 50% of the PsA population.1,2 Disease burden is comparable for patients with oligoarticular or polyarticular disease, and most patients progress from oligoarticular to polyarticular PsA.1,2 Evidence for the efficacy of biologics in patients with oligoarticular PsA is limited, as inclusion criteria […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-provides-clinical-improvements-in-patients-with-active-oligoarticular-psoriatic-arthritis-results-from-a-pooled-analysis-of-5-phase-3-studies/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109065111\",\n \"publishedAt\": \"2022-02-09T00:27:47.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3739592,\n \"message\": \"Secukinumab Provides Clinical Improvements in Patients with Active Oligoarticular Psoriatic Arthritis: Results from a Pooled Analysis of 5 Phase 3 Studies - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9027999,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/kGNtKJoAQwS778f7YdoG_ACR_1063501_1.jpg?file_detail=84192c4a54d63a894533d17d67ea52046e992cf2f1e98ac9e116d34ed72d713f2f22c9bb7753ae0a60a3414ea90e05438cb6bf84fd794da8dbf0f320727406f1287d1c394362dab50eb9f02c46bcd65600da66e067ff8530fc20ca1b3f26ebcb2c6af98209c64b0daaeaab2e1e29dd99:b825c2f7c603ca56a00eb78218be8a10:57ba31d01767375b571d1dc135ca72d0&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjExNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.oOkN6rxMrEognQv0DX3EeovBMMeCJj46s8v2mWTwPzg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Provides Clinical Improvements in Patients with Active Oligoarticular Psoriatic Arthritis: Results from a Pooled Analysis of 5 Phase 3 Studies - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Oligoarticular psoriatic arthritis (PsA), defined as involvement of ≤ 4 joints, affects approximately 50% of the PsA population.1,2 Disease burden is comparable for patients with oligoarticular or polyarticular disease, and most patients progress from oligoarticular to polyarticular PsA.1,2 Evidence for the efficacy of biologics in patients with oligoarticular PsA is limited, as inclusion criteria […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-provides-clinical-improvements-in-patients-with-active-oligoarticular-psoriatic-arthritis-results-from-a-pooled-analysis-of-5-phase-3-studies/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-3558f69b-9010-4f8f-a01c-a77c9f91a052\",\n \"slug\": \"structural-damage-in-axial-spondyloarthritis-is-there-a-pre\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-09T00:31:14.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Structural Damage in Axial Spondyloarthritis: Is There a Preferred Way to Assess Progression over Time? - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9028003,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/UAL8ylMwQvKWDcEEGqgR_ACR_1062800_1.jpg?file_detail=e4dc7d6fff336f48899f34c10e389e0d42b2a7e1a9363e6b8c174e58e4fb31eb0ce161793c08d52bde56f05e8eab0d69a9f9459c2fc3302120049c6d62d2ca089b7db6b72799b756cf825b798c19a3424382b84ec688d6b4e9f65a809b247e952f9e9b2d71ad24d00b0324f9aabf32d1:05dfdfa5cf787222ba970e017c1dd470:c52caebcbb943f0fe96a6eb5b7112da5&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjEyOSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.dIy5eIoxSWBLPTaHjtJIqdh5L7rIjatP5sla-a1OZRI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Structural Damage in Axial Spondyloarthritis: Is There a Preferred Way to Assess Progression over Time? - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The aim of this study is to investigate the performance of the modified Stokes Ankylosing Spondylitis Scoring System (mSASSS) in assessing spinal radiographic damage and progression in axial spondyloarthritis (axSpA) using different approaches of radiographs (CR) evaluations. Methods: Complete sets of cervical and lumbar CRs of patients with axSpA from the German SpA Inception […]\",\n \"url\": \"https://acrabstracts.org/abstract/structural-damage-in-axial-spondyloarthritis-is-there-a-preferred-way-to-assess-progression-over-time/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109065113\",\n \"publishedAt\": \"2022-02-09T00:31:14.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3739594,\n \"message\": \"Structural Damage in Axial Spondyloarthritis: Is There a Preferred Way to Assess Progression over Time? - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9028003,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/UAL8ylMwQvKWDcEEGqgR_ACR_1062800_1.jpg?file_detail=ae6184cb066c0899e46d26ee909e5a66f38f2371932f819404e720a2f29c277c869f167785bce5348b8f9f291c19d234418b9dcce050ec6306792dea6efb89852cd17885ea8756ccf4ad539723172706076324e965b075b459a1da78cc7e62988387ff4d31eb8247278e533f7cd76d87:86ca84b4d89b20fad0367c1986431157:02b2ec59174dfc226a445be14a5ad68e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjE0MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.9Di4XnOO3jNsR6b6Fo5zBxLjKFkUhHRu053drQT0ugA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Structural Damage in Axial Spondyloarthritis: Is There a Preferred Way to Assess Progression over Time? - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The aim of this study is to investigate the performance of the modified Stokes Ankylosing Spondylitis Scoring System (mSASSS) in assessing spinal radiographic damage and progression in axial spondyloarthritis (axSpA) using different approaches of radiographs (CR) evaluations. Methods: Complete sets of cervical and lumbar CRs of patients with axSpA from the German SpA Inception […]\",\n \"url\": \"https://acrabstracts.org/abstract/structural-damage-in-axial-spondyloarthritis-is-there-a-preferred-way-to-assess-progression-over-time/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-2bf9b6ae-2701-403c-b8f9-10632727b3b6\",\n \"slug\": \"secukinumab-versus-adalimumab-for-psoriatic-arthritis-compa\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-07T10:57:22.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9022701,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/6szozBATqyWZKQO41u4Z_pubmed-meta-image.png?file_detail=628a28d8279e942018765c17087613f03d694264ad896d946a67395184dc4d5a2125630864c728c6309f9a3985976345909d68cdab497079db8d93440248797c658ccce6006a82e4a2ea3f81e408cc1643cc3ddf74c90348120dddcc7f4b9f8f806fa3e272105a7a81fd44e662d3c85a:987a8603c86bd0c31b2e168501a158ad:23e632193782e870d8af05350de212aa&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjE1MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.7sSR8hn93OzAnfF8I_mzaeGSvvfGmk4YXwCnGF_YIQc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison - PubMed\",\n \"description\": \"Novartis Pharma AG.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/29605841/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109058700\",\n \"publishedAt\": \"2022-02-07T10:57:22.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3733213,\n \"message\": \"Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9022701,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/6szozBATqyWZKQO41u4Z_pubmed-meta-image.png?file_detail=52a8dcf15fa1fe79a23184b6e93036a54e88ed4c54fc714d9fb0bc26b776ad659890e80f77c549815aeb3efce6f1866d252f105f166508228a0d33feb96d265fc669510c6d85c31c838d3d78b8a4ea3e27e9533e37e80651df0447c69664be09c93295a9cace71e3f3b5796cb8b83a11:61244aae52facf737ad8ff16c52abe6f:2e5d417d8c85753c9f768c16feaa1093&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjE2NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.oBJP-rboyMmTwa3wl8SqScLEAT-3CxU7uTcTB_3DpbY&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison - PubMed\",\n \"description\": \"Novartis Pharma AG.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/29605841/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-2beb3575-6ca2-4f4f-afd7-030efc744871\",\n \"slug\": \"biologic-treatment-of-primary-sjogrens-with-ianalumab-rheu-biologic\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-02T21:21:29.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Biologic Treatment of Primary Sjogrens with Ianalumab | RheumNow\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9011379,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/p0e6W2e2RQyJ1n0AuOxT_Sjogren_syndrome_salivary%252520bx%2525282%252529.jpg?file_detail=e7cc24ffcc09a865ddc863eb2cbb9eb78800098980737bb7336aa89ac2287b6fda27ac64fc64dd215a51327aa310d58677dbeeea22af7b761e451a0538b159e4280ae8a1127f41a2e2aaf6d2ce625c1d55e58404acfdf35454a085f19db22267a4af19cf58266fb988678721c05ad337d14598375b66a6de2ce968194d7150ac:3d435188414c3ce17a14d304a4047299:5f3940a948433f3c045e3df8c226259f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjE3NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.SuU2EwfErx3ZuBKNBc1lPV9CNA2TQl3hDsUHDNlfqV0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Biologic Treatment of Primary Sjogrens with Ianalumab | RheumNow\",\n \"description\": \"Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.\\nThis was a phase II, dose-finding trial, aimed to assess the safety and efficacy of different subcutaneous doses of ianalumab in patients with moderate to severe primary Sjögren's syndrome. The primary endpoint of the study was the EULAR Sjögren's Syndrome Disease Acti...\",\n \"url\": \"https://rheumnow.com/news/biologic-treatment-primary-sjogrens-ianalumab?utm_content=bufferecc30&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109045640\",\n \"publishedAt\": \"2022-02-02T21:21:29.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3720229,\n \"message\": \"Biologic Treatment of Primary Sjogrens with Ianalumab | RheumNow\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9011379,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/p0e6W2e2RQyJ1n0AuOxT_Sjogren_syndrome_salivary%252520bx%2525282%252529.jpg?file_detail=a51f28701e19ec159fdbb3e6a357e76671cb401718df8b79a9fbf1bc33a3ee4bd09fe1e6970a9b1db96581b3a341bd0e1a442137350ed2921a9ffc1da7ed002ee3f6e394fbffa9ebac9f5ed7d92ec103c36167495c18181cd44363118e26fcc5d686606bcd624f65684097ba3c980d0a835e4621b396e1c779d9274a4af8252b:b3af3af686219a11bf4f24bf3c9644ab:fff55622ac7643325e7719d5e5fdc779&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjE4NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.-2DGjS0Tauf3ftazQK1EwyoeYiKh62uGN9P4ozhdRSk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Biologic Treatment of Primary Sjogrens with Ianalumab | RheumNow\",\n \"description\": \"Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.\\nThis was a phase II, dose-finding trial, aimed to assess the safety and efficacy of different subcutaneous doses of ianalumab in patients with moderate to severe primary Sjögren's syndrome. The primary endpoint of the study was the EULAR Sjögren's Syndrome Disease Acti...\",\n \"url\": \"https://rheumnow.com/news/biologic-treatment-primary-sjogrens-ianalumab?utm_content=bufferecc30&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-4cd252eb-7a15-4cc3-86d8-822296b43c8a\",\n \"slug\": \"interleukin-levels-are-increased-in-juvenile-idiopathic-a\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-13T12:53:52.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9045585,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/T1KwBMqgQHM4S3TETUPz_pubmed-meta-image.png?file_detail=402eb4db4b02728024f47f39c52ea3535f9724dddc9dd3c77cff69b6227ad773b2d515c0587086f563bd2c2468c6df9c4a0ba0e30bae30a18d69c60d62f0953a15b5cead74ca948bd5bb4624d6e022947d271b202df31779cbe0fd6b8649fd2d964e7ca26cdb083fadf6332a9aa9072b:6cd36e990418d9ff0440ed906eaeaca7:de0a6f7c1caf8487c76af89c5252d06d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjE5OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.2cLApAtXedcgA2rziIxLHbP4qQcPwYZ6ICJJuC-VL_A&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases - PubMed\",\n \"description\": \"Increased IL-17 levels in ERA SF correlate with disease activity and this may be due to increased production of MMP and cytokines by IL-17.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/18203309/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109082585\",\n \"publishedAt\": \"2022-02-13T12:53:52.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3758155,\n \"message\": \"Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9045585,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/T1KwBMqgQHM4S3TETUPz_pubmed-meta-image.png?file_detail=d0d92f5128e72a46e65b8cd4e0f9695619d945c5f35c999e45d77e5ebb92d8a7ec69e8c18809b5563096846a94038003a24aa4bd7f0f76108bce322d12ae499c3e3413ac10030273520f920b22797061bdcccf4a1d5f07a5dece9b350319b3056a3ed326b18ecb7afe84186aa2c19aa2:93b5284aa8be1d56f320a124c5c0c9cd:76d71361430aede03706e8ac30b1a74c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjIxMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.eA31nBg-aFltS4B6wnRrv2D_Q219L5Aqop02UM0NL9Q&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases - PubMed\",\n \"description\": \"Increased IL-17 levels in ERA SF correlate with disease activity and this may be due to increased production of MMP and cytokines by IL-17.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/18203309/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-3c623bbb-6292-41d5-9850-5ff9d746d57f\",\n \"slug\": \"il-a-inhibition-by-secukinumab-induces-early-clinical-his\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-06T12:21:16.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018517,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/3qU4ZnUQ9azwjf6n9X9w_pubmed-meta-image.png?file_detail=7fd04cb14d03e8e77ec0c6998739868fbec3f06809a25debe57ff98457c067bf4fd81a4f3bfd7b76be65b021e1d49d7ba72bbd50508b1651c9d93bc00aae7e3264bcf447f9f7d1ede69136383b5c3c63763bbc222ea8f0d37014bbe54633665b02aa05742566e9dff4c164795a3faf5e:06ae56024d73864ef0881908b410384b:c241f7afc6c75bc44d1357f78d442df7&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjIyMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.nyKYYuJA02UFZZ9yWmLR6Yo0_Udti8WUZ7DhsUQ0iqg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis - PubMed\",\n \"description\": \"Our data suggest that IL-17A is the critical node within the multidimensional pathogenic immune circuits that maintain psoriasis plaques and that early reduction of IL-17A-dependent feed-forward transcripts synthesized by hyperplastic keratinocytes favors plaque resolution.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31129129/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109054441\",\n \"publishedAt\": \"2022-02-06T12:21:16.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728959,\n \"message\": \"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018517,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/3qU4ZnUQ9azwjf6n9X9w_pubmed-meta-image.png?file_detail=65d5ab1f89459de81a156ee2c74ab5d6d06fe5d6a53b2eaf73817d5f18bcb3b7e1d0fe03de87b6b16228fe4d003b4f2ee9a5d746350e3843b4372e6a0fbbea71c11a277fc60d3979567a8bbe5e02256e3614ed939827c77216be65ecd6344766e45193121cecefe65aeb8acf31b175f5:7388a6d3f824647275778a48ea5c5b60:40ab35c4d6894858e9735f776ee09a51&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjIzMyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.iuXxBLehNjd_oQFEmqL_1vJ1FWjH5pWSPgsNqx6Cz9I&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis - PubMed\",\n \"description\": \"Our data suggest that IL-17A is the critical node within the multidimensional pathogenic immune circuits that maintain psoriasis plaques and that early reduction of IL-17A-dependent feed-forward transcripts synthesized by hyperplastic keratinocytes favors plaque resolution.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31129129/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-5babe4cd-5853-40a3-ae93-f30889166332\",\n \"slug\": \"the-epidemiology-of-psoriatic-arthritis-over-five-decades-a\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T20:18:06.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population‐Based Study\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018053,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/VBcEqF3iRWmNnZnORH8w_art.v73.10.cover.jpg?file_detail=37b055720f8758d998cf25fb4abbb5546b0c2f130fa649e45eafa6c32ea644f0f8bc087961c8871b218cc1b3baaa3f35f80ab2d717853e5ff97fd569e1852ff8c5a404d182d397bbba718861cd4f3e54a5c43d06cfa56c46cf2086362746f5ce518caecf5dfaf48e1db2dc0e1fba4288:ac6d0036bfb122edcb83e7857aca140b:83773c37f929bc4519b2d5313ff98ac6&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjI0NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.W2q2eLDmk3t2biozbSjLoyy8GuTnjFliuv1TzahbiX4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population‐Based Study\",\n \"description\": \"Objective\\nTo determine the incidence of psoriatic arthritis (PsA) in a US population and describe trends in incidence and mortality over 5 decades.\\n \\nMethods\\nThe previously identified population-bas...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.41741\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109053989\",\n \"publishedAt\": \"2022-02-05T20:18:06.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728519,\n \"message\": \"The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population‐Based Study\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018053,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/VBcEqF3iRWmNnZnORH8w_art.v73.10.cover.jpg?file_detail=cb958d3f0074faac3ee210b4416d1b432e19a293c81d6f3f11030a9b2acc30d35a8e98e377eae179bbec2ed68fb8d0e737c86d8d958d2e12105928077933a1c178742a33f78b5ffe7a7c5137111c0e34cdfdb077db367c0c2312c878925f6fb459cd7cd1cc7275a97683a2e8d630c089:6d2e38cf41cbbd32d4ac069363447129:1af02e0573ee602077ed9c0389bb99ba&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjI1NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Xca8JlXJMPIjh_wY9pDN4wl8Nho9WYEGmZFjNkiX8-o&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Epidemiology of Psoriatic Arthritis Over Five Decades: A Population‐Based Study\",\n \"description\": \"Objective\\nTo determine the incidence of psoriatic arthritis (PsA) in a US population and describe trends in incidence and mortality over 5 decades.\\n \\nMethods\\nThe previously identified population-bas...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.41741\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-5c9184cf-55cf-4fd9-9315-326392e9038e\",\n \"slug\": \"secukinumab-effects-on-cardiometabolic-risk-and-systemic-inf\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-09T00:26:25.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies - ACR Meeting Abstr...\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9027997,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/fUQdQRBvSTO3TOJUcdvH_ACR_1066471_1.jpg?file_detail=cdc6a779763335f1a962c826534040972a99d65729980aa866359acc3e58ab4c1deedddef5ea5c97e12a6befda5375b34a9aecfa7e4fac0d9cc2187db0961f24a845800cda3dd9fd71af64629a7461b9dd3e54a156b9b92a76fd7519db84ca5711cef45a90cb3473c1ed96c9dbf640ab:5e8ef3c833880a6284c345cbcdd99de0:ea5464d4358833c243447a5904ff25e2&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjI2OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.jFGdugzcCplU9ix3H_AqbKz9JBdYbsQTssJbRXOMDlM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies - ACR Meeting Abstr...\",\n \"description\": \"Background/Purpose: Psoriasis (PsO), Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (AxSpA) are chronic immune-mediated inflammatory diseases (IMIDs) requiring long-term treatment. Systemic inflammation in these IMIDs is associated with cardiovascular (CV) disease1,2. High sensitivity C-reactive protein (hsCRP) is an independent surrogate CV risk marker. Recently, high neutrophil-lymphocyte ratio (NLR) has emerged as a novel inflammatory biomarker predictive […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-effects-on-cardiometabolic-risk-and-systemic-inflammation-in-patients-with-psoriasis-psoriatic-arthritis-and-axial-spondyloarthritis-results-from-post-hoc-analyses-of-pooled-data-from-19/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109065108\",\n \"publishedAt\": \"2022-02-09T00:26:25.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3739589,\n \"message\": \"Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies - ACR Meeting Abstr...\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9027997,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/fUQdQRBvSTO3TOJUcdvH_ACR_1066471_1.jpg?file_detail=bf47b70a584335b4e89588e30cbccbc9f60f9e0bc16aaa14ea4e3f3825efa0bfb516370ed1ffb20eb4af9b3f29109c883c64965eb225106ce067daa37c38a8125d6acdc92c8b47acd843387bda77a179dd10490fcbd2f0e4c06ef45e82b096a9b74aabea4be9c01c6f63fe585b52fadf:9f54be1979563ff071827ad7f8b1ac64:b99e3977a789726f564d90c694c32f09&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjI3OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.i5-E24nUfCmryrVhVg8_cpGwyKDH0swfGGP5qdSGIkc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies - ACR Meeting Abstr...\",\n \"description\": \"Background/Purpose: Psoriasis (PsO), Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (AxSpA) are chronic immune-mediated inflammatory diseases (IMIDs) requiring long-term treatment. Systemic inflammation in these IMIDs is associated with cardiovascular (CV) disease1,2. High sensitivity C-reactive protein (hsCRP) is an independent surrogate CV risk marker. Recently, high neutrophil-lymphocyte ratio (NLR) has emerged as a novel inflammatory biomarker predictive […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-effects-on-cardiometabolic-risk-and-systemic-inflammation-in-patients-with-psoriasis-psoriatic-arthritis-and-axial-spondyloarthritis-results-from-post-hoc-analyses-of-pooled-data-from-19/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-5f81708e-3bbb-4b77-a586-5e4b85f87aa4\",\n \"slug\": \"measures-of-psoriatic-arthritis-tender-and-swollen-joint-as\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T12:09:39.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds ...\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9017710,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Wq3VpIpeSDqvFDgFtFdP_acr.v63.11s.cover.gif?file_detail=13fe5966d87857f3f9b008379e82b6e9ddca1fd26f8ccfcd1a7c49cf61cde56abce5d11f3024d4e7b10097f28b19d4ac9e19e91e7b444dd78f23759baa7291692b3196b92606f5f6a3db057c11bac2f26a8f334ff4aacafc9b8c92b83e3f404ba14d0a7b0956f7d6355ebb88e14dc5ac:62a65ba4f79aa46f2567d3080982cbf0:cf2203206366f7fe560b5bdecce93ec8&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjI5NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.V0YpGS535vnRryy_ARtcUX9ntJXA6uvZCTW36u9Pkig&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds ...\",\n \"description\": \"Click on the article title to read more.\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/acr.20577\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109053650\",\n \"publishedAt\": \"2022-02-05T12:09:39.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728181,\n \"message\": \"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds ...\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9017710,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Wq3VpIpeSDqvFDgFtFdP_acr.v63.11s.cover.gif?file_detail=60f0a882f9c24537a8d8c3b17c358c62d3f1879bf83801c2e1215689843ea205aa93dfc1901b4abf9bb27b291bc950b9a0630882ecdef1c7c0a9dfaa322b98f77c9f3aaa1fcbf077b1b8380b2e5d425ec8c0f265f2779dcf70f9232a89075fad8ed584d227b61804449d11c4604f274a:63387ca915f06a514cb8144c64bbaa8f:2b78e4aa3d2cdf18f0b53193d77ac917&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjMxNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.4LrmAU8orH7zxaf3bdk3txIr7OR31qWlv4qgonWorGw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds ...\",\n \"description\": \"Click on the article title to read more.\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/acr.20577\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-e25952ef-9f5f-4d22-83cc-82d7ab0d1b93\",\n \"slug\": \"il-23-il-17-in\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-04-28T14:05:27.000Z\",\n \"duration\": 300,\n \"title\": \"IL-23/IL-17 in AXSPA\",\n \"message\": \"IL-23/IL-17 in AXSPA\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": null,\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109336719\",\n \"publishedAt\": \"2022-04-28T14:05:27.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4011220,\n \"message\": \"\",\n \"language\": \"en\"\n }\n ]\n },\n {\n \"id\": \"ECL-ddca0d00-94d1-4767-abf2-20156aa342cd\",\n \"slug\": \"real-world-months-psa-response-retention-remission-rate\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-05-05T17:07:23.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Real-World 6-12 months PSA Response,Retention,Remission Rates PSA Cosentyx\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9280329,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/PHIg7yMlSEy1NmeqpQIX_AS6_9217-268%20(NXPowerLite%20Copy).jpg?file_detail=6f2aaa58f5d8871f7fe017890f803104020fc85ce5535734cdbfbef23b9f7f9850dec48e40b8b1ce60b7a6de9f2bcc5e45ff8ba4561ae64f98a85056bb1602eda6e96ebf657966365040491ac61612dd212d01b1f436315c145d448c8c2adad72c391e7300c1124f578cd6600f544a9382673d7d7f22e1680ac71de842c9b466:81f1030f41c0a1d0605baecd086c8a0e:c668cca41886770c8d1ac48d51a42d78&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjMzMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.mnZYtjPne3mIM7hOVan6PZbibZxXKAh0SjI-eksyInQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Real-World 6-12 months retention,response,remission rates in PSA\",\n \"description\": \"Retention,Response,Remission Rates Cosentyx in PSA\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/acr.24560?af=R&utm_content=bufferae840&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109358294\",\n \"publishedAt\": \"2022-05-05T17:07:23.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4032660,\n \"message\": \"Real-World 6-12 months PSA Response,Retention,Remission Rates PSA Cosentyx\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9280329,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/PHIg7yMlSEy1NmeqpQIX_AS6_9217-268%20(NXPowerLite%20Copy).jpg?file_detail=612993124cc0bd7eb892fcf3bc564d310b2b9b985d6e8e321c9f42790f812adfcf46688cc65d892daa43afdd3a5b92a43fb2530da79cd979f052b12d5caab91dddea32d59f417feabaabad518d43efe5219b202864f8ddb7ff038dc124448acbe3ff5f01b99e36ce84ef7989bcef9881277f7e8a0e1521b23641ede69f891b7c:c57a0a09cc28ed405f860cadfc3266d1:85a62c345b31c218c7a2bcf45f3c9dd3&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjM0MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.q8DNsftsOEq7JXx-E_5troWjHLpI2-T_f0LBJRNZ4fg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Real-World 6-12 months retention,response,remission rates in PSA\",\n \"description\": \"Retention,Response,Remission Rates Cosentyx in PSA\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/acr.24560?af=R&utm_content=bufferae840&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-4d35946f-0ce1-439f-9351-d656b27e8586\",\n \"slug\": \"efficacy-and-safety-of-selective-tyk-inhibitor-deucravacit\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-05-02T00:36:04.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis | Annals of the Rheumatic Diseases\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9269511,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/5NsUH3mHRVe74qBUtZya_5.cover-source.jpg?file_detail=083be541461171e80bdc346745262d7cad9b3d76f17e9662638604db73b1b56d2c9ecc605e8e705bc4867fc1946ff4f53af46a3fb11cf7e630c5afcd7a6679474fdd6f651ec3431855192edc64c36fd8a02a982c93987b7b593e8d24851e1607c50873fdb592c8860e4f112d2b1ea139:f821c418fcc968c0d30aef15c16f1f30:66cec82dc9ee9d738023d24513a6d8b3&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjM1NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.UtTztM7vHDTqBRnpXk1HPAzG41fvYQoVkGbJO8KnIgY&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis | Annals of the Rheumatic Diseases\",\n \"description\": \"Objective To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA).\\n\\nMethods In this double-blind, phase II trial, 203 patients with PsA were randomised 1:1:1 to placebo, deucravacitinib 6 mg once a day or 12 mg once a day. The primary endpoint was American College of Rheumatology-20 (ACR-20) response at week 16.\\n\\nResults ACR-20 response was significantly higher with deucravacitinib 6 mg onc...\",\n \"url\": \"https://ard.bmj.com/content/early/2022/03/14/annrheumdis-2021-221664\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109344954\",\n \"publishedAt\": \"2022-05-02T00:36:04.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4019393,\n \"message\": \"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis | Annals of the Rheumatic Diseases\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9269511,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/5NsUH3mHRVe74qBUtZya_5.cover-source.jpg?file_detail=ba037856fd77c5a1ffb326cca03fba6c8794bd0d626adff6e66e2908ddfe55f3657103a94c8157f58c1ed1ada1ade3518a44fd90bea0560a4ea77cd84f41e36c9f80ad1e43d8e4c1a5ee952b5bed2f1de56074317d47957aa93b34d80bb96c012f2ff206a56c165fd3738ca19e15281a:6a77502d0d8b443479560a3a6cb6a03b:7ff128917da4dfde6f07912f0d88fb28&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjM2NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.qgqrf49fEkwZil73yvWus3LG9MoFyIJtax5vo8kpe8c&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis | Annals of the Rheumatic Diseases\",\n \"description\": \"Objective To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA).\\n\\nMethods In this double-blind, phase II trial, 203 patients with PsA were randomised 1:1:1 to placebo, deucravacitinib 6 mg once a day or 12 mg once a day. The primary endpoint was American College of Rheumatology-20 (ACR-20) response at week 16.\\n\\nResults ACR-20 response was significantly higher with deucravacitinib 6 mg onc...\",\n \"url\": \"https://ard.bmj.com/content/early/2022/03/14/annrheumdis-2021-221664\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-9d773f2a-366c-44c5-90b3-5c42c6587229\",\n \"slug\": \"measures-of-psoriatic-arthritis-tender-and-swollen-joint-as-measures\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-05T12:06:39.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds ...\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9114245,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/dH98hn5bRgqIzgSeTH7D_pubmed-meta-image.png?file_detail=3fc10f9625f5dec34a796e8fe6c75ab1d2bf4c222ad5ea8f48f5db714d5e349c4ede68a08a135974f235ece8303918cd22589299bc981b4e9597a40667837454086e34a39be1b9b1136cc1e75d1186b1922d13305e8c11b5257aea82a2c81c0f1e0b4e807b41308141bf99a3da598882:75ff0c9b94e4d0639283b51319d15d40:5399e08a909a15bea6b3d07c031869d4&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjM4MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.-dfucFrQQu2DSDHyfg5zq3eVYAzJLs1IO2eVImrn0Xo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds ...\",\n \"description\": \"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), P...\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/22588772/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109158866\",\n \"publishedAt\": \"2022-03-05T12:06:39.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3834046,\n \"message\": \"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds ...\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9114245,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/dH98hn5bRgqIzgSeTH7D_pubmed-meta-image.png?file_detail=ea8b6ca7f50e13c4ab8afe6389d5c788451cc260d2ce8e5541f164a857b8904ba34a4eac84de3f7b0fc921f31962d2b83f5bf35b718766795ce45046e50d3a1d53cb9b7d53ebac69c6484ad0ebdbebde481a686f5182dba1acc55ed78f19cc72df81df9afdf912d9ebca4e77db6ab1d2:a59c0147b5d5afe7f53c382655ff5aae:02ea7580318369b7bb18893cd6f456ff&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjM5OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.jX6FZNQmTwERvrsyRBl68-R4rexdgh6M_5sq100n0ow&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds ...\",\n \"description\": \"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), P...\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/22588772/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-a6441549-848a-484b-93d3-58b954897292\",\n \"slug\": \"prevalence-of-extra-articular-manifestations-in-patients-wit\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-02T22:38:49.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9106435,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/x8SsQeEmQyGJrZMopTMR_pubmed-meta-image.png?file_detail=4f057e2052d6e0c668587e323b0282d6993379108a5973d5710be18bf52cf0dbaed5e04ae26259b8fa81e5e04e41fb8260a98a65fc6205de5433c7dd64e033de5aeb071b63d62ce87e807416adb933c0bb8d04f719044aaff182c667622e97d901a71d967f28af6f5e82f96d45e6b2df:51dcbe218613b7dcc04b4eb32bb46708:d43fbd6df06866ec73bb0f371c1d8131&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjQxMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.D4aBkBEkqMLGoklWL4MnOD1tEbydHZreORaIADH9TYk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis - PubMed\",\n \"description\": \"EAMs are common in patients with AS. The large heterogeneity between studies can be partly explained by differences in clinical as well as methodological characteristics.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/23999006/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109150085\",\n \"publishedAt\": \"2022-03-02T22:38:49.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3825332,\n \"message\": \"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9106435,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/x8SsQeEmQyGJrZMopTMR_pubmed-meta-image.png?file_detail=8e346365be8544332b91da4bbbc2e98897aeb0746920c4a15b57aada94777e24804706c62afd790a73ef32ca2ccfe07ec429dcd1086cb7319f5c42f43de48169908ca5b9479d1df94660aea02ea60f029653e6ca594e92cc86f2b5b84b3e4ad812cf10d3d1b4f4757fae73c352579867:544134ae27c549005a51b636da122c47:79d800193104d551de5e809818e0f996&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjQyNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.9_UDi1CP7am-MKGS7boJ4WKmeixdvyszwx0n8E0TaPQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis - PubMed\",\n \"description\": \"EAMs are common in patients with AS. The large heterogeneity between studies can be partly explained by differences in clinical as well as methodological characteristics.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/23999006/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-ac874ea9-fd2a-4b32-998f-2ea39940081b\",\n \"slug\": \"biologic-agents-and-secondary-immune-deficiency-pubmed\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-04T01:59:41.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Biologic Agents and Secondary Immune Deficiency - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9110304,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/hkhd1XeQI69Gd136yeRd_pubmed-meta-image.png?file_detail=68ca9b21726db1002cd5ba6b118336c99a186f7728505c47fdb25b6a07a1c5bd0817b52a462b71fe7a4d1ec908baf09825d65794738d8a7973a2ca17b748471aa615faeda51002dcac0b340e30e0ba966ed91d43877ad14bf59a7424b6e7870d2ad54cdced52b84a24e3c4bc766bb241:1984c9c2934e94a84f7f11e062cb0616:2201881e26eb7d59ef223ca19634e763&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjQzNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.YZz9HmAhKccro0hAVi1D9m5D5qpzN54p475K9_vMMFE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Biologic Agents and Secondary Immune Deficiency - PubMed\",\n \"description\": \"Biologics are protein-based pharmaceuticals derived from living organisms or their proteins. We discuss the mechanism of action for currently approved biologics and a give summary of the studies on immune suppression from biologics. Most of these studies have been conducted with rheumatology patient …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31466676/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109154649\",\n \"publishedAt\": \"2022-03-04T01:59:41.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3829869,\n \"message\": \"Biologic Agents and Secondary Immune Deficiency - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9110304,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/hkhd1XeQI69Gd136yeRd_pubmed-meta-image.png?file_detail=4f619f64e4afd98bef559d36f46e30de2aa12bc92414eb9275f578a2fd42cdf3bba102d8b9ad35560667f444563c04ab195a28b738e00e7ab731ac34efa218b8cbe57e2afea69d96d19222781bbc3206160d3136b7d397241aa299f7a73712e8daea03db2bec59b6d6edc36ef73b5eb3:969edcd688a06f6684207f37712cfc1c:deacf54e895ae431405d33418c502f81&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjQ0OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ETDL3ViG3ojOXpca7vlaI60YOFmysaiBmkTgcpaHHdQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Biologic Agents and Secondary Immune Deficiency - PubMed\",\n \"description\": \"Biologics are protein-based pharmaceuticals derived from living organisms or their proteins. We discuss the mechanism of action for currently approved biologics and a give summary of the studies on immune suppression from biologics. Most of these studies have been conducted with rheumatology patient …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31466676/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-af9fc30e-31ca-4577-86fb-83fcea056522\",\n \"slug\": \"secukinumab-an-interleukin-a-inhibitor-in-ankylosing-spo\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-28T01:55:51.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9095963,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/RVLmNbLDRoypKWuVdpSc_pubmed-meta-image.png?file_detail=4e3591bd608ebc166b67e89987f830c04c8070e5f3b22883cde7832f643f1d04f65225e26598ea31daa7decf611d8802ab6fa04619e86ebea97997b5f4ae55a92ecf533d1d42a3910743399f6a4a2f15e79fc4b7664c340204663140a456adf2898ea25037d6fa5a1a94dae679f25a9e:153d436d5189119f4abf01e6db1d9c70:0cb19b3f7c0678613c061ff13d1b8a45&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjQ2MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.brxlt67b3GXQh8KJMuydVlA5o2KZnGHWmgWpo9tcBkA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis - PubMed\",\n \"description\": \"Secukinumab at a subcutaneous dose of 150 mg, with either subcutaneous or intravenous loading, provided significant reductions in the signs and symptoms of ankylosing spondylitis at week 16. Secukinumab at a subcutaneous dose of 75 mg resulted in significant improvement only with a higher intravenou …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/26699169/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109138352\",\n \"publishedAt\": \"2022-02-28T01:55:51.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3813665,\n \"message\": \"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9095963,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/RVLmNbLDRoypKWuVdpSc_pubmed-meta-image.png?file_detail=096281be438ece3fb0ba2a89a2395553c9e57d39c76889114c771aa382d645172f481937350f1cc2eec848bd19679f523fc25d2f4c8beac0b9dea93d8cb1ef8d4dd3b71a0b6118f6824bb1fa21c5aa6a7e82ae041c312686922d6530ef9fb30f47a62f57fe4bae10a16ac9e59a43b1dd:fcab9c27465decf7253a1d81144f6fff:f324b55d9646bfa7d2168dac9289039d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjQ4MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.exfYLZnz8LcaHXnsW7aTSiFqjgAhUozf15CYcgKcme0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis - PubMed\",\n \"description\": \"Secukinumab at a subcutaneous dose of 150 mg, with either subcutaneous or intravenous loading, provided significant reductions in the signs and symptoms of ankylosing spondylitis at week 16. Secukinumab at a subcutaneous dose of 75 mg resulted in significant improvement only with a higher intravenou …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/26699169/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-b61b3b1d-f208-4081-8245-02c687b9e0e8\",\n \"slug\": \"geoepidemiology-and-environmental-factors-of-psoriasis-and-p\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-27T00:12:29.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9094162,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/E3sYhJgBQ4ajfQKeXiDR_pubmed-meta-image.png?file_detail=13b0ace90d2a3e17c98cb0a258dc21e9f6a68788a230f5affc48343e8501572a6993a9ba2d40ce040763d691b3504ca4502ea1a4ab7ef59c93fe72b41e4f2ba3a5f472c98df452a9202f67477189a222594d1ba530968b3b1f594615f883a5b7f1cfae76559721bd6d3ec6f0e11d1084:839c1de061ee3f44295460df6a47867f:8a05142f0be92e1ccfb43b43e136969c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjQ5NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.TL2QPSqmGn6qCiroeeqg9tJ8158vvXidui5u2aDW2TE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis - PubMed\",\n \"description\": \"Psoriasis and Psoriatic Arthritis (PsA) are chronic inflammatory diseases that have a major impact on health. The prevalence and incidence estimates of these two closely related diseases show ethnic and geographic variations, being generally more common in the colder north than in the tropics. In Eu …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/20034760/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109136658\",\n \"publishedAt\": \"2022-02-27T00:12:28.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3811987,\n \"message\": \"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9094162,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/E3sYhJgBQ4ajfQKeXiDR_pubmed-meta-image.png?file_detail=27c62dbb06476a80dbfd2eb94847bd91286619b408c85fc2d608210a20eb56461ecf7bf75003e22cb6c8fe339a68aae4c762f97cc58caaa8ccaf00610c4b14a2cfa863104e5bf53fb05ea7977e012a59b14751d18c820e31bc68a26b18c073ab4a90c1c830b0bcabddbbc56d8f5ff6cf:1d0617e952dd37a96a75743c2c343bd7:78dc715a7898c75385182b7e22b6b07d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjUwNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.BHpFkwDZM2FGceow1w-wm0FCR7TdOKeJTaS3fBTJlhw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis - PubMed\",\n \"description\": \"Psoriasis and Psoriatic Arthritis (PsA) are chronic inflammatory diseases that have a major impact on health. The prevalence and incidence estimates of these two closely related diseases show ethnic and geographic variations, being generally more common in the colder north than in the tropics. In Eu …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/20034760/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-c020c72a-0554-4bbd-823e-31f9e54b6db2\",\n \"slug\": \"axial-spondyloarthritis-pubmed-axial-spondyloarthritis\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-04T02:04:46.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Axial spondyloarthritis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9110310,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/EAGCEI3SIeZ9PkGFF1gi_pubmed-meta-image.png?file_detail=b5694e221a6985453efc7dc1c052410b672aaeeb557df853071838e440c1ec8a9e77030d54f97ce1977699bfca7f5ac1a937a37171104459766c293e809c7e2b5956e09cc1ce0562d368d5d6651ab2ebb05689e2d682aaea343feb599b307438505cc48721c49b61e0631c2c4e75473a:d411696220c02edfbead11e197eb62c5:f1848b2fef90cec97449b7a2007e3837&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjUyMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.cIP420S8x5xU9gWO7PAFjYmMN8t8Fm4IOM7tujhBlqg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Axial spondyloarthritis - PubMed\",\n \"description\": \"Axial spondyloarthritis (axSpA) encompasses both radiographic and non-radiographic axSpA. It is a chronic inflammatory disease with a predilection for involving the axial skeleton. The most common presenting symptoms are chronic back pain and spinal stiffness but peripheral and extra-musculoskeletal …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34615639/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109154655\",\n \"publishedAt\": \"2022-03-04T02:04:46.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3829875,\n \"message\": \"Axial spondyloarthritis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9110310,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/EAGCEI3SIeZ9PkGFF1gi_pubmed-meta-image.png?file_detail=e888bcad4d10db890b8a893827e39de3613d8bd8e55320362ed65b6a8dd4182653e0a6f20379e6a4e45c6b4cd0f6a67a2475f42c027d7734ce75eb375f20cddcfb58f4d42c3f4390db2d7609db35dc6fb3e426b3c40a35069b04abc8825aa933c7c8a4da1219db54cdc7039da9418ca5:21b977832be5a6b64dcbc84831c6183e:227607686bdb4f336c259d530b2ceefc&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjUzNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Ow7E2f0YzqxOkKJg4cSdnaaygH9VkIVkpatNEpuZ4rU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Axial spondyloarthritis - PubMed\",\n \"description\": \"Axial spondyloarthritis (axSpA) encompasses both radiographic and non-radiographic axSpA. It is a chronic inflammatory disease with a predilection for involving the axial skeleton. The most common presenting symptoms are chronic back pain and spinal stiffness but peripheral and extra-musculoskeletal …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34615639/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-c719455e-2bd2-4a7a-8789-7c4cf732e21e\",\n \"slug\": \"validity-of-patient-reported-outcomes-measurement-informatio\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-01T23:52:47.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Validity of Patient-Reported Outcomes Measurement Information System Measures in Ankylosing Spondylitis Patients - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9102706,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/rTWDsQWgQ7iE9Dj4CMxe_1635_Paper_74734_abstract_116466_0.png?file_detail=729c0a8ca1d5153e17d4ccdbc9bc1cfe2bab5e525d62dda6cee14ffee5f768189f351a650ba78b2fb72b25b84144258a47fa8871294a773aab7cdc37e640df2941277bfaf013d210cb5c4159622f17e2f1652a39b79097650e0834616845a8dad77afb0046275af89c99e46d21538b8222a5f5f9d8efbe779a57cc8f5dcf3a10:a002ea8ddff37af8d70ac80c3ac19215:a286b45081ee1dd91add5738b0197684&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjU1MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ahQbkjl0RAtRgEsVtZdgZhladVykMwhenC0yYxY-erI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Validity of Patient-Reported Outcomes Measurement Information System Measures in Ankylosing Spondylitis Patients - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The Patient-Reported Outcomes Measurement Information System (PROMIS) developed by the US National Institutes of Health is a patient-reported outcomes system designed to measure disease burden across a wide array of chronic diseases and the general population1. We sought to evaluate the validity of selected PROMIS measures in Ankylosing Spondylitis (AS) patients across self-reported Assessment […]\",\n \"url\": \"https://acrabstracts.org/abstract/validity-of-patient-reported-outcomes-measurement-information-system-measures-in-ankylosing-spondylitis-patients/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109146033\",\n \"publishedAt\": \"2022-03-01T23:52:47.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3821300,\n \"message\": \"Validity of Patient-Reported Outcomes Measurement Information System Measures in Ankylosing Spondylitis Patients - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9102706,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/rTWDsQWgQ7iE9Dj4CMxe_1635_Paper_74734_abstract_116466_0.png?file_detail=cccc311b2ffef75d3e4748499910552a54037e43d57ab900ca3c0e579c0f45723e04f7c526bde76de142d3d4e63cc8a81d14d2e797e770b3859ca20583bdcf5a6c771751faf6e16ca302b5b2bba7b79ea4d9a8c9927865b954dc85e8dc7795671de100683c3602d912be9c1afeefdb3216c71148ab4cca1b53451b918df64c65:46797e9a67373d00e569f7068992e0b5:29548750e38f4a343aa601ce599beba5&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjU3MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Ifjny7NQJXcV_2FlzZom1AI0sC14tvpQ1D-y1qEC3RI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Validity of Patient-Reported Outcomes Measurement Information System Measures in Ankylosing Spondylitis Patients - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The Patient-Reported Outcomes Measurement Information System (PROMIS) developed by the US National Institutes of Health is a patient-reported outcomes system designed to measure disease burden across a wide array of chronic diseases and the general population1. We sought to evaluate the validity of selected PROMIS measures in Ankylosing Spondylitis (AS) patients across self-reported Assessment […]\",\n \"url\": \"https://acrabstracts.org/abstract/validity-of-patient-reported-outcomes-measurement-information-system-measures-in-ankylosing-spondylitis-patients/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-bbf4d05b-35d5-40ae-bb15-8d68b0765f5e\",\n \"slug\": \"effect-of-secukinumab-on-the-clinical-activity-and-disease-b\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-27T00:21:45.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9094186,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/7huUChTQ7uLJOIQBYUQw_pubmed-meta-image.png?file_detail=6ab674b0f1242acae4948c2f48f343ca0cf45d5c377f3b687c5f712f790245045cc4bd7279350b5d1fc38e36eee6e258d608ef6ef10b59662d04593e948184b52162f886a85eecbc07d5191d32312249d39531caf2439ff832e24d7e9d53eb75a4157d2fc34031acd5914b0f64dd17a1:84985a31061dfca53a2ce77b3b298717:d62a7229ba8b2c4040fce5945b34fcaa&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjU4NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.XuzZ8hLhlwQC0WalMrnStbw5yBAqxXA5Ji3Zj7qKBAA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial - PubMed\",\n \"description\": \"Secukinumab demonstrated significant and clinically meaningful efficacy and quality-of-life improvements for patients with nail psoriasis up to week 32. What's already known about this topic? Nail psoriasis is understudied and there is a lack of effective treatment options. Nail psoriasis is correla …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/30367462/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109136673\",\n \"publishedAt\": \"2022-02-27T00:21:45.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3812001,\n \"message\": \"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9094186,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/7huUChTQ7uLJOIQBYUQw_pubmed-meta-image.png?file_detail=06e205c7f6cd9fa0d18000e68a9b4b380addb0f941e7abc13cc57620864e4e7e29c3f12dd5fb1be17331328ccd51e327f33ed0f2be2a3899e836507b48f01c7800c396aaaa32745c12a790862285509c71a7423c150d944900b363f8c18b3650be9d2cdfa2f86582f0bdc7d3bdb6f79a:de816ffea33c066276f79ee965335299:b9dc15ae5497e8a315e6902154b0dc69&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjYwNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.oOyHSjrLK6-xiTRfr9Mn1ohGA1AYfRbwriwVlpiZLjs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial - PubMed\",\n \"description\": \"Secukinumab demonstrated significant and clinically meaningful efficacy and quality-of-life improvements for patients with nail psoriasis up to week 32. What's already known about this topic? Nail psoriasis is understudied and there is a lack of effective treatment options. Nail psoriasis is correla …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/30367462/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-c86ce64e-6832-4794-a848-b233f94db1a7\",\n \"slug\": \"mechanistic-rationales-for-targeting-interleukin-a-in-spon\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-28T02:06:27.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Mechanistic rationales for targeting interleukin-17A in spondyloarthritis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9096014,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/aEET0XbS7uh49iyuhzqg_pubmed-meta-image.png?file_detail=4605d063fb41ab6d400f8011057e0852cd984116608bcaab66d74dc48e3ae3f57aefba3a477dca29665ccf5169646c70539bd659ea9f16d8b8c55133a52a4076a1a325b38f83b20b474592a8f6db07c6ec6606d20e6063a371829c7b12a7c68e34913ebd0abe95171359d95b8c7c35b1:75b5f50bc355de7695b2474b671f1962:c5db9b6256138b6b9f667c4c8bd72f58&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjYyNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.4wXw-GsUeBsrMILmzVWb2NHKelz7UjvGkVhtn6ibcYg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Mechanistic rationales for targeting interleukin-17A in spondyloarthritis - PubMed\",\n \"description\": \"The term spondyloarthritis (SpA) is used to describe a group of inflammatory autoimmune diseases, including ankylosing spondylitis and psoriatic arthritis, with common genetic risk factors and clinical features. SpA is clinically distinct from rheumatoid arthritis and typically affects the spine, sa …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/28270233/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109138397\",\n \"publishedAt\": \"2022-02-28T02:06:27.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3813710,\n \"message\": \"Mechanistic rationales for targeting interleukin-17A in spondyloarthritis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9096014,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/aEET0XbS7uh49iyuhzqg_pubmed-meta-image.png?file_detail=d7d8e9f1177f46edbdd7017f2798da2d778249966bdb0538e6aa69527c238c375399bd8c16e64ee26bc70e6b199c429b91c3391047e4a99015333dac0cfa58d689e9d957a42e4e84451fdf1d730d1b6cd5a93ec935ab3449acbe6c8d9c7c6d40b0479969f13af64a066790f0de1a836e:bbcb87a5b16408b171b354b2ecc23bd4:88a19b3ef36e3c8dbf72ab5f942fee3f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjY0MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.5k8Ck5WNNhE3JPYHgSEg5utPRRAC3tLf3VFbGsZ7Jr4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Mechanistic rationales for targeting interleukin-17A in spondyloarthritis - PubMed\",\n \"description\": \"The term spondyloarthritis (SpA) is used to describe a group of inflammatory autoimmune diseases, including ankylosing spondylitis and psoriatic arthritis, with common genetic risk factors and clinical features. SpA is clinically distinct from rheumatoid arthritis and typically affects the spine, sa …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/28270233/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-cf26b6e8-71b9-49bd-9b50-28908eaf79dc\",\n \"slug\": \"selective-targeting-of-pik-suppresses-human-il-producin\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-28T01:54:11.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9095961,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/IpzfGRCSRHu5PgjflGEV_pubmed-meta-image.png?file_detail=fe6b95bbaf92314f3d564da035edd88b46effb79149a57c17608a68286fe8025d5503ede9a4b2bcbb16a53ff24493b615e3f09728a00a70bbae251d09696220a4ab3f56dd386de4185b6cbc8f0ef85d437434592af8a36439b9ce773bb71bd5b1f7d5e9fb679e43cccc42eb29166ae27:757c8cbb9dab7a38afc9d2f5e89ff19d:52aef107def387fbbb5fcf6435211ca3&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjY1MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.RmcEFW7BuXEB5qkW1cvuyUp8K9jXWHpbxIvhdLzvmL0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases - PubMed\",\n \"description\": \"The delta isoform of phosphoinositide 3-kinase (PI3Kδ) regulates various lymphocyte functions. Considering the key pro-inflammatory role of IL-17A and IL-17F cytokines in psoriasis and spondyloarthritis (SpA), we investigated the potential of PI3Kδ blockade to suppress IL-17A, IL-17F and associated …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32360069/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109138351\",\n \"publishedAt\": \"2022-02-28T01:54:11.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3813664,\n \"message\": \"Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9095961,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/IpzfGRCSRHu5PgjflGEV_pubmed-meta-image.png?file_detail=c9bd55fff6dca8370221af89786f44dc56e2494012fec066da36e4bafedb5b7bbc5cb9e5fdbcb86644ff47c56d8b8da6def0e2650b278740bdcf32ced52ed9a3566c7c0253cee7e55d186734c1f0ae9006d9fbeb2e1c54ee4de7b5b1335b7cdfd41893286bcbb3bb7fb2b72f7cd1aa40:58580dff0fb2390dee4e349c5a2dbca0:b0acb71be4f083691496d4460fb7ae41&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjY2NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.mrwvfCKNtxo3Rzw_12a9VAwplkvX2i1-aAvBRPsC3Nc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases - PubMed\",\n \"description\": \"The delta isoform of phosphoinositide 3-kinase (PI3Kδ) regulates various lymphocyte functions. Considering the key pro-inflammatory role of IL-17A and IL-17F cytokines in psoriasis and spondyloarthritis (SpA), we investigated the potential of PI3Kδ blockade to suppress IL-17A, IL-17F and associated …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32360069/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-c3174c90-cb9d-4516-b8ea-8f9336848d8a\",\n \"slug\": \"efficacy-and-safety-of-canakinumab-treatment-in-schnitzler-s\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-27T16:19:35.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9095350,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/IsBEtGLaTdOF2DxRQLkE_pubmed-meta-image.png?file_detail=0e5f32f32c6dd856adf230778e87f5889e8cafa597c006f0d329d8a414cced4c19e4eb81a6e62386d3932d24cab763260e882897dcdceaff250e321caf7fac854a3b634fc036cc7eb30f40ff456bb0489da75239b5286cefdf34d96bb066dddb869b20cfd3cf79e473b62987e2b5fb27:5fe56ede03b4786f3ff6fe681fe06926:087f0906f9104c224c7335edd880c650&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjY3OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.yFoIE92tybY_G3_aXeCbR3qJxOjra_f5asMpH9_ZxLQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review - PubMed\",\n \"description\": \"Based on the results of the current systematic review, canakinumab is an effective long-term treatment with a favorable safety profile in patients with Schnitzler syndrome.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32502728/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109137789\",\n \"publishedAt\": \"2022-02-27T16:19:35.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3813109,\n \"message\": \"Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9095350,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/IsBEtGLaTdOF2DxRQLkE_pubmed-meta-image.png?file_detail=0625d64d1ec565a33ccdc16099906175b8d8d3b59a026a7bba0cd0ad7db10077402318abfa146570d8aa00ba8b93e3d918cabfb1d819c9394a714b17f0826607d44387bb136c415b7785690ca568b58cbdd87ac58a20832276bea56f3fa7f535bf1e5b9828d7e13176d976040b5a5b78:692e11d5e7a74fff0beeee7099560a32:ead08b9cfe661015a2353ba8df38d2f2&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjY5NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.j43bUwaunpeZTtM-I84idqHp2tbMIOBDphfXvKr9CuI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review - PubMed\",\n \"description\": \"Based on the results of the current systematic review, canakinumab is an effective long-term treatment with a favorable safety profile in patients with Schnitzler syndrome.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32502728/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-ac13f534-da08-4f8e-9f29-9d40316a1b1f\",\n \"slug\": \"overexpression-of-bmp-is-associated-with-loss-of-salivary-g\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-23T00:41:53.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Overexpression of BMP6 Is Associated with Loss of Salivary Gland Activity in Sjögren’s Syndrome Patients and Mice - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9081659,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/icczwVVQQ9iPC68QtL6N_IMG_7867-27%20(NXPowerLite%20Copy).jpg?file_detail=d4012ace03dd92a13e7ad04f0d18806f4795c49292ec0df55ea29c24d360cfcea7711182f2a55d28b6f7b3e140de2f524487e2275a7f0c3966d675f9957c9585ee400983ec23dce9c7a3b4dcf70ebd6d8e93982e04476a14cd65942f5605733f868a39696fca85d77880c2ff7c36444c0c67cabe3881ef8f28edfa67137e5c51:ae064fb922e54075e217556cdae950b2:9dd628e3c4f5b903d55e300bf4c950fc&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjcwNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.npkHO0AJpkpr9J9geajyxzZr3fbp1GxXMUPf8-MMHjg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Overexpression of BMP6 Is Associated with Loss of Salivary Gland Activity in Sjögren’s Syndrome Patients and Mice - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: A hallmark of Sjögren’s syndrome (SS) is the loss of activity in secretory epithelia, specifically the larcrimal and salivary glands. The mechanism(s) driving this disorder are poorly understood and may involve a combination of environmental and genetic factors. To date extensive efforts have been focused on understanding the changes in the immune system in […]\",\n \"url\": \"https://acrabstracts.org/abstract/overexpression-of-bmp6-is-associated-with-loss-of-salivary-gland-activity-in-sjogrens-syndrome-patients-and-mice/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109122915\",\n \"publishedAt\": \"2022-02-23T00:41:53.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3798340,\n \"message\": \"Overexpression of BMP6 Is Associated with Loss of Salivary Gland Activity in Sjögren’s Syndrome Patients and Mice - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9081659,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/icczwVVQQ9iPC68QtL6N_IMG_7867-27%20(NXPowerLite%20Copy).jpg?file_detail=4c1aaf822989a5f081b902f20c004b9c803c24f2e218f2afd65088a88aef116a56ff75e2bddacba4a80bae6d89f2466350a4bbab87812cfad7456b842f0f29f6e2845a198afc2adbede6a11b8f10f7333af247ef8b256e231d010e7c566a837b80f3e3e2a1417ee955db17ea9556133de2c236613db82f432bc63d7ca45dc383:487a6fe7390fc43d79157f4ceceffee5:bacae6e922d321555dec301410c20875&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjcxOSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.b8ETK2MzAermjo4_nj59MbSN-pRzNJcCQgTx304fLLc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Overexpression of BMP6 Is Associated with Loss of Salivary Gland Activity in Sjögren’s Syndrome Patients and Mice - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: A hallmark of Sjögren’s syndrome (SS) is the loss of activity in secretory epithelia, specifically the larcrimal and salivary glands. The mechanism(s) driving this disorder are poorly understood and may involve a combination of environmental and genetic factors. To date extensive efforts have been focused on understanding the changes in the immune system in […]\",\n \"url\": \"https://acrabstracts.org/abstract/overexpression-of-bmp6-is-associated-with-loss-of-salivary-gland-activity-in-sjogrens-syndrome-patients-and-mice/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-bf447503-97a8-4f2d-b063-c11291a654a9\",\n \"slug\": \"long-term-safety-of-canakinumab-in-patients-with-gouty-arthr\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-23T00:35:30.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Long-Term Safety of Canakinumab in Patients with Gouty Arthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9081652,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/vFGv1e7dSLWOJjDQvayk_graphicstock-little-girl-with-light-bulb-on-the-blackboard-background_BOMluk3Pesx%20(NXPowerLite%20Copy).jpg?file_detail=d96e70018e4a24c6bb4ce0944f16aa22a839ee0242df740c2c451f3e4af29ccc204a4ea04f743ac7ff139ca8c9970bcacc2c4809684d1441d96ebe036d2e98398daf1f3be7545ab5e9cac602fbd8910de35fcd992b37acd7285b65688ff6ee337904e30246aa8f60a65b52265e70337eb3d265588976ea35e6fa67bef5e4cfb2787538eb7323bc491a54d6a849894efb2f2238d9dfcd475c0d7eb9b932a3b7f6dc40d5f52b37b1e084722bdbbc5f0c6e98b66c497ef3be2b02e00da1065a6371:c83c24892b0374145e189de360bc15b7:77e938fbb80f5cd3b8b4ce1edb96f3e0&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjczMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ca38vVtbskBeXYXxAzsPYHU3MBAhSOBMIFY4izKk9vs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Long-Term Safety of Canakinumab in Patients with Gouty Arthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Gouty arthritis (GA) is a chronic inflammatory disease. Targeting the inflammatory pathway through IL-1β inhibition with canakinumab (CAN) may provide significant long-term benefits. CAN safety versus triamcinolone acetonide (TA) over initial 24 weeks (blinded study) for patients (pts) with history of frequent attacks (≥3 in year before baseline) was reported earlier from core (β-RELIEVED […]\",\n \"url\": \"https://acrabstracts.org/abstract/long-term-safety-of-canakinumab-in-patients-with-gouty-arthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109122907\",\n \"publishedAt\": \"2022-02-23T00:35:30.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3798332,\n \"message\": \"Long-Term Safety of Canakinumab in Patients with Gouty Arthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9081652,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/vFGv1e7dSLWOJjDQvayk_graphicstock-little-girl-with-light-bulb-on-the-blackboard-background_BOMluk3Pesx%20(NXPowerLite%20Copy).jpg?file_detail=a3044edbfc8656c07e16074d5019b031516070e2c25d0e83d95ea1cea13616445a75e7574b328fab064f41ebd86c962910e9fbea660dc545a63e4f02e9916f69573713249488e4ec7919177e79afbd717306e923cdc65b7fa50229d29d40305d64c398a0c0fb416211a71255eb40b9d2a8f0153a926188d710890af7800a752af172abe89c0d48e55cbe0f71cdada048e3e89a58427dcc47f76db88e28a022a6d486c1dedef1a70bf51e8fdf7453d0031d1c478f19881c6862c227bd62381cfd:0ab9e61d41302de9d0b8f7b49ac3b7df:e3a69358dd5e1001365f4b5b4040f05d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4Ljc0MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.1GHTbNWusZZmErNGb925PpWzJl_43IbrTPkt5cFdCjc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Long-Term Safety of Canakinumab in Patients with Gouty Arthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Gouty arthritis (GA) is a chronic inflammatory disease. Targeting the inflammatory pathway through IL-1β inhibition with canakinumab (CAN) may provide significant long-term benefits. CAN safety versus triamcinolone acetonide (TA) over initial 24 weeks (blinded study) for patients (pts) with history of frequent attacks (≥3 in year before baseline) was reported earlier from core (β-RELIEVED […]\",\n \"url\": \"https://acrabstracts.org/abstract/long-term-safety-of-canakinumab-in-patients-with-gouty-arthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-c3d2db33-9966-4bdf-ab53-fa5bc8abd97a\",\n \"slug\": \"efficacy-and-safety-of-canakinumab-in-patients-with-periodic\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-21T19:35:25.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9077388,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/RN1zEPZNRe65lc42DOtR_IMG_7867-27%20(NXPowerLite%20Copy).jpg?file_detail=6e1c244d368996a6f40867382a301f182af95a4dcf52d591bfd2512f4cb51a7711442d266bc671d778b4a46e32c8863218031e6d359a485dcba91feac562c0e8cc4d2cea94e7cd1537b8f981df30cde928abf8d8354f6b287e97c07c0e921b5a2e150b0fa24c43852d79519762940b05b03088207541a556069edb3163256078:59426e4461a91650bf044d948e40ca70:48a56ec161efae61d417a88b085b0e47&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4Ljc1NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.dmsdyh-7ky_0N226Fee1hMM-X5vXYalGlVQho1OW1Og&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Open-label studies have suggested the efficacy of canakinumab (CAN), a fully human, highly specific anti-IL-1β neutralizing monoclonal antibody, in colchicine-resistant-FMF (crFMF), hyper-immunoglobulin (Ig) D syndrome/mevalonate kinase deficiency (HIDS/MKD), and tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS).1-3 We report the efficacy and safety of CAN from the randomized treatment epoch of the Phase 3 pivotal […]\",\n \"url\": \"https://acrabstracts.org/abstract/efficacy-and-safety-of-canakinumab-in-patients-with-periodic-fever-syndromes-colchicine-resistant-fmf-hidsmkd-and-traps-results-from-a-phase-3-pivotal-umbrella-trial-2/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109116811\",\n \"publishedAt\": \"2022-02-21T19:35:25.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3792275,\n \"message\": \"Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9077388,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/RN1zEPZNRe65lc42DOtR_IMG_7867-27%20(NXPowerLite%20Copy).jpg?file_detail=94e472c5807d16b9224b886e9f483cac1c0502b1a298c9ce0d9cc6a32b6944c491fed7fb09cafc19f8010017e90c5af596777789a3404beb99d21a04729ddeac49d98992b071dcc33d36e7336f795565c547bb038d5fc339d21da9e4fb5898086d09665b67d842badd5ff814787735ecd22544c6f0b79ed1dde64ce80779750c:1f912d3dcc9b5757095439da32fb02c6:eaf232938f37387851cb4893b952c2ae&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4Ljc2NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.PeEQjzyza1zrbUQgd0tmiyHgYlk39oPmwMSH-I7vHn0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Open-label studies have suggested the efficacy of canakinumab (CAN), a fully human, highly specific anti-IL-1β neutralizing monoclonal antibody, in colchicine-resistant-FMF (crFMF), hyper-immunoglobulin (Ig) D syndrome/mevalonate kinase deficiency (HIDS/MKD), and tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS).1-3 We report the efficacy and safety of CAN from the randomized treatment epoch of the Phase 3 pivotal […]\",\n \"url\": \"https://acrabstracts.org/abstract/efficacy-and-safety-of-canakinumab-in-patients-with-periodic-fever-syndromes-colchicine-resistant-fmf-hidsmkd-and-traps-results-from-a-phase-3-pivotal-umbrella-trial-2/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-ae600f19-7a95-447f-ae35-726592ebde7a\",\n \"slug\": \"tapering-of-tumor-necrosis-factor-inhibitor-and-healthcare-c\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-23T23:59:54.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9085368,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/lSjwIkwNRDaANj33R8Dc_GTUOHVCE-695856-1-ANY.jpg?file_detail=a9f203747ed3ea047f308ba3ab19f507254af8edb348328051ee80b957ed8d6892857c68574e536db754f63ac6b01fc53829c362853bad697d4a4e3c038497c5818ba32547d3f5d48513bea2af0272bca94c84026655391f99d0c64240aa1eb33c40b3431c9e0dcec6bb110d1d00bc7a:4d570e15ebd390c16de77fb065c5fab1:39c17709601b360520469d00c2e99b47&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4Ljc3OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.D8uNLeqGdLkmOHCDdrFVYFKEthRkxAa4BWeBN3kL3Tg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Tapering of tumor necrosis factor (TNF) inhibitors may be considered in patients with ankylosing spondylitis (AS) with low disease activity. However, there is still a lack of evidence that TNF inhibitors can be safely tapered and maintained with low medical costs. The aim of this study was to analyze the pattern of tapering of […]\",\n \"url\": \"https://acrabstracts.org/abstract/tapering-of-tumor-necrosis-factor-inhibitor-and-healthcare-cost-differences-in-patients-with-ankylosing-spondylitis-a-retrospective-analysis-of-korean-national-health-insurance-data/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109127552\",\n \"publishedAt\": \"2022-02-23T23:59:54.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3802947,\n \"message\": \"Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9085368,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/lSjwIkwNRDaANj33R8Dc_GTUOHVCE-695856-1-ANY.jpg?file_detail=a1b6364d841df3cf9d5d9792a9175014874ec168d78a2e3000c1e8c2426a3b8ffbf6715b241b3dc9fb062b48fbf921362e66a0023ee534e72e0e25034104e90744ac8d20efd122440ee1cfa807edc2621633142ff9f475b30e612f9af52741ed3a42042697ec294d403e8a85a51cca2b:55c63dde53a6305f0843543acb8b5bf1:95e377ca23dae3c4bdb64c2fec31a25e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4Ljc5MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.bpqf7RpkeRHzRdwwefL2cQ4uWImfuGvlKWaL7Vk2JQU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Tapering of tumor necrosis factor (TNF) inhibitors may be considered in patients with ankylosing spondylitis (AS) with low disease activity. However, there is still a lack of evidence that TNF inhibitors can be safely tapered and maintained with low medical costs. The aim of this study was to analyze the pattern of tapering of […]\",\n \"url\": \"https://acrabstracts.org/abstract/tapering-of-tumor-necrosis-factor-inhibitor-and-healthcare-cost-differences-in-patients-with-ankylosing-spondylitis-a-retrospective-analysis-of-korean-national-health-insurance-data/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-c7c0cbad-c065-4394-8278-419e74327cb6\",\n \"slug\": \"secukinumab-nbsp-provides-sustained-improvements-in-the-sign\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T20:55:17.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072182,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/1kYYnyW9TzSiu8KXoUQO_2568_Paper_72309_abstract_109325_0.jpg?file_detail=89a9f9e635958298bc56045c91802dc3e50ddd1a19aefd1f7bb5c178416ac515df2f6c97e77896672d830925f3164013047d31b9472edd4bb05b5fa331f7e6f36f5e186ad3a5277f2380ff4ad6d2ad0cf2b9626adee7dbe89f2abfecfaea500ac289bd3416cb0de278e181dd246e46a3d0a3e93d857eef04fec8a54ab1d00e25:085df8532dba88c9fb36e9bf0667456f:64c7340a4ef6b64372f9deffd9038636&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjgxMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.uAz2Eux81K2vulTgESP-ZwSgDkngs2ZM8PvTQVfBUMs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Secukinumab (SEC), a fully human monoclonal IgG1 antibody, provided rapid and significant improvements in all key clinical domains of psoriatic arthritis (PsA) in the FUTURE 1 study (NCT01392326) with improvements sustained through 3 years.1 Here, we present the final 5 year efficacy and safety results of the study, including efficacy results in patients who had […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-provides-sustained-improvements-in-the-signs-and-symptoms-in-psoriatic-arthritis-final-5-year-efficacy-and-safety-results-from-a-phase-3-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109111779\",\n \"publishedAt\": \"2022-02-19T20:55:17.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787258,\n \"message\": \"Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072182,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/1kYYnyW9TzSiu8KXoUQO_2568_Paper_72309_abstract_109325_0.jpg?file_detail=2d99efc3aa7572b5dd00b366e826ec546348dff959037a3a9be0ad5e6482a7dcca0ab9ee0ae34bc3389aee53ba44e560e7fc7b5eb12c33de07e0bfb5863ba66431908dd73eacda6426148a4b6c5aec28d8c73edc6ab70011408348c53a0a13e3ba29c1af5f01a6dfaf7978ea47b86ee62bac49709363992088e9f13eb273a4c0:944d0d0fe8761ff01cd174d6692abbe8:785730a20dd3485fd2603fe8e1c997f0&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjgyMyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Q5DxfciUbSKQSqTt2uLitri8_Dm4Gp6sx8h7_1NH7Qs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Secukinumab (SEC), a fully human monoclonal IgG1 antibody, provided rapid and significant improvements in all key clinical domains of psoriatic arthritis (PsA) in the FUTURE 1 study (NCT01392326) with improvements sustained through 3 years.1 Here, we present the final 5 year efficacy and safety results of the study, including efficacy results in patients who had […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-provides-sustained-improvements-in-the-signs-and-symptoms-in-psoriatic-arthritis-final-5-year-efficacy-and-safety-results-from-a-phase-3-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-bf82a8e1-137f-4bdf-86b3-66b148287fba\",\n \"slug\": \"comparison-of-demographic-clinic-and-radiological-features\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T12:55:15.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloarthritis Patients with and Without Accompanying Familial Mediterranean Fever - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9070929,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/22KeXAfMTZWZat5jPD6S_ACR_1065644_1.jpg?file_detail=5288927d74a2abf9f3f58b0570b57ad8b526f9b6f837b8f8e230a7ab905cc3c67f018aca4821f58d82adad30ad0c5ac88a6b046f589f7a26a9032da21b911b0afd3aa8ca4e42c5f424786d9205e7eb5d9bc608d491f83f935d853358874e499e8ca73974b8d7e995bd67a230762192d6:e692597f1a62c77a9edd1e16b78868bf:af51f313c328d0499be2c4eb881dcb69&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjgzNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Z7qdnA-EbNKEtdlXjMc2LjZXq5YckwSmKY4Okun22P8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloarthritis Patients with and Without Accompanying Familial Mediterranean Fever - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The co-existence rate of Familial Mediterranean Fever (FMF) and axial spondyloarthritis (axSpA) in adults is ranging from 0.5% to 7.5%. Clinical implications of this association in the course of FMF is still a research question. Compared to axSpA, FMF+axSpA tends to have more peripheral joint involvement and start at an earlier age, but may […]\",\n \"url\": \"https://acrabstracts.org/abstract/comparison-of-demographic-clinic-and-radiological-features-of-axial-spondyloarthritis-patients-with-and-without-accompanying-familial-mediterranean-fever/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109110547\",\n \"publishedAt\": \"2022-02-19T12:55:15.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3786036,\n \"message\": \"Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloarthritis Patients with and Without Accompanying Familial Mediterranean Fever - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9070929,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/22KeXAfMTZWZat5jPD6S_ACR_1065644_1.jpg?file_detail=2f7d455733882dc11ae9f731f64c7c833f1fab8627e15aa23731203b265281606ac9f3895d5d1e82bed247a9201271288fbb5ce15a7a3a63df973f1c5f59038ddff500e26642020bc770c2706b46e40f2606cba27db54229a680b6aad1d8a97d982adaec7c417f77b7b3760fa2efa9c3:21079b532c9fe7dbad2ced2b139e2dca:5a0bdd7e983c970e30db722131560f17&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4Ljg0OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.TdstgIPNhYL7_wk5BveSnGdoQh9mOLCAx9fMhdr8TCI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloarthritis Patients with and Without Accompanying Familial Mediterranean Fever - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The co-existence rate of Familial Mediterranean Fever (FMF) and axial spondyloarthritis (axSpA) in adults is ranging from 0.5% to 7.5%. Clinical implications of this association in the course of FMF is still a research question. Compared to axSpA, FMF+axSpA tends to have more peripheral joint involvement and start at an earlier age, but may […]\",\n \"url\": \"https://acrabstracts.org/abstract/comparison-of-demographic-clinic-and-radiological-features-of-axial-spondyloarthritis-patients-with-and-without-accompanying-familial-mediterranean-fever/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-dac1d4ba-a9e0-4017-9d6f-24cecd7307fd\",\n \"slug\": \"secukinumab-is-a-promising-treatment-for-patients-with-juven\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T20:38:19.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072170,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/wkouKOWrTFK9KNvj9mpr_abstract-business-concept_7JFweW_L%20(NXPowerLite%20Copy).jpg?file_detail=34324cfd088adce60ec63ec56c084181f4fa9df3d49c40b8313f7e137e783f3ccaf3926a1601a68dc32b6eb1cd713a696edf530c8ef7e798fb01846ea60aad6addd665444e2fc9d091a0ba19c2c414762e813d22738a0ed6bdbf459b91b5ce8dcc36a918bbab3be945e762a1125b1aa4e4790a740f8b9a756d911a4aec09715002c002ef7cf2fc0799465a396aa7417b:822afad8e74aafde44ba21b900f26649:a6d713e4266689e7451a18670e76db37&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4Ljg2NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.bjaN3CYIgu697P1inELuzowiB9rxJJmD9mhU62unXAo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Secukinumab (SEC) is licensed to treat adults with spondyloarthritis and psoriatic arthritis. It is not licensed for juvenile patients yet. As biologic agents up till now only etanercept and adalimumab are licensed for enthJIA. Not all enthJIA patient reaching remission with an anti-TNF therapy. We review our patients, who did not reach remission under […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-is-a-promising-treatment-for-patients-with-juvenile-enthesitis-related-arthritis-nonresponsive-to-anti-tnf-treatment-according-the-juvenile-spondyloarthritis-disease-activity-index/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109111767\",\n \"publishedAt\": \"2022-02-19T20:38:19.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787246,\n \"message\": \"Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072170,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/wkouKOWrTFK9KNvj9mpr_abstract-business-concept_7JFweW_L%20(NXPowerLite%20Copy).jpg?file_detail=a3ec0bbad21045c95826bf24a2a17d8589add8acde83b29d209d9514998fdccd423adf9fefae825b51a0a731f18a0836f712c096f4a46860d4a09fb0052f1c21150007c7e54b229f5a2a161d311646ceae9103db45f9b4af38425bd31c05e9487b0af732819ae1fa7f504807db1d6de841a5c5a5f86e9900066a806929c0c13209dec0636c91539d4db47048d2a57858:1ce2376eaea279ace1dd91c1b787d7af:799b7534b5a8e7c3a279000c92767368&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4Ljg3NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.rJY0o5j_OAugU5GiKIQdsj2U-SJW-aIG5nZJYmPyXW4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Secukinumab (SEC) is licensed to treat adults with spondyloarthritis and psoriatic arthritis. It is not licensed for juvenile patients yet. As biologic agents up till now only etanercept and adalimumab are licensed for enthJIA. Not all enthJIA patient reaching remission with an anti-TNF therapy. We review our patients, who did not reach remission under […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-is-a-promising-treatment-for-patients-with-juvenile-enthesitis-related-arthritis-nonresponsive-to-anti-tnf-treatment-according-the-juvenile-spondyloarthritis-disease-activity-index/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-ca64fde6-c303-4793-ba30-c1e1acd1115b\",\n \"slug\": \"network-meta-analysis-of-targeted-immunomodulators-in-the-tr\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-22T01:46:08.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9077745,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/GDUJDiZvRVWRLUO0xKCO_701_Paper_74435_abstract_115991_0.png?file_detail=9b15a4d984496c8c449768aee65a5ed9a7369d56bde93608922d6d1a3d92b99bf13ba46bb2a2aabd5b3bf51d5da61d0a4785cc67469082abe10150efddef165332e78cab5e8aeea5307fd80cff9d0927f3d9e5aa3033eef9cb6e351649fa873a880bf9a323c4e46b648931aa1f6d689cdd55d644347993933176588890138cce:0ef625119014b5b92027aa92960bf6a8:865ae7827959d981e158ec5d3dcc6c69&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4Ljg4OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.PJZSHIcyBkCqBHtRnTgLgUWgQkp_ax4blXzsN-FPJzk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: With multiple targeted immunomodulators (TIMs) approved by the FDA for the treatment of psoriatic arthritis (PsA), the relative efficacy and cost-effectiveness of these TIMs remains uncertain, particularly for the newly introduced agents. In the absence of head-to-head trials, indirect comparison provides valuable informative evidence for decision makers. This study compared the clinical (ACR 20/50/70; […]\",\n \"url\": \"https://acrabstracts.org/abstract/network-meta-analysis-of-targeted-immunomodulators-in-the-treatment-of-psoriatic-arthritis-patients-without-prior-biologic-treatment/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109117963\",\n \"publishedAt\": \"2022-02-22T01:46:08.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3793425,\n \"message\": \"Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9077745,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/GDUJDiZvRVWRLUO0xKCO_701_Paper_74435_abstract_115991_0.png?file_detail=217473fdd2835b83cab562f0375323b36366fdc19e84e2580148f704ab62f3421e78b82b7c59172c9196c8ef90e976e5d63bbf5b10c56c8c042aa784a230e6005a5588c85b8348b51c5699ee4461bf26180be3dd5ab7d7da1f7d1bb4b496a4a7fe4865d0843e93bf8e5c505b18a9e76d0de441025d804876f0ea0c8c488de99e:098ebb7a6ce958173efe6f975e396ccb:e5cf15a4c82ae3ac138c9a764e6ff4bc&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjkwNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Xhmb5b7kOK9NKbZNDFTlIX8il0GWj_-aihnfc_PkA38&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: With multiple targeted immunomodulators (TIMs) approved by the FDA for the treatment of psoriatic arthritis (PsA), the relative efficacy and cost-effectiveness of these TIMs remains uncertain, particularly for the newly introduced agents. In the absence of head-to-head trials, indirect comparison provides valuable informative evidence for decision makers. This study compared the clinical (ACR 20/50/70; […]\",\n \"url\": \"https://acrabstracts.org/abstract/network-meta-analysis-of-targeted-immunomodulators-in-the-treatment-of-psoriatic-arthritis-patients-without-prior-biologic-treatment/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-db7ea885-6779-4190-9f2b-455e65cd6b33\",\n \"slug\": \"examining-a-role-for-th-regulation-and-toll-like-receptor\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-23T00:27:37.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Examining a Role for Th17 Regulation and Toll-Like Receptor Signaling in Psoriatic Arthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9081646,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/CYMATVSMQYOlrTRtxOIX_young-stylish-businessman_MJnNcFSd%20(NXPowerLite%20Copy).jpg?file_detail=8291fcc0fe3a858fa2700dc7cbf19a2b9a4bb874ccc5b70d7c62e4361ee9f4c975129ecaa5ac1638508c772312e05898cb259cff4110d38544332b1c82fe70e82b9d494eef3adaf785f6a53722171837dee4e118db45d3871b01aec878a2eff2e20131097930d4d611beecfacd99d31de6f97d9750c4702fcc9da679adcabeed42ae9f7ab30abca55d213da38e580c1f:d622fe93d75bfc802bf093e2f6cedf74:86ba975b72c14aeec1ff53a86343635b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjkxNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.8lDDXtTk1UR3QyZCtwpIJDB3EaPpsxCjchDe7scNLQo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Examining a Role for Th17 Regulation and Toll-Like Receptor Signaling in Psoriatic Arthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Psoriatic arthritis (PsA) is a seronegative inflammatory arthritis that develops in 30% of patients with cutaneous psoriasis (PsC). Joint inflammation in PsA is mediated in part by natural killer (NK) cells which are an important arm of the innate immune system. We have previously shown that PsA is associated with activating ligands of NK […]\",\n \"url\": \"https://acrabstracts.org/abstract/examining-a-role-for-th17-regulation-and-toll-like-receptor-signaling-in-psoriatic-arthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109122902\",\n \"publishedAt\": \"2022-02-23T00:27:36.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3798327,\n \"message\": \"Examining a Role for Th17 Regulation and Toll-Like Receptor Signaling in Psoriatic Arthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9081646,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/CYMATVSMQYOlrTRtxOIX_young-stylish-businessman_MJnNcFSd%20(NXPowerLite%20Copy).jpg?file_detail=72dfe165f55b82f56c12b2c064d2036500f063c5fc24bf843bc4d72234bd7bde45e7a85cb7de6ce8aacff12a73755adcf54f9f730bb8c0a080ed8d2a95ae9c4026a8b6f7654e5319a28efe5d6dd25bf44609f589ccc01c48408b9f95cd07cea89237f0c29905dd2e2c84335d052f78214325a3ba356590b4270d3bee4faffd2d95e16e09897b42468b680f324a3d8d63:b99e41abf58380360a6ce3ac53214d83:8030272899edc29f6221e00dd719811d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4LjkyOSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.On1xGkwB6oqAlKkqQwHIoaORx_3oJQUcq-W87_ITn1E&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Examining a Role for Th17 Regulation and Toll-Like Receptor Signaling in Psoriatic Arthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Psoriatic arthritis (PsA) is a seronegative inflammatory arthritis that develops in 30% of patients with cutaneous psoriasis (PsC). Joint inflammation in PsA is mediated in part by natural killer (NK) cells which are an important arm of the innate immune system. We have previously shown that PsA is associated with activating ligands of NK […]\",\n \"url\": \"https://acrabstracts.org/abstract/examining-a-role-for-th17-regulation-and-toll-like-receptor-signaling-in-psoriatic-arthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-e7d2ca64-6e9d-4a28-9134-61d3a987ceb9\",\n \"slug\": \"ema-starts-safety-review-of-janus-kinase-inhibitors-for-infl\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-18T01:13:23.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"EMA starts safety review of Janus kinase inhibitors for inflammatory disorders | European Medicines Agency\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9066754,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/WJgLMdQiSF223TwgiCyg_DM_03242016_0659%20(NXPowerLite%20Copy).jpg?file_detail=ae12acf1f3d6ba9852cdd7fdfab0fe68932e157fca8fd07d6649ec07a5dd34cef0101fe25bc78644cbc4b6d9e59c43002dd3189d2b733f3382978acfeedf987008da04bc3a7ad0425d5fa69e0305fddf743f914ace115dd809189fb68aa37d966e410bba9a49ab54cdb2c4ecd8efa0dec5c0b9f113f11806d806a73e28909e23:0b1dddc1b33600af2fd2faf0d778238d:34a51dfe867d0a3464d02fded398bf83&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4Ljk0MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.QXbotxDU_hYgj54IbQfTqR0bZADAZJIdB0XT8O5r7kM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"EMA starts safety review of Janus kinase inhibitors for inflammatory disorders | European Medicines Agency\",\n \"description\": \"EMA starts safety review of Janus kinase inhibitors for inflammatory disorders\",\n \"url\": \"https://www.ema.europa.eu/en/news/ema-starts-safety-review-janus-kinase-inhibitors-inflammatory-disorders?utm_content=buffer2acd2&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer\",\n \"siteName\": \"European Medicines Agency\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109105670\",\n \"publishedAt\": \"2022-02-18T01:13:23.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3781190,\n \"message\": \"EMA starts safety review of Janus kinase inhibitors for inflammatory disorders | European Medicines Agency\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9066754,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/WJgLMdQiSF223TwgiCyg_DM_03242016_0659%20(NXPowerLite%20Copy).jpg?file_detail=f2f97d65067f53fc36bdc549528a94a5bb2295f52b300e3d0a1c52231cb93967ad0627e93fb589e91042bacbcb0bfa717449460adcacd7d3e664998ecfb6e227fa7902cf6ca27ab760ecee5b92d91b959c8526e66d07e0bda96c4f7158bebce81692ab2ff740473ee8bf4ade5555bc44281088db71f7bc5d2e725fe4ee072dff:39b9c3e0a0903fd05ae2921bb2db5e67:299d4c6962e8664e52081aa5a743a3d1&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4Ljk1NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.g0Z5v4-mhxOrjT8qsNtAIx0XiR-grWqMnR7HjCFUOcg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"EMA starts safety review of Janus kinase inhibitors for inflammatory disorders | European Medicines Agency\",\n \"description\": \"EMA starts safety review of Janus kinase inhibitors for inflammatory disorders\",\n \"url\": \"https://www.ema.europa.eu/en/news/ema-starts-safety-review-janus-kinase-inhibitors-inflammatory-disorders?utm_content=buffer2acd2&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer\",\n \"siteName\": \"European Medicines Agency\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-dc4405cf-dbf3-476b-9f24-5e3f10eb7fdb\",\n \"slug\": \"a-review-of-the-efficacy-and-safety-for-biologic-agents-targ\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-27T00:40:21.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9094246,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/keQKU8SBSwaZw2AvMv4Q_pubmed-meta-image.png?file_detail=fccb69cd6c47ae72c846bbd1185dae1192d5c8800811063614731df67031dfb6e10b0fcc1d5664931affef0457702d26c4a71eba327c6e855c15fd41c5f237e6b6da792c3d211180f079654fa32d2246a4477c000a18265b6b1b0f3cd213a97a17e0145335972f66e3d952c3401263f9:8086e56b055efca8d6321b5cd06e4e00:d4e690291f113de0a009a6ee2ee98050&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4Ljk3NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.G8sZ8m7U_rmOtdRe5bJoWJ_BfC-O00nJpRevPI4iP5Y&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab - PubMed\",\n \"description\": \"Psoriasis is a chronic and debilitating inflammatory immune-mediated skin disorder. Several cytokines including interleukin (IL)-23 were demonstrated to play a central role in the pathogenesis of this disease. Treatment options for psoriasis range from topical to systemic modalities, depending on th …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34447766/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109136722\",\n \"publishedAt\": \"2022-02-27T00:40:21.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3812049,\n \"message\": \"A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9094246,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/keQKU8SBSwaZw2AvMv4Q_pubmed-meta-image.png?file_detail=840d7a3f811804b6b09da9895d3a1bba428cdb804b598b9b74e15dd11f2c7ea13697a5dd5824820b8e744fbc05bfff815c0d9eb4823b4d208ec3cc203d23f8281938677b72ecff49385f4484109241847c81a3d670f59dfe28b365bad850208a1e23b3bf978c437c2d755f946140f982:72febe2b5e43c006b65d206919f48698:d89bed0f623f4cedcb073595dbad63fd&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM4Ljk5OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.TjTh5qqLiRRsFd4R9qqE1vfwlqhOWdGqv1d7W-R-0u8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQyfX19XX0_&Signature=HPIJlJvSVxMyPeUtNse4DPcV~nK~PVUwve4mw8QYCN34nxfeVcaEsRBo2WK0umZrYGaICFgfUfZdfLZH9kRONZcIyBzKCkHXNmVWA3byq8G91-haelLfAtU4pRNCmY5FotN~CXCcLx7Wzuu3-MA2wRPsIbhumh1N5DnXNiX8zMvaHETqzozYIxLU7iBNlRVzTvOOu2DoWrc~f1bapO81NcXr-rfXC57WtPrvYXLuBgzgrH7bfq5kbk4PrtT3T~sHoSSz8Se~nllWv3zBAFHwFZMoNat~6Rp5M6xAAGWCeU~bDU2iOGQ~5xayvgbUj9BV7kTFNSdFyW8pZxxEe3U4Fw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab - PubMed\",\n \"description\": \"Psoriasis is a chronic and debilitating inflammatory immune-mediated skin disorder. Several cytokines including interleukin (IL)-23 were demonstrated to play a central role in the pathogenesis of this disease. Treatment options for psoriasis range from topical to systemic modalities, depending on th …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34447766/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-dabd8eb6-71b1-4003-976a-e7f22b04f84b\",\n \"slug\": \"efficacy-and-safety-of-ixekizumab-in-patients-with-active-ps\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-04T02:09:34.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1) - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9110316,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/E9iweRqT2OsTumfH2Inw_pubmed-meta-image.png?file_detail=3a16ad3f621eb079d243ba45614223a7e581a217093c5c6e3f3fde85cfd5d54e8bb3d589b87deb28bc3e6ed101eac03321034c7cf173479853241f468a70d3f602929469c71d40350895396b3ea34ae5ee2375214b7a450de2076f53e2421729797215ef7c06948c4e1873717f1515c2:1a3c15ef6d0184f96055311f5924f962:16f0f10267e718ad360931ce34aac4c6&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjAxNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.tpNjTW661XWG87ByPpHKiBTTd-pPSTtknYvlzt4GbUs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1) - PubMed\",\n \"description\": \"During the extension period, IXEQ4W or IXEQ2W treatment demonstrated sustained efficacy in key PsA domains with a safety profile consistent with other studies investigating IXE. Clinical trial number: NCT01695239; EudraCT 2011-002326-49.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/29247148/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109154661\",\n \"publishedAt\": \"2022-03-04T02:09:34.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3829881,\n \"message\": \"Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1) - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9110316,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/E9iweRqT2OsTumfH2Inw_pubmed-meta-image.png?file_detail=a84614ae2a28deecf6fe4de7b7606d7b887abdfed677505c3f9d83d59182d499acdccc7522e5d4f97e0cde01777aa10a1d83ec0be1d77c507a134660939e86881e8cc67adf973953255ef26670fa428a505f53c52b1c4359adb53d04dcb173173d186635fff82cc32580ec8cd05f2291:110be29c52aff176c58c9c0cb53250ef:0d6d48fbc42462edf7074f48db57bf9e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjAyOCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.4TDCSD1xOq1Yg3NyABbRIpFbclg4iL4FYnznGBhTusA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1) - PubMed\",\n \"description\": \"During the extension period, IXEQ4W or IXEQ2W treatment demonstrated sustained efficacy in key PsA domains with a safety profile consistent with other studies investigating IXE. Clinical trial number: NCT01695239; EudraCT 2011-002326-49.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/29247148/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-d756b5eb-4572-4b39-a7e9-f77051c0376a\",\n \"slug\": \"serum-levels-of-thymic-stromal-lymphopoietin-a-possible-nov\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-02T00:31:31.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Serum Levels of Thymic Stromal Lymphopoietin: A Possible Novel Biomarker in Primary Sjögren’s Syndrome and Related Lymphoproliferation - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9102775,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Hbs58qnSdyRnvRfMz1F5_635994041268567115-1015095974_education+stock+diversity+school+students+classroom+raise+hands.jpg?file_detail=d5f8b8371159e00c6f9f12afa433464952b1c9f4fc5dc6cf090bcf5872cdf2278812a6cf6c43b50ff72cd0a38b11b53f2852d346bc34a9ec8fe21ac21985c9df7f2a91436dbfe443592739a23e3307ff1c1e452eccd1b639798fcc1cea9c7907e552040731f290530c6077f663ff3c1047e3acedd2e64869d6b9540e98754a17a6903cd5a5c75a5d39588a2181754bd11020ca206ea5e9adf9ff286fb3d1db697da6b63da06074a7b3f690f4242dc6a3e08730f9640ef1407fbd7fcf6fd257ef:ce07e038d04e4a3734eb043f8accbdb9:3d62795d1259c8e1a92c86bbd7b2024b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjA0OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.yYOzhOZBb-sSF_okDnGomr8jXrFNijuOnUZwmOcY0DY&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Serum Levels of Thymic Stromal Lymphopoietin: A Possible Novel Biomarker in Primary Sjögren’s Syndrome and Related Lymphoproliferation - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Thymic stromal lymphopoietin (TSLP) has been demonstrated to be involved in B-cell lymphoproliferation and lymphoma mainly by tissue studies on salivary glands (SG) biopsies of patients with primary Sjögren’s syndrome (pSS) (1). The aim of this work is to study serum TSLP as a possible novel biomarker in pSS. Methods: Ninety-one antiSSA-positive pSS patients […]\",\n \"url\": \"https://acrabstracts.org/abstract/serum-levels-of-thymic-stromal-lymphopoietin-a-possible-novel-biomarker-in-primary-sjogrens-syndrome-and-related-lymphoproliferation/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109146103\",\n \"publishedAt\": \"2022-03-02T00:31:31.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3821370,\n \"message\": \"Serum Levels of Thymic Stromal Lymphopoietin: A Possible Novel Biomarker in Primary Sjögren’s Syndrome and Related Lymphoproliferation - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9102775,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Hbs58qnSdyRnvRfMz1F5_635994041268567115-1015095974_education+stock+diversity+school+students+classroom+raise+hands.jpg?file_detail=1afe7a28e7fefebefb8350da618e0d1e5197d67ae026800b56dc7cee4ac27facfc7b6d1ea5264ad2acfdb30045583ea454b23f1090643deee320f0f9765314a64edc06b24e2769eefa03bf9b76a83bbc577a00ba122b6b772fc8c00d2e8a74a62d47e2d38916a518666805b57d128b8b3efe9cd5a588b5fbedb422f3697a3dfcb2a7c9c911aecbd5e444b897b0f75593cc3da8b173a0d9bd79ff4c1970e5cb2988151b481ce8a51767469c289175330896653f334aaa03ea6360040c499814e9:93f58d893aed00d580cb7b338d619c44:3dc2a1deac553da930ebc00dee07a516&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjA2MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.vcz_9jk8rKvamy1ySxKieAZx-F8tkN_N3a8hMqfL6vY&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Serum Levels of Thymic Stromal Lymphopoietin: A Possible Novel Biomarker in Primary Sjögren’s Syndrome and Related Lymphoproliferation - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Thymic stromal lymphopoietin (TSLP) has been demonstrated to be involved in B-cell lymphoproliferation and lymphoma mainly by tissue studies on salivary glands (SG) biopsies of patients with primary Sjögren’s syndrome (pSS) (1). The aim of this work is to study serum TSLP as a possible novel biomarker in pSS. Methods: Ninety-one antiSSA-positive pSS patients […]\",\n \"url\": \"https://acrabstracts.org/abstract/serum-levels-of-thymic-stromal-lymphopoietin-a-possible-novel-biomarker-in-primary-sjogrens-syndrome-and-related-lymphoproliferation/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-d3ba6ca2-edd0-46dd-8639-fd2438d05b20\",\n \"slug\": \"bimekizumab-versus-adalimumab-in-plaque-psoriasis-pubmed\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-27T16:15:13.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Bimekizumab versus Adalimumab in Plaque Psoriasis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9095341,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/DYBwUkgrQMyem75Ndody_pubmed-meta-image.png?file_detail=046240ae4948156e2d63f73c956e7f5f42f5c9b3a6f3f761c48bd932c435f87f2e8c4e7bc361c69e0c557098df4ae9fc33b9776eac60f94a8b7da70df47f29da4dd8ec74b5e3619a0b1466068b64e2c6904696e6bbf99b06569cb50e31c4844cb6b2a4ffe5003e509728def30bd9abed:e84be39d8d7d3c470ca280ffd899a8f0:4896ce936a9ce561fdc3640bbc89a697&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjA3OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.QCEKxYj0XUBvn1kfQgn454ThIAvr97b-rP4y9Rebjuc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Bimekizumab versus Adalimumab in Plaque Psoriasis - PubMed\",\n \"description\": \"Bimekizumab versus Adalimumab in Plaque Psoriasis\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34525293/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109137784\",\n \"publishedAt\": \"2022-02-27T16:15:13.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3813104,\n \"message\": \"Bimekizumab versus Adalimumab in Plaque Psoriasis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9095341,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/DYBwUkgrQMyem75Ndody_pubmed-meta-image.png?file_detail=06043af57d93356d95e8ea10dd8396391d44db5ccb685d1310dde499d580fc2fd4b382c3b47be2d6577a5cf3523073cd5463e39c921d1bf0e7c10abb79b78ccf91649958d292bbcd58eefd172253e3b6c7b3473b560415cc31919afc81dc1cb192531284eb6384d592a896f07bfb0455:a29e9243c33c7e0af6c06d1af9508f89:b8e4b233fdc917ae9f10c9f1e4d94220&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjA5MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.sjKhUBVizbvuMkbJKYObm4wzj0zR7v9O4GpErec19Gc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Bimekizumab versus Adalimumab in Plaque Psoriasis - PubMed\",\n \"description\": \"Bimekizumab versus Adalimumab in Plaque Psoriasis\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34525293/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-e412830d-b516-46ba-8fa5-514a89468c21\",\n \"slug\": \"the-diagnostic-utility-of-the-relation-between-mri-bone-marr\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-02T00:10:20.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"The Diagnostic Utility of the Relation between MRI Bone Marrow Edema and Other Types of MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9102757,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/vFGv1e7dSLWOJjDQvayk_graphicstock-little-girl-with-light-bulb-on-the-blackboard-background_BOMluk3Pesx%20(NXPowerLite%20Copy).jpg?file_detail=0bc1d7f96bff90dd65b8d67ca053ca04f6b31c3622be9a120b5782156218bf480339621d0570080bdd3f2a4f95a70873eb76fffbbde8b7121571ac9998c20030bb34e813844cc00ad2e28866a57ea1e1d9f5a23256086f1f2db1737dae124917d17ec5d5be2de59c1ba8c0e02ceccbd9e0a448059f75fb23b30fc9416441cc7c6cc84d4d0cc37168636de76cd26cc6ecb086d30be677bbdfec7315299c34b8aa0ac8d997d88a4e02a0234b1f243768c344a01bdcc74f04176433c72f3fd5c51f:e38b2e1f8778dd5b20c488076b4887a2:2ef31fb8b83a0db080d8536b3a78a947&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjEwNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.bcuNq5Rg_dKn4oBZvrj85XSVy6Ca09w8R-Nl64MV56k&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Diagnostic Utility of the Relation between MRI Bone Marrow Edema and Other Types of MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: MRI detected bone marrow edema (BME) plays a central role in the ASAS (Assessment of Spondyloarthritis International Society) classification criteria for axial spondyloarthritis (axSpA). However, several studies have shown that BME in the sacroiliac joints (SIJs) is also present in other conditions1, 2.. The aim of the study was to investigate the utility of […]\",\n \"url\": \"https://acrabstracts.org/abstract/the-diagnostic-utility-of-the-relation-between-mri-bone-marrow-edema-and-other-types-of-mri-lesions-in-the-sacroiliac-joints-in-axial-spondyloarthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109146083\",\n \"publishedAt\": \"2022-03-02T00:10:20.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3821350,\n \"message\": \"The Diagnostic Utility of the Relation between MRI Bone Marrow Edema and Other Types of MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9102757,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/vFGv1e7dSLWOJjDQvayk_graphicstock-little-girl-with-light-bulb-on-the-blackboard-background_BOMluk3Pesx%20(NXPowerLite%20Copy).jpg?file_detail=8eed97af14782cacf13829d5b716d10c2ca0522fdf42c57b3fe40e054a492a8578b1dabaf89d15194d5cb35fe8263f01c6e0d2212bc9458a39dfbef623d689a23cedb3e603c091fedb4bc5562c5160d77a1a9b97f0a8f9c6b53da45f57e4545043eb494ecf77145d38949a0849eac3563319462128f59871dd92527a5836374f67ddc42a869f68c1ab92f89f40191f7611e783e4835d9e6e3f3421479a25ac1a5dedaed9858d919736c77774336ce904f7e07c7a081d8df897b1ed5686984635:2f2bd4483081ba9b5d0df77cabd3b184:778d227ebb3c75dbe4f17fda518e3e95&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjEyMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.CaxXZK6eyocnVA0Rtq8uJFWnjaeon1OwomenrKAfCEM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Diagnostic Utility of the Relation between MRI Bone Marrow Edema and Other Types of MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: MRI detected bone marrow edema (BME) plays a central role in the ASAS (Assessment of Spondyloarthritis International Society) classification criteria for axial spondyloarthritis (axSpA). However, several studies have shown that BME in the sacroiliac joints (SIJs) is also present in other conditions1, 2.. The aim of the study was to investigate the utility of […]\",\n \"url\": \"https://acrabstracts.org/abstract/the-diagnostic-utility-of-the-relation-between-mri-bone-marrow-edema-and-other-types-of-mri-lesions-in-the-sacroiliac-joints-in-axial-spondyloarthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-ec0f507c-edd6-4d4f-b579-8f0f9fbeb35f\",\n \"slug\": \"long-term-efficacy-and-safety-of-secukinumab-in-the-treatmen\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-27T00:47:58.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9094262,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/IkZO0s7LRb6xmWo3huLP_pubmed-meta-image.png?file_detail=c51448bc4bccf1336065d4b569389b69b83eb2ed8185bdad142ae9cf9d5242dfdbb817e53795d02ba4c8de640980c54e186ea48466f6dde28e483ec0a6164a6a7192e16e470e5af4d6be6fa41941d983922c269f02c6cdf9dc89d958fba1dfbdbc333f58459ba1222c951f594cc8a60e:c34bfc85c245d8f5b2dff37097b0e280:613393a30580fd5ac853649c7602550b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjEzNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.H8LzW9kRHl40yykBeOnANfKQNLKho3Tz1j-bK5bqHww&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease - PubMed\",\n \"description\": \"Psoriatic disease is a multifaceted disorder, which develops in the skin, its appendages and joints. Though characterized by different pathogenic background and clinical manifestations, skin plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are related, sharing key in …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31785165/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109136733\",\n \"publishedAt\": \"2022-02-27T00:47:58.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3812059,\n \"message\": \"Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9094262,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/IkZO0s7LRb6xmWo3huLP_pubmed-meta-image.png?file_detail=3412ef2d68c8f387e8103ed9d2262ca009889b17fe0659ac798c6927752443e47052dec1a09ff5119209f70581bebe8f428603ffb77e93dac66ab06dba2d99926caf69a189d39a7b29c46e5ba742ffe312bf43143a336299d3396faaa30d3827a0ddffa6719fabd390bd4b305bcac7db:d687f205b061b38218e30837cfa708ee:563b8d295ed56e02e9b64d0859ac2aca&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjE0OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.bJkieHQ-TX9wXOsNuDgR5gH9dm60b4OVBfSOT7onrws&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease - PubMed\",\n \"description\": \"Psoriatic disease is a multifaceted disorder, which develops in the skin, its appendages and joints. Though characterized by different pathogenic background and clinical manifestations, skin plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are related, sharing key in …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31785165/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-f4905df6-2327-4bca-a1e7-e1dfbfc9abd5\",\n \"slug\": \"axial-spondyloarthritis-pubmed\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-26T23:16:44.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Axial spondyloarthritis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9094099,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/HXC6rHeRDugXHwzCrcub_pubmed-meta-image.png?file_detail=1c260dcf9c18afc8bfe659d8dac5c29159cbbaca9d766e620fb784205c89a9c8cd6489c3f487235ec43ee429b6f8b9d6a7e9a8407d15dd3481cf79134ababb17b383502765ded843f1066032204a0f775fb1dd443abe637e0d1e6ef9e7cf67726b1bf0b01dc4963761d4ccdb7116f902:c3e03a03b90c41567e24d31907c8ae7e:15a24041f8b3436494d4347e57fac7ef&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjE2NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.VVMuIkF6qYHazisSiOuZosbyaz_JtAVhsvNagFMZoGc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Axial spondyloarthritis - PubMed\",\n \"description\": \"The term axial spondyloarthritis covers both patients with non-radiographic and radiographic axial spondyloarthritis, which is also termed ankylosing spondylitis. The disease usually starts in the third decade of life with a male to female ratio of two to one for radiographic axial spondyloarthritis …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/28110981/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109136610\",\n \"publishedAt\": \"2022-02-26T23:16:44.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3811940,\n \"message\": \"Axial spondyloarthritis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9094099,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/HXC6rHeRDugXHwzCrcub_pubmed-meta-image.png?file_detail=0936fcf0646ab820f3c682c282728dfe72e865ba7cb1cd7444c17abf8df7711eb68ed5646e3074daf06c02a28a1c9cf9caad49d3efc7dd923f1742ed892cf914c51722bd8dbffe47035eeb6d2c3fe61015d1e872187e4964b50728a118a3ccae452fbbb43522e1f9a2134062a05fe5b3:1630b83e41f9f23adc9814026d3dff75:32f35742c63960df13e7021aae623f58&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjE4MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.BTlxeJliPjxhyH1nQLxoeLN253lVmDAigA53MrHc5Dk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Axial spondyloarthritis - PubMed\",\n \"description\": \"The term axial spondyloarthritis covers both patients with non-radiographic and radiographic axial spondyloarthritis, which is also termed ankylosing spondylitis. The disease usually starts in the third decade of life with a male to female ratio of two to one for radiographic axial spondyloarthritis …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/28110981/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-ec3ef71d-5956-421a-b4b7-b53d1774bbc2\",\n \"slug\": \"extra-articular-disease-in-patients-with-spondyloarthritis\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-02T22:38:03.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Extra-articular disease in patients with spondyloarthritis. Baseline characteristics of the spondyloarthritis cohort of the AQUILES study - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9106434,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/pQKgzXNtSNGSXOUKFE3q_pubmed-meta-image.png?file_detail=d4af5799be593af6275e3722ac102f190262b84525d1ad6cf78655ff06fa283aa9d3b3f3fe7ca37664d71d31505705f6af8472b2610acad1a9e2324b23fb1826eecd7dcac94e89054a3f939a3a70694437a0ef4c3e31dce2a2da37ba20fc409ada06a788b7d190e09b4db66918d497df:3a84b360cf15d75bb1de4a51be6dc693:cba024c1c072b63cbc709e0d2b681d08&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjE5NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.xtW96x4hoBAi2rv58XwzFa6M4QFwgqEnd6Hw_AV5JOc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Extra-articular disease in patients with spondyloarthritis. Baseline characteristics of the spondyloarthritis cohort of the AQUILES study - PubMed\",\n \"description\": \"Extra-articular disease in patients with SpA is common and, in this study, it was associated to age, female gender and the presence of other SpA-related extra-articular manifestations.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/25441489/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109150083\",\n \"publishedAt\": \"2022-03-02T22:38:03.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3825330,\n \"message\": \"Extra-articular disease in patients with spondyloarthritis. Baseline characteristics of the spondyloarthritis cohort of the AQUILES study - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9106434,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/pQKgzXNtSNGSXOUKFE3q_pubmed-meta-image.png?file_detail=707b858e78bfe5a05adde3e22158cfcbef938af0cfe622cd94599a654dfcba1fde635368d163bcae475edf287511cf00a4a5ae57c4e50844f93de7e7aac07ea67a15e58470b0e879e208e825d8c23c0131c79fc391969df6fd524c0bd03fe58a7041ba0ee12944c4803916372c60c9b0:35ac568d256f09692f432ec7e2f37c6f:a221629ab9b5af00de26ce460e79f997&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjIxMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.IKTaz4jcIyvIo-zGTgqQKe49LGKdHsM8F5UqMtmFjpU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Extra-articular disease in patients with spondyloarthritis. Baseline characteristics of the spondyloarthritis cohort of the AQUILES study - PubMed\",\n \"description\": \"Extra-articular disease in patients with SpA is common and, in this study, it was associated to age, female gender and the presence of other SpA-related extra-articular manifestations.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/25441489/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-f0e65b66-c02a-4297-8847-b007f46dc25e\",\n \"slug\": \"management-of-psoriatic-arthritis-in-rheumatology-and-dermat\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-06T13:04:29.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9116123,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/we64Ru9cQn6tTTBFZ1Nx_pubmed-meta-image.png?file_detail=0d62d8cb67520e397dfdf42f306c7e81e7e9b36ca19637da03dbd306d48cd169b9bd0851348d2f485408a2607706078108cd7a0c6201cad8e1a9e30bc313ddd4abe3f752ad8a22d9d260fbcb161ce8fe06984913268d7955fa5a39ceabaca4e8330ab35e9b469db8581481971634f66a:59215078c0bf1fba4463a7cd002ee9c0:cd24fec1c0c2980b911f0a942481d10b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjIyOCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.xZk__Gfc2zpmtpSLWcd015LNqIg-pGuP0ruWNK0wUpI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study - PubMed\",\n \"description\": \"Psoriatic arthritis (PsA) patients are often treated by dermatology and rheumatology specialities and may receive different treatments. To evaluate the impact of dermatology/rheumatology specialist settings on diagnosis and therapeutic approach in PsA patients. This cross-sectional multicounty study …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33155160/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109160680\",\n \"publishedAt\": \"2022-03-06T13:04:29.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3835857,\n \"message\": \"Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9116123,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/we64Ru9cQn6tTTBFZ1Nx_pubmed-meta-image.png?file_detail=c2c30566c35c7e177cb60ad8fed6182d1c65090f8d3b9f650b0e881c51a7ad6f1c10f1995b45e5754f85f664cf3f561179bb8fc6008df07937de77fe23d1dd08d2e238bdd9be6f8afb3ea22e3e5bac8e38a1be5bd74ea9e1e9e3788da04ba2263cff2a77b5cdd52d4600ffc8a962182e:5627c98f5f2aa993a1c64c52ca258c56:061163668c69f9a7ad01fc37aecabfde&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjI0NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ORi6kfpOrcjbm1TP3J5Ltpvs1DjRgZ0-1jX_8lmUr1s&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study - PubMed\",\n \"description\": \"Psoriatic arthritis (PsA) patients are often treated by dermatology and rheumatology specialities and may receive different treatments. To evaluate the impact of dermatology/rheumatology specialist settings on diagnosis and therapeutic approach in PsA patients. This cross-sectional multicounty study …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33155160/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-fa04006c-742b-4c35-8fea-a79b5367ef22\",\n \"slug\": \"drug-survival-differences-in-ra-psa-spa-and-pso-rheumnow\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-04T11:31:58.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Drug Survival Differences in RA, PsA, SpA and PsO | RheumNow\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9111487,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/YgzlNgnHReib2jEPtKS4_infusion.biologic_5.jpg?file_detail=5ccd685f492a2b5a419756703820c3e4b29ef181f0ca134c67c1f1b13bad0711fddf7388e5e6a8b5eca390e8f9c75c85896581c655c70883c78078e2aedae811605e5ff2067f3a0f6a5f0b2c511b0a1174f95a73e844ecb3688a14b04123e40cf46c12122eaf54ec026d528b1276831c:c1dfebdf47296790a996cd1f978dab05:be1a80b4baa9a5f425759ef3baf6b7e4&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjI2MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.8YfjODNG_Dm9ALX8UcNxj6U4oZRLEkxeaAjnWVgRXAc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Drug Survival Differences in RA, PsA, SpA and PsO | RheumNow\",\n \"description\": \"Drug survival may be the best measure of efficacy and safety. A new study of novel therapy durability (survival) in patients with RA, axial spondyloarthritis, PsA, and psoriasis shows that while all these drugs are approved for said conditions, drug survival varies by condition, suggesting an ongoing need for individualized treatment.\",\n \"url\": \"https://rheumnow.com/news/drug-survival-differences-ra-psa-spa-and-pso?utm_source=RheumNow+Newsletter&utm_campaign=2793716578-EMAIL_CAMPAIGN_2022_03_03_09_29&utm_medium=email&utm_term=0_11adbca03a-2793716578-243787117\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109155942\",\n \"publishedAt\": \"2022-03-04T11:31:58.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3831155,\n \"message\": \"Drug Survival Differences in RA, PsA, SpA and PsO | RheumNow\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9111487,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/YgzlNgnHReib2jEPtKS4_infusion.biologic_5.jpg?file_detail=daab3ed2a447dbb693e2939a8a65afbe7636b722bc0b9c14e6ec6ce74d90085c84d0b5b250ea13cce2eee205d254229a83e1931e1c937633679e158716bd21981d98a6b9e99486ec71b409169091ef986556ec2ed1425ab0b13b39bdf19e605505b190ef4bf28c0f4470625071dc5738:aa0fc584bed339f82c21188e9ae1cbc7:ee729921741fba7767ebcde93a6d9700&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjI3NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.pnBjsLL9eC7086q35vsVLwUXrKXMSG9t8VUY-OJPHdc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Drug Survival Differences in RA, PsA, SpA and PsO | RheumNow\",\n \"description\": \"Drug survival may be the best measure of efficacy and safety. A new study of novel therapy durability (survival) in patients with RA, axial spondyloarthritis, PsA, and psoriasis shows that while all these drugs are approved for said conditions, drug survival varies by condition, suggesting an ongoing need for individualized treatment.\",\n \"url\": \"https://rheumnow.com/news/drug-survival-differences-ra-psa-spa-and-pso?utm_source=RheumNow+Newsletter&utm_campaign=2793716578-EMAIL_CAMPAIGN_2022_03_03_09_29&utm_medium=email&utm_term=0_11adbca03a-2793716578-243787117\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-fdeaa66a-5451-4854-8909-1b2977aba389\",\n \"slug\": \"just-a-moment-just\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-27T16:41:14.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Just a moment...\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9095380,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/U4Db9QEDQU6f4nz8NiuE_white-spotlights-in-a-row-on-stage-for-highlighting-or-showing-a-product_zJMd17Du%20(NXPowerLite%20Copy).jpg?file_detail=a7c40b702ee9e6975bac9c92d8392b361c7e8dedf8316f4a99d2b663978fb8e1c5f7ed0ea40f58a72698f3d54dcc7382f60ac0de5da353c8818698b71fcd5c1803773dd50010ae3ed6c6835d343a387f62f5b5f4a15544643cf2afa132bf1e8f419eec129cc19f98f5c222cf5c3516115edfb74c614d5c6c0814583c834243c5a3baaf4158d2ddd509652705a1dd17d164af761b4c4bd6174c6501ec01b92caeba4935c33a79c1c5e823caf69142c75939b5267badcc36b44969418a603e9566:a569408942c9ad492b2b80a1a637c003:cafd2b4bc32ad0148296e3431f6e4921&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjI5MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.EmGWt3CZ57DGPDAHuYB28Emcl5SAZ6cnO9B_dnKbuY4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Just a moment...\",\n \"description\": \"Erthrodermic PSO W COSENTYX\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1111/dth.13348\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109137807\",\n \"publishedAt\": \"2022-02-27T16:41:14.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3813127,\n \"message\": \"Just a moment...\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9095380,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/U4Db9QEDQU6f4nz8NiuE_white-spotlights-in-a-row-on-stage-for-highlighting-or-showing-a-product_zJMd17Du%20(NXPowerLite%20Copy).jpg?file_detail=95109233a267756d854350b22f70fee149d54584e290703a763985ca48ace6f3e87dde71cb33613d488c69ceb867b3f056f356a2826a2d9d0fb1b1dccc2e4a03d8f078d87628b7fd7db3702467489b77a34e3a262f5ab5948fac50f3d06b19ad5e767ffa25458a92d6981804ac403d295c2c95f3bf3263a714bc9656cabaf7eee1079a6cac2ba83ca1fce340fe33113b5d99fac3dc97406a2551f6bf5d7f80ea7b4556fa32286c43cae97815cbb5378d7241b926e7ea4c310021bb4710056c2c:c7977fbd8bf44f962f5da292685cf622:6623a80af8f8754f26c414282eaca27b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjMwNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.gQSGmgr5tZM5N2UqKtoSyku-olwvvH1hGC8k010Rhx4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Just a moment...\",\n \"description\": \"Erthrodermic PSO W COSENTYX\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1111/dth.13348\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-a9c2eb71-18cc-46e9-a8e9-08834ca7113a\",\n \"slug\": \"do-primary-sjogren-s-syndrome-patients-with-normal-major-sal\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-20T02:46:37.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Do Primary Sjögren’s Syndrome Patients with Normal Major Salivary Gland Ultrasound Have Less Active Disease? - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072350,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/pEsjczHRq2VkPRPlzbUQ_ACR_1064742_1.jpg?file_detail=a43442b12f607dc7633994b9f52cd589a7a54bca2e13772369922b078825c2d2b80b33f0ec8dcbd597f4e631e0d540820369bbe0fc693c215d90995d7e0bb25620af124e403b50ca9513f6fe6d1568903b0ac44ada37ef964b577f22de7caab241d70142e63ca1df905331eb2fde43a0:b3f76a1ea9f0ba89c69946eddf0435c2:0d987f51e56e7c28185bd428a6afb080&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjMxOSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.QWVcHqtKGDiTGDWZ1blTcFFHzLYH2wxBvLXDaT5IhS4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Do Primary Sjögren’s Syndrome Patients with Normal Major Salivary Gland Ultrasound Have Less Active Disease? - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Ultrasonographically depicted morphological changes of major salivary glands (SG) have been recently correlated with the disease activity in primary Sjögren’s (pSS)1. The aim of our prospective, cross-sectional study was to determine whether pSS patients with normal SG ultrasound indeed have less active disease at baseline. Methods: We included 129 consecutive adult pSS patients, diagnosed […]\",\n \"url\": \"https://acrabstracts.org/abstract/do-primary-sjogrens-syndrome-patients-with-normal-major-salivary-gland-ultrasound-have-less-active-disease/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109111943\",\n \"publishedAt\": \"2022-02-20T02:46:37.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787421,\n \"message\": \"Do Primary Sjögren’s Syndrome Patients with Normal Major Salivary Gland Ultrasound Have Less Active Disease? - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072350,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/pEsjczHRq2VkPRPlzbUQ_ACR_1064742_1.jpg?file_detail=0ac1a12f5ff6a83027f7b835ce5d8ea6a9d94b2cfd4c695266edf4aebbce8d503c64485636d857143510ad716f55b44dfa6c77604c656f447408c860401095245030b6ea629585531587af63ad62e895d46c0361c60ba9895fe6284edd6f2a2f02f7bcc8b7d10fbd9cff2054894ca8a8:9fc8578b02fdaad34fecd47f66911662:dcbbe38c9a0dbf06d5737f0361c6833b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjMzMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.c4vhndRTTGewHsURPZmzPh15fsjWAcr8hSgrYzMZvRQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Do Primary Sjögren’s Syndrome Patients with Normal Major Salivary Gland Ultrasound Have Less Active Disease? - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Ultrasonographically depicted morphological changes of major salivary glands (SG) have been recently correlated with the disease activity in primary Sjögren’s (pSS)1. The aim of our prospective, cross-sectional study was to determine whether pSS patients with normal SG ultrasound indeed have less active disease at baseline. Methods: We included 129 consecutive adult pSS patients, diagnosed […]\",\n \"url\": \"https://acrabstracts.org/abstract/do-primary-sjogrens-syndrome-patients-with-normal-major-salivary-gland-ultrasound-have-less-active-disease/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-ab200bed-6431-4fc1-a142-6551480b6e16\",\n \"slug\": \"high-degree-of-inter-patient-heterogeneity-in-synoviocyte-hy\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T13:13:35.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"High Degree of Inter-patient Heterogeneity in Synoviocyte Hyperplasia and Immune Cells Infiltration in the Synovium of Juvenile Idiopathic Arthritis Patients - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9070946,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/yG10IbNSFqChAZmbBB06_hot-air-balloon-over-landscape-of-bagan-myanmar_rD1xopeuhzx%20(NXPowerLite%20Copy).jpg?file_detail=5a0c96a6f4cabe0e778e027fa01e45f5b35298a5c0351f991a5f942128179a6cfd711eec267a9c6f7eacf66f90f1ab0ccbb6822062321c827999300cb097e0fa972db08fb05e96b7c5b50abb72ccc214141814d9a6d6d3f59f0ac91b80f6862d10da48a304b7d9ed8b8a8f92ddda455291baa8bef98f0609d51e78967c5b6ce5ee42b0daf078727fc0e964bbbeb861075dc4db0f9a06b59bc5899ae1a552cef3722f1484aaaba0665d2d4802c7e23894:638c80a4150fa6c3fe8e14dbf89538cb:e6305d3c31ffda080382efc3fc21085e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjM0MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.htG-vskgUrLFcjUoP7N3HXXFq76O23mZ7gi5KPdMjqo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"High Degree of Inter-patient Heterogeneity in Synoviocyte Hyperplasia and Immune Cells Infiltration in the Synovium of Juvenile Idiopathic Arthritis Patients - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Increasing evidence indicates that synovial tissue analysis can deliver pathophysiological insights but also individual clinically-relevant information in adult-onset inflammatory arthritides. Little is known about synovial pathology in juvenile idiopathic arthritis, especially regarding inter-patient variability of histopathological features. To assess the heterogeneity of main synovial features (synoviocyte hyperplasia and immune cells infiltration) in juvenile idiopathi...\",\n \"url\": \"https://acrabstracts.org/abstract/high-degree-of-inter-patient-heterogeneity-in-synoviocyte-hyperplasia-and-immune-cells-infiltration-in-the-synovium-of-juvenile-idiopathic-arthritis-patients/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109110563\",\n \"publishedAt\": \"2022-02-19T13:13:35.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3786052,\n \"message\": \"High Degree of Inter-patient Heterogeneity in Synoviocyte Hyperplasia and Immune Cells Infiltration in the Synovium of Juvenile Idiopathic Arthritis Patients - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9070946,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/yG10IbNSFqChAZmbBB06_hot-air-balloon-over-landscape-of-bagan-myanmar_rD1xopeuhzx%20(NXPowerLite%20Copy).jpg?file_detail=4d3662004cbed7eab36d49417a9fc013784b8b64c208d77a1210dcf4e6ccf0aaf5bde95de2002347f87d171f2c398136b2e9b9234ccaef44e43dc19a1b871b372f5ae22ad24e112e02ba1c9659937f25bb6de007774e5b9e1d3040180cd96c9a24d2121860a9bdf6bf752d00c48b34fcde0320da1c17365bee24e538c998732cec8815b6bce52e0407acd33421d7cf8e828abff21817733565276591da272d52772c476ebf34d39c11329f524eb976b7:0866485401b55197a8d14819d12ad018:bdd9faa5d31b3385274be28b3cee8888&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjM1NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.yy1FRGcCCyGF10YmVb9Q2qCxLKgGnz-xRhrihBfRxnc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"High Degree of Inter-patient Heterogeneity in Synoviocyte Hyperplasia and Immune Cells Infiltration in the Synovium of Juvenile Idiopathic Arthritis Patients - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Increasing evidence indicates that synovial tissue analysis can deliver pathophysiological insights but also individual clinically-relevant information in adult-onset inflammatory arthritides. Little is known about synovial pathology in juvenile idiopathic arthritis, especially regarding inter-patient variability of histopathological features. To assess the heterogeneity of main synovial features (synoviocyte hyperplasia and immune cells infiltration) in juvenile idiopathi...\",\n \"url\": \"https://acrabstracts.org/abstract/high-degree-of-inter-patient-heterogeneity-in-synoviocyte-hyperplasia-and-immune-cells-infiltration-in-the-synovium-of-juvenile-idiopathic-arthritis-patients/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-efb302bf-0c32-4ddd-901c-8ed18e818929\",\n \"slug\": \"detection-of-radiographic-sacroiliitis-with-an-artificial-ne\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T13:00:26.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Detection of Radiographic Sacroiliitis with an Artificial Neural Network in Patients with Suspicion of Axial Spondyloarthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9070932,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/4pXv17RGTy2KIUG9QLLM_ACR_1055557_1.jpg?file_detail=6c2d31e03d8609d61fb2c7b281987bd1079269aedffaaaf994978ea548a3d200e8033a87ba2d44b091691676a97e71801727309148554f038c5e435b7cad8a2e63c9a9286108ffe66fdedd500ccd6dcb3342878268518c46840d473b9ce7c29f829bbbe4eae1125f4c6ae614cd2234c1:7796765046eed198c1ab62f6333bc50d:8368e2bff5b7bc0a7b52e8cb1be2e9b6&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjM2NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.lU9BrKrI4r8iEONQud-w_SLG5PI-zNK8ufj-Ivfd-rE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Detection of Radiographic Sacroiliitis with an Artificial Neural Network in Patients with Suspicion of Axial Spondyloarthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Conventional radiography of the sacroiliac joints is still recommended as the first imaging method for the diagnosis of axial spondyloarthritis (axial SpA). In many clinical settings around the world, this is the only widely available imaging method to diagnose axial SpA. A high specificity of radiographic detection in the diagnostic setting is required to […]\",\n \"url\": \"https://acrabstracts.org/abstract/detection-of-radiographic-sacroiliitis-with-an-artificial-neural-network-in-patients-with-suspicion-of-axial-spondyloarthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109110550\",\n \"publishedAt\": \"2022-02-19T13:00:26.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3786039,\n \"message\": \"Detection of Radiographic Sacroiliitis with an Artificial Neural Network in Patients with Suspicion of Axial Spondyloarthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9070932,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/4pXv17RGTy2KIUG9QLLM_ACR_1055557_1.jpg?file_detail=5045c1f232bd9160670915d8afb341dd14162b7746d476e732eeb01bb14b239b63e286fd556f32a0384a0a224aac4abad24fa1039aac401515c5b820e89e848b05505be985dfe8ac19eca133e4eb074936145ce081247749ffb05b7c4b511e22005b9c8538d356950ad99e1f05b92af1:a897d058ec366e9de7c6e3a2bd6ed667:b4bc8d22b7f7b3332296b3be463d96df&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjM4MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.LQqShPUGZXMVEXgFslCN5NqjfTL4rGmQhlBoICHiN4I&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Detection of Radiographic Sacroiliitis with an Artificial Neural Network in Patients with Suspicion of Axial Spondyloarthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Conventional radiography of the sacroiliac joints is still recommended as the first imaging method for the diagnosis of axial spondyloarthritis (axial SpA). In many clinical settings around the world, this is the only widely available imaging method to diagnose axial SpA. A high specificity of radiographic detection in the diagnostic setting is required to […]\",\n \"url\": \"https://acrabstracts.org/abstract/detection-of-radiographic-sacroiliitis-with-an-artificial-neural-network-in-patients-with-suspicion-of-axial-spondyloarthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-f5e7c669-2a24-4b57-bd76-df418ee9999f\",\n \"slug\": \"secukinumab-provides-sustained-improvements-in-clinical-and\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T19:29:12.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072157,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/62OkHnViSdqAKafPQfrj_OCMVWLVW-887230-1-ANY.jpg?file_detail=891d17dcf4bea99444a6fd5c2b4e0003ac9317089908035645ba9c33d70e5b50ccaca505e78681f28b05bb0035b9c8b21f148c37bda3a9595c6704697a90a72979bed7882b14ec9d7f38d39697d4398f81b0eb247581c08260dee5d1155c020e98e31b71e300668bb55d9191a63220de:abfa19120b86d9cdf64bf5d4176e6e74:e0960b67ca3d9d73692be17b0311c523&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjM5NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.TyINcId5E5uUHfQ4JEBNuJiyksaqjdS4fjPRVYL3RE0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Axial disease may affect up to 25–70% of psoriatic arthritis (PsA) patients, depending on the definition used. Current evidence on efficacy of biologics in the treatment of axial manifestations is limited,1 particularly as validated classification criteria for this subtype of PsA are not yet available. MAXIMISE (NCT02721966); the first randomized controlled trial evaluating the […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-provides-sustained-improvements-in-clinical-and-imaging-outcomes-in-patients-with-psoriatic-arthritis-and-axial-manifestations-results-from-the-maximise-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109111755\",\n \"publishedAt\": \"2022-02-19T19:29:12.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787234,\n \"message\": \"Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072157,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/62OkHnViSdqAKafPQfrj_OCMVWLVW-887230-1-ANY.jpg?file_detail=085d185652fa34ed837de34413aead4e8038ce54a693aa89ca8b43d7d00b9d56e4bac12db5602fd64bff65d636c2c852ba48d4ef7e31249ac2f51c25c99357dbf4e6beff954292ba73d03c0fff1946a253e9af95267738dc8c7a4af481b6d785d13130ab6e631c8931f5fbdc2d720781:b557efdd45196704e520efebbd471605:156e38f49554b9abe693319ae99133b3&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjQwNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.S8qBvSMilqNp-4dYIUgYWrT03gKLXhQBiImV5oBXxHc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Axial disease may affect up to 25–70% of psoriatic arthritis (PsA) patients, depending on the definition used. Current evidence on efficacy of biologics in the treatment of axial manifestations is limited,1 particularly as validated classification criteria for this subtype of PsA are not yet available. MAXIMISE (NCT02721966); the first randomized controlled trial evaluating the […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-provides-sustained-improvements-in-clinical-and-imaging-outcomes-in-patients-with-psoriatic-arthritis-and-axial-manifestations-results-from-the-maximise-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-f5193608-bf97-40db-af18-0106a728206e\",\n \"slug\": \"real-world-use-of-secukinumab-in-psoriatic-arthritis-first\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-22T01:55:03.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9077793,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/7271Pn4lTKmyYBaN1Lgw_abstract-summer-background_My_0w3___L%20(NXPowerLite%20Copy).jpg?file_detail=9b56b056e436688a25c9dc590c36b1de0204295eef588d4fd8a1c0a0547b0ef995affacef97343c1128cd22929e90c0ce0c4468ae5b5830324dfe7104b13bcc97df77064c414e02415275e5cfb34e4e5ecb305d26849043420cfda6101066ea4029a296d3bf62cfa9a98eebf769c009d14b7c6c10840275d1907baef0faad23d5bf64b8d3115ef78d37d462d9049fb43:b8104a61a0dba64dc0128a0bcd5e10fe:6ef61de2910575627caf68e3f7579bb9&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjQxOCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.VyiVnUCseHeLj-yGr5nhE1lc-rwl6bALvjlOwD3-m3g&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Until recently, inhibitors of TNF (TNFi) had been the only bDMARD treatment option for patients with psoriatic arthritis (PsA). This situation changed when anti-interleukin-17A monoclonal antibody secukinumab (SEC) became available in March 2017. We aimed to characterize and compare patient populations starting treatment with SEC versus TNFi during the first year of SEC availability […]\",\n \"url\": \"https://acrabstracts.org/abstract/real-world-use-of-secukinumab-in-psoriatic-arthritis-first-year-data-from-the-czech-national-registry/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109118011\",\n \"publishedAt\": \"2022-02-22T01:55:03.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3793473,\n \"message\": \"Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9077793,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/7271Pn4lTKmyYBaN1Lgw_abstract-summer-background_My_0w3___L%20(NXPowerLite%20Copy).jpg?file_detail=0370041191c0ea0c136331e6ab7a6019a526155e111acd30e9b4d4609f65c8ec7bb03a96163723169e3ac0f40f37df181e059f3c1898e8bb9ddfb782c593e2fabf6706d4742eba10cee59a71ce5f2f216c3ea78371e176c938176f0aa44d67d6f0000fd8110c8e7c217350e030c980690d28ddb00af31ea007fdad0f0f93177879d90d4d6af4d5092de45dfa3b14edf1:27510aa2efe59733455650d5772084d1:d9e18269d17d454d98a8ed7feef477d8&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjQzMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.UB9eTuucOWynwOI_bb5Tjiy8cvgRQI5xbhyw5QmWobk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Until recently, inhibitors of TNF (TNFi) had been the only bDMARD treatment option for patients with psoriatic arthritis (PsA). This situation changed when anti-interleukin-17A monoclonal antibody secukinumab (SEC) became available in March 2017. We aimed to characterize and compare patient populations starting treatment with SEC versus TNFi during the first year of SEC availability […]\",\n \"url\": \"https://acrabstracts.org/abstract/real-world-use-of-secukinumab-in-psoriatic-arthritis-first-year-data-from-the-czech-national-registry/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-fe8889f7-3a5f-437c-a9c7-cd4fba9b58d7\",\n \"slug\": \"upadacitinib-effects-on-entheseal-domain-in-psoriatic-arthri\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-20T02:52:46.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Upadacitinib Effects on Entheseal Domain in Psoriatic Arthritis Patients – a Pooled “post-hoc” Analysis from Two Phase III Studies (Select PsA 1 and 2) - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072352,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/tgfUPRbLRQmss9gNeFTs_ACR_1060215_1.jpg?file_detail=0f1264fbb1240b8cca9466bc44fa5d1db89ef320e3961065cb0d5e8dc9ed5ff7e60575a8db2fc1db184b34468f02577b053c0739e8968bf9e0b42c253d4aa036fe6741d9a83d543ba8b15eedaf95dd6020a8bb1ffb70b0ac8fc8fc79fc499fffbbbd32f8e92d646a7a7ad2ef09d50f71:2827328cd34218b54624fd4458cc1ec6:6149198f39af84f2bee2cbfc6e3b2335&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjQ3NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Ayt91lYR0HUpOOPp8ga-0TjqCDBIvCh1aXpUclNJ5Pk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Upadacitinib Effects on Entheseal Domain in Psoriatic Arthritis Patients – a Pooled “post-hoc” Analysis from Two Phase III Studies (Select PsA 1 and 2) - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Reaching control or improvement on enthesitis domain in psoriatic arthritis (PsA) is challenging, and it continues to be a priority for patients (pts) and rheumatologists. Upadacitinib (UPA) has demonstrated efficacy across key manifestations, including enthesitis, in pts with active PsA with inadequate response to non-biologic or biologic DMARDs from the SELECT-PsA Clinical trials program […]\",\n \"url\": \"https://acrabstracts.org/abstract/upadacitinib-effects-on-entheseal-domain-in-psoriatic-arthritis-patients-a-pooled-post-hoc-analysis-from-two-phase-iii-studies-select-psa-1-and-2/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109111945\",\n \"publishedAt\": \"2022-02-20T02:52:45.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787423,\n \"message\": \"Upadacitinib Effects on Entheseal Domain in Psoriatic Arthritis Patients – a Pooled “post-hoc” Analysis from Two Phase III Studies (Select PsA 1 and 2) - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072352,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/tgfUPRbLRQmss9gNeFTs_ACR_1060215_1.jpg?file_detail=4087085de217035581bd801179cef8a38c49ce13743f257cd6b8621fea8c50960f9cd36370f2219797de4bca1406da0887539225363b156b83915b9ff933450b81b53577b49641637f7c8858fe1d31750a110e3bcb457f859ff84fb49a511199c711bf072533979b72a79256b36117bd:4671d2b13130ab465b4bda59d02589f7:8978004ce18558073aad39e801b738d8&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjQ4OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.g8ykmfzkGoFp3XhdWqwG4hhq8yxpPy0_xaRVQK8NwOQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Upadacitinib Effects on Entheseal Domain in Psoriatic Arthritis Patients – a Pooled “post-hoc” Analysis from Two Phase III Studies (Select PsA 1 and 2) - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Reaching control or improvement on enthesitis domain in psoriatic arthritis (PsA) is challenging, and it continues to be a priority for patients (pts) and rheumatologists. Upadacitinib (UPA) has demonstrated efficacy across key manifestations, including enthesitis, in pts with active PsA with inadequate response to non-biologic or biologic DMARDs from the SELECT-PsA Clinical trials program […]\",\n \"url\": \"https://acrabstracts.org/abstract/upadacitinib-effects-on-entheseal-domain-in-psoriatic-arthritis-patients-a-pooled-post-hoc-analysis-from-two-phase-iii-studies-select-psa-1-and-2/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-f9782753-40ef-43fa-bddd-708ec3f7879b\",\n \"slug\": \"non-steroidal-anti-inflammatory-drug-use-is-associated-with\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T13:22:00.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Non-steroidal Anti-inflammatory Drug Use Is Associated with Disease Activity and Reduced Significantly in Patients with Axial Spondyloarthritis Treated with Tumor Necrosis Factor Inhibitors; Data from a Real Life Experience - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9070954,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/HQ18hiTCQQOGmx4caP4D_ACR_1066389_1.jpg?file_detail=70cb1812fbd45477f4747805fb5830b106ec53b3c634f63846b47c1db4d2f0980570b75f967ff6d0eb47474e33442039ad12be6b87c4e95ed2a19c97f05f43eb7fc3814613866cf487115ac33e1421ba186bf7db56c4454cf3f00edce5eb6a8413e8bba3d5226c55a2daa70f01fb910a:b1011193bfc1a3fde03ad5a9843bdf67:2d4bf2334c70d586ccd0bc3637234ded&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjUwMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.J41mrckMWgy0Oj_kxgkgMj46IMd92m4LKY1FE3tVxLo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Non-steroidal Anti-inflammatory Drug Use Is Associated with Disease Activity and Reduced Significantly in Patients with Axial Spondyloarthritis Treated with Tumor Necrosis Factor Inhibitors; Data from a Real Life Experience - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Bacground: Non-steroidal anti-inflammatory drugs (NSAIDs) is the first line treatment option in axial spondyloarthritis (axSpA) patients suffering from pain and stiffness. However there is only limited data regarding the concomitant use of NSAIDs during tumour necrosis factor inhibitor (TNFi) treatment. Objectives: To evaluate longitudinal concomitant NSAIDs use with the TNFi treatment and the determinant […]\",\n \"url\": \"https://acrabstracts.org/abstract/non-steroidal-anti-inflammatory-drug-use-is-associated-with-disease-activity-and-reduced-significantly-in-patients-with-axial-spondyloarthritis-treated-with-tumor-necrosis-factor-inhibitors-data-from/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109110568\",\n \"publishedAt\": \"2022-02-19T13:22:00.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3786057,\n \"message\": \"Non-steroidal Anti-inflammatory Drug Use Is Associated with Disease Activity and Reduced Significantly in Patients with Axial Spondyloarthritis Treated with Tumor Necrosis Factor Inhibitors; Data from a Real Life Experience - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9070954,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/HQ18hiTCQQOGmx4caP4D_ACR_1066389_1.jpg?file_detail=a7123ffbcbd5337f868bf9dd872767f913fc1bd47faea262a3d3b77b20a8b9e0f0866e2d0add3294fbfc161951213280a998269fbcff9caa40c39fb4b5e0abb88e9bf064a4385a3a3998fa327ad6c06fa3968189027b772178dc072757ea4992ae724c220c00f01c764e4b6af7f8e6b8:3167002066a3a67f270b2ac713bc79f1:b2a92aefd2e317dbcf2168f5b281f52c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjUxMyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.DNkGjyvdNhuX0__xJpv1oLSziQopV7sNYmWXWvmd8aw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Non-steroidal Anti-inflammatory Drug Use Is Associated with Disease Activity and Reduced Significantly in Patients with Axial Spondyloarthritis Treated with Tumor Necrosis Factor Inhibitors; Data from a Real Life Experience - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Bacground: Non-steroidal anti-inflammatory drugs (NSAIDs) is the first line treatment option in axial spondyloarthritis (axSpA) patients suffering from pain and stiffness. However there is only limited data regarding the concomitant use of NSAIDs during tumour necrosis factor inhibitor (TNFi) treatment. Objectives: To evaluate longitudinal concomitant NSAIDs use with the TNFi treatment and the determinant […]\",\n \"url\": \"https://acrabstracts.org/abstract/non-steroidal-anti-inflammatory-drug-use-is-associated-with-disease-activity-and-reduced-significantly-in-patients-with-axial-spondyloarthritis-treated-with-tumor-necrosis-factor-inhibitors-data-from/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-0b139226-7b7c-4ce8-baf3-d80264d39353\",\n \"slug\": \"enthesitis-in-psoriatic-arthritis-the-sonographic-perspecti\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-02T22:39:30.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Enthesitis in Psoriatic Arthritis, the Sonographic Perspective - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9106437,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/ERyAJ86R8m2Pj2NmCKXg_pubmed-meta-image.png?file_detail=bd672812eff0530f0dd91e076d57a1929cf3d52d5590dd26cd43ee8e53299fd5c0a7a8e9a687ed6417d7a13a586de9d6c58b3298814f2e8a30dcf740875523e48dc60956efc8ebe76113af9b943ac9996bb995703df735def92666e661927c756a0f51608b5fdaae693627630aa37f57:9f7a6918be317b12c89d40fd97221fc6:7994b7b0489246c68847913ef8067a34&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjUyNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.AoKB4j2O_bWaE-Ehhul5y1Mr_cL6KyY9utNegaTbF1g&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Enthesitis in Psoriatic Arthritis, the Sonographic Perspective - PubMed\",\n \"description\": \"Last-generation US equipment has demonstrated the ability to detect subtle morphostructural and vascular abnormalities at entheseal level. US is able to identify pathologic changes in both \\\"classical\\\" (i.e., the site of attachment of tendons, ligaments, and joint capsules into the bone) and \\\"functio …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34427783/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109150091\",\n \"publishedAt\": \"2022-03-02T22:39:30.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3825338,\n \"message\": \"Enthesitis in Psoriatic Arthritis, the Sonographic Perspective - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9106437,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/ERyAJ86R8m2Pj2NmCKXg_pubmed-meta-image.png?file_detail=c5ed55be18ace423d70bd13a859bcda722a7cc132a9b75b99ae1d8fb0643b43d5e281c261b58ed71e5c7eca93b6473344b2a723c89f66d0a367a2fd1cce969f68386e9a479531d4bf56cb4455db7859993e44989f89b8ecb41bae06827515d7c5fbbf0eba55a10d0a33f21d21444369d:19b514149f1507d20ef005af892fbc66:7f130a7e9adfa5ba1cbf1ea40ca48aa1&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjUzNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.v_T6Y5Mwe3ctdCyFTWMUTrE1Br87K57Nqs1nK9xgVGc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Enthesitis in Psoriatic Arthritis, the Sonographic Perspective - PubMed\",\n \"description\": \"Last-generation US equipment has demonstrated the ability to detect subtle morphostructural and vascular abnormalities at entheseal level. US is able to identify pathologic changes in both \\\"classical\\\" (i.e., the site of attachment of tendons, ligaments, and joint capsules into the bone) and \\\"functio …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34427783/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-0f6d6eb9-803d-4234-a98f-4256583ed8d6\",\n \"slug\": \"management-of-nail-psoriasis-pubmed\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-27T00:19:07.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Management of Nail Psoriasis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9094182,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/JhzjFGv1QMWSvF1QDTVm_pubmed-meta-image.png?file_detail=c83a1fadcda6e1477636bb725bfc8765127380346fdd694eb83f67afc6c9f03eb58293c10ae6ec3a4d452cd18ab518880c7611fe30f16ea02e5abf682693c54c73760593a37108302e79cb1f260c2abf971e6e5331db06cee53b0584dd27d076a7bd52ed66975d5d872fd43d4135d475:7d002ae10c40f8f07aba0480f5efcb83:759b7b86f44af521cc780b8addf01b89&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjU0OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.rWac3Lw3s5FoQ9ShQdU2BlWPTg6W_58-if1WDiMfU_Q&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Management of Nail Psoriasis - PubMed\",\n \"description\": \"Nail psoriasis is a chronic nail disorder that requires personalized treatment. General prophylactic measures are suggested for all patients. Topical treatment is considered when treating a few-nail disease, with involvement of 3 or fewer nails, without joint involvement and without (or with mild) s …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33745634/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109136670\",\n \"publishedAt\": \"2022-02-27T00:19:07.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3811999,\n \"message\": \"Management of Nail Psoriasis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9094182,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/JhzjFGv1QMWSvF1QDTVm_pubmed-meta-image.png?file_detail=065c6432110f24ea538abcd7999a3aef4371a3bd94f3216808b6351adebd5fbe8f3b36245459d8c4c9e2d505fe3791dd5729d6c339a8a9cb44d0a610398bb9d34ff85fa55114a50c34f22f5a67a35b0896426c026e024c41d62cc578df5e7fc73b78f2ffb6462b0fdf2e955cd6a425a8:ebd5675fac724014df050b1e5172dfe8:4a0fcce4ae44da3107daad8be58963a0&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjU2MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.3xGq2RMoQSKMnLhyMEQVKjZ8ez9d8OR5Sg7b-NGZKK8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Management of Nail Psoriasis - PubMed\",\n \"description\": \"Nail psoriasis is a chronic nail disorder that requires personalized treatment. General prophylactic measures are suggested for all patients. Topical treatment is considered when treating a few-nail disease, with involvement of 3 or fewer nails, without joint involvement and without (or with mild) s …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33745634/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-2851b78a-aee8-4e45-8b68-22f8b9cea83a\",\n \"slug\": \"b-cell-involvement-in-the-pathogenesis-of-ankylosing-spondyl\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-28T01:50:51.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9095912,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/QRaGm6zQQ0ub4J8fXKLf_pubmed-meta-image.png?file_detail=51e50a8f03486884360a03bb90dd5744cdc4cb9cbbf79e5fc33eaae90a0650c28ade1e9c8ae271970d92e14c757014b1346a84d8e8926956eb6cf03e39f268121be3e598d03774ddda8e12c2f88425dc0fc36f4acbcdd342272f96e3969b67afef9daf113314449e9ad4dede129183ee:8f703a9ad8010abf605ac98073f82fbd:a1ceb901594aa56e4a0039b72077ece4&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjU3NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.j30aPTy7x-cYnw4zYlPU1AlXCy1cYEk_dHd0LHzEh7E&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis - PubMed\",\n \"description\": \"Extensive research into ankylosing spondylitis (AS) has suggested the major role of genetics, immune reactions, and the joint-gut axis in its etiology, although an ultimate consensus does not yet exist. The available evidence indicates that both autoinflammation and T-cell-mediated autoimmune proces …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34948121/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109138342\",\n \"publishedAt\": \"2022-02-28T01:50:51.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3813655,\n \"message\": \"B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9095912,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/QRaGm6zQQ0ub4J8fXKLf_pubmed-meta-image.png?file_detail=fa745fdfafbf00ef942b37ba76ad38561e144d00539df82466f0f53287c87a37259042aec323487ddc99320436bbce9211f7c040929177a4f24fbe9aa449507b01d6497c37418eb6a17370a2f433d952cf2134a7c14de8f091ea270e843af2b1d5cb3fe54ef305e5df93ec9ada4a15e3:c03053636dd0f6aba352a83ce690918b:34fa4916ee2c33662a8844ab9f40a47f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjYwMyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.MmqGPoaSdj4wCtSVVbsBiCnFVRCbePZNA8cKQxJ5AGk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis - PubMed\",\n \"description\": \"Extensive research into ankylosing spondylitis (AS) has suggested the major role of genetics, immune reactions, and the joint-gut axis in its etiology, although an ultimate consensus does not yet exist. The available evidence indicates that both autoinflammation and T-cell-mediated autoimmune proces …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34948121/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-060214ed-7e25-4bab-a51f-09b2d6011be6\",\n \"slug\": \"early-achievement-of-asdas-clinical-response-is-associated-w\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-28T02:04:04.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Early achievement of ASDAS clinical response is associated with long-term improvements in metrological outcomes in patients with ankylosing spondylitis treated with TNF-α blockers - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9096010,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/UwEt5HqXSmiBi4lkZGFJ_pubmed-meta-image.png?file_detail=fcd7ea4bf36ce9d698dbf8a1b362b88172ee86f0d51e008b4a576b73e395cbb1618c8ef4be6907cb7296901f282f499ed42ee02ae4fdcd82b6231de0951776203947b59c92f903b144c8d4478841254236d27403a348236e0b8f87faac11df798b2c2e658f5bd1aa80df6c9caeefe4e7:e56081e9f63de0fb51a06a309ed55925:81f16f1487f02f51faf4fb178e50fe72&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjYyMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.SM6vJzyoJYyY9zjl6fFv9bkQ3M-YwodnYFQXZHael9o&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Early achievement of ASDAS clinical response is associated with long-term improvements in metrological outcomes in patients with ankylosing spondylitis treated with TNF-α blockers - PubMed\",\n \"description\": \"The aim of this study was to investigate the relationship between long-term spinal mobility improvements and early disease activity changes or achievement of clinical response criteria in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor (TNF-α) blockers.This retrospective …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33031332/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109138391\",\n \"publishedAt\": \"2022-02-28T02:04:04.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3813704,\n \"message\": \"Early achievement of ASDAS clinical response is associated with long-term improvements in metrological outcomes in patients with ankylosing spondylitis treated with TNF-α blockers - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9096010,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/UwEt5HqXSmiBi4lkZGFJ_pubmed-meta-image.png?file_detail=6bbb20a545b43bae23cd2182fbe3b425adc1dbde7450e306bf92760f65a5b3c1eb67331e54e6e72775c3cb20ebeb0924c8b01f3e0ce942b89a7d9e44ad08fcc61331590da821902b17547e3904e2fe44d1633be99cf7290347703b0b22a13787fbf21d0877ce893446d7ceb77f053522:2d91e6e40c935be5e61c38de7c803f9b:7592c06ae3d64239c01e6c85336128a1&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjYzNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.TFcpz8ujIthtgJfyY5Tqaewcc_WZD_p_4mjAa1kDko0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Early achievement of ASDAS clinical response is associated with long-term improvements in metrological outcomes in patients with ankylosing spondylitis treated with TNF-α blockers - PubMed\",\n \"description\": \"The aim of this study was to investigate the relationship between long-term spinal mobility improvements and early disease activity changes or achievement of clinical response criteria in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor (TNF-α) blockers.This retrospective …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33031332/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-157dcc54-7e2c-4477-b4c1-3bef9673a248\",\n \"slug\": \"measures-of-symptoms-and-disease-status-in-ankylosing-spondy\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-27T00:17:29.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankyl...\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9094178,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/SdYqpn9GQvWMaNOnzkJY_pubmed-meta-image.png?file_detail=b8d09a8a1db9862e7ca60947134446f2dc9f84a06eb666d32eaf80c458fd65a59ce0ec7b4e951a0a7c3cf834f52b0d1eb0fbd749ebe78754d709e402bfac82ca532266f25400763d076aceb4425fff6cef05c3ba2bf1b84c4eb253b8b8002c9e0932089c56b63775350797ad25d32051:4c7b2bd530f5ab92fb49ae4f6d775996:43de328799ff145e06f1e59fe693b11e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjY1NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.iMBOAdhjiXdSAWc3tA-U9M6uqruCx-DN6Xb1qe_DH9w&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankyl...\",\n \"description\": \"Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S)\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/22588768/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109136666\",\n \"publishedAt\": \"2022-02-27T00:17:29.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3811995,\n \"message\": \"Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankyl...\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9094178,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/SdYqpn9GQvWMaNOnzkJY_pubmed-meta-image.png?file_detail=9eea7c6e4e66fc2d5b0ed095b9e59210ad2e1e8f26517ff97dd1c12fe884cb03edaba378c8501f29d30dd67bf32e9db55b88b920eaf420a16d65184568e0e2b59bcdca2210f85bac52430b34c900c68ebcff7601333501e609636582cc12c504916ae6321114ee1918389b52018126ab:e48b5eb6982e813cec94563ce998c92e:28db617012076c9f519492221f9c539e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjY2NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.EjiidJiQwzQuBayL1jth82qyeLp5zcRbh2ar9mH0VF0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankyl...\",\n \"description\": \"Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S)\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/22588768/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-28ce2c6a-516d-4034-ab34-be44bf587800\",\n \"slug\": \"ultrasonographic-evaluation-of-achilles-tendon-in-early-axia\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-01T23:55:09.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy? - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9102712,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/wqXoxkKT2GknMqLUufYr_IMG_8395-1724%20(1)%20(NXPowerLite%20Copy).jpg?file_detail=87db9c8c1c33b6c7a9bcf9021fcc306623e7d9787e30c1f6a34115b29f56262c82b09d77ea65c22786383bdff98f1c046f3365441409b24d8e7d5ddf4e1bc3a9faed93944ec062650e2579c34ab054c32f0e1834825eee308fc872522c3d7107642d9ddfc9ed467d7c07df136b220706c8357cc24a9d293be225d0093e7e8436:393d03cab317d323f6c8dd81b3ebddab:dc4d9febe81ba3cfd3fad7ad115ee899&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjY4MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.VZrBk3sC-twvl5BLeuxCUPkXyrB9EWXnjZrr2LW2Nqc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy? - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Along with emergence of the term of ‘non-radiographic axial SpA’ (nr-AxSpA), studies comparing AS and nr-AxSpA in terms of genetic, epidemiologic, and clinical issues have accrued. The aim of this study is to evaluate the achilles tendon enthesopathy with ultrasound (US) in AS and nr-AxSpA patients and controls. We also aimed to compare these […]\",\n \"url\": \"https://acrabstracts.org/abstract/ultrasonographic-evaluation-of-achilles-tendon-in-early-axial-spondyloarthropathy-is-there-any-difference-between-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthropathy/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109146039\",\n \"publishedAt\": \"2022-03-01T23:55:09.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3821306,\n \"message\": \"Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy? - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9102712,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/wqXoxkKT2GknMqLUufYr_IMG_8395-1724%20(1)%20(NXPowerLite%20Copy).jpg?file_detail=df489ebe44f0a35372698ed8c0fa721c55aead6400bc97ff586d62ef3c223f154a56e8ce2b22fa0131c320fd4745aec2b2a81012de582ba502f8673f093f4165c65d6d114954fddb8592560f13887e3bacd861ee48df761d60c58148218ca27fcd000af15dac0d0324e7939d7f5bcb263ccd9fda50fcda7f061091b97def85d5:3856fd8e8c2ed8fe547aaa520ca3b416:9818b2ccdb1d70339e628712010ce871&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjY5NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.KnN5QH3K1PXmosL4YduUboxXlD_-i7B44WFU-wu5lds&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy? - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Along with emergence of the term of ‘non-radiographic axial SpA’ (nr-AxSpA), studies comparing AS and nr-AxSpA in terms of genetic, epidemiologic, and clinical issues have accrued. The aim of this study is to evaluate the achilles tendon enthesopathy with ultrasound (US) in AS and nr-AxSpA patients and controls. We also aimed to compare these […]\",\n \"url\": \"https://acrabstracts.org/abstract/ultrasonographic-evaluation-of-achilles-tendon-in-early-axial-spondyloarthropathy-is-there-any-difference-between-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthropathy/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-3318ad39-0070-4904-8a59-bbf34c554dc1\",\n \"slug\": \"management-of-difficult-polymyalgia-rheumatica-and-giant-cel\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-06T12:33:04.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9116018,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/s0AiuSRRFqLTXjAzbEv8_pubmed-meta-image.png?file_detail=50ecb25cf8ba94df32af67e9d555534135caf7ead00ca54f9f9080da1dc3e5d5da7ac9b31d0e90d0fb7780ef3d3f3c5318c07edb22fa0350acf01d5185711d59b509671fd4572046b4a2dc66ac9ce9ae7f9a9e47618c7b187a592e7e45398f4e024c37f9d044ba927879478ee6c68aee:c3ffb12c88bb376eedee830212f25c13:cf79bfa4ac56182c524905ee757620d7&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjcxMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.fWUOv5xlzxjfPV7NbSKvebikpuBeRONokXLv3BObrQ0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice - PubMed\",\n \"description\": \"Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) represent a family of systemic inflammatory diseases occurring in adults aged 50 years and above. Clinical presentation of PMR/GCA can be variable, making diagnosis at times challenging. There has been an increased appreciation of the role …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31427056/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109160582\",\n \"publishedAt\": \"2022-03-06T12:33:04.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3835759,\n \"message\": \"Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9116018,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/s0AiuSRRFqLTXjAzbEv8_pubmed-meta-image.png?file_detail=ae492a8ccdf262f3598d940d6dabb1ddd47894e39113b55ae313872e67fecb38beaede562483b5e86421a16346af46f2ce538e28484297709b5fb067021051db759dd39a2393f2fe0c25971a3e1ff6769e1aa4805a55d8458defc4ddd618870553bf4a355da08a49ee6546b2a6debc22:0ca97b1618e95609763aa526530610a9:5c8f00c9ca563baaa1e1bdb5c5d1060f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjcyNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.BmzjYVFeqUooxdZN1u1X-Ik0Qz0B2TUXm2aRphABJGs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice - PubMed\",\n \"description\": \"Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) represent a family of systemic inflammatory diseases occurring in adults aged 50 years and above. Clinical presentation of PMR/GCA can be variable, making diagnosis at times challenging. There has been an increased appreciation of the role …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31427056/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-6ebef370-5fe6-47ba-96d9-b1c2f241aa8a\",\n \"slug\": \"risk-of-cancer-in-patients-with-psoriasis-psoriatic-arthriti\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-22T02:01:51.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9077800,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Biw7BCTqSYuHya3bb8Bg_graphicstock-business-concept-global-strategy-virtual-iconinnovation-graphs-interface-worldwide-connection-technology-interface_SdXw3sveox%20(NXPowerLite%20Copy).jpg?file_detail=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:8beb8a2f50878168578a2750295b55bb:47db7aea13327500b4afbaad6414dddb&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5Ljc0MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0._SKAMVCYaWh-_SMuguZ4vCVn096p3hZckfbcpWJGvTY&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Psoriasis (PsO) is a relapsing chronic autoimmune disease of the skin. Up to one-third of patients (pts) also develop inflammatory arthritis, known as psoriatic arthritis (PsA). PsO/PsA, like other forms of chronic inflammatory arthritis, are often associated with complications such as cardiovascular disease and infections. However, data on the risk of cancer in pts […]\",\n \"url\": \"https://acrabstracts.org/abstract/risk-of-cancer-in-patients-with-psoriasis-psoriatic-arthritis-a-population-based-study-in-the-province-of-british-columbia/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109118017\",\n \"publishedAt\": \"2022-02-22T02:01:51.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3793479,\n \"message\": \"Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9077800,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Biw7BCTqSYuHya3bb8Bg_graphicstock-business-concept-global-strategy-virtual-iconinnovation-graphs-interface-worldwide-connection-technology-interface_SdXw3sveox%20(NXPowerLite%20Copy).jpg?file_detail=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:99afd6e3c7be744e479fecd7bb8b21e9:f7f3868f2616de0b3312be8ae85d8e3c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5Ljc1NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.A53keK1ga9tz7bzNBoCBzmCN3tfxQzCkKuLBuBEwD8M&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Psoriasis (PsO) is a relapsing chronic autoimmune disease of the skin. Up to one-third of patients (pts) also develop inflammatory arthritis, known as psoriatic arthritis (PsA). PsO/PsA, like other forms of chronic inflammatory arthritis, are often associated with complications such as cardiovascular disease and infections. However, data on the risk of cancer in pts […]\",\n \"url\": \"https://acrabstracts.org/abstract/risk-of-cancer-in-patients-with-psoriasis-psoriatic-arthritis-a-population-based-study-in-the-province-of-british-columbia/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-7209047a-2939-4650-8ee7-f5a004b5f815\",\n \"slug\": \"patterns-of-etanercept-use-in-the-childhood-arthritis-and-rh\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-18T21:59:03.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9070135,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/EpUKaMlRzmAs2VoCauFH_AbstractSubmission_825466_1.jpg?file_detail=0308669047ef8ea71f4ec8872577704bc564288e58e7ec3b043481e7cb5742d6ae6a47990952d6c7569775345be2e976bf67d0ef064fb18e7641d6510145f37ffb07556c05ecd0cf70d0112cddebe688310d1b336b9951dfd6d568ce26d4c7be7b1e90f5b3fbce71770b599e2683c9b5:e69e824ecce6379abbf2d582fb5976ee:8e16ae5d53e33953db44cfa2934f3c7e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5Ljc3MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.bURH21awBVciMP-J5VlHmMqkEBaf6KMaOrAV81XpTOk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study describes the use of ETN in JIA patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JIA Registry. Methods: The CARRA JIA Registry is a convenience cohort of […]\",\n \"url\": \"https://acrabstracts.org/abstract/patterns-of-etanercept-use-in-the-childhood-arthritis-and-rheumatology-research-alliance-juvenile-idiopathic-arthritis-registry-2/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109109372\",\n \"publishedAt\": \"2022-02-18T21:59:03.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3784865,\n \"message\": \"Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9070135,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/EpUKaMlRzmAs2VoCauFH_AbstractSubmission_825466_1.jpg?file_detail=606c074b5fbb71a1484d5f899faecf7b1aaf63f8a919313830a19692329f473f14652fc85c4b9f252acb1fe70aea9669897cc809768d70c5ac025d47c7949a6eca069f10a7c47e3bfe76665f2b57bf1c43d9de15fd60687f4f1e0f5af7b82c1b156251b8debb5995b9eae2d32cab8944:dec8ca16654330b289880368e078cfd1:f9396bbf9e430857a3dd210042968c28&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5Ljc4NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.X-QJTe03kKqi0q2986TtWM_Kx6acS_6B-GmaV11BeeM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study describes the use of ETN in JIA patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JIA Registry. Methods: The CARRA JIA Registry is a convenience cohort of […]\",\n \"url\": \"https://acrabstracts.org/abstract/patterns-of-etanercept-use-in-the-childhood-arthritis-and-rheumatology-research-alliance-juvenile-idiopathic-arthritis-registry-2/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-6b49a0a2-9b68-412a-803a-4f91f5618af0\",\n \"slug\": \"impact-of-early-pain-improvement-on-patient-reported-outcome\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-20T02:57:14.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072354,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/u5jCbqmhQfOke5M1Mp9g_ACR_1063943_1.jpg?file_detail=2c0f1b4890a558497ccb3b6f32f181ce1af685136b023fdf5a06cf5f52ef5c2c4a14263c4f9d7e2352c59c26c5177c4570a2034da4f802f8ea1eeadf84141bfa611df0ab329a290e6db40145ae24877b9825270babb4f6dbddf169a5d323ee16ba277299572bb675841e611006fa3bad:0e7c4422d7cc8a3611f0be045b7c9201:c6a4f2fae6241b355c30e60d8b91192e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjgwOCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.X2gF68w9JrOAge-LkvBNk-TAy0XKaRcSPoLnzKkjaM4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Pain is a dominant feature of PsA and has been identified by the GRAPPA-OMERACT working group as a core disease domain. Its control is a largely unmet need, especially in patients failing non-biologic DMARDs. The purpose of this study was to evaluate if clinically meaningful improvement in pain, particularly at earlier timepoints after treatment […]\",\n \"url\": \"https://acrabstracts.org/abstract/impact-of-early-pain-improvement-on-patient-reported-outcomes-in-patients-with-psoriatic-arthritis-results-from-a-phase-3-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109111947\",\n \"publishedAt\": \"2022-02-20T02:57:14.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787425,\n \"message\": \"Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072354,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/u5jCbqmhQfOke5M1Mp9g_ACR_1063943_1.jpg?file_detail=8b33e87091eaed351807b1a8ea5d3113a1e3364024e47818397fa21ce9504d1c9e104c6b830e3f5ed7f9bb82dea180eef7827839e883163084b4a082956a320a1b85c5fd3addb72ea11af2d475a4466e9b8c1553841ecfb8de2657230ca1287a66697b56e58b6ca3d6663b979e949e0c:0f4f2dc6559d23aaf53e89833a73e9f4:c10c451c281a24be583066bfa3b49605&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjgzMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.CzIYaXTeWcoDt7rNmIHJMcymYo1AthHZAroMg_4zOc4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Pain is a dominant feature of PsA and has been identified by the GRAPPA-OMERACT working group as a core disease domain. Its control is a largely unmet need, especially in patients failing non-biologic DMARDs. The purpose of this study was to evaluate if clinically meaningful improvement in pain, particularly at earlier timepoints after treatment […]\",\n \"url\": \"https://acrabstracts.org/abstract/impact-of-early-pain-improvement-on-patient-reported-outcomes-in-patients-with-psoriatic-arthritis-results-from-a-phase-3-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-7adf0c69-beed-48e1-9e2d-6b903a45f414\",\n \"slug\": \"influence-of-juvenile-idiopathic-arthritis-fibroblast-like-s\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-21T19:41:13.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Influence of Juvenile Idiopathic Arthritis Fibroblast-like Synoviocytes and Mature Chondrocytes on Each Other in Culture: A Pilot Study - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9077396,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/SpkcX8eGTa2l8eV0vQba_Paper_61974_abstract_88275_0.jpg?file_detail=1eeff7d1fbfe35bc26fecce62016d28b5a4b555b5d90380dff3519d5fb28cd0fb5290418beca2bd6274df54f9c5cf559670fac102c38a8426576fd45adfc5f693f7bf710ed0b61ef0535b0a76bed7f13f3a610a6dd399743f974c41069b22056da40fc69b655d6fe5fc0e0d882f7514c:6a69dcefeac5ccf7eeb8d1ad87f22e53:5aa806fd21d7daf08f9ebb3fb53337f1&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5Ljg1NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.2FkYqQ9lmwrXPcPeB22cdx_lni2YnKfCCrrEuLM8nTQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Influence of Juvenile Idiopathic Arthritis Fibroblast-like Synoviocytes and Mature Chondrocytes on Each Other in Culture: A Pilot Study - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: A chondrocyte-like phenotype has previously been described in pediatric fibroblast-like synoviocytes (FLS), which may contribute to bony overgrowth in juvenile idiopathic arthritis (JIA). The goal of this project is to study the influence that JIA FLS and chondrocytes (Ch) have on each other along the lines of chondrogenic differentiation. Methods: As part of a […]\",\n \"url\": \"https://acrabstracts.org/abstract/influence-of-juvenile-idiopathic-arthritis-fibroblast-like-synoviocytes-and-mature-chondrocytes-on-each-other-in-culture-a-pilot-study/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109116825\",\n \"publishedAt\": \"2022-02-21T19:41:13.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3792289,\n \"message\": \"Influence of Juvenile Idiopathic Arthritis Fibroblast-like Synoviocytes and Mature Chondrocytes on Each Other in Culture: A Pilot Study - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9077396,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/SpkcX8eGTa2l8eV0vQba_Paper_61974_abstract_88275_0.jpg?file_detail=f975d427be648aea4ae54dd95d8a3ab693cc4aaeff525abda8238ea427ac78ed0c873989b08a11068f7db2da45e4e1c7e8561e965357a006baa110c58f48306b680a9470ba1135aa7faac9453c39d4905f4cc203ca73da2f36b54d5445c2555a7ea763ae09809622a63dc59c0f61b4b5:0396990da69100b0a3a336c8da6f0da7:fff6b5d73522245c1a28418c95734f51&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5Ljg3OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.CN3qEtWHSG6yHXc-FIwvUB-Qxj-c6ePJkz-L0qSDAzA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Influence of Juvenile Idiopathic Arthritis Fibroblast-like Synoviocytes and Mature Chondrocytes on Each Other in Culture: A Pilot Study - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: A chondrocyte-like phenotype has previously been described in pediatric fibroblast-like synoviocytes (FLS), which may contribute to bony overgrowth in juvenile idiopathic arthritis (JIA). The goal of this project is to study the influence that JIA FLS and chondrocytes (Ch) have on each other along the lines of chondrogenic differentiation. Methods: As part of a […]\",\n \"url\": \"https://acrabstracts.org/abstract/influence-of-juvenile-idiopathic-arthritis-fibroblast-like-synoviocytes-and-mature-chondrocytes-on-each-other-in-culture-a-pilot-study/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-79b0446f-a09a-44d7-a4fd-a89e4896d515\",\n \"slug\": \"secukinumab-improved-signs-and-symptoms-in-patients-with-non\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T19:32:30.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072161,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/GfmamrWVSEK25gtUZSQF_OCMVWLVW-903817-1-ANY.jpg?file_detail=ab9e79db2ad40b682ab704f651ed939cb6dbf5b01dbc4de874de5d1f5d0696ada1e15b308dc4925c1067bae439bb610e5351bdc6243bf8693ce42941d342cd160838d44e8569a1ee16082c29b065d9fc2ad541d1f13d5e94a3145671fa1815807650978fc31ab32691ae834ee2d32a70:d3397e012fad97fc56186d8229ae28e9:763d2146cac8f0066b9e4162fe33b8b0&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjkwMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.JITdxY1QT6BJBG6-6HfQ6HGeN7LnGuVU1CIe8HJbIIU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Active non-radiographic axial spondyloarthritis (nr-axSpA) is often determined on the basis of objective signs of inflammation (elevated C-reactive protein [CRP] and/or evidence of sacroiliitis on MRI).1 Secukinumab (SEC) significantly improved signs and symptoms in patients (pts) with nr-axSpA in the PREVENT study (NCT02696031).2 Here, we report a pre-planned exploratory analyses of the efficacy of […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-improved-signs-and-symptoms-in-patients-with-non-radiographic-axial-spondyloarthritis-results-from-a-randomized-controlled-phase-iii-study-stratified-by-baseline-objective-signs-of-inflam/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109111759\",\n \"publishedAt\": \"2022-02-19T19:32:30.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787238,\n \"message\": \"Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072161,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/GfmamrWVSEK25gtUZSQF_OCMVWLVW-903817-1-ANY.jpg?file_detail=b6dec4ab0c813f18d94ff2e570e5eb4872a5e53566ecf350547ffe7019ad398df5e82e60fed872de7b61f241bbd1c221d831c17ad7371b0dc1f8d7d9fbb1dbb6b2d7127aab40c9bca48fe2204cd7b3010955acf5fa7fd407c9ff9e1f469852997816e6679f91019d1580932477b01864:9a7fcaaf593f870674bff549ea8758b3:f6eca5ca5c346942615b08aec0444fbb&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5LjkyNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.hZcnk_puhFeFnNfQU4Y7aAwia6Ijs6ERh-X49uByxkU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Active non-radiographic axial spondyloarthritis (nr-axSpA) is often determined on the basis of objective signs of inflammation (elevated C-reactive protein [CRP] and/or evidence of sacroiliitis on MRI).1 Secukinumab (SEC) significantly improved signs and symptoms in patients (pts) with nr-axSpA in the PREVENT study (NCT02696031).2 Here, we report a pre-planned exploratory analyses of the efficacy of […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-improved-signs-and-symptoms-in-patients-with-non-radiographic-axial-spondyloarthritis-results-from-a-randomized-controlled-phase-iii-study-stratified-by-baseline-objective-signs-of-inflam/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-76bd57ee-4c7d-4452-8e66-337e31a11582\",\n \"slug\": \"designing-a-phase-b-multicenter-randomized-double-blind\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T13:01:14.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibit...\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9070933,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/iQYyx9kISti188qJNnKZ_ACR_1050683_1.jpg?file_detail=efe867e0729496d7e70cf8841b0fd241d4a98dc9f4c7a1cc72ce8c80b8f93714ac194152bbdf83fd7d725b752e4fef8fe0046e46780eac0e75b05feba3e481c33946018192e8b34fc19861001d5c830528995b343ffc0c65d3355b4ef4a7a6820532e1ab3c729e896cdf58a008c27557:93a85515a7fc2daa98f98c604f899083:828e6b8572e30c91f09f8b8c764e2027&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5Ljk0NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.s-0d7dHYWa7hPRjV5u5gW4kvx4WpBLEU1I6bVNz6TsU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibit...\",\n \"description\": \"Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic therapy for patients (pts) with PsA, though a sizeable proportion of pts have an inadequate response (IR), and some may also have intolerance. Guselkumab (GUS), a human mAb that targets the IL-23 p19 subunit, provides an alternative mechanism of action by which […]\",\n \"url\": \"https://acrabstracts.org/abstract/designing-a-phase-3b-multicenter-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-guselkumab-tremfya-sup-dosing-interval-in-psoriatic-arthritis-patients-with/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109110553\",\n \"publishedAt\": \"2022-02-19T13:01:14.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3786042,\n \"message\": \"Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibit...\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9070933,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/iQYyx9kISti188qJNnKZ_ACR_1050683_1.jpg?file_detail=0cb8ebd85c1a852ad30f29ac94d6bcb4182e80ff0c9108b25e7b029556cfcae4678afb6da0374a51f092356de1a2dbc21710ea9910b111b2dc50f8d6742f433ce6ced139b10d0eadf6c350f3c7492f6f121ca428ed0fca72f2ba2fb0625347c42d439cf2aaa4635392008daee7c885c3:c120c44765076a7e84f5a1b687e7154d:16f266c23217f37650487234cbb18e6f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5Ljk2OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.38H3HTjwRrJGkL4K4voLvE2-RdO_ESgYrcN7qvT9B58&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab (TREMFYA/sup>) Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibit...\",\n \"description\": \"Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic therapy for patients (pts) with PsA, though a sizeable proportion of pts have an inadequate response (IR), and some may also have intolerance. Guselkumab (GUS), a human mAb that targets the IL-23 p19 subunit, provides an alternative mechanism of action by which […]\",\n \"url\": \"https://acrabstracts.org/abstract/designing-a-phase-3b-multicenter-randomized-double-blind-placebo-controlled-study-to-investigate-the-effect-of-guselkumab-tremfya-sup-dosing-interval-in-psoriatic-arthritis-patients-with/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-84174c8a-27de-4d07-8717-98eff540bdbe\",\n \"slug\": \"exposure-response-analyses-to-describe-the-relationship-betw\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-25T00:08:50.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Exposure Response Analyses to Describe the Relationship between Ixekizumab Concentrations and Acr Responses in Psoriatic Arthritis Patients - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9088933,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Su6O9GEwTr2EIAVVvdKh_abstract-business-concept_XkRvgW_L%20(NXPowerLite%20Copy).jpg?file_detail=8cbc85093ad7915e09465223a6e649b3c2d33995a2d51583935e4b8a9be0c690d3fe2a7077254a72ab1b100c6b93419554faaa5861f15cbb2f20b64e797c12874f6f141221af6d985bfc240055c1e4242c2f0587869629b897d01ee004cdf29f35beeadb6a28c77483b1e6434181f36eaece81bc5e3de06352b7739cdd8f47ff95336dc51ce732b8cef4031b19e410a7:cde0ddc02c340ba8f36d9ae91f519d07:0567ced4c3d7246016d7006a9ce00f42&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjM5Ljk4OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.YeXgJvWSHlHMT3eZVJwhqGSQ7AtwIbLvntvoYamYTsk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQzfX19XX0_&Signature=MCdVOZJxR5LwUveYT6Q-wFXU5tjPNS-gN9EMTo8~xY8QNx8IFzXow8IArkT3GbcJrfOEyJgB6PxECWXL9Yw2fIsTRErRNQs0qHBmOuTX5WNc7MSJ3-N9jjIdXUzsYP1F47k77A0yf1igK1qeDxpXfRqeLKKh9Dzwp9wMVYWU0tjWzM6MxLmAXeB0GkCP5wk1mCgDp1cOSHiOmDH9O6GMh0iYBzRrfjtOLcmdO2b6ZB0HVv83sN-jZ7VlWaID7YephoL7UqwXWGWq783Sdj6e~NDqqq16zdYA9hJHvDataOIa7BiICi6ElH4SIGvrv4xambhVB8mik54P2c-4TnA1vQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Exposure Response Analyses to Describe the Relationship between Ixekizumab Concentrations and Acr Responses in Psoriatic Arthritis Patients - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A. It has been approved to treat adult patients with moderate-to-severe plaque psoriasis and adult patients with active psoriatic arthritis (PsA). Exposure-response relationships nowadays provide important information to help determine the optimal dose/regimens.1 The analyses described herein characterized the exposure-efficacy relationships for 20, 50, […]\",\n \"url\": \"https://acrabstracts.org/abstract/exposure-response-analyses-to-describe-the-relationship-between-ixekizumab-concentrations-and-acr-responses-in-psoriatic-arthritis-patients/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109131428\",\n \"publishedAt\": \"2022-02-25T00:08:50.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3806804,\n \"message\": \"Exposure Response Analyses to Describe the Relationship between Ixekizumab Concentrations and Acr Responses in Psoriatic Arthritis Patients - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9088933,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Su6O9GEwTr2EIAVVvdKh_abstract-business-concept_XkRvgW_L%20(NXPowerLite%20Copy).jpg?file_detail=5b20a1a822e8118fb86aced965084830d6c5b95f2475622efbc603ace3b4174cce2578faff53b07d0ebfd5b78c12c6234ce34946a52a8ae4e495075cbdf240ac5185b87caaf9621d52226ed9e86451e9d896d8874c11f824b796802898ce8ef756383dfaefd66d840cc51d850bd0275be1e77141cebfb1287c0884789ac79467a01711d28065886e6a5efc644905e216:867d33b8b1cce60721f0426877257a89:8bd577caf5b1084df08ce76f5c99f103&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjAxMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.n5HMf3M7rtlxI68MnU64JiooyCH-RhZC-Jm-5DP0CSI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Exposure Response Analyses to Describe the Relationship between Ixekizumab Concentrations and Acr Responses in Psoriatic Arthritis Patients - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A. It has been approved to treat adult patients with moderate-to-severe plaque psoriasis and adult patients with active psoriatic arthritis (PsA). Exposure-response relationships nowadays provide important information to help determine the optimal dose/regimens.1 The analyses described herein characterized the exposure-efficacy relationships for 20, 50, […]\",\n \"url\": \"https://acrabstracts.org/abstract/exposure-response-analyses-to-describe-the-relationship-between-ixekizumab-concentrations-and-acr-responses-in-psoriatic-arthritis-patients/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-a2d3c7e1-55e9-42b1-9576-0471929e1f32\",\n \"slug\": \"alcohol-consumption-as-a-predictor-of-the-progression-of-spi\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-23T23:54:00.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO) - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9085363,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/fUOw8EiUSkCCTDMDNj9z_GTUOHVCE-675109-1-ANY.jpg?file_detail=0e79314140082963c9a089638c5279ab59ff2f7f98b04d2a3c6271ff74b8c03c2b41edac81892d16aa4bd65a1a610be7b6f1ebbcbac392c462905352b697352a3ca8ef8e9e67d7b9ef56fcfa5f5e7960fa0fb8954cc809d7c6e83074ff57be51b2954ee6481275aea33c4e5ecb3bd62c:0a42f2c491da7b7f216c2c6ce749deb2:6f8413293eacdff529693b01adb68e03&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjAzMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.TwqX0ll0MBSCtUs8NBFeegKkuyy6cKDicwim1Q3kpdY&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO) - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The purpose of the present study was to demonstrate the predicting factors of spinal structural damage in axial spondyloarthritis (axSpA) in a prospective cohort study. Methods: AxSpA patients were enrolled from a single tertiary hospital in a prospective cohort. Baseline data were collected, and 2 year follow-up radiographic data were collected. We analyzed the […]\",\n \"url\": \"https://acrabstracts.org/abstract/alcohol-consumption-as-a-predictor-of-the-progression-of-spinal-structural-damage-in-axial-spondyloarthritis-data-from-the-catholic-axial-spondyloarthritis-cohort-casco/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109127547\",\n \"publishedAt\": \"2022-02-23T23:54:00.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3802942,\n \"message\": \"Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO) - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9085363,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/fUOw8EiUSkCCTDMDNj9z_GTUOHVCE-675109-1-ANY.jpg?file_detail=96dec70e926366c4f2a206f703549a69a6129d10873e6c4f0cf66bf8a56b55169e43d86bc96808a29b049fc2cee00faad650f3b31d5ef1cbac726bcabdc8d77787542c4b87611fe0be3ddd1403262cc7925e7205fe9a0cecb31e8407c46d969a83c50a924b53168d071ad63c51c0eb24:00aaa26f0f72153d31374d5ba76a44b3:e71e68505c3104c7492a077fd3f698d7&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjA0NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.EQoUIknEYoK_eI3mA-tNsmpmSHrUkS5b_sJw1hYcaNg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO) - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The purpose of the present study was to demonstrate the predicting factors of spinal structural damage in axial spondyloarthritis (axSpA) in a prospective cohort study. Methods: AxSpA patients were enrolled from a single tertiary hospital in a prospective cohort. Baseline data were collected, and 2 year follow-up radiographic data were collected. We analyzed the […]\",\n \"url\": \"https://acrabstracts.org/abstract/alcohol-consumption-as-a-predictor-of-the-progression-of-spinal-structural-damage-in-axial-spondyloarthritis-data-from-the-catholic-axial-spondyloarthritis-cohort-casco/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-97e69981-fb3f-4f9d-98bf-403978522965\",\n \"slug\": \"long-term-clinical-outcome-of-anti-tnf-treatment-in-patients\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-24T00:28:55.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9085429,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/tBrmad1yRgqAlwFqMY5I_GTUOHVCE-699560-1-ANY.jpg?file_detail=a7dabe4ee6b6aa56b4b19e72c511497f0cbcc89399bb8e3abe4461be0661b9c6afafe24ce45a802084228afa14fa7ab24d8b7efd415a5fb0f5bf2b1a9427646bf95ac2496f924e42e3f9596bfbb549e8210a9184029ad40d3f800163301f9afc20a0070cab9cbe2ba7674c7ed448fa1b:0de108548fdd5f6bbe57059a19f71d3f:2061d1f5aba7d55d81b1a3fd9f82a204&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjA2MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.4u94_gjDb8VffN9JuY3cOUIvBuEPicmL6hjiDUtGMFg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Long-term data on anti-TNF treatment in patients with early axial spondyloarthritis (SpA) is scarce. The objective of this analysis was to assess the long-term clinical efficacy (up to 10 years of treatment) of a tumor necrosis factor (TNF) inhibitor etanercept (ETN) in patients with early axial spondyloarthritis, who participated in the long-term (until year […]\",\n \"url\": \"https://acrabstracts.org/abstract/long-term-clinical-outcome-of-anti-tnf-treatment-in-patients-with-early-axial-spondyloarthritis-10-year-data-of-the-etanercept-vs-sulfasalazin-in-early-axial-spondyloarthritis-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109127619\",\n \"publishedAt\": \"2022-02-24T00:28:54.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3803014,\n \"message\": \"Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9085429,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/tBrmad1yRgqAlwFqMY5I_GTUOHVCE-699560-1-ANY.jpg?file_detail=79ee4ccd03dba8b614e03b4935989847489294056c73ffb3a64219ee90319f38502b16217d605e928e83c507ec9e8b0dee804cb8f547b7c1f6e73e7240dc45e4e762d28789c5b5d1e50c00c81b6a2631588235fd0ffece03f84aeda6cdec90f37a7b61b959b103b203e196cb626318ee:bd163215aef1b6e4c179f56596ae5836:95ca78ce2cacbb3267b87443252b3d0f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjA3NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.L3Uj_dG5kGMmoFe7rKDPbn6nkLkFVkzp1ukx3CejbII&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Long-term data on anti-TNF treatment in patients with early axial spondyloarthritis (SpA) is scarce. The objective of this analysis was to assess the long-term clinical efficacy (up to 10 years of treatment) of a tumor necrosis factor (TNF) inhibitor etanercept (ETN) in patients with early axial spondyloarthritis, who participated in the long-term (until year […]\",\n \"url\": \"https://acrabstracts.org/abstract/long-term-clinical-outcome-of-anti-tnf-treatment-in-patients-with-early-axial-spondyloarthritis-10-year-data-of-the-etanercept-vs-sulfasalazin-in-early-axial-spondyloarthritis-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-371795dc-0e43-4910-8a22-a503a739096d\",\n \"slug\": \"secukinumab-for-the-treatment-of-psoriatic-arthritis-compar\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T21:22:15.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072199,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/sBYO2U9oRGAZtUTaw6eY_Paper_59020_abstract_86381_0.png?file_detail=e525e1ac1df243f361be0e18844c5a8c880fc16ff8bbf79228d0a74015ff01e6aa6649bbba630be7ca3881998fcb24a9766f53ad5608e9bbf7cac0caab7a755eb7970c40a0056b6fcbe7f39287d5cb867f84e28f49e63c3c783259bf8ee3195df768b95f3799c877911a0d68e6d6af91:8f9f45c09566a714c1934fb817bae302:6ca4eccfc015f8ddcfd8653a9666424a&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjA4OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.0LCgAOormQ1RLori0acujnUygH63CDwFOlNFi5uQzQU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Secukinumab (SEC) and adalimumab (ADA) are approved for the treatment of active PsA in adults with an inadequate response to conventional DMARDs. A head-to-head randomized controlled trial (RCT) between SEC and ADA was recently announced (EXCEED 1) but until the results are available, matching-adjusted indirect comparison (MAIC) can be used to estimate short- and […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-for-the-treatment-of-psoriatic-arthritis-comparative-effectiveness-versus-adalimumab-using-a-matching-adjusted-indirect-comparison/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109111795\",\n \"publishedAt\": \"2022-02-19T21:22:15.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787274,\n \"message\": \"Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072199,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/sBYO2U9oRGAZtUTaw6eY_Paper_59020_abstract_86381_0.png?file_detail=458f21a3cef31a48eeb7643611a0771dc179110d846458a2438c85abf4e493d4cc859ca62a473aca3beae71e05236a8783181ecaccb66a9474c6df61910f88c6201271b255df6de372a440112be311e346b01f2ee5fd0cb4d37cf8c734349efb3d2155af52a51426c84368879f924c68:9d55b5f2f74d777bcdd8cafadd033254:f7d6dcd46ad1cd462ebc456c7b3bb70a&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjEwMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.sy3ZGS6gYT5MDq1AUPq_9aYNF4xpwJ7_av10xGSorrE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Secukinumab (SEC) and adalimumab (ADA) are approved for the treatment of active PsA in adults with an inadequate response to conventional DMARDs. A head-to-head randomized controlled trial (RCT) between SEC and ADA was recently announced (EXCEED 1) but until the results are available, matching-adjusted indirect comparison (MAIC) can be used to estimate short- and […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-for-the-treatment-of-psoriatic-arthritis-comparative-effectiveness-versus-adalimumab-using-a-matching-adjusted-indirect-comparison/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-474baaa7-eee2-42c8-a9e7-22469c77c45b\",\n \"slug\": \"industry-payments-to-rheumatologists-ought-to-be-going-down\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-18T21:46:05.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Industry Payments to Rheumatologists Ought to Be Going Down, Not Up\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9070112,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/oVU1tPQ7ejSvTJtcZjXg_art.v73.11.cover.jpg?file_detail=5e1a052ff724ab8b154973f6a945703e7ddb8730b9850d6ee628d9ca2f7c9f185be8c2d9a26d16d867982ba6f818d42af52a744f73893a5be289ddbb3d9fa38cc862cc0a682b6e0390d402f8793b338e8dbbfa591a28d6a511b4fbbd7afd69ae97b5f37dbebbec632ccf5170ab27a073:109eefbe4ad82cbcbd6c4fd9d5229ad2:2e2e054fe1d5a8a03412187f3c5471cd&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjExNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.AtQ9FUbgb8aIseWGB_S8GrAG2npcLjeFq4_24FliuHE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Industry Payments to Rheumatologists Ought to Be Going Down, Not Up\",\n \"description\": \"Click on the article title to read more.\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.41898\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109109338\",\n \"publishedAt\": \"2022-02-18T21:46:05.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3784831,\n \"message\": \"Industry Payments to Rheumatologists Ought to Be Going Down, Not Up\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9070112,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/oVU1tPQ7ejSvTJtcZjXg_art.v73.11.cover.jpg?file_detail=0137513c43b83d1b87c3592dc59bbd16f2dc2a47cda9446ba68c9ed3119d7207f611970f22ec30bf31a5f9ec0e68ab8e472fced8c16b8436a34ecbdc9b901d038b3ae6b2621b49cd4974643c100bf83d5ad0f1bf13942bde0931f4df66b6e60cc008add4da4b2df0118f435d38c976a1:71bc86ba9494bf71a1cb1736cfe1678f:f09be0915fde65d3563ec070422b6464&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjEyNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.VIg6K7tp7xAPcU86JlO6_THmfP02uFPj-OrrjunJ6O0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Industry Payments to Rheumatologists Ought to Be Going Down, Not Up\",\n \"description\": \"Click on the article title to read more.\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.41898\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-3d44853a-9c55-45e1-8e6f-7123ed44cd06\",\n \"slug\": \"why-is-it-so-difficult-for-axspa-patients-to-find-a-job-res\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-22T23:56:49.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Why Is It so Difficult for AxSpA Patients to Find a Job? Results from the European Map of Axial Spondyloarthritis (EMAS) - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9081565,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/PxMQ0U7ZTTyX1wRubQKw_ACR_1062114_1.jpg?file_detail=48612fb0a7fe83059a13c2940cce3f8ab176a2369272b9467d8eabb0b4d8296c5350a52a305cb0ce1c3f272adc194cb0ba0193526b92990ffe55cba75479eb680768e4b874263dc94be72598775717bc066daf5b99c32a836a3704c74b2e521d5af112e347ea987558bba6532de6376c:9e9f306d67e4c8885f5bd8c70513c0bb:a5134f5ac0e50534492455d72f988732&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjEzOSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.w694R8zlSt0LUbkk2UWQ0dmI4v2kj1cgbzP64DUNfD8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Why Is It so Difficult for AxSpA Patients to Find a Job? Results from the European Map of Axial Spondyloarthritis (EMAS) - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: AxSpA is associated with substantial negative consequences regarding work status and career prospects. The aim is to identify factors associated with barriers to job access among European axSpA patients. Methods: Data from 2,846 unselected patients participating in EMAS, an online survey (2017-2018) across 13 European countries, were analyzed. Difficulties in finding a job was […]\",\n \"url\": \"https://acrabstracts.org/abstract/why-is-it-so-difficult-for-axspa-patients-to-find-a-job-results-from-the-european-map-of-axial-spondyloarthritis-emas/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109122811\",\n \"publishedAt\": \"2022-02-22T23:56:49.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3798236,\n \"message\": \"Why Is It so Difficult for AxSpA Patients to Find a Job? Results from the European Map of Axial Spondyloarthritis (EMAS) - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9081565,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/PxMQ0U7ZTTyX1wRubQKw_ACR_1062114_1.jpg?file_detail=52ceaf952bfac98e580c376f0f7b1c30e0312bc6b21fc4e180bb2c2a436093dfa0b43e270615dd96ddc559b2ce0419eb7132903ace84c7e3f38220fbe8b44be1a7cb6b76b9efe0b4550e481153c0d34f1c368163028883395643ffa92e96fc9a01f145c465b5402bbb18310ea53c02de:cbae654af4ffdc0797af9ad87e321728:6716a38176d2f1cf97cce8da1ddf7dff&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjE1MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.PfjagrqsC9XHOgQjb4UZsHAuqQJOtAl_rwp98anVP-0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Why Is It so Difficult for AxSpA Patients to Find a Job? Results from the European Map of Axial Spondyloarthritis (EMAS) - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: AxSpA is associated with substantial negative consequences regarding work status and career prospects. The aim is to identify factors associated with barriers to job access among European axSpA patients. Methods: Data from 2,846 unselected patients participating in EMAS, an online survey (2017-2018) across 13 European countries, were analyzed. Difficulties in finding a job was […]\",\n \"url\": \"https://acrabstracts.org/abstract/why-is-it-so-difficult-for-axspa-patients-to-find-a-job-results-from-the-european-map-of-axial-spondyloarthritis-emas/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-44a3f45a-b5b4-4c13-b1fa-b2bd46aebecc\",\n \"slug\": \"secukinumab-in-the-treatment-of-dactylitis-in-patients-with\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T19:30:51.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072159,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Lstr5Yp7RcqrzfCifY1F_OCMVWLVW-907523-1-ANY.jpg?file_detail=665b3dce432d857665338cb551e852df0b3c678808ef45ca27d476ed60ac33c282efc3f69d91ea1f30bd6de48de9197e84a0b9a82caa743bfd11c4a01460c0159842da7ce62479c08fc46c2d5e8ac0e21147891cd78378201ac9a9900a58e328d3584a14bdabf8f04812afa9f9fa1e09:da39b16ee1dfa40ccbabffb0ff57f430:2f99aa073feb65f64a58fb8204af9cc9&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjE2NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.UenG83poJh9UY4_jqUiJ_vV2DOcbD6KPsaHLdCdkIAM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Dactylitis is a key and frequent clinical manifestation of psoriatic arthritis (PsA)1 associated with significant disease burden and impaired function.2–3 Randomized controlled trials designed to evaluate the impact of biologics on resolution of dactylitis are limited.3 We report results of a post hoc analysis evaluating the effect of secukinumab (SEC) on PsA patients with […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-in-the-treatment-of-dactylitis-in-patients-with-psoriatic-arthritis-post-hoc-analysis-results-from-a-randomized-phase-3-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109111757\",\n \"publishedAt\": \"2022-02-19T19:30:51.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787236,\n \"message\": \"Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072159,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Lstr5Yp7RcqrzfCifY1F_OCMVWLVW-907523-1-ANY.jpg?file_detail=a5b11e1192f1efceabe5c33d2d2ac7cdd7bd02f6073a5ae1a473966441767c20d282c3e6dd0702102b818ebe05c59a825d0a7f99cd1e4c9af77c521dcd19b358513d9912e8fe0036398ea4bd818a891a5c2c014ab0bfd927a00094c1783914d22e94d8e0bfd0ef12113f362304b12a48:8f4fc241326a7f83733730d2c87fda44:883ba122c85ec382c0773f503e65db66&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjE3NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.vo0fk8CbcB3Ak4i35EwCZTim5iBFjWcPZ_i6DuzcKqs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Dactylitis is a key and frequent clinical manifestation of psoriatic arthritis (PsA)1 associated with significant disease burden and impaired function.2–3 Randomized controlled trials designed to evaluate the impact of biologics on resolution of dactylitis are limited.3 We report results of a post hoc analysis evaluating the effect of secukinumab (SEC) on PsA patients with […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-in-the-treatment-of-dactylitis-in-patients-with-psoriatic-arthritis-post-hoc-analysis-results-from-a-randomized-phase-3-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-52e941ab-5552-45b1-bf5c-c28f8981d672\",\n \"slug\": \"scoring-mri-structural-lesions-in-sacroiliac-joints-of-patie\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T13:32:19.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Scoring MRI Structural Lesions in Sacroiliac Joints of Patients with Axial Spondyloarthritis: How Many Slices Are Optimal? - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9070974,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/5HivLrSy6XqDX0sS1OQG_ACR_1064826_1.jpg?file_detail=ad650c06f1f7dfb54c99c1cdb555af16a4299bf0135eaf36fb3a7b993efaabc8781ca9b6d892b8ecedb8b3de85386335a3e9aeb88be3c160a838ea97d175f01c24486f64f8148bb8601d9bc301946974b5427f0b6ed854b50a965795bcc14f2a11b5b078354290fe33f7bcf179fc3e7e:d2ba8d817a8594c3b089125657f32cd7:f9c7993ef47864ad578ffdcbf1c40526&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjE4NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.C8ZXEGAwiWTYxfmt_f7kdgF95ctX5iWam0uhuvWo8Bk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Scoring MRI Structural Lesions in Sacroiliac Joints of Patients with Axial Spondyloarthritis: How Many Slices Are Optimal? - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: There is no international consensus on the optimal number of slices for evaluation of MRI structural lesions in the SIJ. An “all slice” method evaluates lesions from the most anterior slice, defined as the first slice with vertical height of ≥1cm of the SIJ joint cavity, up to the most posterior slice, defined as […]\",\n \"url\": \"https://acrabstracts.org/abstract/scoring-mri-structural-lesions-in-sacroiliac-joints-of-patients-with-axial-spondyloarthritis-how-many-slices-are-optimal/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109110587\",\n \"publishedAt\": \"2022-02-19T13:32:19.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3786076,\n \"message\": \"Scoring MRI Structural Lesions in Sacroiliac Joints of Patients with Axial Spondyloarthritis: How Many Slices Are Optimal? - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9070974,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/5HivLrSy6XqDX0sS1OQG_ACR_1064826_1.jpg?file_detail=81dc215e5b0bd70f17e1f6833323de334d1daf4da2a25d348d692023e6e5945b14f229c177e445bb442d773bf0e21096163a7709f6f121662c5b28e52db3199547379313a7d62544c94a40c37102bac0c42ce9def3a1dd432bf7d6ca8486b3b32fc82a7d56bd45379cc5a023978c1264:a87d00e16d0458e022e9ddc71f91e22b:90422c6169be907bbb8cb2b072cf20de&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjE5OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.RfrZjOaGOj_o0DaOTOyQnPwLBNgpB5xJBWbD2glZFv0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Scoring MRI Structural Lesions in Sacroiliac Joints of Patients with Axial Spondyloarthritis: How Many Slices Are Optimal? - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: There is no international consensus on the optimal number of slices for evaluation of MRI structural lesions in the SIJ. An “all slice” method evaluates lesions from the most anterior slice, defined as the first slice with vertical height of ≥1cm of the SIJ joint cavity, up to the most posterior slice, defined as […]\",\n \"url\": \"https://acrabstracts.org/abstract/scoring-mri-structural-lesions-in-sacroiliac-joints-of-patients-with-axial-spondyloarthritis-how-many-slices-are-optimal/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-4a78649d-58ff-42d9-821d-17ae13f2b8cc\",\n \"slug\": \"a-randomized-placebo-controlled-study-evaluating-the-safety\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-23T23:47:35.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9085357,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/tGCfEsK6T92QQL7JkFNs_GTUOHVCE-692635-1-ANY.jpg?file_detail=5980c0d5f459dd6d9a5bcfcc724e8598ebfaaa4935adeecda94bdf9f9989050d86155204bc3dcb99d139dd43de017e36d680f3bee4f331f965fe9c224811bd25fb083cf3c54132ecc48c0772669cb2cbde69be287f75c5f4d56f26631257758ce496d3800c284683a1f04b748d70e68d:0bc727a2ef4a6b3d0ac6bceda9e00d3b:a3dc0f0d631c7968e5cbed1010ac40d7&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjIxMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ykAsqKtYwBnxhMh3kR6vjQ3qRqjP_D2wMYVhQmpFLSE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that often develops in patients (pts) with psoriasis. Secukinumab (SEC) inhibits IL-17A, a key inflammatory cytokine in the pathogenesis of PsA. SEC is approved for treatment of PsA based on the phase 3 FUTURE studies, where SEC proved superior to placebo (PBO) in improving signs and […]\",\n \"url\": \"https://acrabstracts.org/abstract/a-randomized-placebo-controlled-study-evaluating-the-safety-and-efficacy-of-secukinumab-in-us-biologic-naive-patients-with-active-psoriatic-arthritis-and-psoriatic-skin-lesions/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109127541\",\n \"publishedAt\": \"2022-02-23T23:47:35.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3802936,\n \"message\": \"A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9085357,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/tGCfEsK6T92QQL7JkFNs_GTUOHVCE-692635-1-ANY.jpg?file_detail=abccda948f0e0a338efa3127f59b281b605fe9b9c5fc982f32fbdd7b58b68ba2d868880ec9149f00fca22737fc7c5344b0014db5aba215a7821a82841270ff3c91c71a47749dc90dc98a409c93c17382f75ae8cdfa707b3aa22222ea3a47752a2ca5585dcadd1ec83e285bd211e1efa2:d86cbe3965fc70eef9491ef3234f7ddb:3657cf9edab664dfb984ccefb00c9d6b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjIyMyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.tM19c5k-ISfUMb87agA5mLLBXJRNLJqJIw5jrVmovdo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naive Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that often develops in patients (pts) with psoriasis. Secukinumab (SEC) inhibits IL-17A, a key inflammatory cytokine in the pathogenesis of PsA. SEC is approved for treatment of PsA based on the phase 3 FUTURE studies, where SEC proved superior to placebo (PBO) in improving signs and […]\",\n \"url\": \"https://acrabstracts.org/abstract/a-randomized-placebo-controlled-study-evaluating-the-safety-and-efficacy-of-secukinumab-in-us-biologic-naive-patients-with-active-psoriatic-arthritis-and-psoriatic-skin-lesions/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-667ce588-c8a6-40f4-aac1-3d56a267757d\",\n \"slug\": \"different-subtypes-of-fingernail-pso-and-psa\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-22T13:26:41.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Different subtypes of fingernail PSO and PSA\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9079515,\n \"imageUrl\": \"https://firstwordpharma.com/assets/fw_pharma_large_logo.png\",\n \"title\": \"Different subtypes of fingernail PSO and PSA\",\n \"description\": \"Subtypes of PSO and PSA\",\n \"url\": \"https://firstwordpharma.com/story/5502715\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109120508\",\n \"publishedAt\": \"2022-02-22T13:26:41.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3795952,\n \"message\": \"Different subtypes of fingernail PSO and PSA\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9079515,\n \"imageUrl\": \"https://firstwordpharma.com/assets/fw_pharma_large_logo.png\",\n \"title\": \"Different subtypes of fingernail PSO and PSA\",\n \"description\": \"Subtypes of PSO and PSA\",\n \"url\": \"https://firstwordpharma.com/story/5502715\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-5c014224-7e41-4333-84ab-4bd7e2bf87c0\",\n \"slug\": \"juvenile-spondyloarthritis-in-the-childhood-arthritis-and-rh-juvenile\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-24T00:30:46.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9085430,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/v8gXf7cRQ1yHb7NweozN_GTUOHVCE-699288-1-ANY.jpg?file_detail=886ea564481a132ce167de8f4f65d1946deff3d8f7193b37a6768a7906bed0d97dce932034f8d2f8a96745b78a657f0171235f3871d4e9376aa7a6ac4711d04d2875e666373dd8dec6dd37260dfba5604f88d9d67e581f0111658dd20fc540fdc40408f7de42249a23c8d26ff2074766:42a4770fbe247273277fa7743d0b3e0c:98d637d8e73a3cd506b7581e6f044047&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjI1MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.jMrR_TC17Xp2MAxGyFaAxRnGsfjAkPrA_rfu0UVccNM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Herein we describe characteristics of children with juvenile spondyloarthritis (JSpA, i.e. enthesitis-related arthritis [ERA] or juvenile psoriatic arthritis [JPsA]) enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, which was established in 2015. Methods: All children with physician-diagnosed ERA or JPsA enrolled in the CARRA Registry between June 2015 and June 2018 […]\",\n \"url\": \"https://acrabstracts.org/abstract/juvenile-spondyloarthritis-in-the-childhood-arthritis-and-rheumatology-research-alliance-carra-registry-high-biologic-use-low-prevalence-of-hla-b27-and-equal-sex-representation-in-those-with-sacr/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109127620\",\n \"publishedAt\": \"2022-02-24T00:30:46.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3803015,\n \"message\": \"Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9085430,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/v8gXf7cRQ1yHb7NweozN_GTUOHVCE-699288-1-ANY.jpg?file_detail=bcad77fb9d3d502cd55f007baf418337cec3cb88043380a18c380e018e711956b7a25bb8c695fc7ec8be1c441fae1a52e4145b65b5785a52e4d8469902070604c32086d4c891b606ed547792c2061759d4e75e2a9243a748f1ad75768df9ee21e233708f763d390534e29d26fabbe389:862fd6642b11433ee8a31dd53ae6807e:2bc38f660ef896d21a04c466f7f78645&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjI2NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.sGQPdGfi55sVyfSy2203APRF0x4CeTgiwxSBdeDRbDk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Herein we describe characteristics of children with juvenile spondyloarthritis (JSpA, i.e. enthesitis-related arthritis [ERA] or juvenile psoriatic arthritis [JPsA]) enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, which was established in 2015. Methods: All children with physician-diagnosed ERA or JPsA enrolled in the CARRA Registry between June 2015 and June 2018 […]\",\n \"url\": \"https://acrabstracts.org/abstract/juvenile-spondyloarthritis-in-the-childhood-arthritis-and-rheumatology-research-alliance-carra-registry-high-biologic-use-low-prevalence-of-hla-b27-and-equal-sex-representation-in-those-with-sacr/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-62803201-6688-40a6-ae0f-6543e3b71f0f\",\n \"slug\": \"factors-that-may-be-associated-with-uveitis-in-patients-with\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-25T00:17:39.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Factors That May be Associated with Uveitis in Patients with Spondyloarthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9088941,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/ZU294CZSSvSq1HkQ7ujl_abstract-business-concept_XJp_x-_L%20(NXPowerLite%20Copy).jpg?file_detail=1301daea89e31d885dbcf6505db21d8f9752d51aaa8d93db07e4a2795fbe06a6f3fe0489fc1ef8407dd3724b4476e9c5ef7fa2821c0456d83ad854f01d73bf725f0b0402b3c41b8975e5778cf8171e9bced7d84870952e67f30e3cfb99550907c98032ffd88590e77f71d0da99ec12f4447a9499c5545ce1a1a2b88d37edd37032251a6de9accd9cfb366e8dc8da5e29:f6814e9ea8d1dc44289216a379ebe882:e8d2d4d2fdef891ab0b62e57bfbf884f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjI3NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.4K8sNQuEWAo6JcENng3fzz7U3JADUryBDgk08mlXiUg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Factors That May be Associated with Uveitis in Patients with Spondyloarthritis - ACR Meeting Abstracts\",\n \"description\": \"Factors That May Be Associated With Uveitis In Patients With Spondyloarthritis Background/Purpose: It is known that uveitis is present in the extra-articular findings of spondyloarthritis (SPA) patients. Sufficient information is available in the literature on the frequency and characteristics of uveitis in SpA patients. The factors associated with uveitis in SPA patients are not clear. […]\",\n \"url\": \"https://acrabstracts.org/abstract/factors-that-may-be-associated-with-uveitis-in-patients-with-spondyloarthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109131434\",\n \"publishedAt\": \"2022-02-25T00:17:39.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3806810,\n \"message\": \"Factors That May be Associated with Uveitis in Patients with Spondyloarthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9088941,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/ZU294CZSSvSq1HkQ7ujl_abstract-business-concept_XJp_x-_L%20(NXPowerLite%20Copy).jpg?file_detail=549952f01447b83594f9522dc6614427f091966adf656210029a721a86e36fb3802f946fef541cce0ae552908099b6bb41ab601559da8d868bd49db3d5a9b0673e8a2a6a54897c4256c37c2bf5d923e815eddfc17f061d8ccce6a045c0f59d8b33ae5ec71b865821324256208f238cb6340c72cc5b2790fc5af579b154f890e72440305bc9a901634ec2d582cd1b66fe:06f490436f028882294cd6341f5673b7:b73cd6317cb453899daf744c2f2f19dd&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjI4OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.3fqgYDJRoPMONnD6HykLzacITA6YvUwjSqNO-FmDYs8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Factors That May be Associated with Uveitis in Patients with Spondyloarthritis - ACR Meeting Abstracts\",\n \"description\": \"Factors That May Be Associated With Uveitis In Patients With Spondyloarthritis Background/Purpose: It is known that uveitis is present in the extra-articular findings of spondyloarthritis (SPA) patients. Sufficient information is available in the literature on the frequency and characteristics of uveitis in SpA patients. The factors associated with uveitis in SPA patients are not clear. […]\",\n \"url\": \"https://acrabstracts.org/abstract/factors-that-may-be-associated-with-uveitis-in-patients-with-spondyloarthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-ddb5c1c6-e053-4809-96de-fa3207721da5\",\n \"slug\": \"secukinumab-demonstrates-high-efficacy-and-a-favourable-safe\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-06T12:23:09.000Z\",\n \"duration\": 60,\n \"title\": \"\",\n \"message\": \"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018520,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/sAmu13hTRKPEZWqsWkiV_pubmed-meta-image.png?file_detail=a7860083b0ab6c4d593d33d0862f7252673451b1edc2c95a2b89fcb65db19d23be521455ef895ef90e73c8d33953da3610e57d9defd2c0d6e84cf6007d5b1ebd887ceaa5c4a7a774f0aa02791df4c4a1a4b40da4fc4989f73d2ecd44107c368084844e847c7476f60bb990a4babc3e33:a2d4ed803baee6857f62ef7d82ff4e6e:7bc63c4a64d0a7eed4829743c0b822f9&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjMwMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.D64Zf5iO9edCg6ZZuylJYRfRLUlulFfKiCUsiAxnVMA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial - PubMed\",\n \"description\": \"Both doses of secukinumab demonstrated high and sustained efficacy up to Week 52 with a favourable safety profile in paediatric patients with severe chronic plaque psoriasis.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33068444/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109054444\",\n \"publishedAt\": \"2022-02-06T12:23:09.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728962,\n \"message\": \"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018520,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/sAmu13hTRKPEZWqsWkiV_pubmed-meta-image.png?file_detail=e4ba89b8d9f0425e796e9cdc23b7c9543cef7a795baf8984f19e9f0f0e3a464c222a7def28b793f933e5cb9b16e3d57543304da888a9e7f4fd891229df5b9cf822b186b36f2071d5a17df5c2bded5098fff2608092edfb1cbdcc99dd82efa001949c23cc953ea82bc1910be88756679a:afce2a627281579c62387d606ece84a0:ded614d4f77fa534aba1fdc6c3a1fc10&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjMxMyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.JW1Gm4WjQj9snEQle-wcS9yZWaC5NTJ0mO9Anz0uxB4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial - PubMed\",\n \"description\": \"Both doses of secukinumab demonstrated high and sustained efficacy up to Week 52 with a favourable safety profile in paediatric patients with severe chronic plaque psoriasis.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33068444/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-eda8eca2-b7d7-4cf9-8d14-2f608c7f7c44\",\n \"slug\": \"comparing-symptoms-treatment-patterns-and-quality-of-life\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-10T01:03:47.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9032075,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/rPFpP2URXS2VR0MGvDnT_pubmed-meta-image.png?file_detail=956e36e485768eed5f1d1c4c4a42fe7b16493f9ee6deac1cd6e05dcf58e66ee322ca28fa97bc2d23cc480c25adf8d62f11ded521529c986f2ed9173f043231948e7471664f3a44a0e7b3cc5bf79ffb5e4208770d35f2fe5dea91ac99be1a5782e5364145a259d83b9ea5fe77cf0cc3d9:a7fa9c52ec6191cc2492b80c445f4547:c28090b5026d571c9a87cd2ef4e59492&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjMyNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.tsR9XMa7dQGMiqpw2plXXUUuQzU7LR1EySmulGKVg38&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey - PubMed\",\n \"description\": \"• Ankylosing spondylitis and non • radiographic axial spondyloarthritis patients share similar clinical features and burden of disease. • Quality of life is similar among ankylosing spondylitis and non • radiographic axial spondyloarthritis after adjusting for current treatment patterns.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33611647/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109069703\",\n \"publishedAt\": \"2022-02-10T01:03:47.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3744177,\n \"message\": \"Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9032075,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/rPFpP2URXS2VR0MGvDnT_pubmed-meta-image.png?file_detail=108ac91380b6874ee069c1e1e72b8bd19e73a818837198e5b0f680f76d672e7bd6e5bde2187a3220ea8c071bd97da7123d5af1e27302dfa3c15de8ed242949ebcdb9eb51a10b927866cf99d8ba110bb0a42e9cd030cd66fcf96e020515a11177977ae7acfcaf34cf0817478116d13561:af8de39ce822ed1f86d6fb66c7606d08:98e2c55b8256453d6ff283f6c2f4f0ca&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjMzOCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.iYY_edzdpAdYnEovZTku-XdkiJHq-PFoT6AfYdfbdPI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey - PubMed\",\n \"description\": \"• Ankylosing spondylitis and non • radiographic axial spondyloarthritis patients share similar clinical features and burden of disease. • Quality of life is similar among ankylosing spondylitis and non • radiographic axial spondyloarthritis after adjusting for current treatment patterns.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33611647/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-f912f6d3-c8c3-4c16-b90b-da529dbe2599\",\n \"slug\": \"associations-between-spondyloarthritis-features-and-magnetic\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T20:27:28.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Associations Between Spondyloarthritis Features and Magnetic Resonance Imaging Findings: A Cross‐Sectional Analysis of 1,020 Patients With Persistent Low Back Pain\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018057,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/kZnSSHZTomu7VbQ3oUXK_art.v68.4.cover.jpg?file_detail=f5e92451b79734b0e7da2fdde083a5c8782f27fee523a94556cb1cfc8eff2eaa79906f02cee3089e207ddbf97f1e8dbe0324e6881eba34df5ed72ff20b4339cf9784576b37718d1d2436eb616f875fc05b1a0ad2141ffca2068d76dcb022e4282eef572d55fa5076c842ca436389f884:7aa31e56cde054fe8541f21ba8f1e3c7:df0f05120f7d87325755564671842e1f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjM1MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.b_83HDjIxLCxU9hl27eiHLas1Sg-HuC2m-1SWG7sLEo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Associations Between Spondyloarthritis Features and Magnetic Resonance Imaging Findings: A Cross‐Sectional Analysis of 1,020 Patients With Persistent Low Back Pain\",\n \"description\": \"Objective\\n The Assessment of SpondyloArthritis international Society (ASAS) has previously published criteria for spondyloarthritis (SpA). In the Spines of Southern Denmark cohort, which included pa...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.39551\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109053993\",\n \"publishedAt\": \"2022-02-05T20:27:28.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728523,\n \"message\": \"Associations Between Spondyloarthritis Features and Magnetic Resonance Imaging Findings: A Cross‐Sectional Analysis of 1,020 Patients With Persistent Low Back Pain\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018057,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/kZnSSHZTomu7VbQ3oUXK_art.v68.4.cover.jpg?file_detail=20220f77a71093b5ef73ce24041e897c99462f36ed24e35efd85e9668225b7f7431c15ff1b7fde054f31f672e15a911163b0652625fe2d90574a477e4ede170189db18057316b622da0920440d1a19c7ae2653fcc389497cdeec1bf4b0b7a0dba1b4ef4fbcbbb67e8286134641a14562:92e25918b14b388324a706e73f2289ca:a564076f55c2a25557b7692f3b45419c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjM2MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.bDuwc7750EqnAcD4FvOHuBBLPGihc_kdejKOmhboMa8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Associations Between Spondyloarthritis Features and Magnetic Resonance Imaging Findings: A Cross‐Sectional Analysis of 1,020 Patients With Persistent Low Back Pain\",\n \"description\": \"Objective\\n The Assessment of SpondyloArthritis international Society (ASAS) has previously published criteria for spondyloarthritis (SpA). In the Spines of Southern Denmark cohort, which included pa...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.39551\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-f103f94c-c4c7-4fb5-a4d9-302d300f283e\",\n \"slug\": \"uveitis-status-in-patients-with-ankylosing-spondylitis-or-ps\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-09T00:37:11.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment - Real World Data from a German Observational Study - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9028008,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/8hGRo7odQXAmNKyB6w0w_ACR_1056245_1.jpg?file_detail=fe472938476e7656290fc3c40f168d21e4e2393b188712d154ff5aa7ac19ae3d04d7432595fe3e6e96b5d1eb23edfaf4b67a9437ae6c01064fd59fc0854923c46254050d6d8db7028f4649436fe92642998b8aa8654dc1afd276d7021c9fd4211619244ce04bb321319ade278f8bcfd8:9696f493491dc0800c922fb272d92eab:74d7c9fa609d7b7705960b5c29d9bf98&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjM3NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.mvRV9Q7hPDRO9wkuqgdRB3cswf9Y07OgXDnlgXvlFlo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment - Real World Data from a German Observational Study - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Uveitis is a well-known non-musculoskeletal manifestation of spondyloarthropathies. Patients typically suffer from blurred vision, pain, and photophobia and have an increased risk of ocular complications. Prevalence varies greatly, as uveitis occurs in up to 50% of patients with ankylosing spondylitis (AS) and in approximately 7% of patients with psoriatic arthritis (PsA).1 The German non-interventional […]\",\n \"url\": \"https://acrabstracts.org/abstract/uveitis-status-in-patients-with-ankylosing-spondylitis-or-psoriatic-arthritis-under-secukinumab-treatment-real-world-data-from-a-german-observational-study/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109065117\",\n \"publishedAt\": \"2022-02-09T00:37:11.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3739598,\n \"message\": \"Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment - Real World Data from a German Observational Study - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9028008,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/8hGRo7odQXAmNKyB6w0w_ACR_1056245_1.jpg?file_detail=af5e83428cb2b0c4be6ab74c79c4d832567f37994ae164dc2b15b6e68a781814a98d9fbd579db5eed52c0a7835753055cc14e14121e5c4bc314544645952539cff2f5630ef5863c6fec3aa1e80469dac44e982df1c3aaa317afffa2695cada6dff42fc4a15588abf2b607d8136555157:052e319810015de8fbf2cc5d0f36192c:3d1b846e48943c72fa5371c2f9afe413&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjM4NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.d1TO_zWJDFqfQTmvZhFNNGKZgTfyInjFzLxG6LJzKY8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment - Real World Data from a German Observational Study - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Uveitis is a well-known non-musculoskeletal manifestation of spondyloarthropathies. Patients typically suffer from blurred vision, pain, and photophobia and have an increased risk of ocular complications. Prevalence varies greatly, as uveitis occurs in up to 50% of patients with ankylosing spondylitis (AS) and in approximately 7% of patients with psoriatic arthritis (PsA).1 The German non-interventional […]\",\n \"url\": \"https://acrabstracts.org/abstract/uveitis-status-in-patients-with-ankylosing-spondylitis-or-psoriatic-arthritis-under-secukinumab-treatment-real-world-data-from-a-german-observational-study/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-f9ee30c0-3aea-454f-8308-e9138a80bc05\",\n \"slug\": \"incidence-of-arthritis-in-a-prospective-cohort-of-psoriasis\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T20:24:37.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Incidence of arthritis in a prospective cohort of psoriasis patients\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018055,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/rZMzAy5T8u6ghy9ejZdA_acr.v63.4.cover.gif?file_detail=fd225d66beea8531e78c2217a4c2e860197dc8ab256a6eafd34ac2142f2f940bbc75f583eb8ecc5cefd147d5af3e3551547a720a76c6486f4b24fa35ed28d079316ec074e9977df9729dd8fe41f75e841e2616f075e08d11b4a8b860cc46699f142e4d59db7ae733ea01c4a1f8d7b410:0b9b72f907d1584a2c687d13f7a33b20:0403cf7f305fb33aca9241429b691b65&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjM5NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.sxePyjdbbdgME3twEkOFmROyglWCPD2unt4c9aY2YVc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Incidence of arthritis in a prospective cohort of psoriasis patients\",\n \"description\": \"Objective\\nEpidemiologic studies about the incidence of psoriatic arthritis (PsA) are limited to a few population-based studies. There are limited data regarding the incidence of PsA in patients with...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/acr.20401\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109053991\",\n \"publishedAt\": \"2022-02-05T20:24:37.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728521,\n \"message\": \"Incidence of arthritis in a prospective cohort of psoriasis patients\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018055,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/rZMzAy5T8u6ghy9ejZdA_acr.v63.4.cover.gif?file_detail=c22b1abe46fe4b2e93e35e09806433fc79ce495df1e830a8cb2f906f8ed5031582131ea67bfd95d01a385dfca31cef77d5d0c992a8da16b39feb3b1cdf483d50df58c59bc86d64e135cc882a9b624946d2049bdd77d3b2dc362f0a590019aa3dde81b09d9cdfc84c33694c50243baa48:33fe121a0482f61b847e70ee667f083a:0a34b27959837df3382bffeb9a388e41&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjQwOSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.drroMb9Xp6gky8FKpovdQq_sMbOTEKGtyVzI-2U2IGY&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Incidence of arthritis in a prospective cohort of psoriasis patients\",\n \"description\": \"Objective\\nEpidemiologic studies about the incidence of psoriatic arthritis (PsA) are limited to a few population-based studies. There are limited data regarding the incidence of PsA in patients with...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/acr.20401\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-66975a9d-94d1-4fd5-b41f-c4688b9355b9\",\n \"slug\": \"pathogenesis-of-spondylarthritis-relevance-for-treatment\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-10T01:25:17.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"[Pathogenesis of spondylarthritis : Relevance for treatment] - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9032111,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/TrIpbZBrTMCsjRygQvRk_pubmed-meta-image.png?file_detail=949fdce979e5d11eb8261ff9417954a8c2513080399413729cda3bdca7cb9728b8da6dc87ff4b03bceffc3c61897cc14721f6c6a63f528179c7e72dd91481efd09b44c1fced69f33557522aaced3cad1b5056ae05add8c4505d04b7051c09e26d6bfd332d4cf7868c87d5851d10d31d0:4cd09fd0750a9d35edc2ef9d86ae6cda:673c48d2af5204718b3a38af04b05f42&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjQyMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.T2iN5mFnNYX2FGExIVtZLrGvPCnY9ZOJWNoqTxAnMc8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"[Pathogenesis of spondylarthritis : Relevance for treatment] - PubMed\",\n \"description\": \"Although the pathogenesis of spondylarthritis (SpA) has been the subject of intensive research in recent years, the consequences for treatment are relatively minor. Basic research studies indicated a potentially important role of the cytokines tumor necrosis factor (TNF) alpha and interleukin (IL)-1 …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31506791/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109069760\",\n \"publishedAt\": \"2022-02-10T01:25:17.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3744231,\n \"message\": \"[Pathogenesis of spondylarthritis : Relevance for treatment] - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9032111,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/TrIpbZBrTMCsjRygQvRk_pubmed-meta-image.png?file_detail=8f3134979469a7807d07dafcdf1da7286a5e0f1cb9a65862eec95653fc21ac739ce4f906220534c545623b6143a407cca36f4e71e9929f06fce6ead9c7ad7511386cf2a98adc52555d4c560a6bed56cadf2e8b62270d33d3076adfdd59f23f5965024d8bf3cba92de1d09d66637a7750:b8a51142b393d8d69c12f4f120704add:e573d474c3a56a022f1d2329ef85a0fc&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjQzMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.4tyxWdNf1PoG71HRudFxyuH83UPlpf-Vc0yUfeEJJEE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"[Pathogenesis of spondylarthritis : Relevance for treatment] - PubMed\",\n \"description\": \"Although the pathogenesis of spondylarthritis (SpA) has been the subject of intensive research in recent years, the consequences for treatment are relatively minor. Basic research studies indicated a potentially important role of the cytokines tumor necrosis factor (TNF) alpha and interleukin (IL)-1 …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31506791/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-7693a159-390a-423f-b062-c83bbde06ae9\",\n \"slug\": \"magnetic-resonance-imaging-compared-to-conventional-radiogra\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-10T01:01:20.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Magnetic resonance imaging compared to conventional radiographs for detection of chronic structural changes in sacroiliac joints in axial spondyloarthritis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9032072,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/PeXNAwI8QNKHr7Saogcd_pubmed-meta-image.png?file_detail=b36728c1f049acd5eff572c92c5ed8888f6e1c4bbed9bda09e84d391c0a80e1cb3995ffc102126d13a0f11f0a17421361e21dd8fa4221890b8835120ced23ae72601a9898af71779ff53c797284c811885f4c5445822ed0dd27b629349c89f98810ea6f95e5966d78bd4123a0a1a042e:de853f06c31ae63ccdc6755ef6e816e7:5feddae37e305546adf721cafcc219c4&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjQ1MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.O7Zvy4lmW5nHUtMgOfvwNVZiNGyvLpNXtLudId_SbT0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Magnetic resonance imaging compared to conventional radiographs for detection of chronic structural changes in sacroiliac joints in axial spondyloarthritis - PubMed\",\n \"description\": \"MRI demonstrated good overall performance for detection of chronic structural changes in the SIJ as compared to radiographs.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/23818713/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109069700\",\n \"publishedAt\": \"2022-02-10T01:01:20.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3744174,\n \"message\": \"Magnetic resonance imaging compared to conventional radiographs for detection of chronic structural changes in sacroiliac joints in axial spondyloarthritis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9032072,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/PeXNAwI8QNKHr7Saogcd_pubmed-meta-image.png?file_detail=c19ffabd18d44823993bed53700611fa60a9e99c742f9a659fd376b64af1a1370cb37973b7c56f587d1ed33aa7acc6c84ca384852284169f296dc8c7ea27708e49c4473672882bb436290a5c260ea714d5a64175686c8a0b5daa5aa22334eee7e7fd5f49a717997860e29dce38394d40:58565a9a8c076f90019f08acaa710f34:64073fbe2fd99c6d26735b83b49ef866&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjQ2MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0._02ZXpU-sVZDwd2dwnA10yJnV8Z1MZkB4oT0OzSqNL8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Magnetic resonance imaging compared to conventional radiographs for detection of chronic structural changes in sacroiliac joints in axial spondyloarthritis - PubMed\",\n \"description\": \"MRI demonstrated good overall performance for detection of chronic structural changes in the SIJ as compared to radiographs.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/23818713/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-7a7663b3-8d26-4f18-8f1c-64ce92bdf808\",\n \"slug\": \"secukinumab-in-non-radiographic-axial-spondyloarthritis-sub\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-10T01:06:11.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9032076,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/tK3SqVNJRuyntyh2QcUr_pubmed-meta-image.png?file_detail=c8f7596f9ffde81a9eb8d49b623028bee129ff3059dd278dedca47a2e2c84b7c713a5cdcf58492972456ebbc44a6cc2e2cd71f9f168ee55b7ad2dbe30a47ab83a68d02d115b011c977f11c5079abcc3c7338b7aaf275a4c2c7729da107799917feb96b2970c4421aa8a1a07ed60bae90:a7deac43cf14354726f5f739e3e294e3:88fb49df20c9c03ed32965c4789c444f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjQ3NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.2OBfUgUKtcoLijuDt5vPUo0Q0tHHtgcoGujlv84fBho&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT - PubMed\",\n \"description\": \"ClinicalTrials.gov , NCT02696031 . Registered on 02 March 2016.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34481517/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109069704\",\n \"publishedAt\": \"2022-02-10T01:06:11.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3744178,\n \"message\": \"Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9032076,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/tK3SqVNJRuyntyh2QcUr_pubmed-meta-image.png?file_detail=f89d15e49465b2558ad56a702bffb6cb676dfc7f965f9d7d58affe625bc387d1779246d6f26fcba501d2dd0c6af8db9469960211aa938f2909bbc75c575b2b8bd92b0082f58195d4876ed4ab83f609999818db4c00e4bbf3133d5d98f5c131266f8180fe4cf5e113f53ab9b1b8a98a91:3b4abe7e26710068cc1801019e936f3c:94f24f7d080295af2ca416614e157fcb&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjQ4NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.pIydKECtdQb6PMuxWLW0YKaCcm3LaOQhkk0CCeDkAtA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT - PubMed\",\n \"description\": \"ClinicalTrials.gov , NCT02696031 . Registered on 02 March 2016.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34481517/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-66c84429-9c05-4c3f-a383-eb51a3de650b\",\n \"slug\": \"efficacy-of-secukinumab-without-the-initial-weekly-loading-d\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-08T18:39:45.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9027320,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/4UPHxk55SLuY0K06Ijgr_pubmed-meta-image.png?file_detail=e38033c967d5cad016e1cf3a9380f0b42f0394a2a44feec28b1dce8a93cd3b2517a6be5529ea52528336d553a3d71e62e3a5f240894dcfd6662c540e1325ead6d446434facead02721173540b33d1a3a0a7cdc11639d3dce9dfdc796bef0d09ca947838eaea7d76bb5b7dccc7527496e:be764032975e6691a576722776db1359:b4f29925e33a231cdb7e29f450510f71&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjQ5OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.1EsQqO00SvdHWfaL4xuhW0hHTsZlP_MDOUFo8KRxAwo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis - PubMed\",\n \"description\": \"Secukinumab administered without the loading dose is associated with a higher proportion of primary inefficacy, and achieved inferior results compared with the labelled dose at week 8 and week 12, but showed similar efficacy thereafter. What's already known about this topic? Secukinumab is an interl …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31004509/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109064397\",\n \"publishedAt\": \"2022-02-08T18:39:45.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3738882,\n \"message\": \"Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9027320,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/4UPHxk55SLuY0K06Ijgr_pubmed-meta-image.png?file_detail=4943b48fdbcf8ac869b2afdbb1cf7c967c8c663d2991be46e8e957f533b179e42b6f5815f2379886ea75a9ae3e0ba5f06876f7da2ba00fef51405b09139563515ecf241c3c16d14bcd73ce60430a5e9c9c35ff2c17feb4ef4aa946dd38d4b02f45f564484ee562450a4826d46e433358:2a834465098488f9380b1e6ba18ed438:f6c01e001e1cf8ee95d85dfef20443d7&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjUxMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.0yei09gHXUXTQ672ym-cblvKD_QUX6a3HRBbrmW3R9k&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis - PubMed\",\n \"description\": \"Secukinumab administered without the loading dose is associated with a higher proportion of primary inefficacy, and achieved inferior results compared with the labelled dose at week 8 and week 12, but showed similar efficacy thereafter. What's already known about this topic? Secukinumab is an interl …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31004509/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-c0357c2f-87fe-479f-8e7f-bad304f26f70\",\n \"slug\": \"risk-of-herpes-zoster-with-il-inhibitor-therapy-for-psori\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-08T18:58:32.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9027445,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/wPlUT1qOTYW3ZA3C2ydW_pubmed-meta-image.png?file_detail=042cf42c51e7a2ac830047cba19f89df41119327a22a9552b34db2799ca966a09a6434fafff9d3b5214ded3b4362964c82df36835a395d5b91135f25537fa05688afa44b7d2e16e3fd83390c2b4ffdfc57a52666afa60421d3d605cf3c72164b389b01a5d3936863edefa0e10b29faa4:aeeb1e2f95affd0939d5faecba0206a1:ad9af31630bce707813206f0db5ddf34&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjUyMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.OTVzdLIinQQ-Dq0JdxeLoumyipntA4Trt8N9_5nl4gs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions - PubMed\",\n \"description\": \"Background: Psoriasis is a chronic inflammatory skin disease that has been associated with a significantly higher risk of herpes zoster (HZ). Several newer biologics such as secukinumab, ixekizumab, and brodalumab inhibit IL-17 and have been highly effective for treatment of psoriasis. Howeve …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/30900514/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109064499\",\n \"publishedAt\": \"2022-02-08T18:58:32.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3738984,\n \"message\": \"Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9027445,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/wPlUT1qOTYW3ZA3C2ydW_pubmed-meta-image.png?file_detail=3b211c232f785c7acd71059a1143167f80ec1b2ce8bf8d0653edc74c0eb5e32675bf516513ef7f81dca5d2aa3176d448a4da137868554ee0417c42d3ea1e0a877b0f6ad15ffa79016fe936728eb1956ec389ee24044ae6ad1f473534482a8b5cfaaf1d17450e9bc06c506c27f8fa62e1:1b97cece3eb639dc742da3ca5a891398:8bd770db27f6be71cb8a023fa919619d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjUzNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.voFjJDmi_Ow9DDHhPvgCAlUEA94JQlnFZKIoontfZhM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions - PubMed\",\n \"description\": \"Background: Psoriasis is a chronic inflammatory skin disease that has been associated with a significantly higher risk of herpes zoster (HZ). Several newer biologics such as secukinumab, ixekizumab, and brodalumab inhibit IL-17 and have been highly effective for treatment of psoriasis. Howeve …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/30900514/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-cb0e1577-aba0-42aa-beba-c794a1e27364\",\n \"slug\": \"characterization-of-patients-with-ankylosing-spondylitis-and\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T12:37:22.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US‐Based Corrona Registry\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9017730,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/spK8OIBFTvmU06afazlG_acr.2018.70.issue-11.cover.jpg?file_detail=e94ff07043bd697cfdae3d9469587e9005aae5a565fff7ce54d62eed84cbd095036d3f8365a2af63c65f5285fe5b368f7194a41971ffa39de4f68bd96b5a286036ca37ce99797ce6cfd45c5622f99da4e3af8bfc6fbcd53957cd1e082ec93d4ac0099041bf7aac83a0da204e41abd1e5:73dc21a549fe061e9d0cc0d0350cb470:d0a696fe496e4d7e3fff78feabc7723f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjU0OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.aijxNuYw_re94K4xCKai-8P3_F8mEFfd_qCPz9wyKpU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US‐Based Corrona Registry\",\n \"description\": \"Objective\\nTo describe the characteristics of patients with ankylosing spondylitis (AS) and patients with nonradiographic axial spondyloarthritis (SpA) in the US.\\n \\nMethods\\nDemographics, clinical cha...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/acr.23534\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109053669\",\n \"publishedAt\": \"2022-02-05T12:37:22.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728200,\n \"message\": \"Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US‐Based Corrona Registry\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9017730,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/spK8OIBFTvmU06afazlG_acr.2018.70.issue-11.cover.jpg?file_detail=001f51e32c3a29d7a707dfac3b5216429429142dfc6db4c70b656d5580d59b14252b057a662c7f451e937164a5bfbf559da19791cc46b15dc7b4241ca548456c7f43d289177a8b63da00f8629f3fa5bfb8852e3f9d6a4796942660c2cdbb35f3dca050e3b31ffcbf637ccec481a00337:ebfec8d8eb28ac50b44c2ea8b743e248:2be0ec86853f79899f01afc78819cc2b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjU2MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Q9tQDbnOwvmkwlI2agvf2ZIKOtpYoiwx-T5l1WxIO0g&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US‐Based Corrona Registry\",\n \"description\": \"Objective\\nTo describe the characteristics of patients with ankylosing spondylitis (AS) and patients with nonradiographic axial spondyloarthritis (SpA) in the US.\\n \\nMethods\\nDemographics, clinical cha...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/acr.23534\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-1378f7eb-25f7-4df8-8dc1-d3e04c5ba6e7\",\n \"slug\": \"the-initial-treatment-of-systemic-juvenile-idiopathic-arthri\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-20T12:37:21.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072723,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/MvxymkjQoWwcNYbPmMCi_AbstractSubmission_824593_1.jpg?file_detail=2472d0f2da86bd57da96170fd096c357a3e3b471262247c68f8d23880fe71c7eab85d06069127cdfb09e442b69860749647fdf0fbfab7aaefa581d7cbc6bab601550d25baccace6e216d86aef1d84c4649fde6902e3b2842ff9d0ecd708b5d6708148ce5e6502264c0bbab309fe1bda8:14b1af2e66fd26350f155ef02165f0b2:d72b6512101752054a24d0bf0bd9bbff&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjU3OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.5KbsaV8I9nLoxcdH4enfRvm5o-Y_aMCFtZvbP5tGfOs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The introduction of biologic medications has revolutionized the care of children with systemic juvenile idiopathic arthritis (SJIA). Differences in treatment approaches among different countries and how they have changed in the modern era of biologic medications have not been well studied. We sought to contrast the presenting features, initial treatment and 12-month outcomes of […]\",\n \"url\": \"https://acrabstracts.org/abstract/the-initial-treatment-of-systemic-juvenile-idiopathic-arthritis-an-international-collaboration-among-10-registries/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109112257\",\n \"publishedAt\": \"2022-02-20T12:37:21.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787734,\n \"message\": \"The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072723,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/MvxymkjQoWwcNYbPmMCi_AbstractSubmission_824593_1.jpg?file_detail=a9813cf1bf226b198c25caeda8ba41ea257e0ea1920e52f41e976239313c84e6fc5c91b081dc2cdd2c4d466ee9be64fe9954786182baa9cbc4273659f7b5517a8a45275f74345a5c1f3c5b36fd3c58efac05fb6da2928c87b01c0d845b8d89c2171d308ee8cb5bce572cfd026461d95a:8c3426d490344d05f0dff448fa23d797:2af1ffddf6f03a4d4e6261cb98d9085e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjU5MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.bWBqjWHcVudFisIKn1IN3En-U4zp96mc6VuZbKFQCJM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The introduction of biologic medications has revolutionized the care of children with systemic juvenile idiopathic arthritis (SJIA). Differences in treatment approaches among different countries and how they have changed in the modern era of biologic medications have not been well studied. We sought to contrast the presenting features, initial treatment and 12-month outcomes of […]\",\n \"url\": \"https://acrabstracts.org/abstract/the-initial-treatment-of-systemic-juvenile-idiopathic-arthritis-an-international-collaboration-among-10-registries/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-1de1bbcc-c41f-4a46-a9a5-cf377ef36bd2\",\n \"slug\": \"two-year-guselkumab-benefits-in-psoriatic-arthritis-rheumn\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-18T01:11:11.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Two Year Guselkumab Benefits in Psoriatic Arthritis | RheumNow\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9066753,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/YVkJJOkuTeig1AprTZjr_20140915_084544~2.jpg?file_detail=3989e4dd9c5f025c4f22b0bee3cb2743fb4e6fedce8160e2e27911648df07fe7cb3be361e1d165262e7cb4aa5e75f21133deb53d8d3b07b0e8f23e3c8f8fe12a36c4719dea773da9f15516cccf7919869e492f2c5d3a8f7ca63c0847c4db93c2e5d3c19d937fcb1c8c638cc103ce2aaa:8e56af175804a353a9dedb75232079d2:d6d3c815f833ef790973219c5e748e7c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjYwNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.KfYRCJcRbqYHtAKuN0-3JLWQLBFNsrcZCVzZe56dLHw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Two Year Guselkumab Benefits in Psoriatic Arthritis | RheumNow\",\n \"description\": \"Patients enrolled in one of the pivotal trials of guselkumab (Tremfya) as therapy for psoriatic arthritis (PsA) and followed for 100 weeks continued to show significantly reduced symptoms relative to pretreatment baseline, researchers said.\\nACR70 responses, indicating a 70% decrease in symptom severity by American College of Rheumatology criteria, were still seen in 34% to 39% of participants at 100 weeks, depending on the dosage, reported Iain McInnes, PhD, of the University of Glasgow in Sc...\",\n \"url\": \"https://rheumnow.com/news/two-year-guselkumab-benefits-psoriatic-arthritis?utm_source=rheumnow+newsletter&utm_campaign=2ef0458a2b-email_campaign_2022_02_18_12_39&utm_medium=email&utm_term=0_11adbca03a-2ef0458a2b-243787117\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109105668\",\n \"publishedAt\": \"2022-02-18T01:11:11.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3781188,\n \"message\": \"Two Year Guselkumab Benefits in Psoriatic Arthritis | RheumNow\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9066753,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/YVkJJOkuTeig1AprTZjr_20140915_084544~2.jpg?file_detail=2cf1851cbd5588b469da3466d806f247ad172131bfb3f69d62f1eafaa09669dccb7a6cf89a14be804e12ef17ea9c8a871fba3302ede408a0b8dd5b8256507edc8dd0989ef7eddae31c98590977b52ae75fdcea8d97121c4d507fac2587486c4a72fc03cf21c18c2ddd6381338c6d6432:827d05c6eb280e6af95611482bf4da50:0a766ed7011ea7d2ab91fbb82ff3c227&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjYxOSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0._qbjvIExsvOKUoNROEoRnwcjF7iKEtmzzPgU98w__AY&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Two Year Guselkumab Benefits in Psoriatic Arthritis | RheumNow\",\n \"description\": \"Patients enrolled in one of the pivotal trials of guselkumab (Tremfya) as therapy for psoriatic arthritis (PsA) and followed for 100 weeks continued to show significantly reduced symptoms relative to pretreatment baseline, researchers said.\\nACR70 responses, indicating a 70% decrease in symptom severity by American College of Rheumatology criteria, were still seen in 34% to 39% of participants at 100 weeks, depending on the dosage, reported Iain McInnes, PhD, of the University of Glasgow in Sc...\",\n \"url\": \"https://rheumnow.com/news/two-year-guselkumab-benefits-psoriatic-arthritis?utm_source=rheumnow+newsletter&utm_campaign=2ef0458a2b-email_campaign_2022_02_18_12_39&utm_medium=email&utm_term=0_11adbca03a-2ef0458a2b-243787117\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-13b6a5aa-6262-4d5f-97e5-bd44e94df819\",\n \"slug\": \"what-is-the-optimal-screening-strategy-for-early-recognition\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-22T23:53:55.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"What Is the Optimal Screening Strategy for Early Recognition of Spondyloarthritis in Patients with Acute Anterior Uveitis? - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9081562,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/BpF25DauQDWzcvukuLvn_ACR_1065159_1.jpg?file_detail=1cbaabb1c9fe5c49092e08ad730ac5ae8c0440268e235a981c1b3d7ae7b380f71ea9dd1c4737aa2c8ed9e3ab05b7851d0c125eacb51d20a8d38452e05537bbf5841338baa0c4143381f200e238dd0c033a843e71fef04df893fd0c609a788b9fd16665609c0b2215a8321b3d958eddb1:f9ad73a8b9b096f25c255c7689b11d16:4466c20b4cd92db7e352db0f4416edf2&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjYzMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.rTJpk3CYzvH43wPsmIJGKbJGP6VkkqjHvXfq4pYvb5c&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"What Is the Optimal Screening Strategy for Early Recognition of Spondyloarthritis in Patients with Acute Anterior Uveitis? - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The diagnostic delay remains long in patients with spondyloarthritis (SpA), thus effective screening/referral strategies for early recognition are needed. Up to 40% of patients presenting with acute anterior uveitis (AAU) have an undiagnosed SpA [1]. The Dublin Uveitis Evaluation tool (DUET) was presented as a referral tool for ophthalmologists [1]. The objective of this […]\",\n \"url\": \"https://acrabstracts.org/abstract/what-is-the-optimal-screening-strategy-for-early-recognition-of-spondyloarthritis-in-patients-with-acute-anterior-uveitis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109122807\",\n \"publishedAt\": \"2022-02-22T23:53:55.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3798232,\n \"message\": \"What Is the Optimal Screening Strategy for Early Recognition of Spondyloarthritis in Patients with Acute Anterior Uveitis? - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9081562,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/BpF25DauQDWzcvukuLvn_ACR_1065159_1.jpg?file_detail=88f505892a0444381b7946cefae1382ab65363778521f20b76c8b7bc2d715a0c1f05edd4f3e3e2318272c77dd7259386b78ace116d25c34d5d64d8342fdaf4afdb0879ba4c851d76a6e4a6c7f4fbc0516957d2f0b6c48fd3e53107d575c03302f9553e46f868dc9a2a4e07f575828824:a904d14c604bd5eea88d3a9c8ff973c6:ec636b40b819816d9c37dad3ff8b3457&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjY0MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.POeKVrqNK6sEZKmVis0McxcV2Agob5nJK_wdKX6g6_I&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"What Is the Optimal Screening Strategy for Early Recognition of Spondyloarthritis in Patients with Acute Anterior Uveitis? - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The diagnostic delay remains long in patients with spondyloarthritis (SpA), thus effective screening/referral strategies for early recognition are needed. Up to 40% of patients presenting with acute anterior uveitis (AAU) have an undiagnosed SpA [1]. The Dublin Uveitis Evaluation tool (DUET) was presented as a referral tool for ophthalmologists [1]. The objective of this […]\",\n \"url\": \"https://acrabstracts.org/abstract/what-is-the-optimal-screening-strategy-for-early-recognition-of-spondyloarthritis-in-patients-with-acute-anterior-uveitis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-1e2169e7-b602-4c25-8dff-2a6d0c0e10d9\",\n \"slug\": \"secukinumab-demonstrates-rapid-and-sustained-efficacy-in-ank\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T21:02:03.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072186,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/k0y58SwQQb6ixPZyzcYc_Paper_64689_abstract_100973_0.jpg?file_detail=bee53deaa3780786c0696860156c088e3fcd17ffd9b2a6fa58a1bfdaa711d0c5042b09562caff305712551d32397fd235c1ba99bad2e7f069a8cc84222028d8fae1f33f74adf46a93bd49e18389dbeff24c1b2cd23cf3ef5c45021f50d3ed3953564d95c958ceb08061ca53d910546abf477604a14983aacca997bee01062494:2af37483ce9466391c57b86404cdba5a:fc86276edc584bea5a86b9189955ac69&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjY1NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.J6VoSuXThNh46Qp27-aXhEwIAnSHKeyl7zgJeExoRe8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Inhibition of IL-17A with secukinumab is an approved therapy for patients (pts) with AS.1 It has been previously reported that response rates with TNFα inhibitors (TNFi) are higher in AS pts with elevated baseline (BL) CRP levels;2-4 however, this relationship is unclear for IL‒17A-inhibition. This post-hoc analysis assessed the response to secukinumab treatment in […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-demonstrates-rapid-and-sustained-efficacy-in-ankylosing-spondylitis-patients-with-normal-or-elevated-baseline-crp-levels-pooled-analysis-of-two-phase-3-studies/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109111783\",\n \"publishedAt\": \"2022-02-19T21:02:03.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787262,\n \"message\": \"Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072186,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/k0y58SwQQb6ixPZyzcYc_Paper_64689_abstract_100973_0.jpg?file_detail=59027f95ad9c79d8a625e4774e64e7de05d7f0273fb03c09744ef447987182e01045955cd6388d18818abe42b75db695760592f9bc6814d492b672ef1c5e1ae20e797d6c7ef1036675f03bd8ccd37249d61cdb1e13e366471383ca499e8b0f8c212e06b220568e0dc6299ec4a5dcbeb0062d826f933ef3e3987f13fada9f7659:cdb64b4bd48efeec376c2f64e87e9e07:1344960e7fd23bff7e7cebd6af145b44&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjY2NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.k_WHGJHBrt31XZDaIckYLusEveycF64r11sqbIxlrZI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Inhibition of IL-17A with secukinumab is an approved therapy for patients (pts) with AS.1 It has been previously reported that response rates with TNFα inhibitors (TNFi) are higher in AS pts with elevated baseline (BL) CRP levels;2-4 however, this relationship is unclear for IL‒17A-inhibition. This post-hoc analysis assessed the response to secukinumab treatment in […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-demonstrates-rapid-and-sustained-efficacy-in-ankylosing-spondylitis-patients-with-normal-or-elevated-baseline-crp-levels-pooled-analysis-of-two-phase-3-studies/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-1a52313e-5a5b-4b35-98e3-164f4f12ebd0\",\n \"slug\": \"clinical-and-imaging-characteristics-of-spondyloarthritis-am\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T12:52:59.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Clinical and Imaging Characteristics of Spondyloarthritis Among Crohn’s Disease Patients - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9070927,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/uNolizCpQjOVRTDtyXOs_ACR_1057054_1.jpg?file_detail=ac85e998936f42bcf90cfa1119a92286e31144604251d9c43d2387b148e43d53471e4a5667b09bcf2b0822a9e77b5eae1bcb477edece6542ba06b9f768ff02c13d954a1bab1126b1c5f908b4fc6cca0e3ca7ac2d51d79099c3c5b9bf117445ec523fc50a73f8cac62f77e70e73b6dbc7:b941055b319294841bc3a6bebfcafcf4:25a62ea440449391f236f18c703ee618&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjY3OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.vgt5A8sfeGofZXp1wVRzXQDgH4StqIqVWk8oIwXgDTQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Clinical and Imaging Characteristics of Spondyloarthritis Among Crohn’s Disease Patients - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Inflammatory bowel disease (IBD) affects up to 1.3% of the population and is associated with musculoskeletal manifestations including spondyloarthritis (SpA). Axial SpA (axSpA) is estimated to occur in 3-10% of IBD patients, but variation in imaging modalities and diagnostic criteria may underestimate the prevalence. Early recognition and identification of inflammatory changes on imaging can […]\",\n \"url\": \"https://acrabstracts.org/abstract/clinical-and-imaging-characteristics-of-spondyloarthritis-among-crohns-disease-patients/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109110545\",\n \"publishedAt\": \"2022-02-19T12:52:59.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3786034,\n \"message\": \"Clinical and Imaging Characteristics of Spondyloarthritis Among Crohn’s Disease Patients - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9070927,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/uNolizCpQjOVRTDtyXOs_ACR_1057054_1.jpg?file_detail=cd3afbf95e23c05b0c2f02275a607a8230d131e108c275462740b518311de251fbec957f6c8fae1cfd6e734245468c756e33b1151416646c3622c083a165a7f017eff9cfabcf09307509d97cd820153f94bf1ba901feab7b059b16890f9663e5deea1c86cdd3c9e4573b99df8d76d1d8:12c80201bc536d7978948c6456dfb3e5:fdabeee9d94a4b62bc880b1808520482&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjY5MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.RdwhjwcPetS2zRqUnnn4CytfY_-RGIaXKy3Lv5i19E8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Clinical and Imaging Characteristics of Spondyloarthritis Among Crohn’s Disease Patients - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Inflammatory bowel disease (IBD) affects up to 1.3% of the population and is associated with musculoskeletal manifestations including spondyloarthritis (SpA). Axial SpA (axSpA) is estimated to occur in 3-10% of IBD patients, but variation in imaging modalities and diagnostic criteria may underestimate the prevalence. Early recognition and identification of inflammatory changes on imaging can […]\",\n \"url\": \"https://acrabstracts.org/abstract/clinical-and-imaging-characteristics-of-spondyloarthritis-among-crohns-disease-patients/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-369dc019-0484-417d-8c0d-86b6a7430a92\",\n \"slug\": \"prevalence-of-paradoxical-psoriasis-after-exposure-to-tumor\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-20T12:29:01.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072713,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/qp4HZX4gRqqzhwZ6DwbQ_AbstractSubmission_812342_1.jpg?file_detail=66a50a3cb74c575c3e5146c4799e2514172092edc63732d5ea8c0622d4a4289d5c48083abfbdea32965ec993094fe55f506e8b4472a184b7f1cd6c5964e3d30c84bec26c25ffa67fab099fe50fd42f72b59031536a9dafcdbad36637ed82e817bc51e122fc21c3df7733a7a3af3bd5ad:9b6cc38d7a5fda4b4d8453a41fceb5eb:0bf09cd87cde0daf425705cffaa8632e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjcwNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.FBmEuJnJEvAzTnMwAgVKiwI9gcNCTj8H91XaoUDpOUQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are lacking. Most case series that are available describe the disease course of psoriasis. Recently the relative risk of psoriasis was shown to be increased in children with inflammatory bowel disease […]\",\n \"url\": \"https://acrabstracts.org/abstract/prevalence-of-paradoxical-psoriasis-after-exposure-to-tumor-necrosis-factor-inhibitors-tnfi-in-children-from-a-single-tertiary-center/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109112244\",\n \"publishedAt\": \"2022-02-20T12:29:01.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787721,\n \"message\": \"Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072713,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/qp4HZX4gRqqzhwZ6DwbQ_AbstractSubmission_812342_1.jpg?file_detail=70f30fdce1b00c47264d31ee629599f72b7ebb81e0c3801ed24ec5d1161a86780c7b0889b5504f2d8fb5f9c7369c8ff69b68d71307640a1adbb5796c5213301d8d7e2de073c700eb7e4133cd4d87acd9c8a65d5f301aacc5e2e95050bf2cf6568901d6c7466f0f2c84a7b97a8aaadc07:aff8e864b9a92ae457cab8ea607689b5:db77d58a0dca96979815a7179a4b9a40&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjcyMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.SOkXBbC0mTKRrp3pLYbPfNrPXp8o8XSf7i8801Keyao&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are lacking. Most case series that are available describe the disease course of psoriasis. Recently the relative risk of psoriasis was shown to be increased in children with inflammatory bowel disease […]\",\n \"url\": \"https://acrabstracts.org/abstract/prevalence-of-paradoxical-psoriasis-after-exposure-to-tumor-necrosis-factor-inhibitors-tnfi-in-children-from-a-single-tertiary-center/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-1033ebf9-92bf-44a7-b01b-85a8d20ebcf9\",\n \"slug\": \"efficacy-and-safety-of-risankizumab-vs-secukinumab-in-patie\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-06T12:15:20.000Z\",\n \"duration\": 60,\n \"title\": \"\",\n \"message\": \"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018511,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/P60uTOLSeOLNCYNt6nCT_pubmed-meta-image.png?file_detail=83b03c3ca0db9116ccd2875128c171e176f46dada7e800da12482636d44bc11bcd02e3b1d717140d517c8ac40c96d241f7b6e6190fcf7d0c2564ee434eef63e661fe0bf3b0968bb5ef446f503e25057717fd902d64602fc11b706529c01fcf2149ba3cd2c8f824a0e5df0d18c97ca642:abb8a292482724a58416a12cdce1ed91:3ae806bca261402254ec4926ae371068&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjczOCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.WvTCNkdTAbm0f5JwsOcBuuhhmcLbnlntmTr2af0fRCI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial - PubMed\",\n \"description\": \"At week 52, risankizumab demonstrated superior efficacy and similar safety with less frequent dosing compared with secukinumab.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32594522/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109054435\",\n \"publishedAt\": \"2022-02-06T12:15:20.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728953,\n \"message\": \"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018511,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/P60uTOLSeOLNCYNt6nCT_pubmed-meta-image.png?file_detail=25da5fd5e918c63c7f0266558191e77cd9da25b701a7a054f7b695dff6cb01724136256ec6bea0dff8e49f1f6aa5eaa7d227a875de33cbc456088da713ad8abb7a05e90d91683a1add70dc3050661188f793c5202ed98981a5a0bc584b81a9740ec84ee8678c77133cecc3a014ac8977:bb6c071fd0de0880b7f378d783da659b:ea361b27947afc5c8ca9df87102ae839&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjc1NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.NNxdrLnn0IMsBeGTVdmDQfHNmGzdpBv2K6TIHH-k6VQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial - PubMed\",\n \"description\": \"At week 52, risankizumab demonstrated superior efficacy and similar safety with less frequent dosing compared with secukinumab.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32594522/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-0822a9ff-7a1e-4168-b01b-605e77402347\",\n \"slug\": \"do-patients-with-non-radiographic-axial-spondylarthritis-dif\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T12:35:44.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Do patients with non‐radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9017724,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/xXJFmKcjTZWITMJLhtFC_acr.v64.9.cover.gif?file_detail=efff6ba2362387511f24f30e18f327c523b74c0c85980a5ba46465e4b01b410a88cf6ea2f2cd62dd49168127f71ec1b5d45dc9b0cf351478beeab7ed7ad6ee303a90d28f6885abc88135d124dc7e8206aba99de2434dd5074d88b37bb2b531182c6c9b7940c7db90a024341c585539f3:8bd80981454219e5eab3f7bd176946dd:bd97c129432e6c9542ed192cf72934b8&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjc3MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.5e3XEAchaWtbNLBUyc4ZeAj1n4DM3SeAhbIFWEcGVSE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Do patients with non‐radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?\",\n \"description\": \"Objective\\nPatients with axial spondylarthritis (SpA) who have structural changes in the sacroiliac joints and/or the spine have been classified as having ankylosing spondylitis (AS), while those wit...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/acr.21688\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109053667\",\n \"publishedAt\": \"2022-02-05T12:35:44.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728198,\n \"message\": \"Do patients with non‐radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9017724,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/xXJFmKcjTZWITMJLhtFC_acr.v64.9.cover.gif?file_detail=ba89146b4251cce804e62c6a6da082d10813f859ac272b160018ee4f1e81b72f107aa5c515fde446746cbaab7134a580654781af125560c2d21ab577769d1d5469ee4fe256aae7bcbeef29dde1b80be69fcb6fd6d98f68e782c11a6ca09b73600dc8e4df1503928568bdabe3178a39d2:5fa242a02e69af6c3ca0638fd088df1b:eb887f66d3ce5345d68de91776eeac75&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjc4NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.l2yh4tWIM9eS0W_DuXxa16JN95oLF9EPl5ePdwAX6DU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Do patients with non‐radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?\",\n \"description\": \"Objective\\nPatients with axial spondylarthritis (SpA) who have structural changes in the sacroiliac joints and/or the spine have been classified as having ankylosing spondylitis (AS), while those wit...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/acr.21688\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-0911e8f8-ab49-43f5-9900-60a096fef9c2\",\n \"slug\": \"secukinumab-for-ankylosing-spondylitis-and-psoriatic-arthrit\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-07T10:18:48.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab for ankylosing spondylitis and psoriatic arthritis\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9022517,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/3KFla7LSAlQuaghJ6J5g_pmc-logo-share.png?file_detail=c2427ebda96e8f35a2af8e7388594e5158c9645e7234a57cb4f4aa7689c11bcfaddb6da913e522da4b9716e2674ee1b3cad0800b13c54f6e10dd65039d0e93beeaa942a7f7c4fae792f9c911530d0fdedd62353dfb65e02285ed2edc961f8ddc02e8faef8434d7f8017e57cfc8c4704b:a73c8026ffa895bd5bb55de96e8b524f:7c26fe2b173e93da95ec37f9c253e956&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjgwMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.0OZMxo4hydYbSDA067FT276CLYTy0fvInJjj8uV2f1c&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab for ankylosing spondylitis and psoriatic arthritis\",\n \"description\": \"The treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) positively changed since the introduction of anti-TNFα drugs. These treatments were shown to reduce the symptoms and signs of the diseases and improve the quality of life. ...\",\n \"url\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5085310/\",\n \"siteName\": \"PubMed Central (PMC)\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109058502\",\n \"publishedAt\": \"2022-02-07T10:18:48.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3733016,\n \"message\": \"Secukinumab for ankylosing spondylitis and psoriatic arthritis\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9022517,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/3KFla7LSAlQuaghJ6J5g_pmc-logo-share.png?file_detail=18441c969c9b01fabc73b4b07d123569e52500c45ff273523810d291685f138f481200645f8ee2b6fb85ee531168dd76b20d397de610d6ac309a25245228fa4a2395cf11de672c4de7c551f50277ec79ecb555db5876b1172856941a049899da43593512023cee88a1d475e4c489a983:f873bfab3e81a08f8a57a764b961ea3c:04753da2bd21a72479e5711d2b350cf6&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjgxNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.0OHj0Vo2RBGC3xs_li9KUfvGTgAYOK6IlV3EFEZlSMw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab for ankylosing spondylitis and psoriatic arthritis\",\n \"description\": \"The treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) positively changed since the introduction of anti-TNFα drugs. These treatments were shown to reduce the symptoms and signs of the diseases and improve the quality of life. ...\",\n \"url\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5085310/\",\n \"siteName\": \"PubMed Central (PMC)\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-30521604-adde-4a6e-9d5e-0dc58689a8bc\",\n \"slug\": \"systemic-pharmacological-treatments-for-chronic-plaque-psori\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-27T00:41:16.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9094248,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/YfNmGZsQ9S1QSvGFAUi1_pubmed-meta-image.png?file_detail=07dd7a41749e9da498fdada0f42c9b59d886e70a36f3e447bd75c18adac46dc542b86300abbfc137909320ec99c072307733e833df21fe0ee30fd4503baadf8822d719a5962cfe8e45f1ff99337b68058dee258e436cbfac3dc24ff8c948ffbe44d8237fc510f99d4efd96492738197f:f95c27b245344cdbe58f1e233de3c51e:515743ee6f6f17bc11401a15a9521ac0&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjgzMyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.5i4cEsLhojeTN4PeQvC-k6YbLk1DDcvZIigkiVnVKtg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis - PubMed\",\n \"description\": \"Our review shows that compared to placebo, the biologics infliximab, ixekizumab, risankizumab, bimekizumab, secukinumab, guselkumab and brodalumab were the most effective treatments for achieving PASI 90 in people with moderate-to-severe psoriasis on the basis of moderate- to high-certainty evidence …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33871055/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109136724\",\n \"publishedAt\": \"2022-02-27T00:41:16.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3812051,\n \"message\": \"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9094248,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/YfNmGZsQ9S1QSvGFAUi1_pubmed-meta-image.png?file_detail=ec087052a183345c7cefc7b0865b2166f7bf19f3c2f7bb6af8021657bb02f5c7577d82db002652ac4b8aaa055493d5d2541229c26631a404f7703f8bdfcabe5901d6a14eedefb25ace70f7869f382fc9cc6ee0040279d1280b7aa17d7c991b53652af0086ba4473742a90042df692aa8:9f243eb8804f8083804ecafec7601bef:766e5323488d2910c8f584293a9c093c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjg0NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.-vgV47HYRuiLHbCmAuE_yz1kvhag0m37enB3Iz_gv9Q&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis - PubMed\",\n \"description\": \"Our review shows that compared to placebo, the biologics infliximab, ixekizumab, risankizumab, bimekizumab, secukinumab, guselkumab and brodalumab were the most effective treatments for achieving PASI 90 in people with moderate-to-severe psoriasis on the basis of moderate- to high-certainty evidence …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33871055/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-39b32dfa-1ffe-427b-880f-a740e2c0c67a\",\n \"slug\": \"treat-to-target-study-for-improved-outcome-in-polyarticular\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-02T00:28:56.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9102772,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/wkouKOWrTFK9KNvj9mpr_abstract-business-concept_7JFweW_L%20(NXPowerLite%20Copy).jpg?file_detail=8d07306a709f7742e242c79be74fb24c483c74f748b3e3b9fac2628825d99bc76803dcbae0036e62007635dfa48022caedb39a5c085bada1c703da06d326c0f81c17a7ab0263c16e78b8bd93a52ec4e05868ab417866599dff5329d0f80e1326c6106e5156e9afcca4e6d297c840f4625aede92fcc1907ed8af7d6534a62fc1d4446ff154759746eff09d09e0a8b7537:6649a8e378b1fb0af708e1012b07c6fc:1bd26d0084f2170ce13625f3de1a1aaf&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjg1OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.p9lX6MqYSXUJlBqN8Gk8P6HhTaCcPhtn19WE-g0f_m4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most prevalent chronic diseases of childhood and adolescence. Evidence suggests that early effective treatment is important to minimize the burden of disease during childhood and in further life. We hypothesize that a guided treat to target (T2T) approach as recommended by the German Society for Pediatric […]\",\n \"url\": \"https://acrabstracts.org/abstract/treat-to-target-study-for-improved-outcome-in-polyarticular-juvenile-idiopathic-arthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109146100\",\n \"publishedAt\": \"2022-03-02T00:28:56.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3821367,\n \"message\": \"Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9102772,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/wkouKOWrTFK9KNvj9mpr_abstract-business-concept_7JFweW_L%20(NXPowerLite%20Copy).jpg?file_detail=d01df15b52532cda0666f9c332012325d544ab90135159e3c81c1e92ff564f3a7b7fe38104ac083b532ec21ffeeb3080c2c3af9f65ac4e0e9d2f1ba1dd6971c4586a93b4d56d1354217f0ec74ef0743bee6e7834d242d53d840c482be7b382952b28e861b5e093920dde83b41690a7b5d36325af79752cbc37e709fe58d0720670e7b28bd00430d5e7187b1903a3e483:0e79b1538e05d6257263c8654ce78cae:855852aa24cae1cb07d7484206b2327d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjg4MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.nqmjiojhF7WFsm8EueQjJNWlBJEVpZJJvu9qiFmXMO0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most prevalent chronic diseases of childhood and adolescence. Evidence suggests that early effective treatment is important to minimize the burden of disease during childhood and in further life. We hypothesize that a guided treat to target (T2T) approach as recommended by the German Society for Pediatric […]\",\n \"url\": \"https://acrabstracts.org/abstract/treat-to-target-study-for-improved-outcome-in-polyarticular-juvenile-idiopathic-arthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-54db9e9c-6c9e-4d4d-94d8-eadea65b19f4\",\n \"slug\": \"nail-psoriasis-in-older-adults-intralesional-systemic-and\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-05T12:05:14.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Nail Psoriasis in Older Adults: Intralesional, Systemic, and Biological Therapy - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9114244,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/zEFd0IODSuiZsdb4cieF_pubmed-meta-image.png?file_detail=14b69edb1e083f281d47df7ebc10f5984905508176fbeeca77d84f6fd537fc98356d061d37b2678e96b676fc7ccadd658f486e97454cbac5329a165837266f2824454c62bb26b5cd0dc9f2061508a3a48b10114bff71f48739af3613ed10792f16b2f5e01dd174a680081dc7ad4786e8:b543490572ef5ff254520576d6a7f14b:0fa3fdc267caaa01244e543e8b61f276&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjkxMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.1DMUfP6uGHrrktTsIuYYqggwRq2D4AcLpFbswq05QpU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Nail Psoriasis in Older Adults: Intralesional, Systemic, and Biological Therapy - PubMed\",\n \"description\": \"Psoriasis may affect the skin, scalp, joints, and nails and is common in older adults. Intramatrical injections with triamcinolone acetonide are safe and effective in older individuals. Conventional systemic medications are relatively effective, but side effects, including laboratory abnormalities a …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33745633/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109158865\",\n \"publishedAt\": \"2022-03-05T12:05:14.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3834045,\n \"message\": \"Nail Psoriasis in Older Adults: Intralesional, Systemic, and Biological Therapy - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9114244,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/zEFd0IODSuiZsdb4cieF_pubmed-meta-image.png?file_detail=3905b04212ea2cd8db30ef658f72f30fd9c24b9bf3230c27f3692af641eb24784b7d2980be54a642a7d006bea343f6ae9acf889c45c14b482c2333839303199f14030d7119a203223ccc66de5000d826fa6a5fbc4629d3eb4bb7b39a58ef46631f71906f9a64729f9c4edaf5fddb40e7:0fb44d675a1f2c8b0f55bb9e18717fb2:4850e6c541c4254ed304195c5e987108&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjkzNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Slf0Y8hByS7bV8f9qcQFrkRvTSHJ9sM53KaM4cTDJSA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Nail Psoriasis in Older Adults: Intralesional, Systemic, and Biological Therapy - PubMed\",\n \"description\": \"Psoriasis may affect the skin, scalp, joints, and nails and is common in older adults. Intramatrical injections with triamcinolone acetonide are safe and effective in older individuals. Conventional systemic medications are relatively effective, but side effects, including laboratory abnormalities a …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/33745633/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-385dcf1f-7b8d-4b9e-b6d1-495e82ce7c8b\",\n \"slug\": \"uveitis-as-first-symptom-in-patients-with-spondyloarthritis\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-02T00:05:06.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Uveitis As First Symptom in Patients with Spondyloarthritis. Data from the Spanish Registry Regisponser - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9102749,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/ncpliv2WTpqeIJ0THwx4_1639_Paper_72356_abstract_109297_0.gif?file_detail=1fa8aea113f396a822ca23a8aa5b13aa5eff824009cb0799145c88bf25fa75613789049e28fb0b2cf42ff380a1df334dd2434f75c7bac594d3fc415160591419e7824542dbd3408bb388c65790bda5a895c7c764f1a8a40fd3db33890cfa4cf86aa51dfeedb0cd8c4f60987e09e3aa81a4fc849f287b4e376eaf957e7d038b61:ee7c03b0bd3e24c720668b56ba26599e:2e72fc76c90dd722415860c0ceb18aa6&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjk2NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.jE3mgUO0ll2OGrLblMPpZoMcYNFnCuLFpFaK84O-l_w&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Uveitis As First Symptom in Patients with Spondyloarthritis. Data from the Spanish Registry Regisponser - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The objectives of this study were: a) to assess the prevalence of uveitis in patients with Spondyloarthritis (SpA) in the Spanish registry REGISPONSER; b) to describe the moment of appearance of the uveitis regarding other SpA symptoms and the date of SpA diagnosis; c) to evaluate the impact of the moment of appearance of […]\",\n \"url\": \"https://acrabstracts.org/abstract/uveitis-as-first-symptom-in-patients-with-spondyloarthritis-data-from-the-spanish-registry-regisponser/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109146076\",\n \"publishedAt\": \"2022-03-02T00:05:05.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3821343,\n \"message\": \"Uveitis As First Symptom in Patients with Spondyloarthritis. Data from the Spanish Registry Regisponser - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9102749,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/ncpliv2WTpqeIJ0THwx4_1639_Paper_72356_abstract_109297_0.gif?file_detail=32b0ca942d2cd83de6ef6120cc90f145261537fb3ec5f09866534b1b9d3d5d411f0bf5af243c90f9469c54476723b927304a717ec8f81b66196d851147c5837fe6b70ef6fc1ca86ee97561a585ad513fd3c722ec4f67a422accb16c69ed1398ac747c15288a957ff8076676b5c542fe2aa8ce06c089a3cbf4013e5ef2fc59f45:c5fa6b0a6dcbc6e5000f834197c7a0d4:4892b88a03ab654696a99dda1a01c93f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQwLjk4NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.WJwokT19cQ6QjAMJTMVxwZZTyOgxGPXGzrGynEjdrl4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ0fX19XX0_&Signature=QZ1QK-LNfcB1UdagNZeLsZsXL1f2PZMccAVlTOWJYHlHHQ6rRQh9t-o71rxKN1oyRykKsZXhSSpBhTD4qZNF4lwjSoQdU~~rDbVL12Hoe4FU9MWD-Xg3b3vJRGaY30j7IcJFZJqsu52w8SkBweGmpME3oJc7QVa5t-bO8OrQykn3btsHz8De7uNP982Y95efNAuv19ZUd9AzigBg8-~ICloZoh2yjd4~QNndeZiPnPz9Q6xn-hDejJiAtg61u69MU1Q6pD4NDqLjOrOXC4TkN1e4sYpi5nHNoZTKqvndkHUE~O0vuVo7cDbfD~w6Zi8iA5akVV679cDachqviAgx1w__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Uveitis As First Symptom in Patients with Spondyloarthritis. Data from the Spanish Registry Regisponser - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The objectives of this study were: a) to assess the prevalence of uveitis in patients with Spondyloarthritis (SpA) in the Spanish registry REGISPONSER; b) to describe the moment of appearance of the uveitis regarding other SpA symptoms and the date of SpA diagnosis; c) to evaluate the impact of the moment of appearance of […]\",\n \"url\": \"https://acrabstracts.org/abstract/uveitis-as-first-symptom-in-patients-with-spondyloarthritis-data-from-the-spanish-registry-regisponser/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-5aecf862-e333-4332-a099-dceebaaead02\",\n \"slug\": \"systemic-pharmacological-treatments-for-chronic-plaque-psori-systemic\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-06T12:57:00.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9116116,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/DKzIjazQQ03evtDfEKdk_pubmed-meta-image.png?file_detail=0e1bae02466e84e3670bfca03278c5110dd74cf9aedd6c0cfde8e5f8b7f710d7764024f00fd4c96979648e9c62188da7e719390522d02da8770b1f67d3a9c88337818f87275ab22db0b16dae0089ee6443e33be4bb231649dbf2ef92fa322d64c3bd6898ed025c16c71031e16810d741:6cd9c3814e18a2c9a6b4d8eaafd6a779:fcbfdcc0b90225c0f1809d3a1a0d11d6&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjAwNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.q4z2uHprRGpuM8JuAA1d9tOyj4-z5Prboe7kOspWQKI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis - PubMed\",\n \"description\": \"Our review shows that compared to placebo, the biologics infliximab, ixekizumab, risankizumab, bimekizumab, guselkumab, secukinumab and brodalumab were the best choices for achieving PASI 90 in people with moderate-to-severe psoriasis on the basis of moderate- to high-certainty evidence (low-certain …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31917873/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109160673\",\n \"publishedAt\": \"2022-03-06T12:57:00.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3835850,\n \"message\": \"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9116116,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/DKzIjazQQ03evtDfEKdk_pubmed-meta-image.png?file_detail=4e945ebdd2a2c153f5ea4ed696da6b18c11e167c7295a8582946e96ecd59c944f64857f86931bb394470fe2524af1ba33079b4b83aaaaf0da24b61ab65e9b979b4b7fed8bfe33e12d4b2e9ba3034966c8b602b382e722d5244bc454a32bbd68f3b9769667598056540379be3a8ba548b:250bf08cabc317e408233223b30883eb:6c49379af80d801be2336b671cfe4eea&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjAzMyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ji6K6XSPfQP9mQBbAwnDi6KIa4bM0IUlPs7GyA8A7Ho&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis - PubMed\",\n \"description\": \"Our review shows that compared to placebo, the biologics infliximab, ixekizumab, risankizumab, bimekizumab, guselkumab, secukinumab and brodalumab were the best choices for achieving PASI 90 in people with moderate-to-severe psoriasis on the basis of moderate- to high-certainty evidence (low-certain …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31917873/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-660618ed-ee92-4a36-a0d6-9e5dfb790784\",\n \"slug\": \"cost-effectiveness-of-secukinumab-as-first-biologic-treatmen\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-27T16:26:25.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9095364,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/ce2QXEWZQoqTfAbQfWGm_pubmed-meta-image.png?file_detail=69897c9240055c9a7040b468b018dc9698d994e4497d6e1fe3e696d54ecd6bdada624e6a2d3afed1ff82323f4236aed3e2cf1deffd9ce851986bfc4550137fadb23ef1517c39fc51dc4fe29c1c0cc014f971471e483e5be067cfb510fbb767ecd86fed65c627f690860c71cc9c579167:07b9cf369e29cdb11ddb7495e0d8acaa:a772d7ef9c214b502c8d54924b192d4a&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjA1MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Av3l6sRng4YZmiVCMQHgtL2_SUjQP-qgs4sZds7Pwvw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany - PubMed\",\n \"description\": \"First biologic treatment with secukinumab for moderate to severe psoriasis is cost-effective, with lowest cost per responder compared with other biologic treatments in Germany.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/29729105/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109137796\",\n \"publishedAt\": \"2022-02-27T16:26:24.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3813116,\n \"message\": \"Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9095364,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/ce2QXEWZQoqTfAbQfWGm_pubmed-meta-image.png?file_detail=2a404edcf43f7c44251488dc5c99112b3e7af0fe0680bdac829f97997fb30933ab0887cdf0ea1163b3f8ac20af18c414b611a520ae61b8b3d974664b0c3032c8a2a782b4c6f4e014a06b5bac327de9a4102b992e261e2a3205fb10e8938f69ee2c2facb3e8b03a57ac7f9a137b2f97f2:5c88932a21ce56755afef1c0007b1bd3:82c4003940b8e7ebd059c2af83f983ff&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjA3NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.jJtMZ0uEkK2xXmKAnJxWoR8QkgpTyZb_QnKMeeO1AX0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany - PubMed\",\n \"description\": \"First biologic treatment with secukinumab for moderate to severe psoriasis is cost-effective, with lowest cost per responder compared with other biologic treatments in Germany.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/29729105/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-67d43799-2a20-46a8-9b96-888391490e67\",\n \"slug\": \"monoclonal-antibodies-a-review-pubmed\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-06T12:37:40.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Monoclonal Antibodies: A Review - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9116056,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/dDNKapRTKm6qZsh2X4AH_pubmed-meta-image.png?file_detail=1e3112ff9c7add77cd032d7e455edf1eb058cfd84ae3e163afdb1d17aefb12caad248789818c55c2d5bc70c20c4b6acb45497cc5a895600765b25a5420f86ef0486b57a72ef20c5be3e6d0740e2fe6cad41edef422f328510b13c2012159fadc7b96b0b7791f5c9c5e85ec58f85e922b:1bbe30e1d529b115c58e99d34a690022:dc6cc358bacfb71db865948ca7a92846&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjA5MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.c7rN8_U6IjXlKklZYszb0M14S40-9GgMHM_dTeTOwd8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Monoclonal Antibodies: A Review - PubMed\",\n \"description\": \"With the advent of fully human MAbs, the efficacy and safety have improved in the treatment of various cardiovascular, cancer, respiratory, hematology, autoimmune diseases and infections. The introduction of biosimilars will increase the affordability and utilization of MAbs in the treatment of vari …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/28799485/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109160616\",\n \"publishedAt\": \"2022-03-06T12:37:40.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3835793,\n \"message\": \"Monoclonal Antibodies: A Review - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9116056,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/dDNKapRTKm6qZsh2X4AH_pubmed-meta-image.png?file_detail=1de623c213545aae239d4c200c6a9fce3a1d9b523c2747e3ba30bdcb6f19592572fffc832b47cd9c6a5161fbf6b03fee391c94b7b77c3ac41218bafcf6666fc74a06658d5cf1ee40b6c6aadef18c14b824612316d5d798771ecab6ab65fe1e7a53425972ebcf985e9943fde49f4b7680:223635670886c8263b6fa8ead6885afe:054cd1a0c9d1eff5b4284fef287f9c65&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjExMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.nTkpyoi0VWOgytONeMfHLl2AqWOqCB-PaCx8qoOF_m4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Monoclonal Antibodies: A Review - PubMed\",\n \"description\": \"With the advent of fully human MAbs, the efficacy and safety have improved in the treatment of various cardiovascular, cancer, respiratory, hematology, autoimmune diseases and infections. The introduction of biosimilars will increase the affordability and utilization of MAbs in the treatment of vari …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/28799485/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-7601f065-0d03-4172-b44f-702f5164c1e6\",\n \"slug\": \"the-childhood-arthritis-and-rheumatology-research-alliance-s\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-02T00:09:14.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Updated Report of Baseline Patient Characteristics and Treatment Choices - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9102756,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/VB8ikpl8Qit8jsKtnfKE_2385_Paper_74566_abstract_115915_0.gif?file_detail=65c6c20eaea5e904b7da87e92c548a530f5378278c5f39e9600d56601ad6df006b03100b461e1ae0be050b0c8f766bc863b0b1d0b00e219977ccc7a8ddfd45e1383f00ba5a621ef23b5d2be32840855ff8ce4060a43fe1324452487ad64b85d335378b68569298672d66774438d02b0474607b2c433edaafeaa6002ae3ef4f6c:f66831f104df22bb9392a207e8b94d50:372d2ff3c98c61f7f6f5eb5a39629080&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjEyNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ndWb5op0iWHQBTjrCU9mj3m-OZ8cdRLcK4KMidryisk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Updated Report of Baseline Patient Characteristics and Treatment Choices - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: There is significant variation in the timing of when biologic medications are started during initial treatment for polyarticular juvenile idiopathic arthritis (P-JIA) in clinical practice. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed three consensus treatment plans (CTPs) that reflect the most commonly-used strategies for when to start biologic treatment. The CARRA Start […]\",\n \"url\": \"https://acrabstracts.org/abstract/the-childhood-arthritis-and-rheumatology-research-alliance-start-time-optimization-of-biologic-therapy-in-polyarticular-jia-study-updated-report-of-baseline-patient-characteristics-and-treatment-choi/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109146082\",\n \"publishedAt\": \"2022-03-02T00:09:14.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3821349,\n \"message\": \"The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Updated Report of Baseline Patient Characteristics and Treatment Choices - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9102756,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/VB8ikpl8Qit8jsKtnfKE_2385_Paper_74566_abstract_115915_0.gif?file_detail=0c0cf7741b5121b05147d003224cee863291cadb1a4947ae695e11b59d828dfb0d018594cb8217ceee5869238705a0f9e1ef2ef4fdacd5e79d20704175a24c9ea370dbd3a9372fe84bfa337c4f2b9587fd6c48978f27e0f055387871cda1d97ba9bcc2899aa11edc1530df669ab3f98b0a4c82229de733c7186123492a89f117:742b93a44eb200c6b6f6b83f064c787d:cb4846f35589635b9995ff32eed142af&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjEzNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.q-NqparxqjHa1f2ImeJ9YQLwefDEUYI8csMlVwEdTa0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Updated Report of Baseline Patient Characteristics and Treatment Choices - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: There is significant variation in the timing of when biologic medications are started during initial treatment for polyarticular juvenile idiopathic arthritis (P-JIA) in clinical practice. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed three consensus treatment plans (CTPs) that reflect the most commonly-used strategies for when to start biologic treatment. The CARRA Start […]\",\n \"url\": \"https://acrabstracts.org/abstract/the-childhood-arthritis-and-rheumatology-research-alliance-start-time-optimization-of-biologic-therapy-in-polyarticular-jia-study-updated-report-of-baseline-patient-characteristics-and-treatment-choi/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-7929b638-45ec-44b2-8f61-7ad7957684aa\",\n \"slug\": \"paradoxical-gastrointestinal-effects-of-interleukin-block\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-27T00:47:04.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Paradoxical gastrointestinal effects of interleukin-17 blockers - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9094260,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/eynegFUYQXaX25MeEALS_pubmed-meta-image.png?file_detail=72be885179752aa50a0fb3b49472cb6ce68a70b23318a81e3b354b2869c997f70cb1a20f74bb18e4b681be688f21e79e843634d2fa226d6174f8264ad2e907eec2fd1a451ec0e51e4151ebf66fae3e080af127befe9d3f114b2781b4411da8e46c31401b6255d48abb0f26e4be910d04:8f6fdbe132fd1d1004ec7a2ffa61bfef:8eecc60ea3b9fdecc33e934db02483c7&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjE0OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.QA_5sZ3Oh_7at4lAJfRBpWN8QPrXej7r_dPv5j4AeB0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Paradoxical gastrointestinal effects of interleukin-17 blockers - PubMed\",\n \"description\": \"Secukinumab, ixekizumab and brodalumab are monoclonal antibody therapies that inhibit interleukin (IL)-17 activity and are widely used for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. The promising efficacy results in dermatology and rheumatology prompted the evaluatio …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32719044/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109136732\",\n \"publishedAt\": \"2022-02-27T00:47:04.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3812058,\n \"message\": \"Paradoxical gastrointestinal effects of interleukin-17 blockers - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9094260,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/eynegFUYQXaX25MeEALS_pubmed-meta-image.png?file_detail=4f90e3e5b40aa7d5bec2f6504fa6e707a311753fbdc0d781960324e3e543d1879275b9201f6263fd0a8508ab9cb960cbd2373b006340fef19216aedb784ed0d099709c37e1758c4ba9e925a522ac5dd55665b6364be217360ba055d8f9ba083bac8626c52fce9629f545caf8f7b701dd:7db5164718912e2196cce2cfbe0b1d56:224faa269ab32f6b2a9aed6859a8d8f4&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjE2NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.AFNtLIiU5uDjCZoFns7HQcaWM76MYMp1OEaHfq3SWYs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Paradoxical gastrointestinal effects of interleukin-17 blockers - PubMed\",\n \"description\": \"Secukinumab, ixekizumab and brodalumab are monoclonal antibody therapies that inhibit interleukin (IL)-17 activity and are widely used for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. The promising efficacy results in dermatology and rheumatology prompted the evaluatio …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32719044/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-833152e3-64be-4f4d-a20d-cfe7671f3e30\",\n \"slug\": \"what-are-the-optimal-mri-lesion-cut-offs-that-define-active\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-01T23:44:40.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"What Are the Optimal MRI Lesion Cut-Offs That Define Active and Structural Lesions in the Sacroiliac Joint As Being Typical of Axial Spondyloarthritis By Expert Readers? - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9102689,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/eUlkRPV1TGikh2J5CxjA_graphicstock-city-scape-and-network-connection-concept_HdGlKwnvxie%20(NXPowerLite%20Copy).jpg?file_detail=2997ab2d67b61ae054a645ae6e5c368fc8ca206dbdec2254dc715bba00ad6c2e2dccb060b7a799999aa74c05b53cae6ccd8c4465728e13fad6d7dffdd94edbfad1563581761cee06c5b38ce2449ea80b5e14c637be839cbaa7564b1f0c9aad8d5520869ead1c54df1c517cb6c402759dd5ac3050c3083db7ef4fc8a17bc35ce6ed34591bdda61f17343760420a0215aaaca4302ae17ae80f500891854aa04bf6575db41a1572bed26cee9e89a2f9e010:1d152924c133c7d264f0354294224b94:a965c515e0ac4a569006e742bed1f53e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjE3OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Yb5Xla_rDnf_Tay-tw9A_Yf51rJul1BJb0ylJlAMCMk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"What Are the Optimal MRI Lesion Cut-Offs That Define Active and Structural Lesions in the Sacroiliac Joint As Being Typical of Axial Spondyloarthritis By Expert Readers? - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Defining what constitutes a definite MRI lesion in the SIJ typical of axSpA has been hampered by lack of international consensus for standardized lesion descriptions and definitions. The ASAS MRI group has generated updated consensus lesion definitions (ASAS_MRI_defn) for the spectrum of MRI lesions in the SIJ and these have been applied to the […]\",\n \"url\": \"https://acrabstracts.org/abstract/what-are-the-optimal-mri-lesion-cut-offs-that-define-active-and-structural-lesions-in-the-sacroiliac-joint-as-being-typical-of-axial-spondyloarthritis-by-expert-readers/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109146021\",\n \"publishedAt\": \"2022-03-01T23:44:40.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3821288,\n \"message\": \"What Are the Optimal MRI Lesion Cut-Offs That Define Active and Structural Lesions in the Sacroiliac Joint As Being Typical of Axial Spondyloarthritis By Expert Readers? - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9102689,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/eUlkRPV1TGikh2J5CxjA_graphicstock-city-scape-and-network-connection-concept_HdGlKwnvxie%20(NXPowerLite%20Copy).jpg?file_detail=f1ef9f2b198785a709f2570b1fdc1d2bfe01ca705a6a84f2921cf37564926000b2be37ff29a50d40f29e0ba365baa0d0cca7fcb5d015150241dfe021fa79b2f7fa3125d008971c27b80e1ac6fc38ba7c64728d1c68d32c9b364ee466b77bed9f1d35484c31f95a1b2310310f903a8c00d7e005b23391956200ef22f616fe7117a10dabcc2c47b243c494c131e55447932fce637d7919aaa5dcaca8514835e474738c695e2d4b80db09e64c0f724fccfa:f3efddebe68440a64817fa3c792b4633:05b9ffd6efa38ab6cbcc7e79866e6e71&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjE5MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.qEEQlRCr3uPn5FOYqG6SqMgEyc7O8Y-TgF9QK_wdCJQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"What Are the Optimal MRI Lesion Cut-Offs That Define Active and Structural Lesions in the Sacroiliac Joint As Being Typical of Axial Spondyloarthritis By Expert Readers? - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Defining what constitutes a definite MRI lesion in the SIJ typical of axSpA has been hampered by lack of international consensus for standardized lesion descriptions and definitions. The ASAS MRI group has generated updated consensus lesion definitions (ASAS_MRI_defn) for the spectrum of MRI lesions in the SIJ and these have been applied to the […]\",\n \"url\": \"https://acrabstracts.org/abstract/what-are-the-optimal-mri-lesion-cut-offs-that-define-active-and-structural-lesions-in-the-sacroiliac-joint-as-being-typical-of-axial-spondyloarthritis-by-expert-readers/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-7f0eca58-f3f3-46f3-9623-6e4d90bfa334\",\n \"slug\": \"ultrasonographic-evaluation-of-the-enthesis-in-patients-affe\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-01T23:57:04.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Ultrasonographic Evaluation of the Enthesis in Patients Affected By Entheropatic Spondiloarthritis. Focus on Distal Enthesis of the Patellar Tendon - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9102714,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/2K1MG86zTnKijnOZnN91_IMG_7700-2411%20(NXPowerLite%20Copy).jpg?file_detail=04516cd0d0ad208b9b4ef5599828ec7da2d94075a270937a6eeeedea29882202246f6e4e92fd9c7f56a9c3d8aea009fd8b2b74631f613d3a74da6fa764e50fde8e57246796c4f1a6cabcd4fa46f15004ea266bb970a8f5c5cd1bb4dc2cdf346ad73acdb4a40a41c2ddffd9972de7cf23f7c4189bedee929416e61c82e849479f:2f483a9d90e7df0188b920a1af2e3082:dad46655e4c54c57d23f5b717aecf3fa&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjIwNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.BAVaxN_CpxO_Ou6hgBo98IDRsic1RlY4RrIoj2ddFnU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Ultrasonographic Evaluation of the Enthesis in Patients Affected By Entheropatic Spondiloarthritis. Focus on Distal Enthesis of the Patellar Tendon - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Enteropathic arthritis (EA) belongs to the spondyloarthritis (SpA) spectrum of diseases and occurs in patients affected by inflammatory bowel diseases (IBD). Several works demonstrated that ultrasonography (US) is feasible, reliable and easily accessible means of detecting chronic and active entheseal abnormalities even in a subclinical contest (1,2) in SpA patients. Aim of our study […]\",\n \"url\": \"https://acrabstracts.org/abstract/ultrasonographic-evaluation-of-the-enthesis-in-patients-affected-by-entheropatic-spondiloarthritis-focus-on-distal-enthesis-of-the-patellar-tendon/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109146044\",\n \"publishedAt\": \"2022-03-01T23:57:03.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3821311,\n \"message\": \"Ultrasonographic Evaluation of the Enthesis in Patients Affected By Entheropatic Spondiloarthritis. Focus on Distal Enthesis of the Patellar Tendon - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9102714,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/2K1MG86zTnKijnOZnN91_IMG_7700-2411%20(NXPowerLite%20Copy).jpg?file_detail=7105d98d22f4a4ba6ea031ad6f6881bb31c273266cd5424092753a742f8d2d5af381641b08d680b980397b21741574b54d202cd886114110934d78308edaa686c7c7e02818ceb3013b6b2eabf207230efbdd5bbd97ad9302409b2e140c83eb6b0e34cf05e6f30e18d327464ec271313a6a66b1f169f557e0697ddcb879353ba0:5e8119bca708ca2ae1f9db7aad122d41:49d38073f6f0cfbc423f3c528e73a48a&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjIxNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.PXwmkX63ajAS2gfNX1K4tsH9yBzE9TlLLziFtYlj5EM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Ultrasonographic Evaluation of the Enthesis in Patients Affected By Entheropatic Spondiloarthritis. Focus on Distal Enthesis of the Patellar Tendon - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Enteropathic arthritis (EA) belongs to the spondyloarthritis (SpA) spectrum of diseases and occurs in patients affected by inflammatory bowel diseases (IBD). Several works demonstrated that ultrasonography (US) is feasible, reliable and easily accessible means of detecting chronic and active entheseal abnormalities even in a subclinical contest (1,2) in SpA patients. Aim of our study […]\",\n \"url\": \"https://acrabstracts.org/abstract/ultrasonographic-evaluation-of-the-enthesis-in-patients-affected-by-entheropatic-spondiloarthritis-focus-on-distal-enthesis-of-the-patellar-tendon/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-a263ad48-ebe7-4891-95ac-479d02abc81c\",\n \"slug\": \"brodalumab-for-the-treatment-of-moderate-to-severe-plaque-ps\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-27T00:42:15.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9094251,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/KVvmUBImReOQm0mIBKWp_pubmed-meta-image.png?file_detail=f084ac61e4ae31d4c7a358ab1c8ed11c3fb2d02be8867862840fe3d36d6a7609cb01bbc683ad8394e76fbf928f20def63d68ad846bfc0e06c6fe09683126632d6bb073fc08f6fc1cfce0f5eef1b1cf8ff445a7a29b02b4f664e2276b4ae15b2358b85a98de5514d246ac454c7370d605:935a726f1a2d9b5d9e8acd679c780fba:053e532fba098f180dc66ef91fe0e8cd&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjIyOSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.dgRun0cKv7JR9phtxBvxFeTtaWNIgsSM06iMqtE052U&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal - PubMed\",\n \"description\": \"As part of the National Institute for Health and Care Excellence single technology appraisal process, brodalumab was assessed to determine the clinical and cost effectiveness of its use in the treatment of moderate-to-severe plaque psoriasis. The Centre for Reviews and Dissemination and the Centre f …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/30112635/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109136725\",\n \"publishedAt\": \"2022-02-27T00:42:15.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3812052,\n \"message\": \"Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9094251,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/KVvmUBImReOQm0mIBKWp_pubmed-meta-image.png?file_detail=ef8b1cb74ac55797ccfc5e9166061dd673a3f84938fc454fa2dd4f0ef4ead8782b9286ae4df85d93efd47a327e4834ae75afe2489ea9c461f92722e39b2fc3e22e8105ef8a691cd704e46e8d1086da9e8aafef8edee438430ae4a3e1687884702ca552d1859778e05d3d609435154fd0:3548e274d6512af23e1b5583f26433b0:6df69b2aa5489bd0bcd86c842e6617b2&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjI0MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.RUpdYVPWetWK0zUG61KEyODDA19JOYGmvIVUEh7nUdM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal - PubMed\",\n \"description\": \"As part of the National Institute for Health and Care Excellence single technology appraisal process, brodalumab was assessed to determine the clinical and cost effectiveness of its use in the treatment of moderate-to-severe plaque psoriasis. The Centre for Reviews and Dissemination and the Centre f …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/30112635/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-63a6c1b4-4115-4801-8b06-24a1172d3df1\",\n \"slug\": \"pso\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-01-18T03:22:31.000Z\",\n \"duration\": 60,\n \"title\": \"PSO Cosentyx Data\",\n \"message\": \"PSO Cosentyx Data\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": null,\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109002012\",\n \"publishedAt\": \"2022-01-18T03:22:31.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3676650,\n \"message\": \"\",\n \"language\": \"en\"\n }\n ]\n },\n {\n \"id\": \"ECL-7b3525c3-eae7-4332-ae38-d8215bdb0c47\",\n \"slug\": \"mechanism-of-new-bone-formation-in-axial-spondyloarthritis\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-12T12:36:23.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Mechanism of New Bone Formation in Axial Spondyloarthritis | SpringerLink\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9043063,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/HzGIFtNNQgqGkEicvebs_11926.jpg?file_detail=7b8fee2c74f4ebc8fb68e422a82182c865c8b16ddb7b36169c161d97efe4692e34b874346be847b450cfd1adf458fe38cef71d518f5bed90d3e817bc69775192c6405eddcb0467157d12315ef22bfe096dda3b7123547416c94527ca9929764a:11bd7563b65f75bf46f7095db496a192:0108470ab7a2f9ccbd320a578f01bfe5&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjI1MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.q2aFyiq-WQQEC8NFUdEx8jSLt8vRoSNQhEQTcEYB51Q&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Mechanism of New Bone Formation in Axial Spondyloarthritis | SpringerLink\",\n \"description\": \"The purpose of this review is to discuss new evidence explaining the progress from bony inflammation over repair tissue to new bone formation in axial spon\",\n \"url\": \"https://link.springer.com/article/10.1007/s11926-017-0681-5\",\n \"siteName\": \"SpringerLink\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109080072\",\n \"publishedAt\": \"2022-02-12T12:36:23.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3755653,\n \"message\": \"Mechanism of New Bone Formation in Axial Spondyloarthritis | SpringerLink\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9043063,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/HzGIFtNNQgqGkEicvebs_11926.jpg?file_detail=8a082709e4bc464e0d0c7ae2303565456e107ad70dc90b36166c97668bea196ad8096f095f6cc97e7953fa34ee4ca93dded8993569e95da90862e9f684582c82f0b1a9e92c6bdee30a975b9021e2f12f9b2665c23204e47ec44c7602e8aa1a42:4eb03bfcb33b1406f56b95f074c5fb5e:bb29a9e5af5428ad9baefe0b0ef892e0&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjI2NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.tQ10h-mTK4ahuiPlS71S3TCLQDb08k5OQ7txg7b2MmA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Mechanism of New Bone Formation in Axial Spondyloarthritis | SpringerLink\",\n \"description\": \"The purpose of this review is to discuss new evidence explaining the progress from bony inflammation over repair tissue to new bone formation in axial spon\",\n \"url\": \"https://link.springer.com/article/10.1007/s11926-017-0681-5\",\n \"siteName\": \"SpringerLink\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-937769c5-bbac-47f0-967b-015e1c2a472b\",\n \"slug\": \"secukinumab-on-refractory-lupus-nephritis-pubmed\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-07T10:45:38.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab on Refractory Lupus Nephritis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9022653,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/mhBe6AzSEWpoOVK4PoMY_pubmed-meta-image.png?file_detail=91d7a492ef1e7f6105a4d60e5952dc95fe791d5a4a9d1d76fb4b733ee9df55d1c9a7c4ec60cabf4237e395457225e38191c9f793484b026a1ef382177e8b6a0a478d28346985c6f77a0a58faaee16c661f3c8782a96079b41c3ffcc6cc6dad832c25450ffb956b9e1d5cf9ce80d07527:04dcd7a12812eb02026c8cd2bc595d14:f4228627eb069f00af02cb5d9605b375&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjI3NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.U3jp3br8IDfheaysgpkL0zL8MUfY8WBNI8QPuHPqLhc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab on Refractory Lupus Nephritis - PubMed\",\n \"description\": \"Lupus nephritis (LN) is the most frequent severe organ manifestation of systemic lupus erythematosus (SLE). About 30% of patients are refractory to treatment. The authors report a case of treatment of LN with interleukin-17-targeted therapy, demonstrating its possible benefit, after reports of T hel …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34540426/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109058651\",\n \"publishedAt\": \"2022-02-07T10:45:38.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3733164,\n \"message\": \"Secukinumab on Refractory Lupus Nephritis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9022653,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/mhBe6AzSEWpoOVK4PoMY_pubmed-meta-image.png?file_detail=21ac45b09290b71c5b325e7029a71114ce09194085657caba8988b8951b2c9f892474f5e608f2f5fe124a9759bf0989ecde63359e1fedefea513d07cb8d772f73788d8e0f5a2283bc0fadbe3dc8fc2f0545973e2fbbca29b2c23ef00486390c24f5dcbbe39a8ba699eef652ef75e880c:7d96f50edef8e0052ebb9fd24632a1c5:27fe81ee820ed1861ae4623793119d79&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjI4NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.nmgS9yUvw2pF4zsK3eXG2SFt0nsNn8M5bFfIhT0QG4U&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab on Refractory Lupus Nephritis - PubMed\",\n \"description\": \"Lupus nephritis (LN) is the most frequent severe organ manifestation of systemic lupus erythematosus (SLE). About 30% of patients are refractory to treatment. The authors report a case of treatment of LN with interleukin-17-targeted therapy, demonstrating its possible benefit, after reports of T hel …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34540426/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-9e1bc3ef-325e-4ff5-9c6c-94d410d6fade\",\n \"slug\": \"enthesitis-from-pathophysiology-to-treatment-nature-revie\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-12T20:43:04.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Enthesitis: from pathophysiology to treatment | Nature Reviews Rheumatology\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9044957,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/PzKRP0rrQIqO7iEGKuEw_41584_2017_Article_BFnrrheum2017188_Fig1_HTML.jpg?file_detail=1216f5b071b36f0b39e7eae73cb364b8c57cb56790adaff71e12491a0022d91f2ba4c1c3b9bde1b129ad52d2a45cdcefae0a0b27fae7bb1a3852bdf35f9c9b87092edd6b6eaa23b5c4b78c6deb8c0a74d85caa196e5af837aa5bd210d58cfcfb1812b40829da2152a5534e9aa5c9b6302c4049aa24869ea8244e77a206873b9639200ef79541d9e6edd4d0f61340937e:d216d847a32b3a1e2cb6f763c665e3b6:adf9d18f5702751785909658dae44940&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjMwMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.jNnr4I79ettX0AVwshyCu-F0gMpZm_S83uTi-ypvCN0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Enthesitis: from pathophysiology to treatment | Nature Reviews Rheumatology\",\n \"description\": \"This article provides an overview of the pathophysiology of enthesitis, from induction and inflammation to tissue proliferation and bone formation. Building on these pathophysiological concepts, the clinical presentation, assessment and treatment of enthesitis are also discussed. Entheses are the insertion sites of tendons and ligaments to the bone surface and are essential structures for locomotion. Inflammation of the entheses (enthesitis) is a key feature of psoriatic arthritis and spondyl...\",\n \"url\": \"https://www.nature.com/articles/nrrheum.2017.188\",\n \"siteName\": \"Nature\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109081978\",\n \"publishedAt\": \"2022-02-12T20:43:04.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3757551,\n \"message\": \"Enthesitis: from pathophysiology to treatment | Nature Reviews Rheumatology\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9044957,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/PzKRP0rrQIqO7iEGKuEw_41584_2017_Article_BFnrrheum2017188_Fig1_HTML.jpg?file_detail=56b854ae0d7211aebd8ccfa154f5a325e30a821fdac1223ec89cf43d20eefa37a6532ca0b85561cb5d8b1f70f299606c5da8f8da5b745c5b3c606667ddb323f9698b6438e1ee4274b38430ba83a212752900ca6b6887904790417d9bc7041c1eb4a1c30faacbe7a74a7d9f7744063812ac5b8c9597e1ab53a7be28925c6d4d4ff1e077e5eb5b6fe07873da4d103f1807:acd3e94a49a788524da1766fac60d0ad:26f5a9ee7ac618f0f8b5c8f3d991cfb2&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjMxMyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.3rE9mfk74Sv6MOMAz7mVFa1OXcKpgN8F5r5aVhwHEgQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Enthesitis: from pathophysiology to treatment | Nature Reviews Rheumatology\",\n \"description\": \"This article provides an overview of the pathophysiology of enthesitis, from induction and inflammation to tissue proliferation and bone formation. Building on these pathophysiological concepts, the clinical presentation, assessment and treatment of enthesitis are also discussed. Entheses are the insertion sites of tendons and ligaments to the bone surface and are essential structures for locomotion. Inflammation of the entheses (enthesitis) is a key feature of psoriatic arthritis and spondyl...\",\n \"url\": \"https://www.nature.com/articles/nrrheum.2017.188\",\n \"siteName\": \"Nature\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-968b50a1-c831-4fa0-98fa-f027803b8ac2\",\n \"slug\": \"short-term-efficacy-and-safety-of-il-il-and-il\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T21:00:32.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and...\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018076,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/9R8KCmGxTkaQ4MI2zVD4_pubmed-meta-image.png?file_detail=5a082b6524655dce43995e64ea7340445e8069521525e5fb558883db2eccfa0eef63bf272c29afd50590f5a902303da919b4159b58615951e2bf180ccfbd871378a66591102511518b8899be505e8556360738011e08dcafaf6db45c1c038954928768c9aadfe7ab8c17c57538f9df1c:6e5e33d61254080d281102671419907a:aa55e5fd333dc0afbd685447682a2839&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjMyNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.-09HrWLsPFBPULY_jISPVkTJBBn3TAMmOCkFpyBWcgY&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and...\",\n \"description\": \"IL-17, IL-12/23, and IL-23 inhibitors had high efficacy in the achievement of PASI 75, PASI 100, and sPGA 0/1 or IGA 0/1 or PGA 0/1 in moderate to severe plaque psoriasis after 12 or 16 weeks of treatment. IL-17 inhibitors showed superior efficacy. However, its clinical safety was poor. Risankizumab …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31583255/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109054010\",\n \"publishedAt\": \"2022-02-05T21:00:32.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728540,\n \"message\": \"Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and...\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018076,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/9R8KCmGxTkaQ4MI2zVD4_pubmed-meta-image.png?file_detail=a2a8c51e194ca546682712ba8cde21dcfa82314909aef7a1d309b11fcd539d47252efb17fe57240827f3fb0417ad6c5b566f370d6febf6b55e5b60eb3515cbb62ddd38bfe1b54cd9c86a95258b8a0192bc60f96c48c13a676f1c1cd83c42d04503dcf96bbaa2293a44cbdd99be8da1ab:a35be289749328968045d297c94fafea:b76bdbd34afa6ce263a27ebb24cdc371&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjMzNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.XMHScKFeVt_aknkkRi-RtKFf9BgjZJ4SBrDaHtQIOw8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and...\",\n \"description\": \"IL-17, IL-12/23, and IL-23 inhibitors had high efficacy in the achievement of PASI 75, PASI 100, and sPGA 0/1 or IGA 0/1 or PGA 0/1 in moderate to severe plaque psoriasis after 12 or 16 weeks of treatment. IL-17 inhibitors showed superior efficacy. However, its clinical safety was poor. Risankizumab …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/31583255/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-aafa6220-91a2-48c4-b4ed-5ea751fe36c1\",\n \"slug\": \"burden-of-psoriatic-arthritis-according-to-different-definit\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T12:04:02.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9017707,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/C8EWeTctSDS2CodJuREA_acr.2018.70.issue-12.cover.jpg?file_detail=5ce699553b23e6bc42a639247cfc7b616b3d9e972673a81449e47f442ed7f00cca9524fb365da16c2d4d43688aa0f5f155300e2205b29cc3466aff189e58bf5c6892acfb30632d7c8f7e435ed2c4313ce9439c162fb5091d51e19405c48653d310b3fb44c1c7216f4046bb44b5bc5d77:dbf7d676ce3755b40f1c77c06e46660e:1752233e5e3b7c1b9ec8555c6c323906&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjM2NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.uieuirnjdnAP_zTMJnus6prxFbH9iQRxliEnQJe1tKg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis\",\n \"description\": \"Objective\\nTreat-to-target strategies have improved outcomes in rheumatic diseases. In psoriatic arthritis (PsA), the proposed targets are the multidimensional target minimal disease activity (MDA) a...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/acr.23571\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109053647\",\n \"publishedAt\": \"2022-02-05T12:04:02.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728179,\n \"message\": \"Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9017707,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/C8EWeTctSDS2CodJuREA_acr.2018.70.issue-12.cover.jpg?file_detail=4ee559664812dbbde40e6767887b3ddd7253b258816358f795e39da882a0613db8ee8046a3d08dc4c4697bc8e8da0b4a02d0fa1e73f5c796a7f72bb1c9640d5895dc0b744ff0b98cf5e8dbc1498381add163d8632cde1027565e3eb1c3e12deacc25b7ca41185f63cf61e607ca320dbf:41afad45c7414b75d4d7f19e58a8231e:18d84f662798b23ad65321ecc093c6c8&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjM4MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Sj-4SsbQjyUejqjiBq_ejlY_k0OkN_UbNgnr8OkWm5Y&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis\",\n \"description\": \"Objective\\nTreat-to-target strategies have improved outcomes in rheumatic diseases. In psoriatic arthritis (PsA), the proposed targets are the multidimensional target minimal disease activity (MDA) a...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/acr.23571\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-b3c87cc9-dd1f-4a38-b1c0-a6892db4b8a4\",\n \"slug\": \"review-nonradiographic-axial-spondyloarthritis-new-definit\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T12:38:57.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Review: Nonradiographic axial spondyloarthritis: New definition of an old disease?\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9017734,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/0lCq5AWXSMaqiDJBbxKn_art.v65.3.cover.gif?file_detail=7f5babbfc979524873c272e25afe7d9d659171eab7565b777043fea49ba21fb055d44a52ef4613f9e5febc4e042da587536208a2ef7bba25565b24671ef08f2236b12e18c072e3d903b7b16d69c9a097e1b36320a263cd507612061d49f3a7a0d8ef09c26da1943753651133ca2317e1:a9931c13a7363bb9e91ef5fc00423e68:7a5445ab2a7180c80c259f50d8e97cdd&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjM5NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ee585UMVciw4vahOcYUjvpLPay1kTiaazfqNuYUmXNs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Review: Nonradiographic axial spondyloarthritis: New definition of an old disease?\",\n \"description\": \"Click on the article title to read more.\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/art.37803\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109053674\",\n \"publishedAt\": \"2022-02-05T12:38:57.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728205,\n \"message\": \"Review: Nonradiographic axial spondyloarthritis: New definition of an old disease?\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9017734,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/0lCq5AWXSMaqiDJBbxKn_art.v65.3.cover.gif?file_detail=2eae7d0261910cc6eafcc16c3cd2b0d5bac29c16f610760e51534aa4e572fe0b8c528321f861e2bd3d43cb886bfbd91a82042d7967f214c87732a21c5790c782b7e7c48ed9ff15e79652d29b0dd5e8878c8d1e502b4490a8869f45d5d4d49d03ef4e92bd42b6d397a1f52a4d307257e6:7328aaafe3c8ea7fd4620648f4e93a67:27f834ab949726d66ccf83afa8ccb002&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjQwOCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.KVxGxcB0Zskj3eZopRAebuIUjrLiq9eLVM49Z8994mg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Review: Nonradiographic axial spondyloarthritis: New definition of an old disease?\",\n \"description\": \"Click on the article title to read more.\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/art.37803\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-be45bb2c-c2ce-4997-9480-ff50b2a2929f\",\n \"slug\": \"il-17-pathways\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-04T01:52:15.000Z\",\n \"duration\": 60,\n \"title\": \"IL-17 Pathways\",\n \"message\": \"IL-17 Pathways\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": null,\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109049178\",\n \"publishedAt\": \"2022-02-04T01:52:15.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3723738,\n \"message\": \"\",\n \"language\": \"en\"\n }\n ]\n },\n {\n \"id\": \"ECL-b812bca8-c10c-4992-a27a-3f3a0f7f4ec4\",\n \"slug\": \"biologic-therapy-and-spinal-radiographic-progression-in-pati\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-08T18:48:28.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9027440,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/NxS8WrCcRie8IEvhq4Ai_pubmed-meta-image.png?file_detail=00517c74c44d1e9983843fc8851a8b7bfa80434bfe5d7dac4611cbb401498bd6b2c1dfda37e34bbfc40a8fa1413365896bc849e5f9f583ebc1a68d5ac8654b97d9e46d5645c0be479a03abffd7974d475f484d9dadb300617bb27eccf0204dad91b8127bf10766c9073fd4cf34eeeb29:82e1049a7fed289dd58cffea7d07edc9:4d1868b05261e779376e3ec7b67ecda5&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjQyMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.P1CcOdD2epvErlBAiZJz8y69JPEu1VhLHYXPF-Y9hmM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review - PubMed\",\n \"description\": \"We aimed to perform a structured literature review of spinal radiographic progression, as assessed by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), in patients with ankylosing spondylitis (AS) or nonradiographic axial spondyloarthritis (nr-axSpA) treated with biologic therapy. Sear …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32180840/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109064494\",\n \"publishedAt\": \"2022-02-08T18:48:28.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3738979,\n \"message\": \"Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9027440,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/NxS8WrCcRie8IEvhq4Ai_pubmed-meta-image.png?file_detail=db6282897b93cab23b5c3472b1cdc45872e57d7cc3bf332347f2cf245ba961f82023d5678f3a522723a0e7c3f51ecc3358cb905c7cc9d2a66cf2ce25d31d7d7b23b9521fd6e75710540fb0b3d4f915172db8a1f5fa831bf2659852f861259c7858dc6162020f977310af1ea5a3bcefcd:a6c32aa345d7521698e0517a7f61d347:633a0cf395244b29d5b28af89f72760c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjQzMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.UV1Z2OKQLiWI_Tj3wLfMrg8xpkdEBJbxmYsCnUA7qNg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review - PubMed\",\n \"description\": \"We aimed to perform a structured literature review of spinal radiographic progression, as assessed by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), in patients with ankylosing spondylitis (AS) or nonradiographic axial spondyloarthritis (nr-axSpA) treated with biologic therapy. Sear …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32180840/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-aff2497b-4c99-42b9-a272-0f9a12b313fd\",\n \"slug\": \"secukinumab-treatment-provides-sustained-resolution-of-enthe\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-09T00:29:20.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9028002,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/cizHmUZAQWnrXRUULg9k_ACR_1063257_1.jpg?file_detail=a2fbd568227d67b5e61f0f65e2481d0b1c581f3bb2ecfdaa35ba21328b7712ed0087afb2d06ec4aecfaa79e87cde128306282a8a390a882cea693a4461ef9c9e7da9bc4930291994ed704135bd62efd0f68b492bbc85ca15415187d2e3121e42be45490dd41b80fc61f10f90087db309:1a614d5ad03015c404993d45f4ecf49b:f6d06d119441e1ba1b954970482d311b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjQ0NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.QcnHXH8uzObWvmBRUXBiDezTCgnqFnuxNblZ_QoOftk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Enthesitis is a key musculoskeletal manifestation of psoriatic arthritis (PsA). In the double-blind, head-to-head EXCEED study (NCT02745080), although the primary endpoint of superiority of ACR20 response for secukinumab (SEC) vs adalimumab (ADA) was not met, similar efficacy was observed across a range of musculoskeletal endpoints, including resolution of enthesitis at Week 52.1 However, a […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-treatment-provides-sustained-resolution-of-enthesitis-at-individual-joints-through-52-weeks-in-a-phase-3b-double-blind-randomized-active-controlled-study/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109065112\",\n \"publishedAt\": \"2022-02-09T00:29:20.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3739593,\n \"message\": \"Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9028002,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/cizHmUZAQWnrXRUULg9k_ACR_1063257_1.jpg?file_detail=3f77aa60ed14c1ef76c0c82a8ce5948924cc79b9d2af3faeea044a10aef75ec770138bf65278dbae63c7b741b1dbe98a911062dbd25ffa90650f2f90f3abd743a13312b92bf74d0827d9fd66e4bebe6417e07940c94451c671a50442beb9b36d70912abfad5661afac4fbd2371b4c917:993ef4dbda28779b09d96eb50390ff72:f74cc71d99236774acace8d0adbd6ba5&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjQ1NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.GeRYj_aME2Je7qzehdgEd1HoQS8XSVeR8qYNBKb409Q&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Treatment Provides Sustained Resolution of Enthesitis at Individual Joints Through 52 Weeks in a Phase 3b, Double-Blind, Randomized, Active-Controlled Study - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Enthesitis is a key musculoskeletal manifestation of psoriatic arthritis (PsA). In the double-blind, head-to-head EXCEED study (NCT02745080), although the primary endpoint of superiority of ACR20 response for secukinumab (SEC) vs adalimumab (ADA) was not met, similar efficacy was observed across a range of musculoskeletal endpoints, including resolution of enthesitis at Week 52.1 However, a […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-treatment-provides-sustained-resolution-of-enthesitis-at-individual-joints-through-52-weeks-in-a-phase-3b-double-blind-randomized-active-controlled-study/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-b96afa76-0c75-4554-b3c9-9b7039ba32c0\",\n \"slug\": \"safety-and-efficacy-of-upadacitinib-in-patients-with-active\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T12:16:45.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9017714,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/waYy43uHTyq3JVyhlDdD_art.v74.1.cover.jpg?file_detail=edd31007a7e959be23e38569324055e14ea869f34a807995f76c7f92634b3dba6c0c2d42b368f546270b1b96200148fe7d82f5b7f96a459744624a2e7e186775d5ae59d1e56d48d4c18742917e86b7acb5c232d7a36f9272d8b844fbbb67ed30afccbd7dd18dc1f4477c8ad742beb7d6:f0b8cb6125cd7536fa5ea09573486167:2450cb79900a9ff12b6a88ae446c8d74&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjQ2NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.5tsYd1cbE1WPGve5DbvyXihvErdYQXnIUgCf5RN3Oq8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension\",\n \"description\": \"Objective\\nTo report the efficacy and safety of upadacitinib through 1 year in patients with ankylosing spondylitis (AS).\\n \\nMethods\\nIn the SELECT-AXIS 1 study, adults with active AS and an inadequate...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.41911\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109053654\",\n \"publishedAt\": \"2022-02-05T12:16:45.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728185,\n \"message\": \"Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9017714,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/waYy43uHTyq3JVyhlDdD_art.v74.1.cover.jpg?file_detail=6dddf1cd53dead0703ae5693d70f1f0f8ea622e17b26c228b5525533afe4a222e5da678bf24e31a350f6b74084073828d6ced2f0b6b25b31ccf213f72d6e0cff70705eb65174fb657e9f263d2269bbef182faeb0842cada745246aa230000c90b0ad87dcfb10c0423f298d1714df4e78:81e9e243196ba9d7fd53cfffe6ca6b9f:8c0d6226157a493303f589c42fa549e2&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjQ3OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.tPdlj0JBV0ehUbk4DwATZjZL80ouwt9NZOkt7-wtk5I&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension\",\n \"description\": \"Objective\\nTo report the efficacy and safety of upadacitinib through 1 year in patients with ankylosing spondylitis (AS).\\n \\nMethods\\nIn the SELECT-AXIS 1 study, adults with active AS and an inadequate...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.41911\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-15cc5c3b-200a-4fe3-802f-63175eb9e036\",\n \"slug\": \"biologic-persistence-in-psoriatic-arthritis-and-psoriasis\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-05-20T12:52:27.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Biologic Persistence in Psoriatic Arthritis and Psoriasis | RheumNow\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9322501,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/4ueKZO1BQPepbEGbbhUX_psoriatic.PIP__1.JPG?file_detail=552d1687d9d3fa9cbd63335c5d306e91e5ea59d3e94d03d4c431e20e43bb0ad309d46ae28df315c1bc164ef29b0f2cf78698d75e0e19e1ee6aca1c596338ba0c5a0f9e96ccbd717048d8c1fa3afa672f866e42c45dec87f73f55be430b6ac8417e8b739550115804aa05b189206467c6:7946133240048d1998a86bc13480b333:677d21efbb32a51941853a4fb077d694&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjQ5NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.BL5JXa-ZRmlJ4dFD7TNpTQHwGVAfqt4z4X_t6_rD6-0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Biologic Persistence in Psoriatic Arthritis and Psoriasis | RheumNow\",\n \"description\": \"Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.\",\n \"url\": \"https://rheumnow.com/news/biologic-persistence-psoriatic-arthritis-and-psoriasis\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109408709\",\n \"publishedAt\": \"2022-05-20T12:52:27.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4082820,\n \"message\": \"Biologic Persistence in Psoriatic Arthritis and Psoriasis | RheumNow\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9322501,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/4ueKZO1BQPepbEGbbhUX_psoriatic.PIP__1.JPG?file_detail=6ff348cc39d24287a3ef89b17a0c8dc5c8dc91e6e2bf114847f888269a0966b0e40b6f34eee518760fa91e43dfcb6c149b7fb698eba807b9d1e81494c653cf4a09ec5ceb94727648a70a2f14fe65c936ccdde8095dadf86e6ef55670852b9ed2011600c99b232b799e1ea73c678246ab:6410e41d3eedc09a211d14523a200b97:60306f190d9b0c0e3a8867a38b035294&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjUwOSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ej3rbtLAWSCoIUIHPf7MGW3L_rc_iBUra4nRRZMUhIk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Biologic Persistence in Psoriatic Arthritis and Psoriasis | RheumNow\",\n \"description\": \"Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.\",\n \"url\": \"https://rheumnow.com/news/biologic-persistence-psoriatic-arthritis-and-psoriasis\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-50155630-1975-4d97-a749-459f4deddeba\",\n \"slug\": \"real-world-risk-of-new-onset-inflammatory-bowel-disease-amon\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-05-17T01:06:47.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9310929,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/EpKgoqMyS2AQsjQJfLrC_pubmed-meta-image.png?file_detail=4db748ef05bf34cfe5fd4d16a9f8a05259e7310e1e0686121c502a3ffa85393930c853ee703e2ebece8854a644fe2d522f0faa0e51116ca38c101ade6fb387ae9e6b56eac8ad39a124c350bd90d7c64cbbd2e1be6fb158384263a921827cff8bd18c63574ecbab10a910b59ece06aded:9174979512e6180d981abe4bdec30ef9:55ae33c166391e32a394b87475763e27&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjUyNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.qz2jGiR-hL9wO1lqIMygR_NLHxDFxzycT_zF3xoE284&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors - PubMed\",\n \"description\": \"The incidence of IBD among patients with psoriasis exposed to IL-17i is low, and the risk appears similar to that for unexposed patients with psoriasis.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32289401/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109394745\",\n \"publishedAt\": \"2022-05-17T01:06:47.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4068929,\n \"message\": \"Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9310929,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/EpKgoqMyS2AQsjQJfLrC_pubmed-meta-image.png?file_detail=4b76eb14bfc67656e6d3bf2b38773ed07436bc881e5c85f90a5fff4b83eb4617e7d979566715aaa3540f5e0187dce4a2ab408ec268d3acc7a6432e697acd5df7005c3fa4fd5bd9ea0ac61b51cae907f4e22fcc4bbf818c6905cc1bfecd9e0c54b50e2fe51e944325a8bd0feacb35a165:63e11f6cbbf50d4c5f41f30413326992:16efd4997f33cb71f956075d6bb76a61&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjU0MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.C66yUQCjsNTvTmnO2RmsyxRmGFa5J84zYsn1Uqv8e20&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors - PubMed\",\n \"description\": \"The incidence of IBD among patients with psoriasis exposed to IL-17i is low, and the risk appears similar to that for unexposed patients with psoriasis.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32289401/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-f05379c8-70ce-4339-8347-4406355f66a7\",\n \"slug\": \"pregnancy-outcomes-in-the-tofacitinib-safety-databases-for-r\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-06-15T23:48:13.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9403141,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/CWTNQkIRTKGgqTwtpxDg_pubmed-meta-image.png?file_detail=a572c71401edcd21c5eafc82d15fdd647a0e8ce96a60487f5f6a04ac20a6a0f490037adbd498fd39cdfa925eacd5f0f6a17bc59c6349710a3475d49e3384675f8ee592b1b9047be71950a2465f4cefbf6e82211158a211ec08ffc5b7ff6bd2c76e39a7f494b285ce4b329f8ff90637a4:68c377a52a36c620c495f62645a8d0b1:450618119c161810253a17044888f2d5&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjU1OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.caY3Pk3h3kZsiLKYffGD6aGC2hHz638PX0LqaO-ZQmw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis - PubMed\",\n \"description\": \"The pregnancy outcomes reported in this small number of RA/psoriasis patients appear similar to those observed in the general population and in patients treated with biologic therapies for inflammatory diseases. However, definitive conclusions cannot be drawn, and pregnancy outcomes in patients rece …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/27282428/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109503446\",\n \"publishedAt\": \"2022-06-15T23:48:13.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4178153,\n \"message\": \"Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9403141,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/CWTNQkIRTKGgqTwtpxDg_pubmed-meta-image.png?file_detail=6b4f7ed63633d94e20868659aeb85a4ca0631af46208ee979547550ebd58cecdd01f18a4d5cb46eb849245007b8979c061ba3954841974e58d21290d1ec7a0794b89c88b35416d84333cd3da05ac85862c6d3b04c8483bbbf0be852fffe42cf9d428badca0255f2c5a85a6c62a773596:4b6171b3022b9f6744a9f4cef1470090:167f2a4b6d0e3ae718d1b97c0ce431f4&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjU3OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.E23HqWO87QOx9cF-lpec3ssctAeviFuWWUCUwtBn52o&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis - PubMed\",\n \"description\": \"The pregnancy outcomes reported in this small number of RA/psoriasis patients appear similar to those observed in the general population and in patients treated with biologic therapies for inflammatory diseases. However, definitive conclusions cannot be drawn, and pregnancy outcomes in patients rece …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/27282428/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-dd13b84a-2bd8-4286-aba3-19f9e05055fe\",\n \"slug\": \"secukinumab-provides-rapid-and-sustained-pain-relief-in-psor\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-06-21T00:18:11.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study | Arthritis Research & Therapy | Full Text\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9417419,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/9eDlqMzGTUKj4LAa1iBw_13075.jpg?file_detail=e9f38a1445164ef4db20cbf14dd2b97f942e65935aa10a74fe2b9029cf4260005a82dcf3889c73e42d8100c8e3d43c40e5ea90dbe465ea4222176432c8fb426e06809eb4b023303778060041f5a78e0a7170387a84f49c2cdcc7b7c54207f554:72e9be750a92b1693078e01f497c27b6:ac4640534bda94fae889dbe8cf5fbd9b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjU5NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.cIOada2o3wBQg5uFb7iWp-EtBdhGSOSKJJprDEW7jCI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study | Arthritis Research & Therapy | Full Text\",\n \"description\": \"Pain is one of the most important domains affecting health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Secukinumab has demonstrated rapid and sustained improvements in signs and symptoms, including HRQoL, among patients with active PsA. This analysis evaluates the effect of secukinumab on patient-reported pain in PsA through 104 weeks of treatment. Pain was assessed through week 104 using clinically relevant measures, including change from baseline in a pa...\",\n \"url\": \"https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-018-1610-3\",\n \"siteName\": \"BioMed Central\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109519386\",\n \"publishedAt\": \"2022-06-21T00:18:11.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4194041,\n \"message\": \"Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study | Arthritis Research & Therapy | Full Text\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9417419,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/9eDlqMzGTUKj4LAa1iBw_13075.jpg?file_detail=e48951079f281a1067c564b3bf532640b9cddc7b9988a066d657cc9a4951e94457fba8ddc0b49cb0187af5dbe8849acdc0e8afe27228ea3b0ddad9e9d190379189b62a0b0ec0db137a65baee9b86450d3af1932ee195355eb06db120db4e4a23:9f12a51103e78c8fd407ec26e3d1b85e:da79c790f5e8e15c930139d9a177635e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjYxMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.-NOlR89o4BpTZwZGrR67Ofs8YMZtc0lzCDZpl7shsw0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study | Arthritis Research & Therapy | Full Text\",\n \"description\": \"Pain is one of the most important domains affecting health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Secukinumab has demonstrated rapid and sustained improvements in signs and symptoms, including HRQoL, among patients with active PsA. This analysis evaluates the effect of secukinumab on patient-reported pain in PsA through 104 weeks of treatment. Pain was assessed through week 104 using clinically relevant measures, including change from baseline in a pa...\",\n \"url\": \"https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-018-1610-3\",\n \"siteName\": \"BioMed Central\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-fe55fab3-b630-4d2e-87bb-109534c19086\",\n \"slug\": \"effects-of-secukinumab-on-bone-mineral-density-and-bone-turn\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-06-21T00:22:33.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1 | BMC Musculoskeletal Disorders | Full Text\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9417444,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/vk6vedDTZC6oHfZWdssQ_12891.jpg?file_detail=ae751ec0744b1366bf28faa1f848445ae315386f2480eb6e4a8caa5a186493ea5b0a391c9e5ff86f08ded40ba1e215340e1f4fe4bf131d73396acadef50eb7557e1f866969447d6f2c5f224fbddf00345df865adca783248abd5ddc80b63a68c:da16a5572d9b01253ee78cad1d734403:a2ee7801865e72bc771c3117f7d09d5b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjYyNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.WHLLjDy6AQi_1ILfqZtKabqCmRK9U3MCimwFIkCVTvI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1 | BMC Musculoskeletal Disorders | Full Text\",\n \"description\": \"Axial spondyloarthritis including ankylosing spondylitis (AS) is characterized by chronic inflammation and new bone formation in the axial skeleton. On the other hand, bone loss, osteoporosis and an increased risk of vertebral fractures is known to frequently occur in AS. In the MEASURE 1 study, the clinically efficacious interleukin-17A inhibitor secukinumab was shown to have limited radiographic progression through 4 years in patients with active AS. Here we present a post hoc analysis to e...\",\n \"url\": \"https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04930-1\",\n \"siteName\": \"BioMed Central\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109519412\",\n \"publishedAt\": \"2022-06-21T00:22:33.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4194067,\n \"message\": \"Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1 | BMC Musculoskeletal Disorders | Full Text\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9417444,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/vk6vedDTZC6oHfZWdssQ_12891.jpg?file_detail=ce0c45546f028a1b398fbd9798bca9cefd196e37e1c8f7f877afa3f92c31632d7de9ce687856cb7f411e8752b80d3c57d968bf06cf3131958ee114f89459b393b9104a5703530e42fb3609874632943abc8c66de3896ebdda7464cc6a787c5a5:1545ba13c26778f656478cc1ed698764:e106b03146e86ad5a1b6637a43e214b4&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjY0MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0._-cL3OXogq5nStbnlE6Ro2UQ7CoDjZVQ_iedCe_vHjo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1 | BMC Musculoskeletal Disorders | Full Text\",\n \"description\": \"Axial spondyloarthritis including ankylosing spondylitis (AS) is characterized by chronic inflammation and new bone formation in the axial skeleton. On the other hand, bone loss, osteoporosis and an increased risk of vertebral fractures is known to frequently occur in AS. In the MEASURE 1 study, the clinically efficacious interleukin-17A inhibitor secukinumab was shown to have limited radiographic progression through 4 years in patients with active AS. Here we present a post hoc analysis to e...\",\n \"url\": \"https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04930-1\",\n \"siteName\": \"BioMed Central\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-a8410f2c-e29d-440d-a514-9b50c12d67a9\",\n \"slug\": \"efficacy-safety-and-tolerability-of-secukinumab-in-patient-efficacy\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-06-21T00:19:55.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3 | Arthritis Research & Therapy | Full Text\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9417425,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/KnRmf0f0TLSXyjKEzy5s_13075.jpg?file_detail=2b310e6be3ee828ca553fad6fa29b2ad930f8b578f42d9ae4ea562894df789e7b981f826f40097b9be3050c983b6be850b7b93af93974b867bd5f5e89353b30e3f4d493c4c9a66fa50c49994ee24a8700b800cc530f30845026147987ab532dc:0c8f41bc8a60df928b06c352b14cb986:caf8d588940ee8179319fea7374de187&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjY1MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.QokSLV6PEtVyACE-zv4sRFZQmxMp-Ks0Roaa-sJxU3s&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3 | Arthritis Research & Therapy | Full Text\",\n \"description\": \"Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and MEASURE 2). Here, we present 52-week results from the MEASURE 3 study assessing the efficacy and safety of secukinumab 300 and 150 mg subcutaneous maintenance dosing, following an intravenous loading regimen. A total of 226 patients were randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous se...\",\n \"url\": \"https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y\",\n \"siteName\": \"BioMed Central\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109519395\",\n \"publishedAt\": \"2022-06-21T00:19:55.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4194050,\n \"message\": \"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3 | Arthritis Research & Therapy | Full Text\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9417425,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/KnRmf0f0TLSXyjKEzy5s_13075.jpg?file_detail=246852488341f56b9c477c7ad05cb226efa6ba31c31537d4a9ef9cf78ab5d72ac6bf9c2188ee54973df2aa23eeddab94a9eaa5d402b6a2ac7fe810a856f4a007c5234ba39c71082164b14478746ffd7ed44c5e6a92892f141c24a7146a133b0a:96a6193789eca5f4f2f18bcadc08ea5f:32f087ad00d78b33d412173ae92bc9f5&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjY2NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.w1VZOwOJ3LRXgagi07oKU29HUeckiB8WlHnBpGNvt9U&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3 | Arthritis Research & Therapy | Full Text\",\n \"description\": \"Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and MEASURE 2). Here, we present 52-week results from the MEASURE 3 study assessing the efficacy and safety of secukinumab 300 and 150 mg subcutaneous maintenance dosing, following an intravenous loading regimen. A total of 226 patients were randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous se...\",\n \"url\": \"https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1490-y\",\n \"siteName\": \"BioMed Central\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-9b1486e4-0edd-456a-b441-68cd01f0a707\",\n \"slug\": \"efficacy-and-safety-of-biologics-targeting-interleukin\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-06-21T00:14:27.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis | Rheumatology | Oxford Academic\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9417411,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/RQr03vh8T3CU7jdrMmKe_m_kex452f1.jpeg?file_detail=cedd7b921015819356f9ff8d7e65e194b449501ed1f61e3067888d2b5825f1237799ccad9ea9212f9ba8de51c8cd1a5575bf9e4c3e8c4e6276019eb0a2546905c40b2cec608d47b8b7e41b91e3b28bc2aec9aa630569f9313bba09ceef8e8549:7ead3a843ea52254e11638746b97898b:6c8279350472de3cba6a6256198a01cc&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjY4MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.L7h6NVqKFjVuBem9eesblk32UQF9LjnOrejmKJ8ghcE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis | Rheumatology | Oxford Academic\",\n \"description\": \"AbstractObjective. To investigate the comparative efficacy, safety and tolerability of IL-6, IL-12/23 and IL-17 inhibitors for patients with active PsA.Methods.\",\n \"url\": \"https://academic.oup.com/rheumatology/article/57/3/563/4735217?login=false\",\n \"siteName\": \"OUP Academic\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109519379\",\n \"publishedAt\": \"2022-06-21T00:14:27.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4194034,\n \"message\": \"Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis | Rheumatology | Oxford Academic\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9417411,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/RQr03vh8T3CU7jdrMmKe_m_kex452f1.jpeg?file_detail=3dc01a009056f220b6f431c0a1487f789d2afc728b54164c0214c09729b338b59eb79462e4602c1c0ae4889ca207ffd5702b64cdd2ef3534fad83aa660bb4a35f9790ff92cbd608ef41cc594de8d7fbc10d8b133142f8f3daf46ca78e2bb2ad1:b0dea28d921ed599e2c3d2a14887bcaa:276f19d4bd6170b4d465f43ce1a48a9f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjY5NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.T_ULWV3LWWquXJD6skcRglvihdOVkofLS-TbcoTZdKg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis | Rheumatology | Oxford Academic\",\n \"description\": \"AbstractObjective. To investigate the comparative efficacy, safety and tolerability of IL-6, IL-12/23 and IL-17 inhibitors for patients with active PsA.Methods.\",\n \"url\": \"https://academic.oup.com/rheumatology/article/57/3/563/4735217?login=false\",\n \"siteName\": \"OUP Academic\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-22768efd-4319-4681-b869-a78a2ceaf2cf\",\n \"slug\": \"resolution-of-synovitis-and-arrest-of-catabolic-and-anabolic\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-06-21T00:28:10.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study | Arthritis Research & Therapy | Full Text\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9417448,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/87Mp6D6NT3CSpRnGBSYg_13075.jpg?file_detail=795abef83584eee6ecec8527fc97a48807829b3c6f1b0f72065882d3a13d78ba90d96065e34c59056e5ec4f9662b0bd29ee2a339298d64d775817dbe788b3c89fafeeef88c5ee12b2aa7fc7347a0cbe737b35ed19d2262b1930ac001b1566c25:e692439c2bb36f93af1c821e84e66b18:e6ecf2ba939f94cbf259ead2a1cdb4fc&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjcxMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.JBD_sXVuTWHKY8wyW9TKd-ukyheuC0SHhuE9VAsDNMc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study | Arthritis Research & Therapy | Full Text\",\n \"description\": \"Although the effects of interleukin-17A (IL-17A) inhibition on the signs and symptoms of psoriatic arthritis (PsA) are well defined, little is known about its impact of local inflammatory and structural changes in the joints. The PSARTROS study was designed to elucidate the effects of IL-17A inhibition on inflammation and bone changes in joints affected by PsA. This was a prospective open-label study in 20 patients with active PsA receiving 24 weeks of treatment with the IL-17A inhibitor...\",\n \"url\": \"https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-018-1653-5\",\n \"siteName\": \"BioMed Central\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109519415\",\n \"publishedAt\": \"2022-06-21T00:28:10.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4194070,\n \"message\": \"Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study | Arthritis Research & Therapy | Full Text\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9417448,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/87Mp6D6NT3CSpRnGBSYg_13075.jpg?file_detail=c84649e7e12ccda5dd6f8571e33ee5d918b4cf41fb9f1d78ff85c7fc22f91d0167b76cb62efa9a5603545539ebe2b1846fc330e76dca89a8814026d9dd5d02a160d5b316130a0e3394e6615da1973ff25ad68c7ff9fefc4d4099d8dc8e335195:e4e9f4598878f1444c09343d3a4faa9a:7bd2ee38ae65f1cdc46bd03d289a5fbf&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjcyNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.73MQCCpvBsfjapu953D7RhFHopG3sHcX9AFnJ_GuJ3g&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study | Arthritis Research & Therapy | Full Text\",\n \"description\": \"Although the effects of interleukin-17A (IL-17A) inhibition on the signs and symptoms of psoriatic arthritis (PsA) are well defined, little is known about its impact of local inflammatory and structural changes in the joints. The PSARTROS study was designed to elucidate the effects of IL-17A inhibition on inflammation and bone changes in joints affected by PsA. This was a prospective open-label study in 20 patients with active PsA receiving 24 weeks of treatment with the IL-17A inhibitor...\",\n \"url\": \"https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-018-1653-5\",\n \"siteName\": \"BioMed Central\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-068c1cb6-91e7-4328-908d-60a9289585b8\",\n \"slug\": \"efficacy-and-safety-of-secukinumab-in-patients-with-giant-ce-efficacy\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-06-21T00:25:20.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial | Trials | Full Text\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9417447,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/xa9o9gp6TX6TVRIZQ4mK_13063.jpg?file_detail=917a7be6769f18b51fb0ab5a4cc3b93cb3f4163812bfac65adbb42af1df60e1e2caafa61740f358f66997a9b921ea24217b1a4f94b3474ee8f3bdf80458df500dff4b2f68ade1a1fc6f540cd96c9f20d015fb870ab35d781be1257574806d76c:27bd50e9b8cb4a909dd691787c4ee3f1:69d1f7fbb8e938474699aa6c03438d86&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjczNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.4aX-pX_K08F-0NjkB7XaNqCjSBZ-KhAmcNuS6wnHRTQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial | Trials | Full Text\",\n \"description\": \"One key pathological finding in giant cell arteritis (GCA) is the presence of interferon-gamma and interleukin (IL)-17 producing T helper (Th) 1 and Th17 cells in affected arteries. There is anecdotal evidence of successful induction and maintenance of remission with the monoclonal anti-IL-17A antibody secukinumab. Inhibition of IL-17A could therefore represent a potential new therapeutic option for the treatment of GCA. This is a randomized, parallel-group, double-blind, placebo-controlled, ...\",\n \"url\": \"https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05520-1\",\n \"siteName\": \"BioMed Central\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109519414\",\n \"publishedAt\": \"2022-06-21T00:25:20.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4194069,\n \"message\": \"Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial | Trials | Full Text\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9417447,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/xa9o9gp6TX6TVRIZQ4mK_13063.jpg?file_detail=19c16cc80b737366e9860af30b8d80181bdf891924719fefda015b7032dee3bf7d9a85980167a2ed5e9e34637517a83254579e60ab01d5e88ad71dbee0a34762692bee340a2f9b40e88fc49ea97ffea75ca2b8f9dc067d06943dd5fe1920c286:b6b4681bdf51b3a5114985825151a9d8:c7ea18ad5a3fee66f00d0f4f2bc4130e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjc0OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.nK2kk7HIsCb3JG-U1LVI5WLo90BHAUCXj-CwjdT97eI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial | Trials | Full Text\",\n \"description\": \"One key pathological finding in giant cell arteritis (GCA) is the presence of interferon-gamma and interleukin (IL)-17 producing T helper (Th) 1 and Th17 cells in affected arteries. There is anecdotal evidence of successful induction and maintenance of remission with the monoclonal anti-IL-17A antibody secukinumab. Inhibition of IL-17A could therefore represent a potential new therapeutic option for the treatment of GCA. This is a randomized, parallel-group, double-blind, placebo-controlled, ...\",\n \"url\": \"https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05520-1\",\n \"siteName\": \"BioMed Central\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-cb11217c-f1c6-4c3b-b801-a651574866ce\",\n \"slug\": \"new-onset-psoriasis-with-tumor-necrosis-factor-inhibitor-t\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-07-01T17:03:01.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"New-Onset Psoriasis With Tumor Necrosis Factor-α Inhibitor Treatment in Inflammatory Diseases\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9451313,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Edwwp1YZTCinUZ0Qrdzp_doi220030f1_1654888660.52539.png?file_detail=8485cfe8d6d0f2123e85e6787f7170d84ddba5c9b52cbe1400fcd4f055a8bc98d6cd669cbbb1eef640196207f25c2b6b39a195aa1a2b7a0e4943dc9af01cc154c5d23945425dd24c2e1a4bc11174a0501d8729ad8f0a1de91a4ce38e17b8a0f1b43342c7a5d5265a791868d0a9581f6b:593c523af4461fec5e367aaacbb111ce:f9ca8df9d570b43201dc05ffbfb93aa3&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjc2NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Y1zI5dBIFRZP0CQPXCGnNHP6RfM3d87ci2bohW_p2gM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"New-Onset Psoriasis With Tumor Necrosis Factor-α Inhibitor Treatment in Inflammatory Diseases\",\n \"description\": \"This cohort study investigates the associated risk between new-onset psoriasis and tumor necrosis factor-α inhibitor treatment compared with nonbiologic convent\",\n \"url\": \"https://jamanetwork.com/journals/jamadermatology/fullarticle/2793425?guestaccesskey=52ea5580-7f98-48c7-97bb-8d7bc2615ff1&utm_term=062922&utm_content=buffere101b&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer\",\n \"siteName\": \"@JAMADerm\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109558544\",\n \"publishedAt\": \"2022-07-01T17:03:01.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4234040,\n \"message\": \"New-Onset Psoriasis With Tumor Necrosis Factor-α Inhibitor Treatment in Inflammatory Diseases\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9451313,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Edwwp1YZTCinUZ0Qrdzp_doi220030f1_1654888660.52539.png?file_detail=4385adb03eb323a8dbc60e12371aee2fbd672ef2b34e3e5bef94e9b3ef20c80b80b014e02e1da32e374ea533b5ab04997cc7e91cba6d00af836180469d35e96f629c3827238ee9a54fddab75142e69ce83d512a0b4be876842ec6ade1adf9da16ab24c12b99aca4dd13473e5510a3068:417d28827b94ac1fe6546865ce066666:272b42d5e8bfcbd10f1869b33e5a85df&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjc3NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.bzYZACqENmU2NTq1TErI8pf5q3WUPpFG6weDYr_mrfI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"New-Onset Psoriasis With Tumor Necrosis Factor-α Inhibitor Treatment in Inflammatory Diseases\",\n \"description\": \"This cohort study investigates the associated risk between new-onset psoriasis and tumor necrosis factor-α inhibitor treatment compared with nonbiologic convent\",\n \"url\": \"https://jamanetwork.com/journals/jamadermatology/fullarticle/2793425?guestaccesskey=52ea5580-7f98-48c7-97bb-8d7bc2615ff1&utm_term=062922&utm_content=buffere101b&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer\",\n \"siteName\": \"@JAMADerm\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-40f8ac2a-b74e-4114-b6a5-744419ca946a\",\n \"slug\": \"the-importance-of-capturing\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-07-22T12:26:35.000Z\",\n \"duration\": 300,\n \"title\": \"The importance of capturing the MDA within the first year!\",\n \"message\": \"The importance of capturing the MDA within the first year!\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": null,\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109627779\",\n \"publishedAt\": \"2022-07-22T12:26:34.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4303534,\n \"message\": \"\",\n \"language\": \"en\"\n }\n ]\n },\n {\n \"id\": \"ECL-ab0636e6-ca60-4209-bd76-8238e78e0fae\",\n \"slug\": \"just-a-moment-card-87a8f562-68bf-4031-a2c8-04d5f81dbf43\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-07-25T12:39:45.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Just a moment...\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9517910,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/CYMATVSMQYOlrTRtxOIX_young-stylish-businessman_MJnNcFSd%20(NXPowerLite%20Copy).jpg?file_detail=b3c373dcfb784cbbf0dcb07fdce913187a7bd259df2c30a4ecbb18f412d9e4d890a9f39dbb1a97591f4f6af68295633234e8e045784b23fb032f76d187eeed4fd21d99b0118dd051fa8a1684803a3fb9a424b14d87c751c285f0fc8a8f2a89f9f75dc89fdf46f89b4d0f2c3186aae46100fdf214463be99f9dc165b62332a42f0294e73deaa3d656dbece8e6fc9a7d6c:a377d9df57551406d156e2b0cc050e40:805ef4910f301856bcac9cb6e90abd2b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjc5MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.KiqFgSYG9Ju5ZeM5pWk7LYnz9MC-zJefr8_atgrlZuA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Palmoplantar COSENTYX\",\n \"description\": \"COSENTYX PPO\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.18331\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109635913\",\n \"publishedAt\": \"2022-07-25T12:39:45.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4311642,\n \"message\": \"Just a moment...\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9517910,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/CYMATVSMQYOlrTRtxOIX_young-stylish-businessman_MJnNcFSd%20(NXPowerLite%20Copy).jpg?file_detail=d0043745b72d58c41383b3e5dac5940a91aed4e3770e171e8f349bea8917405e0ef48136714d3033bbdc3b8434ffe6b7e5b1ee496c52c512468fe77291332dff23b96b9ae312ddb523a8abffd1ca912daed3730adb79f3622a6550b5d052f9ee92f8cd9672e5e9c7f757f8a91c60d9e9b2f741126ad1e6ed70d5949070ccd16dc7b378c8a6f45b3965a87f88b4b121af:658edaaa240b79ad3f91b5f22eacb3f7:7382a0407892048d3a4ca261668f5f3c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjgwNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.vD3pi2tjR-LGeIBwsVMHnpkVA8Qt-OSWsvBWBXMVCdc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Palmoplantar COSENTYX\",\n \"description\": \"COSENTYX PPO\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.18331\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-091af156-bc54-459b-aaba-0b0b415cf2c6\",\n \"slug\": \"review-jak-stat\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-01-18T03:43:32.000Z\",\n \"duration\": 60,\n \"title\": \"Review JAK-STAT Pathway\",\n \"message\": \"Review JAK-STAT Pathway\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": null,\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109002030\",\n \"publishedAt\": \"2022-01-18T03:43:32.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3676668,\n \"message\": \"\",\n \"language\": \"en\"\n }\n ]\n },\n {\n \"id\": \"ECL-540c070c-0dca-484e-9930-8030b1b61317\",\n \"slug\": \"secondary-immunodeficiency-and-risk-of-infection-following-i\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-03-04T02:02:03.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9110305,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/1m3ktuzMS0mD7NjJREx1_pubmed-meta-image.png?file_detail=c6e1a83af8e242c722c26046bc2580678a19efa066f9f78a2cce48ffb51fca39bdbc30528fc7c93677034493066f9b7dc0ab0abb0f1d7d3ec4f2c8385604229781a7ec1d5ff937b841bf22cdbbcdc7b3be08dfe2b180e651a4ac9c8e399650381ba1579c23d1b3a4f58bd553e6f8e4a2:400c8eba80e17038f83c6f31725a7dc9:9649cb0f92b2715e36aaeb39bbc3da5c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjgyNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.iOo5ZdayTzIaSSMRia4Qb4xJ-ru6rmojJ5GjjGPxIxw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology - PubMed\",\n \"description\": \"Secondary immunodeficiencies (SIDs) are acquired conditions that may occur as sequelae of immune therapy. In recent years a number of disease-modifying therapies (DMTs) has been approved for multiple sclerosis and related disorders such as neuromyelitis optica spectrum disorders, some of which are f …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34657228/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109154650\",\n \"publishedAt\": \"2022-03-04T02:02:03.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3829870,\n \"message\": \"Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9110305,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/1m3ktuzMS0mD7NjJREx1_pubmed-meta-image.png?file_detail=7d0467373464705b15376e34d323ecf227c2549f25e1342b421713c5452df986e4292ab3f6f496dfb36ae4bc82a8fafe3e450f52a8df466c9b5d71be18dd68c2386827f6a20d8c9fbd5289b23ff00daeb498bfb3b1ad93bcca3e71e27a666113867ab408f3516d67b1a3f6c6c89e520a:47cb36723356f470127889b9a61c6ec9:991daaf9bbee0102551400d7957193ed&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjg0MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.-N6AknVlVgJn5YGD3kfP2PSuXLlqgsEZLsHsLQepp8E&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology - PubMed\",\n \"description\": \"Secondary immunodeficiencies (SIDs) are acquired conditions that may occur as sequelae of immune therapy. In recent years a number of disease-modifying therapies (DMTs) has been approved for multiple sclerosis and related disorders such as neuromyelitis optica spectrum disorders, some of which are f …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34657228/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-2143dde1-593b-4af5-a4a5-fbd8796d5ab7\",\n \"slug\": \"patterns-of-peripheral-joint-involvement-in-psoriatic-arthri\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-08-30T11:22:59.000Z\",\n \"duration\": 18000,\n \"title\": \"\",\n \"message\": \"Patterns of peripheral joint involvement in psoriatic arthritis—Symmetric, ray and/or row? - ScienceDirect\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9631657,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/YfHvhLcSwmlHGoMQMiE1_1-s2.0-S0049017218X00067-cov150h.gif?file_detail=d64520aae62d8f037f378d14c63be7220fdefc93bf06ed83bcf1745aca0195f4cf96d05aaf6d3af2e04005b578e079c08cea38e0c8a757f268ea4e7ad366f157aa63eb8a5da63a9fbefcd11305c4a14ee5980d42fdadfe3d046199eebba6a059a75e3f265d6be80d2a5ca922ce149e1cd63439b7dd1e9e651e5e2cd59ed22f53:becb989b2010552edeb0acb366f4347e:df26c5987acb533dd8112aee52249e75&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjg1NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.DXn-82blkia4OjUGOb_kC4UkfHb9-9BQQWOGfKapcuY&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Patterns of peripheral joint involvement in psoriatic arthritis—Symmetric, ray and/or row? - ScienceDirect\",\n \"description\": \"We sought to examine whether joint involvement in psoriatic arthritis (PsA) follows a symmetric, ray, and/or row pattern using longitudinal data.Data …\",\n \"url\": \"https://www.sciencedirect.com/science/article/abs/pii/S0049017217307059\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109770251\",\n \"publishedAt\": \"2022-08-30T11:22:59.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4446443,\n \"message\": \"Patterns of peripheral joint involvement in psoriatic arthritis—Symmetric, ray and/or row? - ScienceDirect\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9631657,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/YfHvhLcSwmlHGoMQMiE1_1-s2.0-S0049017218X00067-cov150h.gif?file_detail=6294a4a7b2dcfbf54ca0300b786f25175f4b448bd7b85b2b141d1fbac169ac33ca579e018f100bad1659cf11caa230f1bb0bc9036e1e360ab20ed7b0b9ff96c037c98c5e4b1898c6becfa57fd17ba8501fe03a92e60c9a9471842d824371be46e788774c6f291592c5de268b9bcb9c6283a2d8a8687a6d228c713955a01bc4b9:63a151e9e690b6799c61ad5a72bc2046:13921be501cf9b5fce5d94b15935b5f9&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjg2OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ts4svubADbaNXb6k4DIfNGsuUvp2lTiJU55TaRmH0IU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Patterns of peripheral joint involvement in psoriatic arthritis—Symmetric, ray and/or row? - ScienceDirect\",\n \"description\": \"We sought to examine whether joint involvement in psoriatic arthritis (PsA) follows a symmetric, ray, and/or row pattern using longitudinal data.Data …\",\n \"url\": \"https://www.sciencedirect.com/science/article/abs/pii/S0049017217307059\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-ae01f034-1799-4b58-99a5-fc2670106873\",\n \"slug\": \"secukinumab-a-novel-anti-il-a-antibody-shows-low-immunog\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-04T20:04:27.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity - PMC\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9651569,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/THYuPJ6HS2YuEig68Sju_pmc-logo-share.png?file_detail=629b7f34907fe3244c799dcfd440cf13a51329c4eed53b57b451373b3b1fd7e6154321f4c6f7d3d87a2be57a278a3d47dc81709eaaaee9e1cdb170262a4d5cc381de65272cf4d64b426880ff736d9e69c31de9a2b917c5a128eafc503b7fecc3fe5ea0b25bde7a65bff4ae7fea9fdff8:a8929c0affd8605cfc3771ce828ef031:12d030ad8fe4a7be3a0b53d5fa30e2eb&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjg4MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.tBQapIu8eonsR_ZHn1RPZz24R6l2v5n9M23QINnd15Q&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity - PMC\",\n \"description\": \"Secukinumab is a human monoclonal antibody that selectively targets interleukin-17A and has been demonstrated to be highly efficacious in the treatment of moderate to severe plaque psoriasis, starting at early time points, with a sustained effect and ...\",\n \"url\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966846/\",\n \"siteName\": \"PubMed Central (PMC)\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109793938\",\n \"publishedAt\": \"2022-09-04T20:04:27.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4470424,\n \"message\": \"Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity - PMC\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9651569,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/THYuPJ6HS2YuEig68Sju_pmc-logo-share.png?file_detail=6a275636d01f62dd80711e830a70172a298a4fa3f8145a0aed3d21c23dd7eb98c87db72a70c88c8aa1bdb1e068db0966fcf1893335a4a2e1787a807902ad4de389cfcbc35da80b2ad34820c1561b9aa0902b52d0b59fe03c34bcd51a5b1416d28e4b1e490f430be7b2b52eabf7e0914c:11251bc8630fcfd3b7b9f80a87373e92:d260512493b4cecff0431f7943baa5ff&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjg5NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.i2zpI3gOU3axrAKbJGeaptfwJcHZC9sxHBfej-aMqCE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity - PMC\",\n \"description\": \"Secukinumab is a human monoclonal antibody that selectively targets interleukin-17A and has been demonstrated to be highly efficacious in the treatment of moderate to severe plaque psoriasis, starting at early time points, with a sustained effect and ...\",\n \"url\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966846/\",\n \"siteName\": \"PubMed Central (PMC)\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-451ff582-0af7-4f9e-805b-3b16df26ef75\",\n \"slug\": \"secukinumab-efficacy-on-resolution-of-enthesitis-in-psoriati-secukinumab\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-04T19:31:58.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies - PMC\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9651549,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/r3CIKr51S3igveox5FrU_pmc-logo-share.png?file_detail=a6535715bd5c9c0be113176422cc231c29746750c39b2740ecc104b8a87c7d1c5ca378776f92e35079bdbd1c3728e4f9039a94144f2a35efdf540cef84f3f3a63da5d9167096029859f6236a8bf98336aed71551e1b4f88f4b7bdf33ef39f68ef6d1c445684ee19580bc00598ba870da:fa4dd5538ab4484757bad5c848bd5782:7f2f97b2522e931cacf469760b1381ce&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjkxMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.PKfk8QRZaAsysDnnvb2lvvpJbTzv2cNcrk_APCEjaMM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies - PMC\",\n \"description\": \"Enthesitis is one of the psoriatic arthritis (PsA) domains. Patients with enthesitis are associated with worse outcomes than those without enthesitis. The effect of secukinumab on the resolution of enthesitis in patients with PsA was explored using pooled ...\",\n \"url\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894120/\",\n \"siteName\": \"PubMed Central (PMC)\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109793918\",\n \"publishedAt\": \"2022-09-04T19:31:58.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4470404,\n \"message\": \"Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies - PMC\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9651549,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/r3CIKr51S3igveox5FrU_pmc-logo-share.png?file_detail=289865d3c1db90aaa955d91ba3a4f72f2676bdc1f5dd2aa5220e943d6b7c85679ee10d88c3d39178b44cd9b57170e65ad04d664853decd3b38aaa6c7bed3a4d00cc8e5d579ca9e4e5f1fc96da4879787a224c33915b68e63eef246cd5faf8fe29c2a4c8e743919e7fd60997e60198e1e:0ad994c6f11c0ab7ec1e708d8d7dfcc5:370b9a762881a0ffeca688c45e83c799&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjkyNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.1Xe3ox-QZWUXn8mWwUM8Snh2pcB9eiflvobcfJf0pe0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies - PMC\",\n \"description\": \"Enthesitis is one of the psoriatic arthritis (PsA) domains. Patients with enthesitis are associated with worse outcomes than those without enthesitis. The effect of secukinumab on the resolution of enthesitis in patients with PsA was explored using pooled ...\",\n \"url\": \"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894120/\",\n \"siteName\": \"PubMed Central (PMC)\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-f85890ef-8094-4682-aed6-9675fea3b554\",\n \"slug\": \"firstword-pharma-card-551b94a3-776a-47f7-ab7c-174979aafa09\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-13T00:49:19.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"FirstWord Pharma +\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9689747,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/6cWIftMTkqX8dOT3uefg_fw_pharma_large_logo.png?file_detail=5dafa5ba34e18adb3b7bee6bb328ebd51704726fabe2efe9155104c112f7f042560737d2775e125e5a49c5f92212c8e47bd512015577036c847e6e59ea0f0d1a3ff36bd991fd348256fffcc4229d6c6de7793ddd1af35223b9acd071d724457d7da5a571a3158b9600de8b68445123d1:fce85e94e11207f4e5b75272e8d23ba7:bc769ca395dc9195df0cc29174f97ded&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjkzNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.BpWd_agti2-3vlP7uztIGnkncfnpxy9_b1snwFlUHPE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Cosentyx HS\",\n \"description\": \"Cosentyx in HS\",\n \"url\": \"https://firstwordpharma.com/story/5651463\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109837390\",\n \"publishedAt\": \"2022-09-13T00:49:19.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4513789,\n \"message\": \"FirstWord Pharma +\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9689747,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/6cWIftMTkqX8dOT3uefg_fw_pharma_large_logo.png?file_detail=bd84db013cf15b238f88a1c8f0ae82250ffe37763ec70243c0595abf521068a149ccbd9489a76886a6467127c13b6972ec8c08f3b4507522c161f8159ea5e46785a6bae3fcb8ddd20970b13a3b5f3c714ee56670667c4acdddda86bcc124a811aac655e9319c36eab398199d17bb62c3:3dbca973c3bdef179b21ab0de98eb8f7:4532a71025328745da4a56734933c532&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjk0OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.2xj3AHGNnj2TIvVdWcCUoT6kKdPtMnu_aVU9pz5V5yA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Cosentyx HS\",\n \"description\": \"Cosentyx in HS\",\n \"url\": \"https://firstwordpharma.com/story/5651463\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-76a0b608-1f78-4a19-8649-03cd42acf7e8\",\n \"slug\": \"phase-study-shows-promising-results-for-deucravacitinib-in\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-13T01:42:40.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Phase 2 Study Shows Promising Results for Deucravacitinib in PsA - The Rheumatologist\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9689786,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/xf3NiLJtT0eH235o38sT_Generic_shutterstock_DrugsPills_500x270.jpg?file_detail=01043e10bd2b6ed35feff8bc685415561e031420f067bded2b63c88db14b8c2ab806316f14abe42f75642c2d432091caa909fa8824054de34511bfcd5342a8ad7995f1068abffc21a6daffe9793371ea92843ddff0c5fd307d2b99a326be4be8220f30de2b26b1bfb1b8920fadfc2e177143bbbe70fdfc0a624dd60749027d79:348baa8f84ad30f046143d15cffeb894:67514bb9ef4755dd122637369243586a&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjk2MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.vm1OdbG4vjeacAAnW2rQD0F5ydqaC3C0wNmPAT3JWI0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Phase 2 Study Shows Promising Results for Deucravacitinib in PsA - The Rheumatologist\",\n \"description\": \"Research has demonstrated that deucravacitinib is significantly more efficacious than placebo for achieving minimal disease activity in patients with active PsA after 16 weeks of treatment.\",\n \"url\": \"https://www.the-rheumatologist.org/article/phase-2-study-shows-promising-results-for-deucravacitinib-in-psa/\",\n \"siteName\": \"The Rheumatologist\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109837430\",\n \"publishedAt\": \"2022-09-13T01:42:40.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4513829,\n \"message\": \"Phase 2 Study Shows Promising Results for Deucravacitinib in PsA - The Rheumatologist\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9689786,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/xf3NiLJtT0eH235o38sT_Generic_shutterstock_DrugsPills_500x270.jpg?file_detail=175983e7e900da38e011b7eb86bedf400d0177c85b309c2925dd299b81d2ec31d02086887547cd670f74b976b05d097fe7b6992aae600a098c37a0cfb933f0debeffa66a21a94fbe9841952c9d75cd431c202269ea5708a24345321d813b090fad439f3f3b76cf0d83042e59ea840e812563d1483a48ea380364643fa65c56f2:044d9420150cfa96d37c27686ac29114:769d66cf8781a0c7b534c538ced20079&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjk3MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ITbBIAsV7AzNaroii0o19yQUfupvP3RkGG5hxYu5bYU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Phase 2 Study Shows Promising Results for Deucravacitinib in PsA - The Rheumatologist\",\n \"description\": \"Research has demonstrated that deucravacitinib is significantly more efficacious than placebo for achieving minimal disease activity in patients with active PsA after 16 weeks of treatment.\",\n \"url\": \"https://www.the-rheumatologist.org/article/phase-2-study-shows-promising-results-for-deucravacitinib-in-psa/\",\n \"siteName\": \"The Rheumatologist\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-61e9ea2f-75ce-40eb-ada7-956de4a8fe22\",\n \"slug\": \"diagnosis-ax-spondy\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-13T01:34:55.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Diagnosis ax spondy\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9689782,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/YlM2AoDkTEGm19Dg1Ayu_3d-gear-wheels-elements_mJaMGz_L%20(NXPowerLite%20Copy).jpg?file_detail=ae445301aef98cafabcebdb0cbe272a7c35d914e433686d4343cbcad7f69c02a0baa21493ce0d890ffd67cf363f6423d4d9baec312f7828a6685d919ff47148741296ee6d6bbcd01c65187f54f78386d1519b094b70b51d248adfba5105fd432a881a15718c40e63d74fe3a582a90df5ce13c033e4cae9f4327cc80bc6d063ace41daacb9eeb83bcad75a6fa5f8a6586:73e0bb62b01b2cbaee408a5d2f2f8d1b:493b0e45d475e2f3063463d53aafa997&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjk4NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.wm1SL11XmEa5E5Cq5vgC6DfKwU6nL9BPdlXmPmYXIIk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Diagnosis as spondy\",\n \"description\": \"Diagnosis ax spondy\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/acr.24751\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109837425\",\n \"publishedAt\": \"2022-09-13T01:34:55.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4513824,\n \"message\": \"Diagnosis ax spondy\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9689782,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/YlM2AoDkTEGm19Dg1Ayu_3d-gear-wheels-elements_mJaMGz_L%20(NXPowerLite%20Copy).jpg?file_detail=27ab90bcefdaa8581e26d14dd8e2645e713089fa98f795f32b518334da091e3f43088da3790e3f15e91a2533c8a0397b7d0c5a8de60a363569a38e7a570f54defdf3abe4b3236c35ac56747e0cb22a115c454766915f3a530adf238b07cb06473ad2a9c7df5c1fc6d324110e859618188827758a3f55de9ec999ed1bc4eec432ef00e3bc3726a40d41d26e5748912cde:b61abac1d43af8acfd8223fec427c926:91e323a124ce23fe519029f864447251&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQxLjk5NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.2TBFI_UdQxH-Oe4HX1BlFuXSeP-mCl43TOH4O6fDL8k&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ1fX19XX0_&Signature=gB7BMwECRWNI1W2OXtMzLpfYeWGplJLUerNBUiKLe-jMzPJgfcw6XHczsv6DPodVEsZ3CIzXK8dC~S30unYf3ujDddenjPn-sCG35OyFgSu8iJceE1nW4ynuCqZr8Id-PEvfE4FWQcL5du8U3SLLrQhz772nUkxDfBsXjecH8acFYGuzow3hS59UevHnWFUs08gqPT6~~iuLNjCkSDTDemMuiz4QOvVraPibnKPR4oYdQLjHtzO42-Duq0TVH3mcrjsLHBRfJNc8Ws9R4hmuX8J68vThN1EhQLlXZgcz-IorzbrqWkdlOwwTp9YP0aqjlmC8bI7Vhy9SrqLieTIiAQ__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Diagnosis as spondy\",\n \"description\": \"Diagnosis ax spondy\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/acr.24751\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-b3361539-4fac-47da-a31b-9171769c3e67\",\n \"slug\": \"the-swedish-early-psoriatic-arthritis-registry-year-follow\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-21T22:13:36.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"The Swedish Early Psoriatic Arthritis Registry 5-year Followup: Substantial Radiographic Progression Mainly in Men with High Disease Activity and Development of Dactylitis | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9737915,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Ze4IffDnSbSEQMiJ4imQ_shining-vintage-microphone-presentation-on-stand-banner-or-template-design_zy_2Ntj__L%20(NXPowerLite%20Copy).jpg?file_detail=06182dd40faa92d6f40582c50eec3f5bc73d1b5e6f4f2d795257b8022d1964958cdc34e7ee2028751016d18f5e0d9a04f1e336a40d869e564bd2e380b8701c06fb50ea152fb41ce6298d0098fdeb0efb39ee0d0ad7bbb2a4a037ff247b64e8958d53d97fcf8187ffe3d0f431f51f65083f31a91b0f7625aaf007a04db5e0e8234aa684907c9f51cbdf55c07cc001374fea0d90d89b114274d907aa8a2fd41d2243f1ca93bd6b3087c9d91383e4224b1ade7313e66344ebfe3b6851df5abba375:aa4580fe16c114ab8219359364ed5baf:cc7b5d83184f4991562bacb691a62e3c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjAzMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.U1kjsD7AuRn92QZzQZzI5fT3Ix3acG2OolIYt6hU_0k&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Swedish Early Psoriatic Arthritis Registry 5-year Followup: Substantial Radiographic Progression Mainly in Men with High Disease Activity and Development of Dactylitis | The Journal of Rheumatology\",\n \"description\": \"Objective. To describe early radiographic findings in patients from the Swedish psoriatic arthritis (SwePsA) registry, progression of destruction, correlations with clinical disease variables, and predictors of destruction.\\n\\nMethods. Hand and foot radiographs were available for 72 of 197 SwePsA patients followed for 5 years. Clinical data were collected according to the SwePsA protocol.\\n\\nResults. Disease characteristics and clinical improvement were similar in men and women. Radiographic abnormalities were more pronounced in men. Total Wassenberg radiographic score at baseline was 0 in 45% of men and 51% of women. One man and one woman had a score > 10. At 5 years, total score was 0 in 14% of men and 40% of women (p = 0.018); 17% of men and 7% of women had scores > 10. Mean total scores for men and women had increased. Baseline erythrocyte sedimentation rate was associated with baseline total radiographic score. In men, swollen joint count was positively, and in women tender joint c...\",\n \"url\": \"https://www.jrheum.org/content/42/11/2110\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109890094\",\n \"publishedAt\": \"2022-09-21T22:13:36.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4568438,\n \"message\": \"The Swedish Early Psoriatic Arthritis Registry 5-year Followup: Substantial Radiographic Progression Mainly in Men with High Disease Activity and Development of Dactylitis | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9737915,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Ze4IffDnSbSEQMiJ4imQ_shining-vintage-microphone-presentation-on-stand-banner-or-template-design_zy_2Ntj__L%20(NXPowerLite%20Copy).jpg?file_detail=085c30f6ab376ddf09824fba060c1f3bebf3bbe4081806ef1a4feade27bc3c6bc8c7ee3ee24738b3c89710c6f93d6e758c86c9de9ec0fa5df278a00321c620f2549cbb0a5e2a7a3a8f07dbd721bc9a3e7c61549c3f5299ea45aac04482f1b0c3468c6d59627b6dec1c3a6743c0ccc4b4ce0570317a858c7b2d282b85c3634e7c2f3c3892458e64f05fdbf3305bc5f26d0233548abf24c95f5ddaa676f423d89e3960a5e1ac7a9772a2a296ce94e7d95ea8130dfc3767eda1f3bb8a89623442b3:85340120a0cbbfc227b1c431a2735a0c:9771437695790198262a55f079df0055&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjA0NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.CeYOj3KuR5FwTNh6edR_MpKVjR7g0uxMswSJqlMFB7Q&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Swedish Early Psoriatic Arthritis Registry 5-year Followup: Substantial Radiographic Progression Mainly in Men with High Disease Activity and Development of Dactylitis | The Journal of Rheumatology\",\n \"description\": \"Objective. To describe early radiographic findings in patients from the Swedish psoriatic arthritis (SwePsA) registry, progression of destruction, correlations with clinical disease variables, and predictors of destruction.\\n\\nMethods. Hand and foot radiographs were available for 72 of 197 SwePsA patients followed for 5 years. Clinical data were collected according to the SwePsA protocol.\\n\\nResults. Disease characteristics and clinical improvement were similar in men and women. Radiographic abnormalities were more pronounced in men. Total Wassenberg radiographic score at baseline was 0 in 45% of men and 51% of women. One man and one woman had a score > 10. At 5 years, total score was 0 in 14% of men and 40% of women (p = 0.018); 17% of men and 7% of women had scores > 10. Mean total scores for men and women had increased. Baseline erythrocyte sedimentation rate was associated with baseline total radiographic score. In men, swollen joint count was positively, and in women tender joint c...\",\n \"url\": \"https://www.jrheum.org/content/42/11/2110\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-9cc372b0-4c2d-4c88-84a6-29ecb512654d\",\n \"slug\": \"the-role-of-hla-b-in-spondyloarthritis-the-journal-of-rh\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-22T22:09:47.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"The Role of HLA-B27 in Spondyloarthritis | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9742698,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Hbs58qnSdyRnvRfMz1F5_635994041268567115-1015095974_education+stock+diversity+school+students+classroom+raise+hands.jpg?file_detail=b7d9b4e6a9ee72a66bfa6a4658aa73436a9ba29a04eeef901b84ba122a83ab0757396d01feb694ff4b98b8f52f151b9ef44ef4847af97f3369e493d0cfbd2a4fefd3f5bb450029682e9b0c93b0143c47ec0991e7ec2e489d1d82dc63b8f445ac76ec84e2619405cdfdf893bd7996f03e99540c37ad1bbe059fc86af8993c000914df0888ccd495c77ee137f7a3b8fbcab571c6a8c7e048fee62614d10cd2805054ee93d038515294837d20418a8ae428e777c886e54860bd0724e64bf97e4a1b:91725008a43c2890f8d7dab5aba507c9:8207ad1a6c24aba1722afc52ef856c86&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjA2NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Tsfh2cTDaeexd8cxADlxQfiKe1_Ld5XvAUOPuNXpmRo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Role of HLA-B27 in Spondyloarthritis | The Journal of Rheumatology\",\n \"description\": \"This article summarizes the proceedings of a one-day international workshop held in July 2009 on the role of HLA-B27 in the pathogenesis of ankylosing spondylitis (AS) and related disorders. HLA-B27 is found in about 90% of patients with AS, with an odds ratio of about 100, but the mechanism underlying this association is not known. There are currently 3 major mechanistic hypotheses for this association: (1) T cell recognition of one or more B27 presented peptides; (2) B27 heavy-chain misfolding that induces an unfolded protein response; and (3) innate immune recognition of cell-surface expressed B27 heavy-chain dimers. None of these hypotheses accounts for the tissue specificity of the inflammation characteristic of AS. These hypotheses were discussed in the context of known epidemiologic, biochemical, structural, and immunologic differences among HLA-B27 subtypes; data from the HLA-B27 transgenic rat model of spondyloarthritis; the growing list of other genes that have been found ...\",\n \"url\": \"https://www.jrheum.org/content/37/12/2606\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109895552\",\n \"publishedAt\": \"2022-09-22T22:09:47.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4573847,\n \"message\": \"The Role of HLA-B27 in Spondyloarthritis | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9742698,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/Hbs58qnSdyRnvRfMz1F5_635994041268567115-1015095974_education+stock+diversity+school+students+classroom+raise+hands.jpg?file_detail=73ad8719f9d383ac89cbdf3023f9e671258e5ce88ee8ac9ff853684144d06b44d3084c15b6420ea69520b76d4b1809225a590a304b09a2d61152ad579ef43ea9fc779f25a6d9aa57025baaa92f99a7112927efad284d690877dcb70e757c85c827e80b69e9723b00cb91e055c8e275802a9061a97cf4247d157867fb0547b04537ad707d9f513eca82d0c5d790d363c1c0e19821d768a4ca525714a7f85b201e2114c0e1722f7f704fb902008c57514306dbfe08a1a431c93522e7f74e264a43:82531123f6bf26c4c24347a1a746241f:0e9018e2f440b3dbd9b7c6e838de005f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjA3NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ZCAJIpvOQeSLBLTLBzhakG1Pi8I884X0kmmlGvVhxMs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Role of HLA-B27 in Spondyloarthritis | The Journal of Rheumatology\",\n \"description\": \"This article summarizes the proceedings of a one-day international workshop held in July 2009 on the role of HLA-B27 in the pathogenesis of ankylosing spondylitis (AS) and related disorders. HLA-B27 is found in about 90% of patients with AS, with an odds ratio of about 100, but the mechanism underlying this association is not known. There are currently 3 major mechanistic hypotheses for this association: (1) T cell recognition of one or more B27 presented peptides; (2) B27 heavy-chain misfolding that induces an unfolded protein response; and (3) innate immune recognition of cell-surface expressed B27 heavy-chain dimers. None of these hypotheses accounts for the tissue specificity of the inflammation characteristic of AS. These hypotheses were discussed in the context of known epidemiologic, biochemical, structural, and immunologic differences among HLA-B27 subtypes; data from the HLA-B27 transgenic rat model of spondyloarthritis; the growing list of other genes that have been found ...\",\n \"url\": \"https://www.jrheum.org/content/37/12/2606\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-0ad62487-12b9-467e-980f-ab663f3c0d1a\",\n \"slug\": \"the-relation-of-interleukin-il-and-il-to-th-th\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-22T21:08:20.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"The Relation of Interleukin 17 (IL-17) and IL-23 to Th1/Th2 Cytokines and Disease Activity in Systemic Lupus Erythematosus | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9742636,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/oAHYKVrYTuTW7WhAQehq_abstract-summer-background_fJZOu2___L%20(NXPowerLite%20Copy).jpg?file_detail=bc5326b09b0f766f11725e086734da19cd762ff722e4664d55f1169fdf54d5661a21dd492f112c6b9a5ac26b7f11ec17d810df152b913ee3c7bd127241f5d9b0cda69f7d0c10df733862b58741c37f2b5d884460d0b1cf0f4c22c23ebaae07663743b03c84a06373f1d88de4d611ab3d57d099e8e4ce7756167900257d49ee006cfb4aa75e6e717d8f596298a79ba64f:f17e77ec5b2afd306fce0c04cdcfe140:2e8e6a8deb2b988b9bdbcc4c2d8231ac&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjA4OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.wUVMHtIvxsl9PS-4HOrUQjDAXN4Ov-jJKd9Ue2Rcbvw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Relation of Interleukin 17 (IL-17) and IL-23 to Th1/Th2 Cytokines and Disease Activity in Systemic Lupus Erythematosus | The Journal of Rheumatology\",\n \"description\": \"Objective. Interleukin 17 (IL-17) was recently linked to pathogenesis of systemic lupus erythematosus (SLE), but its relation to disease activity has not been well characterized. We examined the relation between serum levels of Th17 (IL-17, IL-23), Th1 (IL-12, interferon-γ), Th2 (IL-10, IL-6, IL-4) cytokines and disease activity in patients with SLE.\\n\\nMethods. Serum cytokines were measured by enzyme linked immunosorbent assays. Disease activity was determined by SLE disease activity index (SLEDAI), anti-dsDNA antibody, and C3 and C4 levels.\\n\\nResults. Serum levels of IL-17 (p < 0.001), IL-6 (p = 0.006) and IL-10 (p < 0.001) were higher in SLE patients (n = 70) compared to healthy controls (n = 36). Higher serum IL-23 level was found in patients with active disease with cutaneous manifestations (p = 0.004) and serositis (p = 0.04) compared to those without. Serum IL-17 level above the detection limit was more frequently found in patients who had active lupus nephritis (11/23, 47.8%) (...\",\n \"url\": \"https://www.jrheum.org/content/37/10/2046\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109895467\",\n \"publishedAt\": \"2022-09-22T21:08:19.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4573762,\n \"message\": \"The Relation of Interleukin 17 (IL-17) and IL-23 to Th1/Th2 Cytokines and Disease Activity in Systemic Lupus Erythematosus | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9742636,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/oAHYKVrYTuTW7WhAQehq_abstract-summer-background_fJZOu2___L%20(NXPowerLite%20Copy).jpg?file_detail=d80b6ba2d281f81c417fb9b3ce59569b3db6f4959f9ee3973d10993fdd3f06d5371e2432536d27ceae61c8ae9b06006c275d7ceecc1fc0ee781572118a98ff2b18e4843d7383a65337d40747a08cb036d6600095c177ada5c940c537637faff5f475afa07de0fdb227561580e947a914befd0e8ed8b0d94ecc0508caaf18d7883f89349b454c5603353b6e3a769620ec:6c8b59acdae62f9e12c51f583b927669:c48a800a632961aa4afb2244afcb8dc2&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjEwMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.p4u5os8rB3CfT1t0zcuyTasf-_vJzYiRqWGqGCgjd4M&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Relation of Interleukin 17 (IL-17) and IL-23 to Th1/Th2 Cytokines and Disease Activity in Systemic Lupus Erythematosus | The Journal of Rheumatology\",\n \"description\": \"Objective. Interleukin 17 (IL-17) was recently linked to pathogenesis of systemic lupus erythematosus (SLE), but its relation to disease activity has not been well characterized. We examined the relation between serum levels of Th17 (IL-17, IL-23), Th1 (IL-12, interferon-γ), Th2 (IL-10, IL-6, IL-4) cytokines and disease activity in patients with SLE.\\n\\nMethods. Serum cytokines were measured by enzyme linked immunosorbent assays. Disease activity was determined by SLE disease activity index (SLEDAI), anti-dsDNA antibody, and C3 and C4 levels.\\n\\nResults. Serum levels of IL-17 (p < 0.001), IL-6 (p = 0.006) and IL-10 (p < 0.001) were higher in SLE patients (n = 70) compared to healthy controls (n = 36). Higher serum IL-23 level was found in patients with active disease with cutaneous manifestations (p = 0.004) and serositis (p = 0.04) compared to those without. Serum IL-17 level above the detection limit was more frequently found in patients who had active lupus nephritis (11/23, 47.8%) (...\",\n \"url\": \"https://www.jrheum.org/content/37/10/2046\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-f6a8ac15-2ee0-42e9-88b6-398bee6f150c\",\n \"slug\": \"enthesitis-myth-or-reality-the-journal-of-rheumatology\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-22T21:30:44.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Enthesitis: Myth or Reality? | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9742654,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/P24By8nkTeWBkzkXBvWB_graphicstock-concentrated-dark-skinned-businessman-working-late-at-night-in-office-with-computer_BLO9g_mdhx%20(NXPowerLite%20Copy).jpg?file_detail=a2b1a80b34e85923b69a126db6f9bb1043c87efe229bcb996732529f167dd04991341486192b9bb81cf9a24727fc2208b5135c90f8bc3394d737d870d59b174206c7ac771c9f7b09954549c2f1cb3d21db89ddba0a8df5f9c3cbd6946e52a0d6d8996ed2b7f253933d68ddd8bf0a5a467165304cd1fb7b2d5eccde99a7b202cc474e957f3c2fd8d31d3aae927ed145fc528abf5014c7fa0ae20878c7101ca771d0a87cb90cf16dad88ac364528f5e62236b987f009115a0f9515bdf92aea5ef23aba2d8ae79f96c9ee039e6ac84d40817cb4dc9dd2ce3dc1aeca3967e6ad30ae:32c5f5e16e5fab0de7169f3622251899:34ccfefbe8983ad836c76c3720cd7b65&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjExMyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.UcmteAzDHslmCVAUZXYXFBMtsXP9FfRDmWPE7jjGxSw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Enthesitis: Myth or Reality? | The Journal of Rheumatology\",\n \"description\": \"Homer’s Iliad tells the epic story of the Trojan War, a 10-year siege of the city of Troy, conducted by an alliance of Greek kings1. According to Homer, the reason for the Trojan war was the abduction of the most beautiful of women, Helen, by the Trojan prince Paris. Since the excavation works of the German archeologist Heinrich Schliemann, we know that the city indeed existed on the northwestern coast of Turkey. The Iliad gives an account of only the 10th year of the siege, in which the Greek warrior Achilles slays Hector, the commander of the Trojan army, and drags him for 9 days behind his chariot around the city. According to Greek mythology, Achilles was unbeatable, yet vulnerable for a single spot of his body where his mother held him as a baby while dipping him in the river Styx. Following the death of Hector, Paris shot an arrow guided by the god Apollo at Achilles. The arrow struck Achilles right at the enthesis of the tendon in the heel, presumably leaving him defenseless ...\",\n \"url\": \"https://www.jrheum.org/content/47/7/945\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109895487\",\n \"publishedAt\": \"2022-09-22T21:30:44.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4573782,\n \"message\": \"Enthesitis: Myth or Reality? | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9742654,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/P24By8nkTeWBkzkXBvWB_graphicstock-concentrated-dark-skinned-businessman-working-late-at-night-in-office-with-computer_BLO9g_mdhx%20(NXPowerLite%20Copy).jpg?file_detail=2e88051c9690d8edca6f6a40a07993088cf3aeedefa3b6b613c1f240b8f8d1837144ac5d871d3e0bb3fe44c2a54801f3aa85a4d93472d5ec74b2f3263e8ba5949aaf7e9486f294d1792c5a75f54df3c6503e9efb44d0e1b6e2372cc5e755c7691c609714c16d99b8535eebc1e4915be3e2bc69eb8caac35a671c44a04f43cf279d2e0de7e715d2fd480ec90eb23012dc05f4b22b5ade828ce4e2ca8688ce79514053bbcb2883f854d173a42c3b69e54da7703a4c5f05fadad967fd97823e9d73b9f01d11f18b481f79c9479cf07808ad6cdbad982be39581abc54ad1522c5c7a:78edf38f23f59b81b9d347f5fc7a2d04:9c432c33b490154368c84f83c027f56c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjEyNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.L6cpXv-pe2MhlIi0CVVx_65F7KK3tCTonb-EDjEYEbw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Enthesitis: Myth or Reality? | The Journal of Rheumatology\",\n \"description\": \"Homer’s Iliad tells the epic story of the Trojan War, a 10-year siege of the city of Troy, conducted by an alliance of Greek kings1. According to Homer, the reason for the Trojan war was the abduction of the most beautiful of women, Helen, by the Trojan prince Paris. Since the excavation works of the German archeologist Heinrich Schliemann, we know that the city indeed existed on the northwestern coast of Turkey. The Iliad gives an account of only the 10th year of the siege, in which the Greek warrior Achilles slays Hector, the commander of the Trojan army, and drags him for 9 days behind his chariot around the city. According to Greek mythology, Achilles was unbeatable, yet vulnerable for a single spot of his body where his mother held him as a baby while dipping him in the river Styx. Following the death of Hector, Paris shot an arrow guided by the god Apollo at Achilles. The arrow struck Achilles right at the enthesis of the tendon in the heel, presumably leaving him defenseless ...\",\n \"url\": \"https://www.jrheum.org/content/47/7/945\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-c7ed4051-f49a-4b58-9a47-09fa24289f75\",\n \"slug\": \"cardiovascular-morbidity-in-psoriatic-arthritis-what-is-the\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-22T21:48:00.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Cardiovascular Morbidity in Psoriatic Arthritis: What Is the Effect of Inflammation? | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9742668,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/wqXoxkKT2GknMqLUufYr_IMG_8395-1724%20(1)%20(NXPowerLite%20Copy).jpg?file_detail=2563ba5c33f2c3dde628aa93ebbd84001c4428f324c53ebb76c77bc8d145d35799cf0246916fe62c67e65a9559ce3f45865a3f557cce3154b835ea02ac85f58a5814c1a4dca879369da54cde31a193524b6479dd90dcace8eb05a4e05d646882bfc35e67832ddf289a0e5561ae1baca28f26ff1c2af1dcb33af4871cffa3efe9:506064c8037e2e65a9390178cc8462f9:0544a0379cf9ee42e91e62a978259968&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjE0MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.VaR3_Lw2g95aAs44WtbIUSh-vIu6hL1tq4NKN0WYgUM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Cardiovascular Morbidity in Psoriatic Arthritis: What Is the Effect of Inflammation? | The Journal of Rheumatology\",\n \"description\": \"The association between chronic inflammatory arthritis and cardiovascular (CV) morbidity is well established. Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis are at increased risk for CV morbidity and mortality1. This risk remains high even after accounting for traditional CV risk factors, which highlights the potential role of chronic inflammation and its interaction with conventional risk factors in promoting atherosclerosis. However, much of the knowledge about CV comorbidities in rheumatic patients, its epidemiology, and its underlying mechanisms comes from studies in patients with RA, while such data are limited in PsA.\\n\\nWhile some overlap can be found between PsA and RA in clinical features, treatment modalities, and underlying proinflammatory mechanisms, major differences exist between these 2 conditions. For example, PsA differs from RA in its demographics, the characteristics and extent of involvement of extraarticular tissues,...\",\n \"url\": \"https://www.jrheum.org/content/44/9/1295\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109895508\",\n \"publishedAt\": \"2022-09-22T21:48:00.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4573803,\n \"message\": \"Cardiovascular Morbidity in Psoriatic Arthritis: What Is the Effect of Inflammation? | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9742668,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/wqXoxkKT2GknMqLUufYr_IMG_8395-1724%20(1)%20(NXPowerLite%20Copy).jpg?file_detail=203316ecabb0483f9f040a7db2f517cae149b86ae85ae2c80cccec6d52146dce17e7b172f1b80a0cc62aa954a207d3f6dd44226a90ba1c68d769584e89bd49f9b45aa71348af68e4a1665f0d9c26c410833723166f08880ee56c61892887c964b2c2c76082810a9c5b25199c0e6d0c3839eff85b7a6568d471fd2f96c8331d34:08dcfbf8ce93ac2b119da310d7a0047c:ee0f836fbc2417e3e23eb10decf9dc6d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjE1OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.yBMZK41GHfHuzSUlHO_nYQLMIgQuYJ-E7vB3ov5eNYU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Cardiovascular Morbidity in Psoriatic Arthritis: What Is the Effect of Inflammation? | The Journal of Rheumatology\",\n \"description\": \"The association between chronic inflammatory arthritis and cardiovascular (CV) morbidity is well established. Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis are at increased risk for CV morbidity and mortality1. This risk remains high even after accounting for traditional CV risk factors, which highlights the potential role of chronic inflammation and its interaction with conventional risk factors in promoting atherosclerosis. However, much of the knowledge about CV comorbidities in rheumatic patients, its epidemiology, and its underlying mechanisms comes from studies in patients with RA, while such data are limited in PsA.\\n\\nWhile some overlap can be found between PsA and RA in clinical features, treatment modalities, and underlying proinflammatory mechanisms, major differences exist between these 2 conditions. For example, PsA differs from RA in its demographics, the characteristics and extent of involvement of extraarticular tissues,...\",\n \"url\": \"https://www.jrheum.org/content/44/9/1295\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-dde360b8-c3ae-4e64-a24e-5f273ea224ea\",\n \"slug\": \"prevalence-of-nonradiographic-sacroiliitis-in-patients-with\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-22T21:56:58.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Prevalence of Nonradiographic Sacroiliitis in Patients With Psoriatic Arthritis: A Real-life Observational Study | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9742680,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/6pCqgakaRuqlppN5GEQN_storyblocks-modern-multi-storey-building-with-open-space-offices_SUglhxIvR-%20(NXPowerLite%20Copy).jpg?file_detail=da98f79eb1ab823533c43543af27aea1e329915345daf9a9b6787f5047e47eef471675c16a889d7e569b9e9487399a2bf354047a09d2bab5928a1ab31bf778aa8d0794604f3646dea6b3cd24f648488878fb8c4176c6cfcb868ed378a68cc141ebd898b5356179f863d6efef3c16c8cf33b94f8a50bab902f42ab5c978bcc73a629bb5062267cd17765dd3de7c026f06159cac96c8383f8901db1c7fbbf244a8041b0ecbdcb7480a3350ffe0b47b9a77d08694cdc6be6f0c75771daf97b521a0:cf21f56668680321b194d98b30428191:03ddd6678a7bddf166f54c74c680c2c8&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjE3MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Gla2r1Q3ShIB5zw5dVb0-De53y1PkYDJ567Qmjny__Q&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Prevalence of Nonradiographic Sacroiliitis in Patients With Psoriatic Arthritis: A Real-life Observational Study | The Journal of Rheumatology\",\n \"description\": \"Objective. To establish the prevalence of nonradiographic sacroiliitis within a real-life sample of patients with psoriatic arthritis (PsA), using pelvic radiographs and magnetic resonance imaging (MRI) of sacroiliac joints (SIJs).\\n\\nMethods. This cross-sectional study included 107 consecutive adults with PsA (Classification Criteria for Psoriatic Arthritis criteria). Participants completed clinical and laboratory evaluation, pelvic radiographs scored for radiographic sacroiliitis according to the modified New York (mNY) criteria, and noncontrast MRI of SIJs, scored by the Berlin score and categorized into active sacroiliitis using the 2016 Assessment of Spondyloarthritis international Society (ASAS) criteria and the presence of structural sacroiliitis.\\n\\nResults. Radiographic sacroiliitis/mNY criteria were detected in 28.7% (n = 29), confirmed by MRI-detected structural lesions in 72.4% (n = 21). Active sacroiliitis was detected by MRI in 26% (n = 28) of patients, with 11% (n = 11) q...\",\n \"url\": \"https://www.jrheum.org/content/48/7/1014\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109895520\",\n \"publishedAt\": \"2022-09-22T21:56:58.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4573815,\n \"message\": \"Prevalence of Nonradiographic Sacroiliitis in Patients With Psoriatic Arthritis: A Real-life Observational Study | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9742680,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/6pCqgakaRuqlppN5GEQN_storyblocks-modern-multi-storey-building-with-open-space-offices_SUglhxIvR-%20(NXPowerLite%20Copy).jpg?file_detail=3b1652f2b7f358ece76e7f715f6caf9a769f4a16bbff7dbbfcb6c0b7ff46a46ddeead7f9df0f05144dfbcd60cb02b5676e95418799a5b9ceea0f438f2ec41ffb18ce2dd70d21b14e0378ddb768ff9cdca870db8d1c8a863231ee68b590a36fd69c27841fd3df1016b36db0e3f49ab6c78f99ba3962182286673d11670fed70186fa66db6672fc0d7708004ec8df300aec1a39e30be5092a74debc61153fa5ef2f6c628d5e2d0f296d6fbed3040faa68fceabcf0bbacb62f04d5b4c9d278097f5:33b090fe424b3059fed806318b137f4e:1a0b20df2b0423ac393765fc4a6249ea&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjE4NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Frctyxxy9rTR_kr8M2kSAMR5a7oTkfSd9BciZJJEzb4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Prevalence of Nonradiographic Sacroiliitis in Patients With Psoriatic Arthritis: A Real-life Observational Study | The Journal of Rheumatology\",\n \"description\": \"Objective. To establish the prevalence of nonradiographic sacroiliitis within a real-life sample of patients with psoriatic arthritis (PsA), using pelvic radiographs and magnetic resonance imaging (MRI) of sacroiliac joints (SIJs).\\n\\nMethods. This cross-sectional study included 107 consecutive adults with PsA (Classification Criteria for Psoriatic Arthritis criteria). Participants completed clinical and laboratory evaluation, pelvic radiographs scored for radiographic sacroiliitis according to the modified New York (mNY) criteria, and noncontrast MRI of SIJs, scored by the Berlin score and categorized into active sacroiliitis using the 2016 Assessment of Spondyloarthritis international Society (ASAS) criteria and the presence of structural sacroiliitis.\\n\\nResults. Radiographic sacroiliitis/mNY criteria were detected in 28.7% (n = 29), confirmed by MRI-detected structural lesions in 72.4% (n = 21). Active sacroiliitis was detected by MRI in 26% (n = 28) of patients, with 11% (n = 11) q...\",\n \"url\": \"https://www.jrheum.org/content/48/7/1014\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-7664169a-35bc-40a6-9897-bd50997994e1\",\n \"slug\": \"methotrexate-in-psoriasis-and-psoriatic-arthritis-the-jour\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-22T21:37:26.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Methotrexate in Psoriasis and Psoriatic Arthritis | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9742662,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/erMe6cNjR7u9pQrno94g_JM-Industrial-YAX_9669%20(NXPowerLite%20Copy).jpg?file_detail=56850349ea1509dc8a0353d2c58cf96596e3601e00b8cfaf6fceb70c1a47c84df88e4eb139ca65995d0ca67ff1960fe68725c97c08e1e7e31cdafb751b8306da4c582930ae7265492d16f926e9b1f1b11d392f2d127c2995bca012809498a51a6e4f37a6181b67e5308322f37d7148d532367195c0e2d3b9536d0c8c6d987ee7:f423ca695658b195cbff277cda4e8faa:0384e8debae94665608ce9386950caee&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjE5OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Gal1o5FkLgbyVtqXD6hAiRFneUFKXu6xaeDCFx_StW0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Methotrexate in Psoriasis and Psoriatic Arthritis | The Journal of Rheumatology\",\n \"description\": \"Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarizes a debate at the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and 1 patient research partner presented clinical study data and the patient experience summarizing the efficacy, tolerability, and toxicity of MTX for both skin and musculoskeletal manifestations. A survey of attending GRAPPA members collected data on current and planned future use of MTX across the world.\",\n \"url\": \"https://www.jrheum.org/content/96/31\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109895503\",\n \"publishedAt\": \"2022-09-22T21:37:26.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4573798,\n \"message\": \"Methotrexate in Psoriasis and Psoriatic Arthritis | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9742662,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/erMe6cNjR7u9pQrno94g_JM-Industrial-YAX_9669%20(NXPowerLite%20Copy).jpg?file_detail=a156236a5ff30b2ae89a6d7d055a578fccab9629201416a4083551fcd1ea503f38b8da0bc030c93420830ab6f65ab0d8f76f9305119446ff29e00ea3c450efffc2561271298865e13b863ed1510093649c78966f7278e056e9ef85b4a684c4aadab83df38006aca38865f5894fa4b62a2bf0a36abdbc8f41044f8364b25662a8:ab3d031a4c097c02fa56b066c0016c7e:ee68fdb0a5da8d409f54542b78193824&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjIxMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.k9nUcdfeCUR71R4dE4MCw1iUFC9BV9m9jdAjuiFQYpc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Methotrexate in Psoriasis and Psoriatic Arthritis | The Journal of Rheumatology\",\n \"description\": \"Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarizes a debate at the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and 1 patient research partner presented clinical study data and the patient experience summarizing the efficacy, tolerability, and toxicity of MTX for both skin and musculoskeletal manifestations. A survey of attending GRAPPA members collected data on current and planned future use of MTX across the world.\",\n \"url\": \"https://www.jrheum.org/content/96/31\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-6e93308f-db14-40ef-a0bd-3b7ba64283f9\",\n \"slug\": \"persistence-and-discontinuation-rates-w-cosentyx\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-15T01:53:35.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Persistence and Discontinuation Rates w COSENTYX\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9714005,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/wjRQTlzFTNS7geVjpzNT_graphicstock-feet-of-unrecognizable-businessman-sitting-at-his-office-desk-brick-wall-background-smart-phone-tablet-and-various-office-supplies-around-the-workplace-flat-lay_r_xjnxLrzb%20(NXPowerLite%20Copy).jpg?file_detail=e1601900a25b7adca0810aca9f428a7d3b53db045c6b133c076e106f5ab63b67066d8698e445357a21e0e00da398900a4d9090050cbecd73253c651e58de6e58c1561b26c15e2cefa8690ec8fc0863e2a88205e8204eeaa95afc56cbe2e43feb52635870147f54ce35cc6030af8eb6baa3e385fc069492f977a2d674fd1d2d46e3989ec682041291bc49f6aec41d2dec334b98cc243cab5261ba62f03d44fb34b05b5695a899990338ed512a3f05238b5e795b1d2775fa5928deb18c3449ecbfb37fe615ab8d90e9aa558a46b1d532523292cfb594e2929e076e9483b11d866c1346d41da649ab8db11d9f2275ed32bb1c48f3dc8852aed8026dd3bf04cfb8b169f8ec4254ba514021cd2b2a80e57d362293f4731b7dc2942e7d409c9f80e8df:44912134f89b92aa388452ece5a5f20f:492f64bab3e8249f069e741e065a848e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjIyMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.h7p3FHdVhed6beodYL6S7tgNtdC89O6HjywcAgVuJwE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Persistency and Discontinuation Rates COSENTYX\",\n \"description\": \"Persistency w COSENTYX\",\n \"url\": \"https://www.futuremedicine.com/doi/10.2217/cer-2019-0023\",\n \"siteName\": \"Future Medicine\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109863338\",\n \"publishedAt\": \"2022-09-15T01:53:35.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4539687,\n \"message\": \"Persistence and Discontinuation Rates w COSENTYX\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9714005,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/wjRQTlzFTNS7geVjpzNT_graphicstock-feet-of-unrecognizable-businessman-sitting-at-his-office-desk-brick-wall-background-smart-phone-tablet-and-various-office-supplies-around-the-workplace-flat-lay_r_xjnxLrzb%20(NXPowerLite%20Copy).jpg?file_detail=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:704ae34ff29191f07ac12201f99a11f0:21c4f9fff838b8ef5dd4a5c7c71ba88d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjIzNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.GcDuuDZ8tEIC85UxmyaxBgUvhlN08q64r7e4ht-agrA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Persistency and Discontinuation Rates COSENTYX\",\n \"description\": \"Persistency w COSENTYX\",\n \"url\": \"https://www.futuremedicine.com/doi/10.2217/cer-2019-0023\",\n \"siteName\": \"Future Medicine\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-2faf9ff8-9e7a-4b2f-8066-05faf1355c8f\",\n \"slug\": \"failure-of-methotrexate-monotherapy-and-subsequent-response\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-18T21:53:43.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Failure of Methotrexate Monotherapy and Subsequent Response to Tumor Necrosis Factor Inhibitors in Pediatric Non-Infectious Uveitis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9070118,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/jrQjYu5xS76uVojIJyzH_AbstractSubmission_826695_1.jpg?file_detail=53bd808158d6e59c27235f1cddb25a9335cbf5dceb40ff2f7dbcdbebdbfc1f22e10bab115fa01c4f390226b5fe2674ba439d58ad7ef65f311366ae9298dbce097104a2c03371beeef0d2fc86dfff41377df9f53ed95b11c2afda4892b31c16ba971452598337f5ce04f44de794622442:112e23846b60e5de88ac6d51fa206773:9d144e61f706e78e63a258081df43822&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjI0NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.6dMDfKB-i_DyBzo7NJAIYtRrBBAAQTeblqW7Ssghc_A&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Failure of Methotrexate Monotherapy and Subsequent Response to Tumor Necrosis Factor Inhibitors in Pediatric Non-Infectious Uveitis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Pediatric non-infectious uveitis is often treated with systemic immunomodulators in a step-wise fashion, with methotrexate (MTX) followed by tumor necrosis factor alpha inhibitors (TNFi) in refractory cases. There is currently limited published data indicating whether some types of uveitis have more favorable responses to specific medications than others. This study aimed to determine the […]\",\n \"url\": \"https://acrabstracts.org/abstract/failure-of-methotrexate-monotherapy-and-subsequent-response-to-tumor-necrosis-factor-inhibitors-in-pediatric-non-infectious-uveitis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109109344\",\n \"publishedAt\": \"2022-02-18T21:53:43.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3784837,\n \"message\": \"Failure of Methotrexate Monotherapy and Subsequent Response to Tumor Necrosis Factor Inhibitors in Pediatric Non-Infectious Uveitis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9070118,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/jrQjYu5xS76uVojIJyzH_AbstractSubmission_826695_1.jpg?file_detail=f3917a4062e0c8589abb0097afc7474f3c666bb660ef2b54a395c4ff91225f2cf8e659ee0f419477ff39794e222476f54d8e2dbe99bfdc44e9ce13f88754df5ced06b30d0f247acbc3a9648b821401d9607fe228d2fa56aee81af696ed122b7438365595ee7721d186194da357d672f0:7300c5aee173dc5915a7b9b459e883d8:0024ea0f0eac71495072dacc861d8a2a&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjI1OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.uuz0UgdDuL2KoiOPe59_2kvngygeLGVsLPdUuXWSkzg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Failure of Methotrexate Monotherapy and Subsequent Response to Tumor Necrosis Factor Inhibitors in Pediatric Non-Infectious Uveitis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Pediatric non-infectious uveitis is often treated with systemic immunomodulators in a step-wise fashion, with methotrexate (MTX) followed by tumor necrosis factor alpha inhibitors (TNFi) in refractory cases. There is currently limited published data indicating whether some types of uveitis have more favorable responses to specific medications than others. This study aimed to determine the […]\",\n \"url\": \"https://acrabstracts.org/abstract/failure-of-methotrexate-monotherapy-and-subsequent-response-to-tumor-necrosis-factor-inhibitors-in-pediatric-non-infectious-uveitis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-2d2d532b-c497-40e6-8270-6a311062bfde\",\n \"slug\": \"efficacy-and-safety-of-subcutaneous-and-intravenous-loading\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-09-21T23:52:04.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9737979,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/EKbPSxc1SDCQLZo79Wn7_graphicstock-african-business-woman-in-dress-working-with-laptop-and-documents-on-workplace-near-the-window_HLqFSvXdhe%20(NXPowerLite%20Copy).jpg?file_detail=612b665488c7813c46654ce85c42c3dc0d62dd10993d6c069f0df231abe63e1ba74db5a265cbbe877315d0b4447619b917748d87551bbc18185cd829c8d2d140ad18e3f18e83eeb5a54940fb47da61a64c6191b7fcee10a6202d21ec41f0a5d1c0e210e932e448de065b6ea5da444c25895caed402d22910b67c2a63cb389cca78d3f992a25aed44f61a65e247e6989146892445f887c8588fdcb8ed186901705d3565ad3c565b258898af827861d04e72c06393c03708eaf74b6db5b60d9d1b6054fc2281d47f41896d57ef25f9316f1ccd5f35a8ec77d27dfd959bb01a0bf7:6e0e1d3956b5b076aeb1e2545f7d686b:77c8eb97804b4460d0be4781a593f9ca&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjI3MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.bbVKWldm6D_q-tK163_UvJlfyUBeIid599Nto0zl44M&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study | The Journal of Rheumatology\",\n \"description\": \"Objective. To evaluate the efficacy and safety of secukinumab, a fully human antiinterleukin-17A monoclonal antibody, administered with an intravenous (IV) or subcutaneous (SC) loading regimen versus placebo, in patients with active rheumatoid arthritis (RA).\\n\\nMethods. In this phase II, double-blind, double-dummy, 52-week study ([ClinicalTrials.gov][1] [NCT01359943][2]), 221 patients with inadequate response to methotrexate were randomized (2:2:1) to secukinumab, IV loading 10 mg/kg at baseline, Weeks 2 and 4, then SC 150 mg every 4 weeks (n = 88); secukinumab SC loading 150 mg once weekly for 5 weeks, then every 4 weeks (n = 89); or a matching placebo (followed by secukinumab 150 mg every 4 weeks starting Week 16; n = 44). The primary endpoint was superior efficacy of pooled secukinumab versus placebo using American College of Rheumatology 20% response (ACR20) at Week 12.\\n\\nResults. The primary efficacy endpoint was not met: ACR20 response at Week 12 was 49.2% for pooled secukinumab...\",\n \"url\": \"https://www.jrheum.org/content/43/3/495\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109890187\",\n \"publishedAt\": \"2022-09-21T23:52:04.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4568531,\n \"message\": \"Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study | The Journal of Rheumatology\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9737979,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/EKbPSxc1SDCQLZo79Wn7_graphicstock-african-business-woman-in-dress-working-with-laptop-and-documents-on-workplace-near-the-window_HLqFSvXdhe%20(NXPowerLite%20Copy).jpg?file_detail=c13603153cf4755e960b39b29e5cd712b1a7f537be2e253d9f64e875f5e9b814e5bc8ff9c7aabc69e2ea21d6ba691af241f83ab3f7ef8a24c41fa4b0966f471301d31b137851bd593d7c177c1f6216f9e8d5aba5214430a606c6abc1f1b18b6320baf45a033d680495e75075c5a72b674624caedc8901e8d3942a819b35f1333fff4d3cc45f3001522ccba36fc9b113f8ba73b9fc56423b8978cf33b671aad387d9d41ba30459e84f899963d88f027a81a2bc022783c673c66caf62239bbf01888f26d284d759d560e67a3f2fe26e94f15d8f763ba4fc0bb21215fa6d67efd5d:828c7d40e0bc9b0de32df3e083873772:562f9bd6c240bd1b4ecf925f376a2758&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjI5MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.yzfNs8HBccV20rnPUcElYLD6Kx1t3BImGWqlyzIfbK8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study | The Journal of Rheumatology\",\n \"description\": \"Objective. To evaluate the efficacy and safety of secukinumab, a fully human antiinterleukin-17A monoclonal antibody, administered with an intravenous (IV) or subcutaneous (SC) loading regimen versus placebo, in patients with active rheumatoid arthritis (RA).\\n\\nMethods. In this phase II, double-blind, double-dummy, 52-week study ([ClinicalTrials.gov][1] [NCT01359943][2]), 221 patients with inadequate response to methotrexate were randomized (2:2:1) to secukinumab, IV loading 10 mg/kg at baseline, Weeks 2 and 4, then SC 150 mg every 4 weeks (n = 88); secukinumab SC loading 150 mg once weekly for 5 weeks, then every 4 weeks (n = 89); or a matching placebo (followed by secukinumab 150 mg every 4 weeks starting Week 16; n = 44). The primary endpoint was superior efficacy of pooled secukinumab versus placebo using American College of Rheumatology 20% response (ACR20) at Week 12.\\n\\nResults. The primary efficacy endpoint was not met: ACR20 response at Week 12 was 49.2% for pooled secukinumab...\",\n \"url\": \"https://www.jrheum.org/content/43/3/495\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-a98c4774-cbf8-4207-bc0b-2dfdfe8b7862\",\n \"slug\": \"use-of-anti-tumor-necrosis-factor-therapy-is-associated-with\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-23T01:08:10.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9081706,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/9TFexu6kToa8vGknrA1m_graphicstock-three-caucasain-business-women-holding-growth-graph-cheerful-business-team-with-growth-graph-concept-of-business-growth-teamwork-and-partnership-vector-flat-design-illustration-square-layout_HQ9qm_88Z_L%20(NXPowerLite%20Copy).jpg?file_detail=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:6362885c08f370f00f545197019c5f4a:be68169e6f73e87998eaef2622419bfd&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjMwNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.YnpY8ygZ7vAS_H7APiMRDekEPWu1oG--m6j7vCVieK8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risks for cardiovascular (CV) comorbidities because of an increased prevalence of traditional CV risk factors and the underlying chronic inflammatory process. We assessed the effects of treatment with anti–tumor necrosis factor (anti-TNF) therapy, methotrexate (MTX), or other nonbiologic DMARDs on CV event risk in patients with RA. […]\",\n \"url\": \"https://acrabstracts.org/abstract/use-of-anti-tumor-necrosis-factor-therapy-is-associated-with-reduced-cardiovascular-event-risk-in-rheumatoid-arthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109122968\",\n \"publishedAt\": \"2022-02-23T01:08:10.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3798393,\n \"message\": \"Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9081706,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/9TFexu6kToa8vGknrA1m_graphicstock-three-caucasain-business-women-holding-growth-graph-cheerful-business-team-with-growth-graph-concept-of-business-growth-teamwork-and-partnership-vector-flat-design-illustration-square-layout_HQ9qm_88Z_L%20(NXPowerLite%20Copy).jpg?file_detail=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:ae742c0a842a472b1c9005a4871277d3:aed623c2da6cfb07185aaa77db85a24b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjMyMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.TFOEN94REYmwBXmHBQwKi5s8SGOXFtKqzfpeAr71-yo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risks for cardiovascular (CV) comorbidities because of an increased prevalence of traditional CV risk factors and the underlying chronic inflammatory process. We assessed the effects of treatment with anti–tumor necrosis factor (anti-TNF) therapy, methotrexate (MTX), or other nonbiologic DMARDs on CV event risk in patients with RA. […]\",\n \"url\": \"https://acrabstracts.org/abstract/use-of-anti-tumor-necrosis-factor-therapy-is-associated-with-reduced-cardiovascular-event-risk-in-rheumatoid-arthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-dfa053b3-cadf-4ee2-ad62-702f0e625ab5\",\n \"slug\": \"randomized-placebo-controlled-trial-of-methotrexate-in-psori\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-10-12T22:50:53.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"randomized placebo-controlled trial of methotrexate in psoriatic arthritis | Rheumatology | Oxford Academic\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9828685,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/ITdFo1XtR3qkH60iroy3_m_kes001f1.jpeg?file_detail=3e599ff9b77d4680022b28e9bb3aa0d2734e8df7254e0c5ebf55c2cb1bbcc28b3d8b67ab81e073fcaea60e29b39cfe04a3ed137404b442e94f7b2fd09d2f634579b071e50519196933d086dfa5dcb503b29e1dff45c204a5c23552c037637d44:f87c6c125baba3e35c20dd5e04ff6b0d:0867bfa8e993c83f555eaebf42223522&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjMzNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0._JZXMp6Wb8LBcy03Pj8c38-G88rzIR-3hdPP-DDdysY&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"randomized placebo-controlled trial of methotrexate in psoriatic arthritis | Rheumatology | Oxford Academic\",\n \"description\": \"Abstract. Objective. MTX is widely used to treat synovitis in PsA without supporting trial evidence. The aim of our study was to test the value of MTX in the fi\",\n \"url\": \"https://academic.oup.com/rheumatology/article/51/8/1368/1841107\",\n \"siteName\": \"OUP Academic\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109992924\",\n \"publishedAt\": \"2022-10-12T22:50:53.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4671071,\n \"message\": \"randomized placebo-controlled trial of methotrexate in psoriatic arthritis | Rheumatology | Oxford Academic\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9828685,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/ITdFo1XtR3qkH60iroy3_m_kes001f1.jpeg?file_detail=bf2d4cdb222d9cacb77f063397e75ae85a298d186e6f9873c988d5a42117b08d7346b77e34d851fb0ed818cdb8972a744dabb0a675fedb9f2b7a6e2511f0b92b3fffd479a0b8ad6d0439c4642f3ef29db9102451b05ea81c015b9eb41a7b9032:45a5f3f1bad29673a068847b020cc0be:3b8bbf37469c08fa8881ae389f2c1d4a&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjM0NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.h3Qr-VaHfLLGBjlm4Zt3RUfGYlKRNfgY-firrug5OQw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"randomized placebo-controlled trial of methotrexate in psoriatic arthritis | Rheumatology | Oxford Academic\",\n \"description\": \"Abstract. Objective. MTX is widely used to treat synovitis in PsA without supporting trial evidence. The aim of our study was to test the value of MTX in the fi\",\n \"url\": \"https://academic.oup.com/rheumatology/article/51/8/1368/1841107\",\n \"siteName\": \"OUP Academic\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-4db1e991-a348-486d-8c66-08fdce836ef8\",\n \"slug\": \"asas-guidelines\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-11-10T14:49:41.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Asas 2022 guidelines\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 10001832,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/lUlYruXROaJ60hr4gAXo_temp.jpg?file_detail=b24ca823e8f99ad5d74eb9121c358c27758e7dc26d4c1c2724df50ab0cf60a61971df62c48a456318228cb00e79e257a1271ea796ee5e07ec38e299474b8cf2e202d7dbb0d648f61b4354965a501fda5604591499747a28575c8a2fd71cf0562:05e4e19ac77f15a415747e3307b7b47c:27bd69e12e102eeaaac66157a4eccc92&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjM2MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.8orpAryWC3XWZsnxv7fh_3PI-zz0qX5GZTdQJndqUJI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"ASAS 2022 GUIDELINES\",\n \"description\": \"2022 ASAS GUIDELINES\",\n \"url\": \"https://ard.bmj.com/content/annrheumdis/early/2022/10/21/ard-2022-223296.full.pdf\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/110178459\",\n \"publishedAt\": \"2022-11-10T14:49:41.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 4858747,\n \"message\": \"Asas 2022 guidelines\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 10001832,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/lUlYruXROaJ60hr4gAXo_temp.jpg?file_detail=894e9f056001f6c1dbcdb80f8b44f60f18d552a3c4cd1495710bbafd5b7fad5d00ac37f2ba51a455d93db75e1e0a7bdbc737ec2d6d2d2f2232123d8b400c6319b6e9caa6c140fc7f29ba8f5a56b5b24d1c8fb75981e5d8d5a6b21f9bf254636b:e41583536f2a79cde59e035e5a95f667:1e87d4c5f6f7585084b80c58670914c3&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjM3NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.D9dmy_yObZxYApEjjxLlZYclXiYGHpklTWrP9e_IxMs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"ASAS 2022 GUIDELINES\",\n \"description\": \"2022 ASAS GUIDELINES\",\n \"url\": \"https://ard.bmj.com/content/annrheumdis/early/2022/10/21/ard-2022-223296.full.pdf\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-77e93ec6-6715-491d-9633-d92cf557a6a4\",\n \"slug\": \"immunogenicity-of\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-01-18T04:00:13.000Z\",\n \"duration\": 60,\n \"title\": \"Immunogenicity of Biologics in Chronic Inflammatory Disease\",\n \"message\": \"Immunogenicity of Biologics in Chronic Inflammatory Disease\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": null,\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109002084\",\n \"publishedAt\": \"2022-01-18T04:00:13.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3676722,\n \"message\": \"\",\n \"language\": \"en\"\n }\n ]\n },\n {\n \"id\": \"ECL-8695642c-dcdd-441d-bf3f-95ed117bf710\",\n \"slug\": \"inflammatory-pathways\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-01-18T02:46:59.000Z\",\n \"duration\": 0,\n \"title\": \"Inflammatory Pathways TH-17/IL-17\",\n \"message\": \"Inflammatory Pathways TH-17/IL-17\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Slides\",\n \"resource\": null,\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109001986\",\n \"publishedAt\": \"2022-01-18T02:46:59.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3676626,\n \"message\": \"\",\n \"language\": \"en\"\n }\n ]\n },\n {\n \"id\": \"ECL-3693b728-dc42-4491-8928-22fe38ed3090\",\n \"slug\": \"clinical-features-domains\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-01-18T04:02:10.000Z\",\n \"duration\": 60,\n \"title\": \"Clinical Features/Domains of PSA\",\n \"message\": \"Clinical Features/Domains of PSA\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": null,\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109002094\",\n \"publishedAt\": \"2022-01-18T04:02:10.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3676732,\n \"message\": \"\",\n \"language\": \"en\"\n }\n ]\n },\n {\n \"id\": \"ECL-59d053c9-73fc-44b9-bafc-e12556821eff\",\n \"slug\": \"grappa-s-patient-guide-booklet\",\n \"cardType\": \"media\",\n \"createdAt\": \"2021-12-15T18:53:57.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"GRAPPA’s Patient Guide Booklet\",\n \"language\": null,\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Article\",\n \"resource\": {\n \"id\": 8900648,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/6uytHxmVSOmw7e3dHfrP_graphicstock-manager-in-a-superman-pose-wearing-a-red-cloak-studio-shot-on-a-beige-background_rAr6iJnZ-%20(NXPowerLite%20Copy).jpg?file_detail=64c35cec29d913f43618c0e15e2654b44651f198854cc855c22185ef8bbf99525c51a640b29381f976d4a9de84c1e7569af27bccfc99639eaf8bf26442bbeb03b4293c191323b1feb46b3753a58aa726c56cefa2628507f9bb92f17d8ad05437dfb3cc34ffa11b346921a0f09f52aa642e8b612b774f231d87b537844494bf96877a04cd2a6f13db9ee5dd48419bf982c543a68f530323235573c7bff406231bf0c3fc6f5a008d0b44b2881e0b23e6a2463fee512c50a8491d5fe95d658d9e9c24965d7a4ec621e077b319a9fbceb207:c17bb1e60f56472d7360b420e23381a5:a8a56fff8393d96cc31225f00cb50894&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjM5MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.sL0wiiTFHngeGbtqiBB4UE_jXHLidkhUFUDY6oTPWBk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"\",\n \"description\": \"GRAPPAs Patient Guide Booklet\",\n \"url\": \"https://www.grappanetwork.org/assets/PDFs/GRAPPA_PsA_Patients_Guide_to_Treatments_v1.1.pdf\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/108919400\",\n \"publishedAt\": \"2021-12-15T18:53:57.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3594468,\n \"message\": \"GRAPPA’s Patient Guide Booklet\",\n \"language\": \"un\",\n \"resource\": {\n \"id\": 8900648,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/6uytHxmVSOmw7e3dHfrP_graphicstock-manager-in-a-superman-pose-wearing-a-red-cloak-studio-shot-on-a-beige-background_rAr6iJnZ-%20(NXPowerLite%20Copy).jpg?file_detail=66dc038761920c4f40a45a4699b73249915e05e67709cea35bebb1e1179c57122cdf34719837ab02b7a7e964fab1d8ee2975af9f2250508abf7fed4a841459887fb247faa6f3b5f15098d5d5c5807ff8a70dee0d6adb1741c6efe88b5d318623e9a22e783269a23cbccbb7468a22918e73171847a0e4c61d1500d5b36c9290116dd72c4519fa269f16a7523c977b15902173ecd9fa01f0db0a5cb583b8a7bdeca6f5e91467ca8ab40c32c6af10cda56206cc2d37f84a3f736c25f7eda411d4fb7a6c57bcaac2dcda7f184a7bac7eebc3:d838493ff4b721dc6fd8111f9b5567e3:8d89d2c01072ea720d4636e85e8b1926&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjQwMyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.gbcJFtnN_o4G9jJtiNJztSvst5WFSgwV2eeBDnfcScI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"\",\n \"description\": \"GRAPPAs Patient Guide Booklet\",\n \"url\": \"https://www.grappanetwork.org/assets/PDFs/GRAPPA_PsA_Patients_Guide_to_Treatments_v1.1.pdf\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-4802347e-9053-4acc-b4e1-f21a75f57879\",\n \"slug\": \"secukinumab-provides-rapid-and-persistent-relief-in-pain-and\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-06T12:31:30.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASUR...\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018528,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/8xmYKMspQeOTBRD0FE8Z_pubmed-meta-image.png?file_detail=764cde64d5a6f6ce64bcd25564115e4b7191f9bc12a7270d642eb8c78e5d38b15bd4675ebd1c546dfb3885a0ff78a30ba2d120ef4a480483db0173505ff3d2e6aea8c532ae4ec70d5d264ba98d0feaa688a3ce25544d2b5da402e3298a10dd4afe81bb9460d1419a415509f21c8735e8:a715d72631e7563f0836297174fa5503:97b64baabba34587814d19790059355d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjQxNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ArG_2SoPu-b3SPqx0_qHnm5ouTavVwa0p4o087eEdNg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASUR...\",\n \"description\": \"Secukinumab provides rapid and sustained relief of pain and fatigue over 2 years in patients with AS regardless of baseline hsCRP levels and prior TNFi therapy.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/30148436/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109054451\",\n \"publishedAt\": \"2022-02-06T12:31:30.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728969,\n \"message\": \"Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASUR...\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018528,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/8xmYKMspQeOTBRD0FE8Z_pubmed-meta-image.png?file_detail=68c7dd1ac8a9d6ba63167bc42ad488cd352eaed2f63db5644113d800e12c035d19ff68fcdbcd4b492584f5caa04d067603788384987eb34ae56b046b53f076f60193f6599a6e76d76a41fff598d115a791912094dbc86213a8aee4c4ef168f523f5cdaf6364ac2b11782b988dbf1eff9:92dbd2ffa6cff84a1658a2ec8fe41af2:6942806bad2c459ee93951d777d8aea8&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjQyOCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.OAqI8fHAXXGTBjzq7jpStU5pSK8N_GocCdyCyIIscm4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASUR...\",\n \"description\": \"Secukinumab provides rapid and sustained relief of pain and fatigue over 2 years in patients with AS regardless of baseline hsCRP levels and prior TNFi therapy.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/30148436/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-582048d1-13e5-4e48-83ed-6f2a8460dd21\",\n \"slug\": \"secukinumab-versus-adalimumab-for-treatment-of-active-psoria\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-06T12:24:30.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018522,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/1o51sEeTi2sGLGf5K7KD_pubmed-meta-image.png?file_detail=7d98752a5e170e024e9faf5b0906580ccbb679d931b57c05c03d422340486551787d2969c6d47364001fa26517917b01b0ed10ec9ef887155cf2f20b679a742b15d738d627b71c802b05d462ae73d5001f76ca6d25b782386bae953b6bce431fd9f3fcb8e85038a9051f18d3a9859f6f:422e1c32c54c0e464927bf67c7cd6e4f:1cf9b86c040956e806413bbc72f4f929&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjQ0MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Lz0vP7g82ngX2Y6IXyowp0CsKnwUlEmvBzPuibLVFqw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial - PubMed\",\n \"description\": \"Novartis Pharma.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32386593/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109054445\",\n \"publishedAt\": \"2022-02-06T12:24:30.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728963,\n \"message\": \"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018522,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/1o51sEeTi2sGLGf5K7KD_pubmed-meta-image.png?file_detail=90b2554258976de31abf3fd7d7bed797c3c50f1cad0d7f8fef1fc4f8c59a51015c769c66a83a42eee8e36eccf36dc26204c079973009365eb65aa0260b318c81790a70e572df478f1a777c6b8878d7df63569e461b40d45d658d095f6e8427fa71b8acd7ddb65483cb77d009ed433a95:410a7d9f6ff0ddba534448604a7e0b55:16e01e11a1d739bdf53842e340aee8b1&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjQ1MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.XQ7zpowZpa2TbYBqTp_wDUDD_N8EAWZEqzgRX2wdNOs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial - PubMed\",\n \"description\": \"Novartis Pharma.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/32386593/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-63f66c32-80fe-4925-8b84-f896bdc58304\",\n \"slug\": \"functional-relevance-of-t-helper-th-cells-and-the-il\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T20:54:10.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Functional relevance of T helper 17 (Th17) cells and the IL‐17 cytokine family in inflammatory bowel disease\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018073,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/UmF1eeSE6DQsI9X3O1nA_ibd.v18.1.cover.gif?file_detail=32b0017f806693c93ac513967ad39094c7c76281c3a7484bad6e6bf52b799eac79096c09693ba3b8f7209982d4ed17a0b274d07189ed8312d5a94b86c19807685661bc3311f46252dd33260953882903de33385bf0c042b7ca25735357657473d070cc39a83b80958e4a909bda43e5d5:56082b79485f4247bf7bad2e0c88eaf9:c210a33a82df5038dda89fd67f226e29&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjQ2OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.mzYTTOpHysdmNZOX8DMITL63uvcJrPD8PW_eW7Ypb70&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Functional relevance of T helper 17 (Th17) cells and the IL‐17 cytokine family in inflammatory bowel disease\",\n \"description\": \"The recent discovery and characterization of T helper 17 cells (Th17) and their signature cytokines (IL-17) represents a hallmark in T-cell immunobiology by providing a new distinctive pathway for th...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/ibd.21677\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109054007\",\n \"publishedAt\": \"2022-02-05T20:54:10.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728537,\n \"message\": \"Functional relevance of T helper 17 (Th17) cells and the IL‐17 cytokine family in inflammatory bowel disease\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018073,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/UmF1eeSE6DQsI9X3O1nA_ibd.v18.1.cover.gif?file_detail=0fd58da2dd080cebc24e1589f045e37afd2b029e83540a8d8c54de28f26bbe3ea092b657153629eac98469ee5b15c759f75175d0af77c6c6f60e4368a50d7466ae41e127ade59f4982d1b878278f0841ed907c330dfc9c8872cb2769b3ad60931f21dc12d2915df4f511ffbc3d3476cd:495c3efaad2fdf1a24f03199d188347e:cfbe6a52220bf7b55d53756632fd12e5&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjQ4MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.zuQEDb8aCDlJQDT7lxcj7OyvjsZ3y9LajjF5Fc2_DMU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Functional relevance of T helper 17 (Th17) cells and the IL‐17 cytokine family in inflammatory bowel disease\",\n \"description\": \"The recent discovery and characterization of T helper 17 cells (Th17) and their signature cytokines (IL-17) represents a hallmark in T-cell immunobiology by providing a new distinctive pathway for th...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/ibd.21677\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-59ae2be5-0ce3-47c8-a48d-b41c3751ac7a\",\n \"slug\": \"classification-criteria-for-psoriatic-arthritis-development\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T20:44:47.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018067,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/cAaOD9QjQ0SjCnVItgXA_art.v74.2.cover.jpg?file_detail=4b21b65ba9405d29f42709eb67f6e714cef151406d9c78f25610f8a3cf7147103f21d45c2c14b97b3a233ced08131c2299cda2ba6ecd6ae243464d42792ee9c3994045d8982c8f8546fdee3059bda9c65f580fb778ce0bcff8d003613437b41522bae7c8b70ef246198868e7d9540ba7:868f51912b467c07ab49ece35f605146:92dc66162a30dd05bfe8042faecbefda&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjQ5NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.WNtb1rHuwHFhM3yNDWzyaAS1Nz4YYhuRMZoUMliIzMc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study\",\n \"description\": \"Objective\\nTo compare the accuracy of existing classification criteria for the diagnosis of psoriatic arthritis (PsA) and to construct new criteria from observed data.\\n \\nMethods\\nData were collected p...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.21972\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109054003\",\n \"publishedAt\": \"2022-02-05T20:44:47.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728533,\n \"message\": \"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018067,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/cAaOD9QjQ0SjCnVItgXA_art.v74.2.cover.jpg?file_detail=cff8979fe7758cfc1bd13527465e55feea5d95c9c10f39d3274230619d3cd367ec46b8b7596e98dbf3a1591ff9611e16e5227b9f046e5113d26939344add49498d6115b25ac61ff6c3fd7d742f1f818dfd814b9c70a93f1afee3655d9d6f8c34adac28f58aca91defaa90dbda90ba450:fc29e449c6ec087a2e279576e312291f:76ac9cd0a582b89bd0dcd864c3104aac&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjUxMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.9NzHCVwY56wEMDa7ebfVWr84F8YMGgVGpWLqDvzP3B0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study\",\n \"description\": \"Objective\\nTo compare the accuracy of existing classification criteria for the diagnosis of psoriatic arthritis (PsA) and to construct new criteria from observed data.\\n \\nMethods\\nData were collected p...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.21972\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-46b0570d-6b77-4eef-adc6-91fd26ca0fb7\",\n \"slug\": \"identification-and-evaluation-of-serum-protein-biomarkers-nb\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T12:18:23.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Identification and Evaluation of Serum Protein Biomarkers That Differentiate Psoriatic Arthritis From Rheumatoid Arthritis\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9017716,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/smwxZYySIuX1VsV3qwIg_art.v74.1.cover.jpg?file_detail=c60a176a3f8c7625b2a38ac1bf3a1b81c56ba52815e05906fd83bb685a34d59e6e1aa07100b77ad21b1219e642a9be9d586460c5973e57533de7e48eca8a1a36137d2a9d85427331303e6b081ad8d60d789c772ef5607a344986657668b2e2be4d8f7cca23d9e09e811217f20f3b6a95:c758542ceee5862a52ecd6ee9610dedd:d4c1a5e818011d116c2018c2499f9782&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjUyNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.a8rITChVPufdh-uTJCVz6p0QNH5cKiN3PjSPRIHtsf4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Identification and Evaluation of Serum Protein Biomarkers That Differentiate Psoriatic Arthritis From Rheumatoid Arthritis\",\n \"description\": \"Objective\\nTo identify serum protein biomarkers that might distinguish patients with early inflammatory arthritis (IA) with psoriatic arthritis (PsA) from those with rheumatoid arthritis (RA) and may...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.41899\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109053656\",\n \"publishedAt\": \"2022-02-05T12:18:23.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728187,\n \"message\": \"Identification and Evaluation of Serum Protein Biomarkers That Differentiate Psoriatic Arthritis From Rheumatoid Arthritis\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9017716,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/smwxZYySIuX1VsV3qwIg_art.v74.1.cover.jpg?file_detail=930b9b532e4a92cb874366685751384dd97f02f12015adaa735e79decac38e14dc5733885677d6dc09b1df2ff781eaa6683b817601939531c66aab697af9e7fe980a844f8ad485e3b900eb2d2dfe35cd6af14d32118c34860fac3ff1e10866b15518db0b7657d1bce8f44d47a42e8435:dce83e0969f1072e2ae6416d61455e3e:cb1c3a222b47d747be99c2ddd0e99919&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjU0MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.IBpgvM0WC9P1DmnZ8WMt99ek1VKOfpq1SfY9GSESUgQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Identification and Evaluation of Serum Protein Biomarkers That Differentiate Psoriatic Arthritis From Rheumatoid Arthritis\",\n \"description\": \"Objective\\nTo identify serum protein biomarkers that might distinguish patients with early inflammatory arthritis (IA) with psoriatic arthritis (PsA) from those with rheumatoid arthritis (RA) and may...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.41899\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-60da7eae-4605-4710-9388-af4bc9a8a31d\",\n \"slug\": \"syndesmophyte-growth-in-ankylosing-spondylitis-pubmed\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-10T01:09:20.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Syndesmophyte growth in ankylosing spondylitis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9032079,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/XJ1GrHGVQGeoQReAj4yL_pubmed-meta-image.png?file_detail=b26ef5f9343fcc241fdc4a779c20afe8cea94a8363950ed5352304d4513ca85e2bc0b5436c15906d49ec084c1b4de3c92e0c2962795bec3b95d518cc276eec6aa174cb2c37d344b31cb1f216c143479e106200c164e45d66a88270bde6827c28ff6c0199e21f2e392a1376e65107b00d:ca0d934f916fa7ddc5ff221a83391674:e82a4f57b0cde8a27089182d47af7649&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjU1OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.QAcPBZul8Ha17JZJuoZwrDQaHp-19SNGV9forgmG77E&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Syndesmophyte growth in ankylosing spondylitis - PubMed\",\n \"description\": \"Although there is better understanding of the frequency of syndesmophyte development, the pathogenesis of syndesmophytes remains unclear.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/26002023/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109069710\",\n \"publishedAt\": \"2022-02-10T01:09:20.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3744184,\n \"message\": \"Syndesmophyte growth in ankylosing spondylitis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9032079,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/XJ1GrHGVQGeoQReAj4yL_pubmed-meta-image.png?file_detail=12cb7875adca41589cca38eaf8caf7870796d38b3f2616c6f2a1535f1abd56258b11698bb73e758ba184e027f65722f0a4a014577389b718797cf29bad86bb2d8d2777fc1649de60bd9b1ef936413a2b809d5fc7bcebd83ddcaf0f8c1060ccafaf5c570c981c0c3526fb246d36560d81:fca170dae7809092c88b294b682e5cb5:1341390939ae217d5af2d63f163b6d74&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjU3NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ORAMk9MV9Q4oD0M37ugN4mwCWWVAILZKi7x30iYOpn8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Syndesmophyte growth in ankylosing spondylitis - PubMed\",\n \"description\": \"Although there is better understanding of the frequency of syndesmophyte development, the pathogenesis of syndesmophytes remains unclear.\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/26002023/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-609684f5-3efd-43d7-8695-1cec6b12c597\",\n \"slug\": \"editorial-sacroiliac-joint-magnetic-resonance-imaging-in-th\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T20:40:33.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Editorial: Sacroiliac Joint Magnetic Resonance Imaging in the Diagnosis of Axial Spondyloarthritis: “A Tiny Bit of White on Two Consecutive Slices” May Be Objective, but Not Specific\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018065,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/4CF8QN9TVuhkljqHW6Yp_art.v68.4.cover.jpg?file_detail=6eef6759049f49addee312073be209aa88e4e4e5b81d975ef2fbf8cd96b498ed536f47b0fcac8b5f9f1caa4c68ba49e775be682747b84c0a30ed3a7a96a1f44e206e135f3698e6f9667754c6876d745a6ab2f21cc5b17edae1b3b40ede56dd22daed4198e9fa7ad0adc6062adc1a8426:a2ad8fd273abbf4f4d041894a9655f32:c259754126e85a2155c9a7a3e885d6cf&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjU5MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.TrsOvE23r5dRRWXQUfJUMuOcexBcAG85IRJrUpl5KxQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Editorial: Sacroiliac Joint Magnetic Resonance Imaging in the Diagnosis of Axial Spondyloarthritis: “A Tiny Bit of White on Two Consecutive Slices” May Be Objective, but Not Specific\",\n \"description\": \"Click on the article title to read more.\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/art.39549\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109054001\",\n \"publishedAt\": \"2022-02-05T20:40:33.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728531,\n \"message\": \"Editorial: Sacroiliac Joint Magnetic Resonance Imaging in the Diagnosis of Axial Spondyloarthritis: “A Tiny Bit of White on Two Consecutive Slices” May Be Objective, but Not Specific\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018065,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/4CF8QN9TVuhkljqHW6Yp_art.v68.4.cover.jpg?file_detail=5fb6da03312a78005a27fb7ba67afb1563d5c3c62987556420352b8996e2b70c270df9eb651c5c8b2a5b558b7789a80ead178fcf2be86420e3be7f80ea68745c7595c39b04e7afb63c1ecd96de0cbcc5447203441386e5054096330e51d746b29a221be9fe5da02c5b882ef79ea9c4b3:ab402051a5a5dbcd5f57edb985b5592b:239e5c2f6a7b2559bfb62b1282e67499&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjYwNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.CJp6g_HaYj6Gi1WS83u9gWMBXjx3d3TAQkTTyFI42EA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Editorial: Sacroiliac Joint Magnetic Resonance Imaging in the Diagnosis of Axial Spondyloarthritis: “A Tiny Bit of White on Two Consecutive Slices” May Be Objective, but Not Specific\",\n \"description\": \"Click on the article title to read more.\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/full/10.1002/art.39549\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-7e2e1c8e-65cf-4e48-bacb-6b8f3b5a5d06\",\n \"slug\": \"evaluation-of-the-nonsteroidal-anti-inflammatory-drug-sparin\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-09T00:06:43.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9027974,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/jEAFAUNGTR2ILBSfMnhi_ACR_1053484_1.jpg?file_detail=34b10f003f51713af74d6d0e073ec4ff514a119e57c0a76de6d5d328d111d2ab85a7c3308cf05aee10e4f2bce927d6fc6a820be14994cd0a67ab60e937af1dabb474a650118f006be12a802577e97512b6ef387b9e5457b3c23b9dd7737fa7d38c52bb0bf5164071ff08ca1dbb5d57e6:4e2bdf8c3ebb425c9c965f536a4818ed:ab751fc7424e2a54adc0d74c1186ad10&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjYxNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.tHS6uL1yFyRGax34FUNfnjwc_nSjYI6RwTPrGmAJoNA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat inflammatory back pain in patients (pts) with ankylosing spondylitis (AS). However, an increased risk of side effects associated with NSAIDs and their dosage has been reported1. Therefore, lower doses and a dose reduction is desirable. The objective of this study is to evaluate the short-term NSAID […]\",\n \"url\": \"https://acrabstracts.org/abstract/evaluation-of-the-nonsteroidal-anti-inflammatory-drug-sparing-effect-of-secukinumab-in-patients-with-ankylosing-spondylitis-multicenter-randomised-double-blind-phase-iv-study/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109065087\",\n \"publishedAt\": \"2022-02-09T00:06:43.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3739568,\n \"message\": \"Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9027974,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/jEAFAUNGTR2ILBSfMnhi_ACR_1053484_1.jpg?file_detail=10c10f52f069d363d4cac7e7ab017ac1a2442eb028911e0568ab61861c8789708fe535fc0ebc54dc38cb753fb35072b1f2d5186f1048651a968bea0636a7dd563d907dea43fb6f6ff66fdf0fd26da9243472b880c5b086c74e33ba7bee9048e1ac13fd92bafb1098779ea660965dd926:287436cdce7c58a71052f0984c3fc605:455bab4475552a3903a85cfd283e2150&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjYyOSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.0SZJl1oCQXFzpoHBUmPfh5rFVeyC0Pn87FMtx45SUWg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat inflammatory back pain in patients (pts) with ankylosing spondylitis (AS). However, an increased risk of side effects associated with NSAIDs and their dosage has been reported1. Therefore, lower doses and a dose reduction is desirable. The objective of this study is to evaluate the short-term NSAID […]\",\n \"url\": \"https://acrabstracts.org/abstract/evaluation-of-the-nonsteroidal-anti-inflammatory-drug-sparing-effect-of-secukinumab-in-patients-with-ankylosing-spondylitis-multicenter-randomised-double-blind-phase-iv-study/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-9321fca3-3afe-4a91-a71c-7e7333743f48\",\n \"slug\": \"association-between-clinically-meaningful-back-pain-improvem\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-08T23:35:33.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Association Between Clinically Meaningful Back Pain Improvement and Patient-reported Outcomes and Disease Activity in Patients with Ankylosing Spondylitis: Results from a Phase 2/3 Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9027927,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/LP7Pd2RSG6iA4t8dQNAZ_ACR_1063208_1.jpg?file_detail=19b22b48b8253475df6e68e35316da4f65b50b1c4659be9792a01a4d2f8246bd4d31e07c81a348a2dc34bfa2d81c3dee2a5749e6fe58e9c0ef259520cfe7966b1e423c69de451cc2ef6249b134483cee059ecdbe2548c14c9619c457149cc5113c9068afafc99cd6f3005aa98e88c5c7:1f05bfeb0975baed42080c3dc5eb305e:7c0f449aff2c015fc34281338ff8cabe&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjY0NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.kkbkptntwdrpTxYmnhBCziXKrl3i7MHMRb68V37-E4U&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Association Between Clinically Meaningful Back Pain Improvement and Patient-reported Outcomes and Disease Activity in Patients with Ankylosing Spondylitis: Results from a Phase 2/3 Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Back pain is the hallmark disease feature for patients (pts) with AS. However, the relationship between back pain and other patient-centric outcomes and disease activity measures has not been well characterized. The purpose of this study was to examine the association between meaningful back pain improvement and quality of life, disease activity, physical functioning, […]\",\n \"url\": \"https://acrabstracts.org/abstract/association-between-clinically-meaningful-back-pain-improvement-and-patient-reported-outcomes-and-disease-activity-in-patients-with-ankylosing-spondylitis-results-from-a-phase-2-3-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109065040\",\n \"publishedAt\": \"2022-02-08T23:35:33.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3739521,\n \"message\": \"Association Between Clinically Meaningful Back Pain Improvement and Patient-reported Outcomes and Disease Activity in Patients with Ankylosing Spondylitis: Results from a Phase 2/3 Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9027927,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/LP7Pd2RSG6iA4t8dQNAZ_ACR_1063208_1.jpg?file_detail=3726ea56bf4ca6993b50dcd29df8b3703f68076df07676679bfccf3173c748c5fbf6877e6382f767083e00e5f515c6e877dee28f13e1e73c06493c054260f04f0f9483f0418f4336f14d6bc975fcb6788957ea07b386052e1f5301e8117eade6eeffa3a36735567522850a15651fbd6c:a340acd8a7e0ee0ce7d348a05721d62c:95ef78dd00c57a023e37dec59d730ce2&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjY1NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.A9BX-a79hAeKhM8t7vioXx1gmbzAPM2R1FgiGVQTlFg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Association Between Clinically Meaningful Back Pain Improvement and Patient-reported Outcomes and Disease Activity in Patients with Ankylosing Spondylitis: Results from a Phase 2/3 Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Back pain is the hallmark disease feature for patients (pts) with AS. However, the relationship between back pain and other patient-centric outcomes and disease activity measures has not been well characterized. The purpose of this study was to examine the association between meaningful back pain improvement and quality of life, disease activity, physical functioning, […]\",\n \"url\": \"https://acrabstracts.org/abstract/association-between-clinically-meaningful-back-pain-improvement-and-patient-reported-outcomes-and-disease-activity-in-patients-with-ankylosing-spondylitis-results-from-a-phase-2-3-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-8b8253b2-13ef-497e-8c7d-a7614a9dc8ae\",\n \"slug\": \"effect-of-secukinumab-on-radiographic-progression-and-inflam\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-09T00:02:29.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Effect of Secukinumab on Radiographic Progression and Inflammation in Sacroiliac Joints and Spine in Patients with Non-radiographic Axial Spondyloarthritis: 2-year Imaging Outcomes from a Phase III Randomized Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9027972,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/hx5OTkrQLai4CIqJWqNw_ACR_1062816_1.jpg?file_detail=942fb7986c2a3984414fce977164c9d430c8e1fcc02827ba68986c2081b5731297f1be7412be36ea05f0c0b9edb006e852895b5c0f5cc473d742222b8e766e542875e78c14eab5207d2e521711778e243d5ff0aa7e522d435937002219788faf76de93b6d6ad924726b1429f58af1432:afa0819e611a34c3f83539baee1bbfab:62e61a760187c98d2ac94ca03f631038&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjY3MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.6E0AGY9le7INOwLAUHs1f9amYTK95S7iVTJw7UPrjG4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Effect of Secukinumab on Radiographic Progression and Inflammation in Sacroiliac Joints and Spine in Patients with Non-radiographic Axial Spondyloarthritis: 2-year Imaging Outcomes from a Phase III Randomized Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation of the sacroiliac joints (SIJ) and the spine. Secukinumab (SEC) treatment was clinically efficacious and reduced SIJ bone marrow edema as detected by magnetic resonance imaging (MRI) in patients with non-radiographic (nr)-axSpA through 52 weeks in PREVENT (NCT02696031) study.1 Here, we report radiographic progression and the course […]\",\n \"url\": \"https://acrabstracts.org/abstract/effect-of-secukinumab-on-radiographic-progression-and-inflammation-in-sacroiliac-joints-and-spine-in-patients-with-non-radiographic-axial-spondyloarthritis-2-year-imaging-outcomes-from-a-phase-iii-ra/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109065085\",\n \"publishedAt\": \"2022-02-09T00:02:29.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3739566,\n \"message\": \"Effect of Secukinumab on Radiographic Progression and Inflammation in Sacroiliac Joints and Spine in Patients with Non-radiographic Axial Spondyloarthritis: 2-year Imaging Outcomes from a Phase III Randomized Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9027972,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/hx5OTkrQLai4CIqJWqNw_ACR_1062816_1.jpg?file_detail=7fed34d5af9795f186d264eb6d4f4bfa4132f010899b00862d232373c8d8a289f28ddbcc4a51b84de054cd31548ae53c1dae0b5afb4b67760b6761c5d30a8ee7a7702bebcec301eca2af063be812c203a00ecc47389781c222d47e384f99c251ac9aa575a13c15bbbd7bcc91af6e74e5:8ed7d122e562eccd1bdcd981bf77b674:c68ff7e4f7806ef60e2f2b945a51827d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjY4MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.lKszNSsfuqJ5H9UDFyw3YtqdYPEruQ9lG-5e9sriAJU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Effect of Secukinumab on Radiographic Progression and Inflammation in Sacroiliac Joints and Spine in Patients with Non-radiographic Axial Spondyloarthritis: 2-year Imaging Outcomes from a Phase III Randomized Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation of the sacroiliac joints (SIJ) and the spine. Secukinumab (SEC) treatment was clinically efficacious and reduced SIJ bone marrow edema as detected by magnetic resonance imaging (MRI) in patients with non-radiographic (nr)-axSpA through 52 weeks in PREVENT (NCT02696031) study.1 Here, we report radiographic progression and the course […]\",\n \"url\": \"https://acrabstracts.org/abstract/effect-of-secukinumab-on-radiographic-progression-and-inflammation-in-sacroiliac-joints-and-spine-in-patients-with-non-radiographic-axial-spondyloarthritis-2-year-imaging-outcomes-from-a-phase-iii-ra/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-a84317ee-b381-4402-ab37-8ae518bbe976\",\n \"slug\": \"high-dose-secukinumab-in-pso\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T21:13:39.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"High Dose Secukinumab in PSO\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018085,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/4EVDRFWTGWFIjDVWt3V0_business-meeting_SY7m3JANo%20(NXPowerLite%20Copy).jpg?file_detail=069c6dcf56483ba58e3f48113b9bdb15cee2725cc1c04ed4f739c2e29267076e0904f54d21740595f74b56e765232b0f1a6fb0871174daad18978a40984c25c033e55d4a22085079b288d9aa50118c391d9b6d75e26ffeb920433c29a4012ad38412a4bc4c0b97fa14f4d3e47b71c554576a2333da4dd960d3ad337c3deb20860242379d6cd9585c3343208288b6a1cc:6a16bb8a03d1379aeea3b243153ba181:551198527c6947974ed2e3b7e15b65b7&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjY5OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.uf0h4jfxh4gkmj6kweRjMHh14vtBXK4W1wPHA7vOpEU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Off Label 450 in PSO\",\n \"description\": \"450 Secukinumab in PSO\",\n \"url\": \"https://journals.sagepub.com/doi/full/10.1177/1203475417721424\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109054016\",\n \"publishedAt\": \"2022-02-05T21:13:39.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728546,\n \"message\": \"High Dose Secukinumab in PSO\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018085,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/4EVDRFWTGWFIjDVWt3V0_business-meeting_SY7m3JANo%20(NXPowerLite%20Copy).jpg?file_detail=74684e168d55df329f68bef2539d9ebe786e5a8a430832b73bae1c5aef12b11a559e2b535839ac9eb96c36367d13bad8378425ae9882998c90312bfafbac20953f708ce1bc76f60691beabb0b1a167af629f7f390251cbe64f465f3a599d301473fdf4058e269b1914909b9dcdcaa89d055dedc8b2d1c41d96431158af9c2e272708a2451c899c3562b7cb943a9664a7:cac302ff35a1583aadfcfa0d745ade45:6846fc2cc3251a3d65509704439e6876&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjcxMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.aruNGpJ1PmYzSWvGaV73MB3j5KwqMJEtkEWag6cWtII&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Off Label 450 in PSO\",\n \"description\": \"450 Secukinumab in PSO\",\n \"url\": \"https://journals.sagepub.com/doi/full/10.1177/1203475417721424\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-816ec624-9f9e-4bfe-8ac3-75aecfedd223\",\n \"slug\": \"significantly-reduced-recurrence-rate-of-acute-anterior-uvei\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-20T02:33:35.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Significantly Reduced Recurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis during Treatment with Golimumab - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072344,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/PQ2GRmBRjaEoGNTDoCEQ_white-doors-interior-backdrop_zJhFYD9_%20(NXPowerLite%20Copy).jpg?file_detail=c02e5553163384eb955b7738e65041f76e5d29fe2abb6275412710e76ea365a87f17857658a2a0c4ed12dd463d1939807539f30999b19514db9c73edc158e975fa1232a466359792a5cd0d7326ac55b242eae5d9e31b977a425072421fb5932a8a0a6b7e4e4d48587374b027652a35b45f6bdf8d274131e0d68ea40f01c525a9ce35becec9c9eafd38a2080add63888a:0a2f45ecc3f5a8159ee2e3164b7eadcb:d2ec158a2c0594d1b7435e2a3f67e020&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjcyNCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.CZWX_DV23g82rdOL0vwYI5IzHIeGJbAHKBUa_OdEAek&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Significantly Reduced Recurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis during Treatment with Golimumab - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Acute anterior uveitis (AAU) is common in ankylosing spondylitis (AS) (1). Golimumab, a tumor necrosis factor alpha (TNF-α) blocker, has proven to be effective in the treatment of AS (2). We have shown earlier that treatment with adalimumab, another TNF-α blocker, leads to a significant decrease in the recurrence rate of AAU (3) in […]\",\n \"url\": \"https://acrabstracts.org/abstract/significantly-reduced-recurrence-rate-of-acute-anterior-uveitis-in-ankylosing-spondylitis-during-treatment-with-golimumab/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109111937\",\n \"publishedAt\": \"2022-02-20T02:33:35.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787415,\n \"message\": \"Significantly Reduced Recurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis during Treatment with Golimumab - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072344,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/PQ2GRmBRjaEoGNTDoCEQ_white-doors-interior-backdrop_zJhFYD9_%20(NXPowerLite%20Copy).jpg?file_detail=6609e998309b00d0041fdbe5501134e2c87ec686848dec214a7b8836b5861635f14b5dc1c9acdaa809b31d2cabe3aa64872872e46b68790e3cee1ce0cb2f22b10aa0ca2c8a0451bd5b96a4dd0469feccbaa03b69c307c862996e373ac4fe338fa7e42f142f1341186fa22c551ba16bca4e2767dc9616b6d26316f748e5514b9bacc0b9a30b78a2650956db6523311398:8275e2d886e1662ec5808c7f00c9deed:93b30a460eae327e2a30142fe5515b7d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjczNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.K12T5HcnXHQJqXqF28mXcm9In6yR6dyIN9NfQ1jMCs8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Significantly Reduced Recurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis during Treatment with Golimumab - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Acute anterior uveitis (AAU) is common in ankylosing spondylitis (AS) (1). Golimumab, a tumor necrosis factor alpha (TNF-α) blocker, has proven to be effective in the treatment of AS (2). We have shown earlier that treatment with adalimumab, another TNF-α blocker, leads to a significant decrease in the recurrence rate of AAU (3) in […]\",\n \"url\": \"https://acrabstracts.org/abstract/significantly-reduced-recurrence-rate-of-acute-anterior-uveitis-in-ankylosing-spondylitis-during-treatment-with-golimumab/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-8af906b6-e847-41ef-94ce-7822a910065d\",\n \"slug\": \"cost-of-illness-in-patients-with-psoriasis-and-psoriatic-art\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-20T03:10:29.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Cost of Illness in Patients with Psoriasis and Psoriatic Arthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072363,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/VfeB1FQORqqFPkwYhEJb_IMG_1690-813%20(NXPowerLite%20Copy).jpg?file_detail=756641d5756eeca1be6abb85044889e1644d24cc89211c8e06dd9a1616c2849645d4c63c53bd758fba9874b69644d02410ed3bad93c86df460a00e70540e070d88a0e020f57bbc05195efc2e1520149a0ec385bf87c3001e1f9e3a9536c3be993974d474b1251d78093c9ff0e0545d32b1fb3eb731f333337e3f35f7500e28cf:42ae3f2b943828cfd82aa56ba710ce9d:f22c775e31a04fc8d2f02fdba02b6a3b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjc0OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.A7_-suqVKwAFETfpFXzeiR9RvLDXlILDnQ2_Nsi3kdY&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Cost of Illness in Patients with Psoriasis and Psoriatic Arthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Psoriasis (Ps) and psoriatic arthritis (PsA) have a major impact on patients’ health-related quality of life. Cost of illness of patients with Ps, PsA and both diseases (PsA+Ps) is an important subject as they are associated with a substantial economic impact, with implications from a health management perspective. The objective of our work was to describe the […]\",\n \"url\": \"https://acrabstracts.org/abstract/cost-of-illness-in-patients-with-psoriasis-and-psoriatic-arthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109111955\",\n \"publishedAt\": \"2022-02-20T03:10:29.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787433,\n \"message\": \"Cost of Illness in Patients with Psoriasis and Psoriatic Arthritis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072363,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/VfeB1FQORqqFPkwYhEJb_IMG_1690-813%20(NXPowerLite%20Copy).jpg?file_detail=77c4914dd9ab299d0122665ed4358c056a47af47cb7f4b675175ace34165a432e25b6b7f3520c7f6f85dc0a8cb2e9479080c03b7feacd441fc1dbd85b24eb4c7f158d8e8d4146a07ff7396a7995651fccff67d9d7a07a59a8005052471b0e3579efe37792927685932394d87a471e871211e0d99b85b91c09d03c53eb65164ab:8de0b2c859db8bde160ec73c1003e194:90f0ab697790b4225ff0cede9946e8df&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjc2NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.UY4dobZSZ-8s1swN7gHZ2tNtvgNwPWV4evK28jqfxBQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Cost of Illness in Patients with Psoriasis and Psoriatic Arthritis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Psoriasis (Ps) and psoriatic arthritis (PsA) have a major impact on patients’ health-related quality of life. Cost of illness of patients with Ps, PsA and both diseases (PsA+Ps) is an important subject as they are associated with a substantial economic impact, with implications from a health management perspective. The objective of our work was to describe the […]\",\n \"url\": \"https://acrabstracts.org/abstract/cost-of-illness-in-patients-with-psoriasis-and-psoriatic-arthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-9dd902bb-df60-4e54-8278-30484c620325\",\n \"slug\": \"psoriatic-arthritis-patients-assessed-by-dynamic-contrast-en\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-23T00:44:45.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Psoriatic Arthritis Patients Assessed by Dynamic Contrast-Enhanced MRI in High Disease Versus Minimal Disease Activity State – a Cross-Sectional Study Correlating Conventional MRI and Clinical Composite Measures - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9081664,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/VoqEmKxdSgmS4eVSWXTa_white-doors-interior-backdrop_zJhFYD9_%20(NXPowerLite%20Copy).jpg?file_detail=e38d65af750016bcb78b81ac508e5cb1817985f03857697c81b282953a4d3ca5afd4228e294696d444b01f90b354cece6d28eff65f7235c89af41aab53e017d4b06c77d282816332372716121cc2c125b469f174a5502d58224068c3861fab29d3a1d82f5595a0a7ba13ea3100350ea3442bddc18fcbbb43a438d063231710d231ec9a02871a95543444512784c74009:4c43b75c20fadf081eebb9b810a39a5a:3eaf0edc3ebc6ffbb7d98c2efd998ef5&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjc4NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.hMgIYwp1Zm07XBZw1DDIia-Sw8XrU1NRKlFHpRgHe9o&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Psoriatic Arthritis Patients Assessed by Dynamic Contrast-Enhanced MRI in High Disease Versus Minimal Disease Activity State – a Cross-Sectional Study Correlating Conventional MRI and Clinical Composite Measures - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) has been validated in rheumatoid arthritis for measuring inflammation, but has rarely been studied in psoriatic arthritis (PsA). The purpose was to investigate whether DCE-MRI can discriminate PsA patients with high disease activity from minimal disease activity (MDA)(1), and to correlate DCE-MRI findings with conventional MRI and […]\",\n \"url\": \"https://acrabstracts.org/abstract/psoriatic-arthritis-patients-assessed-by-dynamic-contrast-enhanced-mri-in-high-disease-versus-minimal-disease-activity-state-a-cross-sectional-study-correlating-conventional-mri-and-clinical-c/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109122920\",\n \"publishedAt\": \"2022-02-23T00:44:45.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3798345,\n \"message\": \"Psoriatic Arthritis Patients Assessed by Dynamic Contrast-Enhanced MRI in High Disease Versus Minimal Disease Activity State – a Cross-Sectional Study Correlating Conventional MRI and Clinical Composite Measures - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9081664,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/VoqEmKxdSgmS4eVSWXTa_white-doors-interior-backdrop_zJhFYD9_%20(NXPowerLite%20Copy).jpg?file_detail=470c99d36723c1b725e53534d521f3b4e96aedd824ee709d707eb61c0c453304b21300289a316f671520b888d69b32bda3427fdea89df1a6d459ac3271c18abcfa89c34370ec03723012785a89c5a55413470d8a665b601f30d54952a05e25818e3bf349b872b770d6acbf41e9594544813818f28f6889fd90be7ea4b98eb5fb454bb48879ed65c9b24ab41dd20efaef:3f8356f7bfb0afc219a764ea4475d871:9b35b9f596b29b0fc1f905978d37bee5&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjgwMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ZE3fxvVXxz3uvsQeM4D5h_D2q6qvltoCHKvOWhEcSjw&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Psoriatic Arthritis Patients Assessed by Dynamic Contrast-Enhanced MRI in High Disease Versus Minimal Disease Activity State – a Cross-Sectional Study Correlating Conventional MRI and Clinical Composite Measures - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) has been validated in rheumatoid arthritis for measuring inflammation, but has rarely been studied in psoriatic arthritis (PsA). The purpose was to investigate whether DCE-MRI can discriminate PsA patients with high disease activity from minimal disease activity (MDA)(1), and to correlate DCE-MRI findings with conventional MRI and […]\",\n \"url\": \"https://acrabstracts.org/abstract/psoriatic-arthritis-patients-assessed-by-dynamic-contrast-enhanced-mri-in-high-disease-versus-minimal-disease-activity-state-a-cross-sectional-study-correlating-conventional-mri-and-clinical-c/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-95ea3582-0df5-4fad-982f-c47d2f5af500\",\n \"slug\": \"brain-mri-and-psychophysics-analysis-demonstrate-neuropathic\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-23T00:11:33.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Brain MRI and Psychophysics Analysis Demonstrate Neuropathic Pain to Be a Component of Back Pain in Ankylosing Spondylitis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9081613,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/XnYw4ecLQA2YnXA99ri0_young-stylish-businessman_My0goYBd%20(NXPowerLite%20Copy).jpg?file_detail=d42b26211e4ec59c7c8bf848356cbb477ff30e57156916d6db347292fabca587c35860cfdf747e782cd2005953bb723b92df7d674646b9f44ac42d6d00f7a017fc5f5e17ed3e2fb23363bf5a7e0b8e9b2507ca11a6361d5200125c657a9808809fd0ac0a7243540f351ce132043b0b6a8419e86619469e05d8c3ac65bd82dacd5059bcac6be7f38a9c4539cb1c30189b:b9a7c1a46cb23121e244ac9425e7b980:af410572909bb38d51a3dfcbebb7df5c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjgxNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.jxWmj9Ox95b5FF_b8LIodxT4kyzZJobc4vvQkqTRVug&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Brain MRI and Psychophysics Analysis Demonstrate Neuropathic Pain to Be a Component of Back Pain in Ankylosing Spondylitis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The mechanisms underlying pain in ankylosing spondylitis (AS) are unclear. The aim of this study was to investigate whether there is a neuropathic component in AS pain and to delineate gray matter brain abnormalities associated with AS Methods: Seventeen patients with back pain secondary to AS (12M/5F; 34.4 +/-12.4yo) and age/sex-matched controls consented to […]\",\n \"url\": \"https://acrabstracts.org/abstract/brain-mri-and-psychophysics-analysis-demonstrate-neuropathic-pain-to-be-a-component-of-back-pain-in-ankylosing-spondylitis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109122861\",\n \"publishedAt\": \"2022-02-23T00:11:33.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3798286,\n \"message\": \"Brain MRI and Psychophysics Analysis Demonstrate Neuropathic Pain to Be a Component of Back Pain in Ankylosing Spondylitis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9081613,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/XnYw4ecLQA2YnXA99ri0_young-stylish-businessman_My0goYBd%20(NXPowerLite%20Copy).jpg?file_detail=ee0216f650f8fa219476edcadd1c27e30e041aad21d224349977147f0213d8898a1f5d58f817264920dec7ca0d0e30e192fa99ce649902c7fb33eccbc5705dd544cbde76a10df6baff055171fd5b5d64fbc7fa46f9830bad8b1528aa2b0aa54806e4411449115f6ae3af5562c3ee7ccbd69348548f3138b020514b9b55410eabbb0f42d82b4882e7ec12d829ea7c7b9d:98d2b1ba30d683ffc74b765704bbeaab:fd755a3a24631e8e9d5df10c74eefc2f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjgzMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.rFmWyl5Ji6mVsqtrRWjWMvjwC3lenVBfTbR4tpzxos0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Brain MRI and Psychophysics Analysis Demonstrate Neuropathic Pain to Be a Component of Back Pain in Ankylosing Spondylitis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: The mechanisms underlying pain in ankylosing spondylitis (AS) are unclear. The aim of this study was to investigate whether there is a neuropathic component in AS pain and to delineate gray matter brain abnormalities associated with AS Methods: Seventeen patients with back pain secondary to AS (12M/5F; 34.4 +/-12.4yo) and age/sex-matched controls consented to […]\",\n \"url\": \"https://acrabstracts.org/abstract/brain-mri-and-psychophysics-analysis-demonstrate-neuropathic-pain-to-be-a-component-of-back-pain-in-ankylosing-spondylitis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-b02c8702-2f5f-4c06-b150-37f9904db855\",\n \"slug\": \"secukinumab-improves-axial-manifestations-in-patients-with-p\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T20:39:17.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9072171,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/nYNwmexjQm2fOW5dRUIg_GTUOHVCE-696049-1-ANY-1-.jpg?file_detail=0a9a60ce2698f9a2725406db727e57fd7508ca9e3557b91d1b2475fa79b0d22c9595fc0042907e2a3ba6cafb24c07685efd2c65fe2386ecd35e5354d7d4fa53141cd1c5c247fbb47503ec4380d17ac21fcd07d7906f50f9e1d0aa2393f80c6fa099ff8c762e1b8eaa52654eb1e5b1bef:ffc63e173c83b4be5e5f0605160c604c:45e6e67ccb8c431335402c1b079e1630&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjg0NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.IPi3hpse5pKJN6myfgHekbJOsm1e1VTCK9RU-QPGhMs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Secukinumab (SEC) has provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) and ankylosing spondylitis1. Evidence is limited on the efficacy of biologics in the treatment of patients (pts) with PsA having axial manifestations that affect between 30–70% of pts2, particularly as validated classification criteria for this subtype […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-improves-axial-manifestations-in-patients-with-psoriatic-arthritis-and-inadequate-response-to-nsaids-primary-analysis-of-phase-3-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109111768\",\n \"publishedAt\": \"2022-02-19T20:39:16.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3787247,\n \"message\": \"Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9072171,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/nYNwmexjQm2fOW5dRUIg_GTUOHVCE-696049-1-ANY-1-.jpg?file_detail=d6686abfb4197c6c36664acefab8ecf38e1bd12223403e4e5654e1c82da3daa6df98e0fd4419d1f4c8c3145e25d84b1b86179eda385cf1ae383cdff01290ea86e0b2a1601ec212de1e5e892968c11c8b7eafacaeb7ed0052c2906a78bf7d2b5b54ffaee27325d5828f4525a1acce51d8:9cec7949466726adc2162c45b5c42e02:5904d5fb94c6f5d0fb780cf3e8393b72&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjg1NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.hYG7vQswWXyyazRjdNnKntS0K5WcgB9JEdBcIXElUaU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Secukinumab (SEC) has provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) and ankylosing spondylitis1. Evidence is limited on the efficacy of biologics in the treatment of patients (pts) with PsA having axial manifestations that affect between 30–70% of pts2, particularly as validated classification criteria for this subtype […]\",\n \"url\": \"https://acrabstracts.org/abstract/secukinumab-improves-axial-manifestations-in-patients-with-psoriatic-arthritis-and-inadequate-response-to-nsaids-primary-analysis-of-phase-3-trial/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-a419a493-2009-4d68-8c3b-783487556fb8\",\n \"slug\": \"frequency-and-specificity-of-mri-lesions-in-the-sacroiliac-j\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-25T00:19:13.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Frequency and Specificity of MRI Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis and Non-Specific Back Pain: First Analysis of MRI Scans from the Assessments in Spondyloarthritis International Society Classification Cohor...\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9088944,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/VoqEmKxdSgmS4eVSWXTa_white-doors-interior-backdrop_zJhFYD9_%20(NXPowerLite%20Copy).jpg?file_detail=70a22df0d2185e6ab2d49528ef00a22c55b3ff3b1598dd6b350f65c6024c3d51a863a42a49561a727c9c7ed3d4b6875475b8a5e81da319d00775b93256980eac6f6ed55d7bc9200897958f9caf281ffb9a115160d2ce247cd28866eaab3ec5ecacdeb4d434b9cddbcf5847efee71e2d48f1c40afdd32d9f0a4653e5c2160cd4cd6467ac1865496a8beb7757732b8b323:c828835cc2c34839b5afc3e0842cfdc9:7caa41df8acc2b2ff6410648360cd04f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjg2OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.DB45eB2fSurskndOfa4bcx6qOdVHnppMjX1xrDiumZk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Frequency and Specificity of MRI Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis and Non-Specific Back Pain: First Analysis of MRI Scans from the Assessments in Spondyloarthritis International Society Classification Cohor...\",\n \"description\": \"Background/Purpose: A broad spectrum of MRI lesions has been described in the sacroiliac joint (SIJ) of patients with axial spondyloarthritis and a recent consensus from the ASAS MRI group has culminated in updated lesion definitions (ASAS_MRI_defn). There has been no detailed evaluation of MRI scans from the ASAS Classification Cohort (ASAS-CC)1 to determine the spectrum […]\",\n \"url\": \"https://acrabstracts.org/abstract/frequency-and-specificity-of-mri-lesions-in-the-sacroiliac-joints-of-patients-with-axial-spondyloarthritis-and-non-specific-back-pain-first-analysis-of-mri-scans-from-the-assessments-in-spondyloarthr/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109131435\",\n \"publishedAt\": \"2022-02-25T00:19:13.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3806811,\n \"message\": \"Frequency and Specificity of MRI Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis and Non-Specific Back Pain: First Analysis of MRI Scans from the Assessments in Spondyloarthritis International Society Classification Cohor...\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9088944,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/VoqEmKxdSgmS4eVSWXTa_white-doors-interior-backdrop_zJhFYD9_%20(NXPowerLite%20Copy).jpg?file_detail=9c272c4e17d8c7045c0b5366ee8f4c441a65eb94fb524353e0876dc14e8bdf3c2dd0f51480790d6c1eddec35cc0521e2982bb08dca34f27243517c8b3d862dc05cfeb15d5e12a349c7c83c643f7633f01365685571d1b1ef96de0fef9b8ffad4f6a66d47390e882237b7e1e36cc730b78a3caeaab3f6044d42b549aa32e82e93dc5d679c1cc6b47dd81b4ede55e775d7:933bf060895b9e3bec7f427e2b441f54:6cc2cc26daeff1f7a08f902265e927c6&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjg4MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.8Rk14lhetBZrk3ZDFabxpOoPE6z53jEbXqWsq-1Xu-o&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Frequency and Specificity of MRI Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis and Non-Specific Back Pain: First Analysis of MRI Scans from the Assessments in Spondyloarthritis International Society Classification Cohor...\",\n \"description\": \"Background/Purpose: A broad spectrum of MRI lesions has been described in the sacroiliac joint (SIJ) of patients with axial spondyloarthritis and a recent consensus from the ASAS MRI group has culminated in updated lesion definitions (ASAS_MRI_defn). There has been no detailed evaluation of MRI scans from the ASAS Classification Cohort (ASAS-CC)1 to determine the spectrum […]\",\n \"url\": \"https://acrabstracts.org/abstract/frequency-and-specificity-of-mri-lesions-in-the-sacroiliac-joints-of-patients-with-axial-spondyloarthritis-and-non-specific-back-pain-first-analysis-of-mri-scans-from-the-assessments-in-spondyloarthr/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-a7499b00-a199-4c3c-8a17-683416a9131a\",\n \"slug\": \"real-life-year-retention-rate-of-subcutaneous-anti-tnf-in\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-24T00:11:52.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Real Life 12 Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis. Results from a Multicenter Cohort of 1170 Patients - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9085392,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/hcpfEgRSMSolsmJMmT5C_GTUOHVCE-694243-1-ANY-1-.jpg?file_detail=bdc1f7fb38bf7e4cf52f92e10d3c5f39119419b8daaceb835ca53226d43f0de612cdf8ed6a46679c97432bc77296cc1cf1810ebee2d62066ded013f05235b4324507f0f7001291498a8adabfb0520899d32870301f2ddebd58d09696e8e1cb704cc6e70849bf8d4df5e145edee0adf5e:8bdc83744e33a3de62da77d43f59c121:31d8d5867f6e059bd301a5e7472c166a&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjg5MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Mu6b_5Q6Y5PoKGc_YfwcjrG111VgGDrCk8CffOVbQUQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Real Life 12 Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis. Results from a Multicenter Cohort of 1170 Patients - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Drug survival is used as a tool for treatment effectiveness and safety especially in real-world data. The objective of the study was to evaluate long term survival of subcutaneous TNF inhibitors (TNFi) in spondyloarthritis (SA) patients and to compared drug survival between the different lines. Methods: Multicentric, retrospective, longitudinal and observational study included all […]\",\n \"url\": \"https://acrabstracts.org/abstract/real-life-12-year-retention-rate-of-subcutaneous-anti-tnf-in-spondyloarthritis-results-from-a-multicenter-cohort-of-1170-patients/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109127576\",\n \"publishedAt\": \"2022-02-24T00:11:52.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3802971,\n \"message\": \"Real Life 12 Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis. Results from a Multicenter Cohort of 1170 Patients - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9085392,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/hcpfEgRSMSolsmJMmT5C_GTUOHVCE-694243-1-ANY-1-.jpg?file_detail=b775f657c690e341518f042a48bd55e59f6884a9c00caa75c2a7bf74627e5831efd6c9dceef17113f8a0e461c2adc3d1be49b500aa444015c5798c47a977aa62918059d961bf1dfdf31799888e52f3b0222844d8981b22c09b544673abade1954633bf51f8b52a3d1c47bc6c61e0c5b1:32c6e535a306ad138a3d1cca44b60a0e:3c1e20f33472ea85df0eaee3916f8aa8&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjkwNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.KeRtkO96t2QxTlt85PSJuJA6eHNBPeSnDuuji0JnMpM&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Real Life 12 Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis. Results from a Multicenter Cohort of 1170 Patients - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Drug survival is used as a tool for treatment effectiveness and safety especially in real-world data. The objective of the study was to evaluate long term survival of subcutaneous TNF inhibitors (TNFi) in spondyloarthritis (SA) patients and to compared drug survival between the different lines. Methods: Multicentric, retrospective, longitudinal and observational study included all […]\",\n \"url\": \"https://acrabstracts.org/abstract/real-life-12-year-retention-rate-of-subcutaneous-anti-tnf-in-spondyloarthritis-results-from-a-multicenter-cohort-of-1170-patients/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-c184486f-6cd0-4b5d-a06d-1941da07f05a\",\n \"slug\": \"hepatitis-a-virus-vaccination-in-autoinflammatory-diseases-u\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-24T00:32:12.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9085433,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/0M31uLSQTXp2NYgbJzl4_IMG_9481-2341%20(NXPowerLite%20Copy).jpg?file_detail=ce61fb63aa1d26796d53d3e56f78cc07728a76f75a64d3edc5e9abecc8f0284f2a0867b88dc094966ed45b6a734d9a4c31cbaabd1fafa68b84a98bd5c0b04b3a32ab47f48dc89e567b7b85982f1123ec982782a1b543a190379be2c9f1e4bfc891d73f828fa40416de16d36cd37f6439794883516df8d8055cc626e038e6303e:f7441eb92ea9065534990cf5e3a22d64:2672370af25f82453af69cf4a14ad111&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjkxNyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.puxOnfDAm57_i_PL3XBacybGBAFHOHJ96TUuq8Wgrvs&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Autoimmune, autoinflammatory mechanism and drugs used in treatment increase the risk of liver disease in patients with chronic rheumatic diseases. Hepatitis A vaccine is a highly effective vaccine that prevents both the formation and spread of clinical hepatitis. In childhood chronic rheumatic diseases, vaccination is of great importance. The risk of various infections increases […]\",\n \"url\": \"https://acrabstracts.org/abstract/hepatitis-a-virus-vaccination-in-autoinflammatory-diseases-under-canakinumab-and-tocilizumab-treatment/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109127623\",\n \"publishedAt\": \"2022-02-24T00:32:12.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3803018,\n \"message\": \"Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9085433,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/0M31uLSQTXp2NYgbJzl4_IMG_9481-2341%20(NXPowerLite%20Copy).jpg?file_detail=bdb66b8a5350008efd125f19dda9926fd14d741479823b705981fc2f391f74ce391604c6e10f3a38be1fe1a20dbc79f31d5414804afb398421a1abdda9ff83ecd802f2ab0afe7ce168fdc51f0294ec612faf3894816223bf57cda5cda2d013f405008e4fb8fd773ff30175096debc9e346b1a97105a926fd37d7ef7fb912e767:353f50c14478276b9b33315d5469f2bb:92d3b24aeca5d87864125a4ee829270d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjkyOSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.hNZNEIfRusM-fvDxZLg2XhmkZZvPbaGyTbD27MwpjG4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Autoimmune, autoinflammatory mechanism and drugs used in treatment increase the risk of liver disease in patients with chronic rheumatic diseases. Hepatitis A vaccine is a highly effective vaccine that prevents both the formation and spread of clinical hepatitis. In childhood chronic rheumatic diseases, vaccination is of great importance. The risk of various infections increases […]\",\n \"url\": \"https://acrabstracts.org/abstract/hepatitis-a-virus-vaccination-in-autoinflammatory-diseases-under-canakinumab-and-tocilizumab-treatment/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-acbd3049-8a5b-47b3-a4b1-d3657d66eabc\",\n \"slug\": \"autoantibodies-present-in-saliva-from-sjogren-s-syndrome-and\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-24T23:51:26.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Autoantibodies Present in Saliva from Sjogren’s Syndrome and Non-Sjogren’s Sicca Patients Are Not Detectible in Serum - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9088903,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/icczwVVQQ9iPC68QtL6N_IMG_7867-27%20(NXPowerLite%20Copy).jpg?file_detail=cce4c7e585dd105ddb23f09bf286f029335dc738271b65bf906c2fe3a5f4157f5382b07b7f37923f93f442cd1a04609f05d6e5a79385a6f97215b29313106c9dfb99cb4378359eab5fbdac511e3d01be02b745ad55b3f1cb9c561ebe3c49cc1a8e32922713aec51e331c1867d703092920661e871430f5fa0eeb50bd88354ba1:4e5ab29424a11a92fd95caa508a72b01:8730089b5d4632f36d997e69c144db49&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjk0MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.qXdTYqaDmEmot_HOpC6EL-_DTeMdeKKG3v-1FAGoNlg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Autoantibodies Present in Saliva from Sjogren’s Syndrome and Non-Sjogren’s Sicca Patients Are Not Detectible in Serum - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: There is evidence for B cell involvement in the pathogenesis of Sjögren’s syndrome by the presence of autoantigen-specific B cells. Autoantibodies toward Ro/SSA and La/SSB are classification criteria. Autoantibodies are produced by plasmablasts within the salivary glands, but whether the serum autoantibodies originate from these cells is unknown. We hypothesized that if serum autoantibodies […]\",\n \"url\": \"https://acrabstracts.org/abstract/autoantibodies-present-in-saliva-from-sjogrens-syndrome-and-non-sjogrens-sicca-patients-are-not-detectible-in-serum/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109131404\",\n \"publishedAt\": \"2022-02-24T23:51:25.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3806780,\n \"message\": \"Autoantibodies Present in Saliva from Sjogren’s Syndrome and Non-Sjogren’s Sicca Patients Are Not Detectible in Serum - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9088903,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/icczwVVQQ9iPC68QtL6N_IMG_7867-27%20(NXPowerLite%20Copy).jpg?file_detail=663dd39c83d8e83579504fc9b3a6a4a90e517d23f36b17a8857ec0dc85358ade6534d93dba41a89222b3fdd7a03aa35f48cefa4e9c0993674ea91b0066bd076a9b88a481fe757503f103780ad8132c4272145dc8e46550d2d1f421c12e2a6fe6c3f0daa137bf6f93134c46d90ff6bf27c04daa5d5168f676ba1313a828b98b95:608cb55c56075173af98d57966f162c6:458b780e77b61ae08e028c7706e02c9c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjk1MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.mEYZCBfQ9671OkqLAZcCurlJMutfYH6ZyyDHiQRX-h0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Autoantibodies Present in Saliva from Sjogren’s Syndrome and Non-Sjogren’s Sicca Patients Are Not Detectible in Serum - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: There is evidence for B cell involvement in the pathogenesis of Sjögren’s syndrome by the presence of autoantigen-specific B cells. Autoantibodies toward Ro/SSA and La/SSB are classification criteria. Autoantibodies are produced by plasmablasts within the salivary glands, but whether the serum autoantibodies originate from these cells is unknown. We hypothesized that if serum autoantibodies […]\",\n \"url\": \"https://acrabstracts.org/abstract/autoantibodies-present-in-saliva-from-sjogrens-syndrome-and-non-sjogrens-sicca-patients-are-not-detectible-in-serum/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-ac157d29-05f6-45ae-b41d-ef5cd48c429a\",\n \"slug\": \"breakthrough-covid-infections-post-vaccination-among-immu\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-18T22:13:13.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository - ACR M...\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9070163,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/deAwVYTTRqXCI940DBpy_ACR_1124292_1.jpg?file_detail=3930ffba2d162bb886bbd95c149f3c0f460b55c80e1e1a3e83eded8690a5499005d4c766d4c3e09ea0f582df69cfd88fc05c689e4419536d2c22eb78e84f9895766ec61bdfb8db69639cea39db955d5d7696daecd5ea4b330734ba3e9c6ab69a6d8f656bc7b5ffbd6207a6c1701f247d:4a2490ff910a1f05b15a679ed6aacf94:a05dd88894b207bce5143bd70047304c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjk2NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.UFQSW7OBWjDhoQLr-5CxCBd4gYG8C1ND3w_gRZrZS_w&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository - ACR M...\",\n \"description\": \"Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination among patients with various AIRD using a nationally sampled cohort. Methods: We used U.S. National COVID Cohort Collaborative (N3C), the largest U.S. cohort of COVID-19 cases and controls that started in January […]\",\n \"url\": \"https://acrabstracts.org/abstract/breakthrough-covid-19-infections-post-vaccination-among-immunocompromised-patients-with-autoimmune-or-inflammatory-rheumatic-diseases-a-retrospective-cohort-analysis-from-a-u-s-nationally-sampled-el/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109109389\",\n \"publishedAt\": \"2022-02-18T22:13:12.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3784882,\n \"message\": \"Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository - ACR M...\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9070163,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/deAwVYTTRqXCI940DBpy_ACR_1124292_1.jpg?file_detail=a4e7672d4d5ace6410a6638210b8b8fb15283ce42fe817e582072dfe1b22d0cfaa956e3623e131a6c1ccb87550d304b7588b038f6775d4626f6d537c0d8165895b7523a53a50074b781aa42d9e3b4c661f891f30dbfca75dbe41cd77e6055f25cb50fb61d91e4e12f483a95170c1087a:b1b2a19f6f53770c88c4f1c4c607a123:f1735a3950a70f2884e32a32ed3c767d&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQyLjk3OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.qX5AirkLJnN8rFYhda-UFwLZasCmUX7YtnYwRnBLyIE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ2fX19XX0_&Signature=dVeFsmvnFSrZma4MpMskxTT2J9t2sPCKL2ZOsItQU4v8B7Cmjh2MmJAPi44vTxO0GQA0J7p-hPQvgoroEuKkihVXDWJ7pG~yH0PPaaWceJxSjlWJnfBUJuMiunuOgnP7EVenUXY~otCmNPSKWMiJvaitNMQmffo99ajRjNv1AEzEMlJCmEyBC9eNq8HlpHUbbiOPK9cgXcFIO2Uuyl-BD~39O08cBaa41I65snbg5xfL8yikPtfrj-WwrIs37S3yEkn-4tV5lohCBjoqlqooZQEyPnSnWeiqASTQguvQ~Tw1xnEHud7RNc1c7dKx1Y1J2FQ8lBZ6mXB67XGlfwSiBw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository - ACR M...\",\n \"description\": \"Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination among patients with various AIRD using a nationally sampled cohort. Methods: We used U.S. National COVID Cohort Collaborative (N3C), the largest U.S. cohort of COVID-19 cases and controls that started in January […]\",\n \"url\": \"https://acrabstracts.org/abstract/breakthrough-covid-19-infections-post-vaccination-among-immunocompromised-patients-with-autoimmune-or-inflammatory-rheumatic-diseases-a-retrospective-cohort-analysis-from-a-u-s-nationally-sampled-el/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-c249068e-6aa6-4a1f-8714-bd8c4df8f792\",\n \"slug\": \"optimizing-a-referral-strategy-for-patients-with-a-high-prob\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T13:22:58.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Optimizing a Referral Strategy for Patients with a High Probability of Axial Spondyloarthritis:the Role of Age and Symptom Duration - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9070955,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/l6VyucnVRWmYeBGzikeq_ACR_1065488_1.jpg?file_detail=73f7a3d83f1b3e0dd132c5660a8ff4c8644bc6e717471b75406cfe119adb8df9fc4d26837aa91490fa2e8895f04666407f5dcfa665dd387ae31f778b0bf81759ee7c186f719c83c329460fc419e1c163b5b6020f1f8928cb772e2852c0bec18c76df8e58cf2716f2158f855ac6754f4a:4ed591e47eb86757c6ba816fde267d49:ed808bf0abb03d3153dfce9d4086cc19&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjAzMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Uxc1pLTYy5V-p68YQ5OnzPdRkvX80h19NhbGC9Did2A&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Optimizing a Referral Strategy for Patients with a High Probability of Axial Spondyloarthritis:the Role of Age and Symptom Duration - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: One of the most important prerequisites for a timely diagnosis of axial spondyloarthritis (axSpA) is the early referral of a patient with back pain to a rheumatologist. In the past years a number of referral strategies has been proposed, most of them in line with the ASAS referral recommendations [1] and with a similar […]\",\n \"url\": \"https://acrabstracts.org/abstract/optimizing-a-referral-strategy-for-patients-with-a-high-probability-of-axial-spondyloarthritisthe-role-of-age-and-symptom-duration/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109110569\",\n \"publishedAt\": \"2022-02-19T13:22:58.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3786058,\n \"message\": \"Optimizing a Referral Strategy for Patients with a High Probability of Axial Spondyloarthritis:the Role of Age and Symptom Duration - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9070955,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/l6VyucnVRWmYeBGzikeq_ACR_1065488_1.jpg?file_detail=b2969ee1c6a93a3b0d0e9162ca81a6eff866a3e9603b28b9d853bc949295ba07b01a0ddd42957ce45c2d5c0a1f0e40cbd516341ef87e3e6467dde659900a6817c0e1f946a68a410c39a326be89f970148a441fb296033a4e7fb26922ddec71507cc4a4a294a9abe2a243ee74504dbc9b:a6815e82bf33dc32bbaa9b6d5deaf3eb:36195d4c070e6052fe296a0ef067d42f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjA0MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.luBzAg7O5rMuRNXEsedUZHMANXYCq8qge5nxf-EXcFg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Optimizing a Referral Strategy for Patients with a High Probability of Axial Spondyloarthritis:the Role of Age and Symptom Duration - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: One of the most important prerequisites for a timely diagnosis of axial spondyloarthritis (axSpA) is the early referral of a patient with back pain to a rheumatologist. In the past years a number of referral strategies has been proposed, most of them in line with the ASAS referral recommendations [1] and with a similar […]\",\n \"url\": \"https://acrabstracts.org/abstract/optimizing-a-referral-strategy-for-patients-with-a-high-probability-of-axial-spondyloarthritisthe-role-of-age-and-symptom-duration/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-904d4458-128f-488e-a96e-360be623f13a\",\n \"slug\": \"regulatory-b-cells-in-primary-sjogren-s-syndrome-acr-meeti\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-23T00:49:36.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Regulatory B Cells in Primary Sjögren’s Syndrome - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9081672,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/x3rtBudFQAW8Rt5WWYmd_storyblocks-young-african-girl-making-notes-or-drawing-in-her-notepad_B3Z0ur1JG%20(NXPowerLite%20Copy).jpg?file_detail=eb88dc01e30df8a542fe0ed7b8c520882419e4915ca886f79c68fb3441ec2ec33fe56e8b0c425617624ef6395021cf73b9ec746e12160694b0b27b76aac7e1bb0d6bcb25d083f1fb09da0d507e284142fa2d5915461f1a81e54ece0f8047119794cb0e2bcff907126fb7eea0c71481b0515439e967eb36fad67ff601430bd57f5961a715cb8f2f2c437ab291945f0fde2e638bb42463506563d12a68af06486945cfaab8d3bac9c9845be0d400fddcfa46c5947123eb60c6d1b895382fcc12a3:e61e518a18d9bd0f44e14276eb13efa2:9cc13cfe83f9fc70af5c7b59fb70f29a&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjA1NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.8CDqqlTBTxTiWRVjJb9YNYnN1kAjlhcWHkkWxnvOufQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Regulatory B Cells in Primary Sjögren’s Syndrome - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: B cells have traditionally been considered as positive regulators of humoral immune response, however their negative regulatory role has recently being recognized. Objective. To characterize the phenotypes of regulatory B cells in peripheral blood of primary Sjögren syndrome (pSS) patients and compare their presence according to the clinical and/or serologic activity disease status. Methods: […]\",\n \"url\": \"https://acrabstracts.org/abstract/regulatory-b-cells-in-primary-sjogrens-syndrome/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109122932\",\n \"publishedAt\": \"2022-02-23T00:49:36.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3798357,\n \"message\": \"Regulatory B Cells in Primary Sjögren’s Syndrome - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9081672,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/x3rtBudFQAW8Rt5WWYmd_storyblocks-young-african-girl-making-notes-or-drawing-in-her-notepad_B3Z0ur1JG%20(NXPowerLite%20Copy).jpg?file_detail=a907b0ad2849221555c8e47aae26d69eeab8f1cf45bf3d8f1965a8031fcda3c3c69110cf962af42be0a86e834a827c353d75cdc18ac0a8363bc55521675ecff3fa0c776ab05aa63a33354a25907c2dbf372a44ed701845de0d0953249a59b92f2a70f0628603b57a52b67beb6504857d13dbcd3a93630c861aa537ae26ae0da2bf976f01fbe6fa17d9e94227ebea20a51e39745d508de0423b64555840234834bd472c1018458806e13ab40cfae6a606832d5c4468f3a3aab5510789f1fe46f9:d759082621af4133d55798c7ac537dfd:cde458ab5533134c9aaab26cf4af039f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjA2NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.VdikXpL-VdJzo3fkXeYhNsgW5QeT6xoloLuXWApeXcU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Regulatory B Cells in Primary Sjögren’s Syndrome - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: B cells have traditionally been considered as positive regulators of humoral immune response, however their negative regulatory role has recently being recognized. Objective. To characterize the phenotypes of regulatory B cells in peripheral blood of primary Sjögren syndrome (pSS) patients and compare their presence according to the clinical and/or serologic activity disease status. Methods: […]\",\n \"url\": \"https://acrabstracts.org/abstract/regulatory-b-cells-in-primary-sjogrens-syndrome/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-4d35555e-82b1-48c9-9c2b-28fa16b96197\",\n \"slug\": \"golimumab-improves-work-productivity-and-activity-impairment\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-25T00:22:39.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): 1-Year Results from a Non- Interventional Trial in Germany - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9088948,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/MTQYguWeReWC3ucLuanB_1147_Paper_71000_abstract_106980_0.png?file_detail=390dc777b9ca5edab8180e4d96eda3a78500e59f0284c1a9188fe8585bf8de49d4e07b747a3225cc08caeff25d08e6584665e9095107a031da2e9772e35a2cb0894161b47fa83d221dc86cbfe845fbd61320473e507cc64909508185cf0d2d68ef87eb478ce1f3117b144938d59d974c47991cf8917c1955493a4f7c3c7c53d2:a6079f87eb8838d525ba0efb982bd55f:de7227efc4336591805d349c8ca77e00&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjA4MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.s7Iqra1zHxM9cj1SeSyKxi0-TzVhN1zUNUyd3GmaolU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): 1-Year Results from a Non- Interventional Trial in Germany - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Non-interventional studies (NIS) are essential instruments in pharmaceutical research not only for pharmaceutical companies but also for regulatory authorities or reimbursement bodies in Germany. Aside from direct costs caused by a disease, German sick funds as well as health authorities have a keen interest in indirect costs, such as costs derived from loss of […]\",\n \"url\": \"https://acrabstracts.org/abstract/golimumab-improves-work-productivity-and-activity-impairment-in-patients-with-rheumatoid-arthritis-ra-ankylosing-spondylitis-as-and-psoriatic-arthritis-psa-1-year-results-from-a-non-intervent/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109131438\",\n \"publishedAt\": \"2022-02-25T00:22:39.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3806814,\n \"message\": \"Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): 1-Year Results from a Non- Interventional Trial in Germany - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9088948,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/MTQYguWeReWC3ucLuanB_1147_Paper_71000_abstract_106980_0.png?file_detail=4e887395f8b7d17f670697596cf5e47eddac33ddd15dc4c5dd65b9649bfa70bd95db3c68257d0448901d611b0a686325b316c65cfd370ce3972de20009a113af4b4c95b97bfbd9b7731f6fe461b761408123c955d73c9fb8b88b048f3eefb3ecb059ecec7f2516780bbf115c8f40147e803e821b8fd43f22c40fb21b8dcb780b:8f590411503dc954c344ac67e6132e9a:86f533237ef43d68a94b1f475dcd5d8f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjA5MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.7TeGJHY-Lp6VuEr90WuDDBWiWXyqzh20BjTO35c4Tqc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): 1-Year Results from a Non- Interventional Trial in Germany - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Non-interventional studies (NIS) are essential instruments in pharmaceutical research not only for pharmaceutical companies but also for regulatory authorities or reimbursement bodies in Germany. Aside from direct costs caused by a disease, German sick funds as well as health authorities have a keen interest in indirect costs, such as costs derived from loss of […]\",\n \"url\": \"https://acrabstracts.org/abstract/golimumab-improves-work-productivity-and-activity-impairment-in-patients-with-rheumatoid-arthritis-ra-ankylosing-spondylitis-as-and-psoriatic-arthritis-psa-1-year-results-from-a-non-intervent/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-508e3e4d-bac5-4700-9e7b-c18c8078f4a5\",\n \"slug\": \"how-important-is-the-assessment-of-asdas-in-the-long-term-ev\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-23T00:33:52.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"How Important Is the Assessment of ASDAS in the Long-Term Evaluation of Disease Activity in Ankylosing Spondylitis? A Comparison with Currently Used Clinical Parameters - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9081651,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/xFER144MRtK9wz74BXSn_graphicstock-african-business-woman-in-dress-working-with-laptop-and-documents-on-workplace-near-the-window_HLqFSvXdhe%20(NXPowerLite%20Copy).jpg?file_detail=a4d67f59ac3d38b43f88273f489111f6963883157ee1d6b3923e689ba6215193530ae3e1daa9ece3c385827fcaf316bc75dd781d4b815f0b00218cf77510fd27e59b0ddc1ebeea66fc4eabe410e744e4ce3a13d5804c10aa6dd28baaef193249b520d4f6193efe799534bfde55e43159506414a455db6966d69bd6df1a796197cd38dac3fad32464150f7b359dc4d0168212c6a6911a546816badafc2b060da0bcef2a52b57fab0b97c4a9b96f8ce5e6bd76ce967bf5b5f3b470314d031506c7e22d2eaa28b8cb859f603bf98d5d414c80115695c570c4853c725547851b98d6:77ed50a98e3cf558316458d5ef682230:9503ca99fdf7c8244a56a5abfd5cf94b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjEwMyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.IeO2eeNECwIOwEzKBhnCzsQ9hw1CqqWWoO9FJVxz2qo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"How Important Is the Assessment of ASDAS in the Long-Term Evaluation of Disease Activity in Ankylosing Spondylitis? A Comparison with Currently Used Clinical Parameters - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Measures for disease activity (BASDAI) or response to therapy (ASAS partial remission (PR)) are widely used in the assessment of patients with ankylosing spondylitis (AS). The recently developed ASDAS is a composite score, which includes clinical measures and CRP and has a high discriminatory capacity for assessing disease activity. However, only little is known […]\",\n \"url\": \"https://acrabstracts.org/abstract/how-important-is-the-assessment-of-asdas-in-the-long-term-evaluation-of-disease-activity-in-ankylosing-spondylitis-a-comparison-with-currently-used-clinical-parameters/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109122906\",\n \"publishedAt\": \"2022-02-23T00:33:52.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3798331,\n \"message\": \"How Important Is the Assessment of ASDAS in the Long-Term Evaluation of Disease Activity in Ankylosing Spondylitis? A Comparison with Currently Used Clinical Parameters - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9081651,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/xFER144MRtK9wz74BXSn_graphicstock-african-business-woman-in-dress-working-with-laptop-and-documents-on-workplace-near-the-window_HLqFSvXdhe%20(NXPowerLite%20Copy).jpg?file_detail=6afd0d36f1c53de9c8c3cf32555db7dbfe4eb392b3e4946ee4ab10afebd816e19a054649dedea32dce149507f02d010310f93c58f457c83daf45c2c2444c9b07241bc6e844a4e0057f1231e93a2a1a08fd3df06e008efbeb00c66edc8431364122aa6017b0a5cabeb580f744e2a915a0eb9502afb9dc40aa3f84021c84c85845baa4a4ef4ae505e7cadeb625ac184568b143c6510c77c3fdf761c4214f2f4fe17180919403df3d7e3a6e355095bbc2f3ae2f044062072016108cd0caf688338f781cd342d652f655da189c0f4477820d756e1758ba8d4b58ae0fa4c9ed61cbbd:9f3d28bd196b3577c05d00f9e3804da2:67703f5fb92eef0bed8949d670d264b9&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjExNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.5GXD5zeff6x_xNtwXfgSXdr01WRV54ywseySX09xjBo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"How Important Is the Assessment of ASDAS in the Long-Term Evaluation of Disease Activity in Ankylosing Spondylitis? A Comparison with Currently Used Clinical Parameters - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Measures for disease activity (BASDAI) or response to therapy (ASAS partial remission (PR)) are widely used in the assessment of patients with ankylosing spondylitis (AS). The recently developed ASDAS is a composite score, which includes clinical measures and CRP and has a high discriminatory capacity for assessing disease activity. However, only little is known […]\",\n \"url\": \"https://acrabstracts.org/abstract/how-important-is-the-assessment-of-asdas-in-the-long-term-evaluation-of-disease-activity-in-ankylosing-spondylitis-a-comparison-with-currently-used-clinical-parameters/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-637d94d1-bd75-4c2c-80e4-97d34f63ff0d\",\n \"slug\": \"critical-role-of-interleukin-il-in-il-induced-inf\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-21T20:13:37.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Critical Role of Interleukin-1α (IL-1α) in IL-1β-Induced Inflammatory Responses: Cooperation with NF-κBp65 in Transcriptional Regulation - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9077423,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/dj9Q1vY8TC29wPzmJqDp_abstract-business-concept_mJC_xb_L%20(NXPowerLite%20Copy).jpg?file_detail=e8847e0ec66cb0c3a692785978889df6279e962ac118f99ba99b2b6d4fce718ff5d10a906726f5ba4ee8b9e57890680f769742a05a2b35d0920f73ac68389f461f2c5a5f0efe01ad792c6055af526ad17e65e8c1c7187e5b19a2d83e905f474d124a1f9f95c1dc931efb9ff296b40813f1f57cb3adc728c3d597c853f3c56bc44dbfb7d889617274c90cd8d247438697:07020812775215c44b7f4cce10cda984:7905de199310be6910dc90bffedbbdca&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjEzMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.lX9KXhMf-Rsz1UJrzWocbEX1BZjTV7vv1vK4Sbl1huo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Critical Role of Interleukin-1α (IL-1α) in IL-1β-Induced Inflammatory Responses: Cooperation with NF-κBp65 in Transcriptional Regulation - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Interleukin-1β (IL-1β) and IL-1α are cytokines of IL-1 family that orchestrate acute and chronic inflammatory diseases. However, their distinct role or the extent of overlap in the inflammatory processes remains poorly understood. This prompted us to explore the role of IL-1α in IL-1β-activated signaling pathways causing synovial inflammation in rheumatoid arthritis (RA). Methods: Normal […]\",\n \"url\": \"https://acrabstracts.org/abstract/critical-role-of-interleukin-1%ce%b1-il-1%ce%b1-in-il-1%ce%b2-induced-inflammatory-responses-cooperation-with-nf-%ce%babp65-in-transcriptional-regulation/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109116865\",\n \"publishedAt\": \"2022-02-21T20:13:37.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3792329,\n \"message\": \"Critical Role of Interleukin-1α (IL-1α) in IL-1β-Induced Inflammatory Responses: Cooperation with NF-κBp65 in Transcriptional Regulation - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9077423,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/dj9Q1vY8TC29wPzmJqDp_abstract-business-concept_mJC_xb_L%20(NXPowerLite%20Copy).jpg?file_detail=b35b545c15a42fba7b0c656a43a3c781dc3d4c15a13d5b7554495522322675e390fb6d1ea24fd3147623cf6c9cd898baa6c409398078aed295850d950a2b8e18bb1d101953c635e1bfdd2161cfd2ca9c16de4c3efaccca0a06f1d8684452e256fdf8b7b4689b101640ff7a16e31832fed9f0c81ae317c6bd6ac991cdc6145cf8fdef8bb009185a9cc672903d21adc780:74d99645add0e148df497b15fce695dd:fe1236b91bd5af3e2e11a29d751f2b5f&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjE0NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.wimVDzfzVwQ3DHyHIQJNG_bCTIflsWJBnN89brWX_18&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Critical Role of Interleukin-1α (IL-1α) in IL-1β-Induced Inflammatory Responses: Cooperation with NF-κBp65 in Transcriptional Regulation - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Interleukin-1β (IL-1β) and IL-1α are cytokines of IL-1 family that orchestrate acute and chronic inflammatory diseases. However, their distinct role or the extent of overlap in the inflammatory processes remains poorly understood. This prompted us to explore the role of IL-1α in IL-1β-activated signaling pathways causing synovial inflammation in rheumatoid arthritis (RA). Methods: Normal […]\",\n \"url\": \"https://acrabstracts.org/abstract/critical-role-of-interleukin-1%ce%b1-il-1%ce%b1-in-il-1%ce%b2-induced-inflammatory-responses-cooperation-with-nf-%ce%babp65-in-transcriptional-regulation/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-7992ec06-3db9-4e57-a478-fde9f8b6a08e\",\n \"slug\": \"guselkumab-tremfya-improves-anemia-in-patients-with-active\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-19T13:11:00.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Guselkumab (TREMFYA) Improves Anemia in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Randomized Controlled Clinical Trials - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9070944,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/MLcnoarITBiJPrPsynyd_ACR_1050687_1.jpg?file_detail=ad6d9e6aeec02f02eafd759c5adcc54f47291341fc51e76a0d3023a93920e18b0a09c758250ddeaf9de479a615c91ab24f0eb7d6ca01935e448fee8d14d3bb2b50a7985305a50850b69f381f5ada8e01900c473976d267d99d65db4e1aca875ff61fca6b6faba4506a62128b370985c5:ac5d44c52a41c9629bddb8e41e228ead:7823b726af0948dc93bfde8a0cedee8c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjE1OSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.6kMETe7pGoJsCiZV2uVH6sRExocCKAjuRqtg2F26ajI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Guselkumab (TREMFYA) Improves Anemia in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Randomized Controlled Clinical Trials - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Anemia related to systemic inflammation can be an important feature of psoriatic arthritis (PsA). Hemoglobin (Hgb) levels have been shown to be inversely related to disease activity in other rheumatic diseases.1,2 This post hoc analysis assessed the effect of guselkumab (GUS), a selective IL-23p19 inhibitor, on anemia in the pooled Phase 3 DISCOVER-1 & […]\",\n \"url\": \"https://acrabstracts.org/abstract/guselkumab-tremfya-improves-anemia-in-patients-with-active-psoriatic-arthritis-results-from-two-phase-3-randomized-controlled-clinical-trials/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109110558\",\n \"publishedAt\": \"2022-02-19T13:11:00.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3786047,\n \"message\": \"Guselkumab (TREMFYA) Improves Anemia in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Randomized Controlled Clinical Trials - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9070944,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/MLcnoarITBiJPrPsynyd_ACR_1050687_1.jpg?file_detail=13987aef874b874066ce9512e05b7c4e4264ee15f34daf6e6333d75aad7f99de807b67b5f30239e750b38669cfa3186001494dbd9401936cafbd9d40e5bb78f9b848802f6a2246bf2bba4d1193316ec42d3d59f4e27d51f16654f844dec458ff1dabc1975ebbb0651bb8c787b455ebd1:fbb148d177fbf5250ea419b3aab448c3:440d14bb7b739e8fb184a24372bcbf3c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjE3MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.EQVyPUB7CZtvAq0bqOSao6UIbDOM2S3sTVp3fYQ-5fU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Guselkumab (TREMFYA) Improves Anemia in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Randomized Controlled Clinical Trials - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Anemia related to systemic inflammation can be an important feature of psoriatic arthritis (PsA). Hemoglobin (Hgb) levels have been shown to be inversely related to disease activity in other rheumatic diseases.1,2 This post hoc analysis assessed the effect of guselkumab (GUS), a selective IL-23p19 inhibitor, on anemia in the pooled Phase 3 DISCOVER-1 & […]\",\n \"url\": \"https://acrabstracts.org/abstract/guselkumab-tremfya-improves-anemia-in-patients-with-active-psoriatic-arthritis-results-from-two-phase-3-randomized-controlled-clinical-trials/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-7e09d1b4-5bc4-4160-8bd7-3d6230882e68\",\n \"slug\": \"a-randomized-open-label-study-of-maintenance-of-partial-rem\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-23T00:03:16.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"A Randomized, Open-Label Study of Maintenance of Partial Remission with Naproxen Vs No Treatment: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial, Part II - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9081580,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/9TFexu6kToa8vGknrA1m_graphicstock-three-caucasain-business-women-holding-growth-graph-cheerful-business-team-with-growth-graph-concept-of-business-growth-teamwork-and-partnership-vector-flat-design-illustration-square-layout_HQ9qm_88Z_L%20(NXPowerLite%20Copy).jpg?file_detail=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:b09bedc14d9c82f113752425a560fbdd:17548e4f2e0121d459065514b57b92e7&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjE4NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Dt-sQyaf65AV9hVs0_UXRIQixHRMoB0rpcrWKOX1Aj0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"A Randomized, Open-Label Study of Maintenance of Partial Remission with Naproxen Vs No Treatment: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial, Part II - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: In patients with axial SpA who have achieved partial remission, it is unclear whether continuous treatment with NSAIDs is superior to stopping treatment. Objectives: To investigate whether continued treatment with naproxen (NPX) was superior to discontinuing all treatment in order to maintain disease control for 6 months in early, active axial SpA patients who […]\",\n \"url\": \"https://acrabstracts.org/abstract/a-randomized-open-label-study-of-maintenance-of-partial-remission-with-naproxen-vs-no-treatment-results-of-the-infliximab-as-first-line-therapy-in-patients-with-early-active-axial-spondyloarthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109122829\",\n \"publishedAt\": \"2022-02-23T00:03:16.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3798254,\n \"message\": \"A Randomized, Open-Label Study of Maintenance of Partial Remission with Naproxen Vs No Treatment: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial, Part II - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9081580,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/9TFexu6kToa8vGknrA1m_graphicstock-three-caucasain-business-women-holding-growth-graph-cheerful-business-team-with-growth-graph-concept-of-business-growth-teamwork-and-partnership-vector-flat-design-illustration-square-layout_HQ9qm_88Z_L%20(NXPowerLite%20Copy).jpg?file_detail=36dea53253e3069222a943616d84ff520798858a1c95de81694859c5a22949df46b406500c3db7cc059dd1a39aa3efa2fb2b943199cd1df59661337a0917795ccd8bd54fb042769af16d93c2995bcf6fc9fb43f74b63492ffc0417ceafa32ef2150c1e0f0a698dd905343343a969c71b1aba27c773f8d2d6c817ed85ab47e78a797095d11429ac27eb45b13bad7aca4c2e02f0ca37d976e5faf0ab7a9b8b465f77d46be217bef2cda725a2d8f27c64cf68a71d9502ca92fb600c26d5b95956daefd421cf9858e03f5aa23bf6bf316758f15d046df71c83370c904932d0069317c8d955fa676169e9e7af635e6508b263de3c41aea56e101507aec6466bb832605f02796a6e4b02d666867f58147f92e5f29048fdef2d0b3ba7a65c7ae7c355d881eba3339cd6f1b83f0799860cfcc72c14aa555a410113d855d0d772a3325bf8:e50472f017af6b076d8cb7580a35911e:61ea13b9dcc168a952d048a7c93f6eaf&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjIwMyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.Enr835MU03_2mMx_EE26LIIwbeB8ca9MGRTStG3b8hk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"A Randomized, Open-Label Study of Maintenance of Partial Remission with Naproxen Vs No Treatment: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial, Part II - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: In patients with axial SpA who have achieved partial remission, it is unclear whether continuous treatment with NSAIDs is superior to stopping treatment. Objectives: To investigate whether continued treatment with naproxen (NPX) was superior to discontinuing all treatment in order to maintain disease control for 6 months in early, active axial SpA patients who […]\",\n \"url\": \"https://acrabstracts.org/abstract/a-randomized-open-label-study-of-maintenance-of-partial-remission-with-naproxen-vs-no-treatment-results-of-the-infliximab-as-first-line-therapy-in-patients-with-early-active-axial-spondyloarthritis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-0a0f9973-5f54-4473-9919-cc14f3f46ee2\",\n \"slug\": \"current-evidence-for-il-blockade-for-the-treatment-of\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-07T10:46:20.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Current Evidence for IL-17/23 Blockade for the Treatment of Lupus Nephritis - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9022654,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/qlZNSXAcTRMgC4vskTQ9_pubmed-meta-image.png?file_detail=853260dbe4ec90332e2aa773e22868cb2d2216ed9c060df6217e79544ac12f75ef4e3cd165dc225c6f7c9784afa20f88190a147bee4f6b97213327474d218c76463b9e5852d5937ab61e4f7facd916e4bc375e2d1ad0b96ac13e75560c9d257ec84d60c3eb3e620c6d10bf4af08c401d:c55e2cf048274959f5dc01d8ac226b4a:0d22e0b30df68d69ed44d6aec76e1c40&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjIxNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.xK5m1XrgYvRhtpPhrh2901PdITPqxkq28BHPnnIvsmk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Current Evidence for IL-17/23 Blockade for the Treatment of Lupus Nephritis - PubMed\",\n \"description\": \"In the current medical literature, there is increasing evidence for the involvement of the interleukin (IL)-17/23 axis and the potential role of Th17 cells in the pathogenesis of lupus nephritis. Knowledge about the interaction of these immunological pathways in the development of autoimmune disease …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34993035/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109058652\",\n \"publishedAt\": \"2022-02-07T10:46:20.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3733165,\n \"message\": \"Current Evidence for IL-17/23 Blockade for the Treatment of Lupus Nephritis - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9022654,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/qlZNSXAcTRMgC4vskTQ9_pubmed-meta-image.png?file_detail=50fbb5242b52dc308b8917f786a063629111bc7efbea0fe3d850fa6988f1056a7380497e546f0876617a6845acbd29e8bf750746366e51ceb56ea7ef9a0715a7a302aaa303ed1e171e49f6c274ed8644a982f2dc8dfeb3e8dd7f3ff413257563f73d7ab333bf446d6de3cc6264e52f6b:05a5ec275bce32587ae8bbc68cce942c:8125d78b77e1af823b05f270d569eb50&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjIzMCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.lLp-w2dLcdZ2OZrZNAcsORwpnBcEIMZdyVIjPG7PMBQ&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Current Evidence for IL-17/23 Blockade for the Treatment of Lupus Nephritis - PubMed\",\n \"description\": \"In the current medical literature, there is increasing evidence for the involvement of the interleukin (IL)-17/23 axis and the potential role of Th17 cells in the pathogenesis of lupus nephritis. Knowledge about the interaction of these immunological pathways in the development of autoimmune disease …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/34993035/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-192c2a96-af29-442d-a804-d3a10b97748f\",\n \"slug\": \"circulating-levels-of-interleukin-and-cardiovascular-outc\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-07T10:16:20.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction | European Heart Journal | Oxford Academic\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9022507,\n \"imageUrl\": \"https://oup.silverchair-cdn.com/oup/backfile/content_public/journal/eurheartj/34/8/10.1093_eurheartj_ehs263/1/m_ehs26301.gif?Expires=1706874654&Signature=m9IBB8zJNQS6S~fO6Vz~iUXCISujcxWHtbGo22fcjijdtmc7LJ58w8UwJgK~qCqb0pXVy-xmIDEKGnsThgEq1SlbCxTmek~oUAy9V1o~N~wFFOxeAPte9yizDLpAPOfDVdFE~0wLQkFJ9BS0xfSae62jz6rENT12rXPi3dt5N0KOYKJyB1SAbk6DL4Rp0kStID6SdlTC9wx0enGPvQ0GafJT3b9jt8b1uBOL2qwCvLAAEagYJgKAgmq2ubJB8Dq8Gt9-R20cnMjo~OZUt1ufg~Qn~1Qwq7Xy-bKnEk0qLJ6JnloG1JJUyW4kTVQx73uU3IJ2f6tlFtRclLtfBabjeA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\",\n \"title\": \"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction | European Heart Journal | Oxford Academic\",\n \"description\": \"AbstractAim. Interleukin (IL)-17 pathway is being clinically targeted in immune-mediated diseases, most of which are associated with a significant cardiovascula\",\n \"url\": \"https://academic.oup.com/eurheartj/article/34/8/570/493922?login=true\",\n \"siteName\": \"OUP Academic\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109058497\",\n \"publishedAt\": \"2022-02-07T10:16:20.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3733011,\n \"message\": \"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction | European Heart Journal | Oxford Academic\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9022507,\n \"imageUrl\": \"https://oup.silverchair-cdn.com/oup/backfile/content_public/journal/eurheartj/34/8/10.1093_eurheartj_ehs263/1/m_ehs26301.gif?Expires=1706874654&Signature=m9IBB8zJNQS6S~fO6Vz~iUXCISujcxWHtbGo22fcjijdtmc7LJ58w8UwJgK~qCqb0pXVy-xmIDEKGnsThgEq1SlbCxTmek~oUAy9V1o~N~wFFOxeAPte9yizDLpAPOfDVdFE~0wLQkFJ9BS0xfSae62jz6rENT12rXPi3dt5N0KOYKJyB1SAbk6DL4Rp0kStID6SdlTC9wx0enGPvQ0GafJT3b9jt8b1uBOL2qwCvLAAEagYJgKAgmq2ubJB8Dq8Gt9-R20cnMjo~OZUt1ufg~Qn~1Qwq7Xy-bKnEk0qLJ6JnloG1JJUyW4kTVQx73uU3IJ2f6tlFtRclLtfBabjeA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\",\n \"title\": \"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction | European Heart Journal | Oxford Academic\",\n \"description\": \"AbstractAim. Interleukin (IL)-17 pathway is being clinically targeted in immune-mediated diseases, most of which are associated with a significant cardiovascula\",\n \"url\": \"https://academic.oup.com/eurheartj/article/34/8/570/493922?login=true\",\n \"siteName\": \"OUP Academic\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-1a3bb659-5ab6-4deb-930d-77e9734f35fe\",\n \"slug\": \"proinflammatory-cytokine-signaling-required-for-the-generati\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-13T00:53:22.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Proinflammatory cytokine signaling required for the generation of natural killer cell memory | Journal of Experimental Medicine | Rockefeller University Press\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9044993,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/oAHYKVrYTuTW7WhAQehq_abstract-summer-background_fJZOu2___L%20(NXPowerLite%20Copy).jpg?file_detail=ec74c6eb416426d976dcaff781b1f5992a6daf0ff8159c8e432b1ed82eddf7f00c5520ba1bc23c6862da2ef6c090be86e8b3175945e7938a1ce5f2f472dc97c306ccc2d3e12876fe9b61a3479db531b1115593ec4f37e6ee9b72e6b87ad55cb9b5069d52dab715e2ee7cf91305bb9af5c7f59694188c0c5dc45f2d6df84308d1420fb8d3f985798da94d67c528a949c5:7959d47960bd7fee359828f79730dd91:7ce9cd11629d9e1068e4e836c67d80e3&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjI2MSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.8OKK35zUvtxhermWJzVahUjky0HAJ1EoZyttkPmk7j0&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Proinflammatory cytokine signaling required for the generation of natural killer cell memory | Journal of Experimental Medicine | Rockefeller University Press\",\n \"description\": \"Responsiveness to interleukin-12, but not interferon-γ, is essential for the generation of long-lived natural killer cells capable of responding to secondary vi\",\n \"url\": \"https://rupress.org/jem/article/209/5/947/41185/proinflammatory-cytokine-signaling-required-for\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109082028\",\n \"publishedAt\": \"2022-02-13T00:53:22.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3757601,\n \"message\": \"Proinflammatory cytokine signaling required for the generation of natural killer cell memory | Journal of Experimental Medicine | Rockefeller University Press\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9044993,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/oAHYKVrYTuTW7WhAQehq_abstract-summer-background_fJZOu2___L%20(NXPowerLite%20Copy).jpg?file_detail=f9d3ff5a19af01e85d5d804d87d3b68f3fd5cbde76b35fdb511e5426e78c7ba5555f6d4b5bbbdc74e7c2140e06a10f0ce0358da3716752b472269bafb228e3f5c68763a4bca9e1a5c480d75e0624613388673df7fe3d8986257da0f074b6b81531ab20399b9203d53c75769421d0e79cb863fdb2b92b60988fa15da884dcd1cec641b1baeb7a2b67ef72aecae32d25d8:b52842a1652e4fc9da45dc5f3cbcd749:7600cd2ee193780795180785e2ada9dd&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjI3NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ay7zUshJuP2D6_LN0MjqK8ymDFRXZ4lexjNaA4cZc-U&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Proinflammatory cytokine signaling required for the generation of natural killer cell memory | Journal of Experimental Medicine | Rockefeller University Press\",\n \"description\": \"Responsiveness to interleukin-12, but not interferon-γ, is essential for the generation of long-lived natural killer cells capable of responding to secondary vi\",\n \"url\": \"https://rupress.org/jem/article/209/5/947/41185/proinflammatory-cytokine-signaling-required-for\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-1c3528b3-055a-47d9-9f3e-e86fa15c0718\",\n \"slug\": \"psoriasis-psoriatic-arthritis-and-rheumatoid-arthritis-is-psoriasis\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-12T20:27:47.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? - ScienceDirect\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9044947,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/H9fIwe3SkWXPfx6T4bFQ_1-s2.0-S0049017216X00108-cov150h.gif?file_detail=2a8100aca10e6f6a818e7798e8b7ec2def4892089ba6374f0d63fca12a5353b71b35f1dae095e707622c363ebade4085541aa12b2fa60b3896898208f899f505233c5608d855db1135b28b20122a4a7575f7852e67608990d8ee3bc0e0f4b1cec38f078e5e564030788ca2a8bf73b0d57b190a3ce46baede83528f998c965817:0628b891023f816836c8412cefda3e09:224dfa623990c4e2c43a9f660c5fa6d9&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjI4OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.l62RZw7PxJnBI2hV11vQVkgO1_LuLqusIWN_zJKxdYo&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? - ScienceDirect\",\n \"description\": \"To review the pathophysiology, co-morbidities, and therapeutic options for psoriasis, psoriatic arthritis and rheumatoid arthritis in order to further…\",\n \"url\": \"https://www.sciencedirect.com/science/article/pii/s0049017216300646?via%3dihub\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109081968\",\n \"publishedAt\": \"2022-02-12T20:27:47.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3757541,\n \"message\": \"Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? - ScienceDirect\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9044947,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/H9fIwe3SkWXPfx6T4bFQ_1-s2.0-S0049017216X00108-cov150h.gif?file_detail=060edf4af0316756b584227b72fef2d5084719a6c2f903c2792b64ec9bfd4c99f8d6c12f88ca55ef6b7c79f18b8514aae764a3cb0dbc3ef33e85c8622c03154bdfa6f7482f44c6046498f677319e531bb30dba5c3a1df7b4ce8b3071049a8325d82fa28886d2e105588458d8e441cc9cd8a494f25dfdc9a0f6f32da4b609af2b:21048bfdf9ab3f9f7ee6aa0362235a1e:553d13d50af2bdcd5f53de483656e1d1&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjMwMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.yGg5VEf0KquaGrZlVZJF693uGPnv7sa6q-t0XIXmKOE&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? - ScienceDirect\",\n \"description\": \"To review the pathophysiology, co-morbidities, and therapeutic options for psoriasis, psoriatic arthritis and rheumatoid arthritis in order to further…\",\n \"url\": \"https://www.sciencedirect.com/science/article/pii/s0049017216300646?via%3dihub\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-1c853831-1367-4ed3-83c6-a3d23f6529f9\",\n \"slug\": \"predictive-factors-for-the-development-acute-anterior-uveiti\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-09T00:20:49.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9027987,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/mXCpB1P7QHisDrx69Ljc_ACR_1065552_1.jpg?file_detail=bfd94fe43bd129b18f7965b7769cb13e25c0ecfd588633c7f26119af5ad3c25e2ed893448ccc7e5ef10e2b241c21ee64181a27f4b930f54436f7d07e95f398c2480f96243b67b0e25ebedf56cad1c41ad89c3fffc389409b19035004935b5e33b039c7af47f6ac0e317887770167e9b0:f3da3908de4ef935ac9a4fb59e77575e:b3da09541b2f1cfcce293b021d6634f8&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjMxNSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.U8U6Yx8u6aVaQ892xWOxAak6YyyW1mFn65dVmE1SYZU&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease mainly affecting sacroiliac joints and spine. Peripheral arthritis, dactylitis and enthesitis may also occur. Acute anterior uveitis (AAU) is the most frequent extra musculo-skeletal manifestation of axSpA which may lead to severe functional impairment. Moreover, an AAU attack can be the presenting symptom that may […]\",\n \"url\": \"https://acrabstracts.org/abstract/predictive-factors-for-the-development-acute-anterior-uveitis-attacks-in-patients-with-axial-spondyloarthritis-the-results-of-a-longitudinal-analysis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109065105\",\n \"publishedAt\": \"2022-02-09T00:20:49.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3739586,\n \"message\": \"Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis - ACR Meeting Abstracts\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9027987,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/mXCpB1P7QHisDrx69Ljc_ACR_1065552_1.jpg?file_detail=bb17e3443499643d8c1df3ff815253cb05b2c7897b0cfbfb42761097a97b5ffe0a0fbd5d257d3157a961b237cf7c0d3679be36d3fd657a6eae868a6e4774c5533a1cb7617a106c44f1c971b76f45202bef283ce59a7e90d8adca54b15a2d09976e1a5b157374525d68095a16ba6df241:2016d27dd34c71ec1729eebcff242736:564a54b5ac353e1a3836562978fa7764&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjMyNiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.05_tsuwxHZbSXI50FySBlBnjXIeYFDo6jUyKN2Eqzrc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis - ACR Meeting Abstracts\",\n \"description\": \"Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease mainly affecting sacroiliac joints and spine. Peripheral arthritis, dactylitis and enthesitis may also occur. Acute anterior uveitis (AAU) is the most frequent extra musculo-skeletal manifestation of axSpA which may lead to severe functional impairment. Moreover, an AAU attack can be the presenting symptom that may […]\",\n \"url\": \"https://acrabstracts.org/abstract/predictive-factors-for-the-development-acute-anterior-uveitis-attacks-in-patients-with-axial-spondyloarthritis-the-results-of-a-longitudinal-analysis/\",\n \"siteName\": \"ACR Meeting Abstracts\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-41cf5e3f-765a-424d-8a87-af81458fa8e8\",\n \"slug\": \"open-label-investigator-initiated-single-site-exploratory\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-06T12:38:30.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018537,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/KUAawN4QAmPJS1ifreAQ_pubmed-meta-image.png?file_detail=0a35b84dcd6a8a2e56e2cf65a81d5bcd36ec558019263ecb85490d39ddf72455aa6c02e7d2050849fe413d2d7529aed8674cdb3ebcdd539c6856b5935674631d46fdd3a5382430a4100a89ceaced329da498bf5ee94b6eb61f1891e5f28d49cc0320bfca2b71f22baeedd3a02e20ec8d:71b8bb3e07a339a1d33195622d704c6a:dd0161a994cb5e2bfbf47ec06201fab2&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjMzOCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.wqdEFXUm5PQvgiA1z3GBDI19f3NtsFwXvzjE7G-WUic&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa - PubMed\",\n \"description\": \"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/30801662/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109054460\",\n \"publishedAt\": \"2022-02-06T12:38:30.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728978,\n \"message\": \"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018537,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/KUAawN4QAmPJS1ifreAQ_pubmed-meta-image.png?file_detail=bb78df621a4eb86eea6a7edf8ecef10570a5329c46e5d59d171ecf0200c30831d99b5b1bd7a225341b901bb6f8e004e85999b730483eebbf8b7181a3a4c1373e65947dc8551f3022c02257ad9e1702f42d9ccbc9684d87d28e737fbcbc82277788eb29c056a0d42066254eb0482addf9:08509ac2db7358fca8f45fe0f940b0d1:f2a1c222956c922a081a4f20f9fc23f0&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjM1MCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.mYFCUnIoO_aiMXrx_n7TEyHS5IpldkFw68sofEwpBkk&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa - PubMed\",\n \"description\": \"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/30801662/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-cd93c769-1a69-418c-836f-18d37b0d4325\",\n \"slug\": \"efficacy-and-safety-of-intravenous-secukinumab-in-noninfecti\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-07T10:50:30.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy - PubMed\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9022664,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/uigxlAzQBuigKoNoBERw_pubmed-meta-image.png?file_detail=ef104225dcb56128937f495a7cd91a2c31017cf340ec53d6140686e742d4cb0550f4f800595774d9fb1634cef901eadba3f013edb20fa925b6ba3a7201a4217c8df1d3ff162196a7a19d381860d0930d9bfdaad02dfe4e22ed1a24b49e911e9a4575e26ecbc722799aad29bb47285ce2:cb81a2a6d76c56c14e4e70796a2e7370:6574b4441faa8290604f90d4d0a293ff&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjM2MiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.N42C_3RAGgSC0_b9ZIUWoWasAXjkJXlNi_JM-2yY0-s&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy - PubMed\",\n \"description\": \"Intravenous secukinumab was effective and well tolerated in noninfectious uveitis requiring systemic corticosteroid-sparing immunosuppressive therapy. Greater activity with IV dosing suggests that patients may not receive sufficient drug with SC administration. High-dose IV secukinumab may be necess …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/25638011/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109058661\",\n \"publishedAt\": \"2022-02-07T10:50:29.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3733174,\n \"message\": \"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy - PubMed\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9022664,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/uigxlAzQBuigKoNoBERw_pubmed-meta-image.png?file_detail=40002358991a52e344ee06e72edbac2ead15cadce9c7f6c84f15a9e050009432fa69bb3051d1d911d17c9bdd211bfc534b95a32dbf53686ff3fd2c9a56b407cfb669d81ab1c6282e9b17815251ec582ac4adce998f7e14e5e52e2a754a22e9077bfefc621fbbf36cff37d9f0cf6786cf:9ca35672b27b09850de67711dc561ccb:aebeadfa995359a714bd053ba9d57d2c&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjM3MyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.c2D99p1V03m18_-NXA_4Jyik4SYVh52RVctXsZxmAkI&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy - PubMed\",\n \"description\": \"Intravenous secukinumab was effective and well tolerated in noninfectious uveitis requiring systemic corticosteroid-sparing immunosuppressive therapy. Greater activity with IV dosing suggests that patients may not receive sufficient drug with SC administration. High-dose IV secukinumab may be necess …\",\n \"url\": \"https://pubmed.ncbi.nlm.nih.gov/25638011/\",\n \"siteName\": \"PubMed\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-c0277624-6cc3-4dd4-92b9-58ff37cba0ef\",\n \"slug\": \"the-value-of-magnetic-resonance-imaging-for-assessing-diseas\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T20:13:41.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"The Value of Magnetic Resonance Imaging for Assessing Disease Extent and Prediction of Relapse in Early Peripheral Spondyloarthritis\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9018044,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/hpgKyBxT6Ou6TFruiTKQ_art.v73.11.cover.jpg?file_detail=1e0bb5800aa4ef7a15e647e0f4fbd7a631e29c6aa5b76a708e1b0184943c4c24e7f63ce0cfc3a0c49659a3f2950ebe8ef07ecfb06bf894ecf2233f8ee1c6b64df8a4215d6f46d1c1b5029bd88e9f4080faaf6b394aa6df16a3c384ece90511bf863565344f5879826aecddf914c83397:2c641f87fcec5e5bd81a9e2cb3324519:6dd618694e0b15e31aece18e263dfe9e&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjM4NSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.G76EwRuwXlSl76eKPcbLWtYYZig5fCuIzX7PqE6fSHc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Value of Magnetic Resonance Imaging for Assessing Disease Extent and Prediction of Relapse in Early Peripheral Spondyloarthritis\",\n \"description\": \"Objective\\nThis study was undertaken to assess the inflammatory burden in peripheral spondyloarthritis (SpA) by magnetic resonance imaging (MRI) of the legs in an early remission–induction strategy s...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.41783\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109053980\",\n \"publishedAt\": \"2022-02-05T20:13:41.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728510,\n \"message\": \"The Value of Magnetic Resonance Imaging for Assessing Disease Extent and Prediction of Relapse in Early Peripheral Spondyloarthritis\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9018044,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/hpgKyBxT6Ou6TFruiTKQ_art.v73.11.cover.jpg?file_detail=1f126fb69333c6eae0ccfbf4c28a09733526e7621fbfe2605ed9025b90e4d967a0ec10970f1b111d8f22df2593f6d456d2f9a8b0d57ab96177373962487482fba8cc5392a3b238ccb45a0f7798a1d1fb8a9265a0f8a06725498e12773f82b4fdc6e918438dce0cb27b668174a3c6a252:1560c06abec36e7427853f03f2a4abe9:e30b2bcf7f55ff8c06d4516bd76da766&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjM5NyswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.HGrWHmkBwJz94JBoJb7ZTzYZ0am-4g5NqdRv40vngLc&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"The Value of Magnetic Resonance Imaging for Assessing Disease Extent and Prediction of Relapse in Early Peripheral Spondyloarthritis\",\n \"description\": \"Objective\\nThis study was undertaken to assess the inflammatory burden in peripheral spondyloarthritis (SpA) by magnetic resonance imaging (MRI) of the legs in an early remission–induction strategy s...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.41783\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-d0a4091f-af41-48f0-9074-5285d8b88b0e\",\n \"slug\": \"risk-of-inflammatory-bowel-disease-in-patients-with-psoriasi\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-05T12:13:15.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin‐17 Inhibitors: A Nationwide Population‐Based Study Using the French National Health Data System\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9017712,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/VDd3Yi7HQHuPWVwh1r5F_art.v74.2.cover.jpg?file_detail=fc63866bd66dbb3650e8415b45cad5a3218969171038e20d5c690ebabafd62a0d5ab354db6466b0210e647535d84f879277804ff4f7bf67bcc6e41a1e023917a79ad2328cce0d4ad7e58e51dba26cd838096636a231eac341ab2514c8f7ecae9634da7aa9fbc25deb61ea012624cd8b6:7904de5d3d385a9c08701c355d7c7566:c95993e4f369c73dfe27e756aa3bccff&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjQwOSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.VHHsDBjM0QvbHULYa-8ipEkJdr4saFlsg182VY9ftr8&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin‐17 Inhibitors: A Nationwide Population‐Based Study Using the French National Health Data System\",\n \"description\": \"Objective\\nTo investigate whether the initiation of treatment with an interleukin-17 inhibitor (IL-17i) in real life is associated with a higher risk of inflammatory bowel disease (IBD) in patients w...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.41923\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109053652\",\n \"publishedAt\": \"2022-02-05T12:13:15.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3728183,\n \"message\": \"Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin‐17 Inhibitors: A Nationwide Population‐Based Study Using the French National Health Data System\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9017712,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/VDd3Yi7HQHuPWVwh1r5F_art.v74.2.cover.jpg?file_detail=4be8203c3f87b6f77c184e1cc530898fb0aec1cdc4f9c15acc1c8518fc3df24d1dbe010a66dcdcd71677319f508f65ab73e72f8d188cb3d7181d44f5e4ddc3a2be8c949a3bf71e417a2df32085418d299bc8dd5fdbe5ebf31137034ce421934e9de8146a17951820d1749bb35a942cb0:a9b87ddb166bd874082d424f996a43ac:fb3196228dcc4b855a59841c8491a1b9&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjQyMSswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.LjZJlio-CaMEfVshMnq3Bo1U8BTUxooiYG5h3NUSkE4&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin‐17 Inhibitors: A Nationwide Population‐Based Study Using the French National Health Data System\",\n \"description\": \"Objective\\nTo investigate whether the initiation of treatment with an interleukin-17 inhibitor (IL-17i) in real life is associated with a higher risk of inflammatory bowel disease (IBD) in patients w...\",\n \"url\": \"https://onlinelibrary.wiley.com/doi/10.1002/art.41923\",\n \"siteName\": \"Wiley Online Library\",\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-d473dd8e-83fd-450c-b595-2c1659a04ad7\",\n \"slug\": \"psoriasis-rate-is-increased-by-the-exposure-to-tnf-inhibitio-psoriasis\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-15T00:07:27.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA | Annals of the Rheumatic Diseases\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9050944,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/x64jyOA6RrS1nzd1N7Fo_3.cover-source.jpg?file_detail=ed245572b5fa611710d1a61152b39bb4a6272a6fd2abe2c9294636f0dbe675313336ed0385d268bec63359cbefb6b376d7d2c2026c0fe6c93132330ecac8c8e13d9656094e875ef86f4e70c712ae1bfbe8c26de2f0064e27147bf2d02c6ba1d13d28e76d4f08d9f7e3ace0cf3d99f264:9d97f07ebd0195568b8095df81d6baf2:375a1ee266e720db7bc00d660c8aa922&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjQzMiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.ygU3apliv4Utky-53nGHkB8bvr7m0F_RWHZZQqoAImA&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA | Annals of the Rheumatic Diseases\",\n \"description\": \"Objective We aimed to investigate the relationship between tumour necrosis factor inhibitors (TNFi) therapy and the onset of new psoriasis in children with juvenile idiopathic arthritis (JIA) using Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry data.\\n\\nMethods De-identified data were obtained from the CARRA Registry. Patients with inflammatory bowel disease or psoriasis documented on or prior to JIA diagnosis date or with incomplete data were excluded. Exposure to TNFi...\",\n \"url\": \"https://ard.bmj.com/content/early/2022/01/26/annrheumdis-2021-221694\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109088582\",\n \"publishedAt\": \"2022-02-15T00:07:27.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3764132,\n \"message\": \"Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA | Annals of the Rheumatic Diseases\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9050944,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/x64jyOA6RrS1nzd1N7Fo_3.cover-source.jpg?file_detail=966401c6e3572fa4a7229a362bba3c729d9da60c02574d3c381c784356d9c40f3594d975f0715b9b8c0670df8f7d246a4e7b655210ce14a4044dd87d7e0356e5bb605ac71d1ed98a5232d594a1a46f5a045d8b7283a6b8df2b3a167497cf0434d554d2ae85cc8e3f149fd83ac08f4c7f:cabb32b3c01d6e78f0de643d9c125b84:9c5c0b399daf74f3c031f583e24e1be3&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjQ0NCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.hd_yLNybhVSay20b6D9fQ7812cJpjDdABgiq-hsGNME&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA | Annals of the Rheumatic Diseases\",\n \"description\": \"Objective We aimed to investigate the relationship between tumour necrosis factor inhibitors (TNFi) therapy and the onset of new psoriasis in children with juvenile idiopathic arthritis (JIA) using Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry data.\\n\\nMethods De-identified data were obtained from the CARRA Registry. Patients with inflammatory bowel disease or psoriasis documented on or prior to JIA diagnosis date or with incomplete data were excluded. Exposure to TNFi...\",\n \"url\": \"https://ard.bmj.com/content/early/2022/01/26/annrheumdis-2021-221694\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n },\n {\n \"id\": \"ECL-d9ee6ef1-97c4-4131-b8c2-8c36f96813aa\",\n \"slug\": \"interpreting-the-efficacy-of-secukinumab-on-patient-reported\",\n \"cardType\": \"media\",\n \"createdAt\": \"2022-02-10T19:59:16.000Z\",\n \"duration\": 300,\n \"title\": \"\",\n \"message\": \"Interpreting the efficacy of secukinumab on patient-reported outcomes in psoriatic arthritis - ScienceDirect\",\n \"language\": \"en\",\n \"prices\": [],\n \"provider\": \"\",\n \"readableCardType\": \"Training\",\n \"resource\": {\n \"id\": 9036613,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/sj3fLBBcRGG4OtdzPiWd_1-s2.0-S2665991322X00027-cov150h.gif?file_detail=ce6aa276a21e648b4498fe02bd70d45e7ae3a2c8fa3fc55134670aca98916bcf7385de5593073ebfd0999d5812b0eea0242e49dc502120deb75a778eae6525779094c258f8438e2c2bc61e9a8117ca3bbffe2d3f14a2aa252d0dbe4dd0b96954ac6b6078bcb6f14c32ae9e45524d4db437e74e67ef4c1fae63fa436894f37e19:535a61455174821d0beb0d9b2f388354:9bd932208d599225e8b9051ffca22493&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjQ1NiswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.LK_7Dr4hap7B7c3eY5lLA8v0kuwxBAV_MxhlWobiLbg&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Interpreting the efficacy of secukinumab on patient-reported outcomes in psoriatic arthritis - ScienceDirect\",\n \"description\": \"Secukinumabon patient reported outcomes in PSA\",\n \"url\": \"https://www.sciencedirect.com/science/article/pii/s2665991322000042\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n },\n \"additionalMetadata\": {\n \"promotion\": false,\n \"discount\": false,\n \"allow_enrollment\": false,\n \"cpe_credits\": \"\",\n \"cpe_subject\": \"\"\n },\n \"providerImage\": null,\n \"shareUrl\": \"https://novartis.edcast.com/insights/109074509\",\n \"publishedAt\": \"2022-02-10T19:59:16.000Z\",\n \"contentLanguages\": [\n {\n \"id\": 3748972,\n \"message\": \"Interpreting the efficacy of secukinumab on patient-reported outcomes in psoriatic arthritis - ScienceDirect\",\n \"language\": \"en\",\n \"resource\": {\n \"id\": 9036613,\n \"imageUrl\": \"https://novartis.edcast.com/cdn/uploads/sj3fLBBcRGG4OtdzPiWd_1-s2.0-S2665991322X00027-cov150h.gif?file_detail=fd293fc5810b0a4c966ccf50f829ee64153bcd6169f19299ce2abda9959284d624751c83af4adcc45de4096a757f49c82ce32499ec768bfa910df3a85491a7031144220c0db27f0beb0ccab6dbdcf0c3b8e213b706ea440dd1c4ba7f6725df75da3eb62bd175c4949fb41e93a88c4a5427a3a6f2d08d3730396f76ebddc177e9:59f1610280cf167af4b3da9acba05595:03efbcd851dc8628f22377e040ed125b&file_hash=eyJhbGciOiJIUzI1NiJ9.eyJob3N0X25hbWUiOm51bGwsInVzZXJfaWQiOjEwMjc0MTI5NCwiaXNfb3JnX2FkbWluIjpmYWxzZSwiaXNfc3VwZXJhZG1pbiI6ZmFsc2UsIm9yZ2FuaXphdGlvbl9pZCI6MTAwMDk4LCJ0aW1lc3RhbXAiOiIyMDIzLTAyLTE3VDA2OjE1OjQzLjQ2OCswMDowMCIsIm9yZ2FuaXphdGlvbl91cmwiOiJub3ZhcnRpcy5lZGNhc3QuY29tIn0.fAAm19zkYmyX8-Ck2yZKPjrUo0R2T7vomyOmupphM7U&Policy=eyJTdGF0ZW1lbnQiOlt7IlJlc291cmNlIjoiaHR0cHM6Ly8qIiwiQ29uZGl0aW9uIjp7IkRhdGVMZXNzVGhhbiI6eyJBV1M6RXBvY2hUaW1lIjoxNzM5NzI4NDQ3fX19XX0_&Signature=jCjUKrHC3Nmh4ZH0U3z-a00hDPhalcdQ-2uYbeGlkuJtUkPuupIp~EFFojviVotYyAqP4jtahw1QAEWqI2ONDgvJsiYiQizBK6NmK5ybBMMno2peaNZGOOQp6ZGqUhDwIcbfJ5K94LvPtp-fHY1aH7~dkzKYVzLM4EOLNhp3kq4EWaGxKwb7Lw6hvhaIDkGdAe5tdpWP7NHqwR2pIVuMWZc7Ydu-V9-QVjf~HsoH-SDFq6Ob8pI15fhJghu5xIzLQ0A5xXsDZ7g7SEuD8D8KXKg1U7tjPA3U4Voxq-RvA8RPg1tpxvLTbal5RWKHD05dATYZ0XNtuvuesGEgbgPXVw__&Key-Pair-Id=K3CHX4FEHG07G2\",\n \"title\": \"Interpreting the efficacy of secukinumab on patient-reported outcomes in psoriatic arthritis - ScienceDirect\",\n \"description\": \"Secukinumabon patient reported outcomes in PSA\",\n \"url\": \"https://www.sciencedirect.com/science/article/pii/s2665991322000042\",\n \"siteName\": null,\n \"type\": \"Article\",\n \"videoUrl\": null,\n \"embedHtml\": null\n }\n }\n ]\n }\n ],\n \"total\": 812\n}"}],"_postman_id":"be257b13-4075-459e-9130-210e5044b351"}],"id":"5abbdb35-f096-4f0b-9601-834172019681","_postman_id":"5abbdb35-f096-4f0b-9601-834172019681","description":""},{"name":"Channel Management","item":[{"name":"Get channels.","id":"6057ff8f-2d70-4b6f-981f-a2e4ebd6b1df","protocolProfileBehavior":{"disableBodyPruning":true},"request":{"auth":{"type":"noauth","isInherited":false},"method":"GET","header":[{"key":"X-API-KEY","value":""},{"key":"X-ACCESS-TOKEN","value":""},{"key":"Content-Type","name":"Content-Type","type":"text","value":"application/json"}],"url":"https:///api/developer/v5/channels ","description":"Request Param Description
\n\n\n\n| Sr.no. | \nName | \nType | \nDescription | \nRequired | \nExample | \n
\n\n\n\n| 1 | \nq | \nString | \nSearch string | \nNo | \ntest | \n
\n\n| 2 | \nfilter_type | \nString | \nFilter results.
Values Description
writable:- will fetch channels in which the user can post
following: - will fetch channels which are followed by user or followed by team in which the user is part of
collaborator:- will fetch channels in which the user is collaborator
trusted_collaborator:- will fetch channels in which the user is trusted collaborator
curator:- will fetch channels in which the user is curator
(Note: filter_type wont work for admin user) | \nNo | \nwritable | \n
\n\n| 3 | \nlimit | \nInteger | \nNumber of records to fetch. Default 10 | \nNo | \n4 | \n
\n\n| 4 | \noffset | \nInteger | \nOffset for pagination. Default 0 | \nNo | \n5 | \n
\n\n| 5 | \nsort | \nString | \nSort results. Values: created_at, updated_at | \nNo | \ncreated_at | \n
\n\n| 6 | \norder | \nString | \nasc or desc. Default: asc | \nNo | \nasc | \n
\n\n
\n
Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nid | \nString | \nid of the channel. | \n
\n\n| 2 | \nlabel | \nString | \nLable of the team. | \n
\n\n| 3 | \ndescription | \nString | \nDescription of the team. | \n
\n\n| 4 | \nisPrivate | \nDateTime | \nWhether the channel is private or public | \n
\n\n| 5 | \nbannerImageUrls | \nHash | \nBanner image of the channel in different size. | \n
\n\n| 6 | \nprofileImageUrls | \nHash | \nProfile image of the channel in different size. | \n
\n\n| 7 | \ncreatedAt | \nDateTime | \nCreated at of the channel. | \n
\n\n| 8 | \nupdatedAt | \nDateTime | \nUpdated at of the channel. | \n
\n\n| 9 | \nslug | \nString | \nslug of the channel. | \n
\n\n| 10 | \nallowFollow | \nBoolean | \nTo disable the follow button on web. | \n
\n\n| 11 | \nisFollowing | \nBoolean | \nWhether the user is following the channel . | \n
\n\n| 12 | \ncurateOnly | \nBoolean | \nWhen true only curator content will be displayed in the channel. | \n
\n\n| 13 | \nonlyAuthorsCanPost | \nBoolean | \nWhen true collaborators can post content to channel else its open for everyone. | \n
\n\n
\n
Response Param Description
\n\n\n\n| Sr. no. | \nName | \nType | \nDescription | \n
\n\n\n\n| 1 | \nid | \nString | \nid of the channel. | \n
\n\n| 2 | \nlabel | \nString | \nLable of the team. | \n
\n\n| 3 | \ndescription | \nString | \nDescription of the team. | \n
\n\n| 4 | \nisPrivate | \nDateTime | \nWhether the channel is private or public | \n
\n\n| 5 | \nbannerImageUrls | \nHash | \nBanner image of the channel in different size. | \n
\n\n| 6 | \nprofileImageUrls | \nHash | \nProfile image of the channel in different size. | \n
\n\n| 7 | \ncreatedAt | \nDateTime | \nCreated at of the channel. | \n
\n\n| 8 | \nupdatedAt | \nDateTime | \nUpdated at of the channel. | \n
\n\n| 9 | \nslug | \nString | \nslug of the channel. | \n
\n\n| 10 | \nallowFollow | \nBoolean | \nTo disable the follow button on web. | \n
\n\n| 11 | \nisFollowing | \nBoolean | \nWhether the user is following the channel . | \n
\n\n| 12 | \ncurateOnly | \nBoolean | \nWhen true only curator content will be displayed in the channel. | \n
\n\n| 13 | \nonlyAuthorsCanPost | \nBoolean | \nWhen true collaborators can post content to channel else its open for everyone. | \n
\n\n
\n
Request Param Description
\n